
CANCER INCIDENCE IN MASSACHUSETTS 2011 – 2015:

CITY AND TOWN SUPPLEMENT

Office of Data Management and Outcomes Assessment

Massachusetts Department of Public Health

January 2019



CANCER INCIDENCE IN MASSACHUSETTS 2011 – 2015:

CITY AND TOWN SUPPLEMENT

Charlie Baker, Governor
Karyn Polito, Lieutenant Governor
Marylou Sudders, Secretary of Health and Human Services
Monica Bharel, Commissioner of Public Health
Abigail Averbach, Assistant Commissioner and Director,
Office of Population Health

Natalie Nguyen Durham, Director, Office of Data Management and
Outcomes Assessment
Susan T. Gershman, Director, Massachusetts Cancer Registry
Massachusetts Department of Public Health

January 2019

ACKNOWLEDGMENTS

This report was prepared by Susan T. Gershman, Director, Massachusetts Cancer Registry, and Massachusetts Cancer Registry staff and consultants. Special thanks are extended to the following: Richard Knowlton and Annie MacMillan for their diligent work in the preparation of this report, Steve Pankowicz formerly of the Mass CHIP Program for his time and his excellent work in creating a program for formatting the tables in the report, staff of the Massachusetts Cancer Registry for their editing and data processing efforts, and Gail Merriam and the staff of the Comprehensive Cancer Control Program for updating the section on Cancer Control Initiatives and Publications.

Massachusetts Cancer Registry Staff

Susan T. Gershman, MS, MPH, PhD, CTR, *Director*
Nancy Donovan, MA, CTR, *Cancer Registrar/Quality Assurance Coordinator*
Richard Knowlton, MS, *Epidemiologist*
Ann MacMillan, MPH, *Epidemiologist*
Mary Mroszczyk, CTR, *Geocoding/Special Projects Coordinator*
Jeremiah Nesser, *Technical Assistant to Non-Hospital Reporting*
Jayne Nussdorfer, CTR, *Cancer Registrar*
Barbara J. Rhodes, CMA, CTR, *Cancer Registrar/Death Clearance Coordinator*
Pamela Shuttle, CTR, RHIT, *Cancer Registrar/Non-Hospital Reporting Coordinator*
Hung Tran, *Software Developer*

Massachusetts Cancer Registry Advisory Committee

Lindsay Frazier, MD, ScM (*Chair*)
Martie Carnie, *Community Representative*
Anita Christie, RN, MHA, CPHQ
Deborah Dillon, MD
Joanna Haas, MD
Joseph Jacobson, MD
Nancy Keating, MD, MPH
Carol Lowenstein, CTR, MBA
Gail Merriam, MSW, MPH
Larissa Nekhlyudov, MD, MPH
Al Ozonoff, MA, PhD
Sigalle Reiss, MPH, RS/REHS
Paul C. Shroy, MD, MPH
Ingrid Stendhal, CTR
Susan Sturgeon, DrPH, MPH
Jan Sullivan, MS
Michelle A. Williams, MS, SM, ScD

The data in this report are intended for public use and may be reproduced without permission. Proper acknowledgement of the source is requested.

For further information, please contact the following:

Massachusetts Cancer Registry..... (617) 624-5642
Research and Epidemiology..... (617) 624-5642
Occupational Health Surveillance..... (617) 624-5632
Bureau of Environmental Health..... (617) 624-5757
Cancer Prevention and Control Initiative..... (617) 624-5479
Massachusetts Department of Public Health website.....www.mass.gov/dph

We acknowledge the Centers for Disease Control and Prevention for its support of the staff and the printing and distribution of this report under cooperative agreement 5 NU58 DP006271-02-00 awarded to the Massachusetts Cancer Registry at the Massachusetts Department of Public Health. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the Centers for Disease Control and Prevention.

CONTENTS

	<u>Page</u>
INTRODUCTION AND METHODS	
Introduction	1
Content	1
Comparison with Previous Reports	1
Methods	2
Data Sources	2
Presentation of Data	3
Observed and Expected Case Counts	3
Standardized Incidence Ratios	4
Statistical Significance and Interpretation of SIRs	4
Example of Calculation of an SIR and Its Significance	5
Notes about Data Interpretation	6
Data Limitations	6
Border Areas and Neighboring States	7
Cases Diagnosed in Non-Hospital Settings	7
City/Town Misassignment	7
Small Numbers of Cases	7
TABLES	
Observed and Expected Counts, with Standardized Incidence Ratios, by Sex, for 351 Cities and Towns, 2011 - 2015	10
APPENDICES	
APPENDIX I	
International Classification of Diseases for Oncology (Third Edition) Codes Used for This Report	362
APPENDIX II	
Selected Resources for Information on Cancer	365
APPENDIX III	
Massachusetts Department of Public Health (MDPH) Cancer Prevention and Control Initiatives	366
REFERENCES	367

INTRODUCTION

Content

The purpose of this report is to provide an estimate of cancer incidence for each of the 351 cities and towns of Massachusetts for the five-year time period 2011 through 2015. For each city and town, Standardized Incidence Ratios (SIRs) are presented for twenty-three types of invasive cancer and for all invasive cancer types combined. These ratios compare the cancer incidence experience of each city or town with the cancer experience of the state as a whole. The method involves comparing the number of cases that were observed for a city or town to the number of cases that would be expected if the city or town had the same cancer rates as the state as whole. The report is organized into the following sections:

METHODS provides a detailed explanation of the data collection, data processing, and statistical techniques employed in this report.

TABLES present data for selected types of cancer by city/town and sex.

APPENDIX I provides a listing of *International Classification of Diseases for Oncology* codes used in the preparation of this report.

APPENDIX II provides selected resources for information on cancer.

APPENDIX III describes the Massachusetts Department of Public Health's current cancer control initiatives, and provides links to bureaus within the department that address some aspect of cancer. Links to resources for publications are also provided.

Comparison with Previous Reports

This report updates previous annual reports published by the Massachusetts Cancer Registry (MCR). It is available on line at <http://www.mass.gov/dph/mcr>. For questions about the report, contact the MCR at:

Massachusetts Cancer Registry
Office of Data Management and Outcomes Assessment
Office of Population Health
Massachusetts Department of Public Health
250 Washington Street, 6th floor
Boston, MA 02108-4619
telephone 617-624-5642; fax 617-624-5695

The preceding report, *Cancer Incidence in Massachusetts 2010-2014: City and Town Supplement*, included data for diagnosis years 2010 through 2014. This report contains data for the diagnosis years 2011 through 2015. There have been no changes in this report's format from the previous report.

METHODS

Data Sources

Cancer Incidence

The MCR collects reports of newly diagnosed cancer cases from health care facilities and practitioners throughout Massachusetts. Facilities that reported the 2011-2015 diagnoses that comprise this report include 69 Massachusetts acute care hospitals, 20 independent laboratories, 10 surgical centers, 5 radiation/oncology centers, 10 medical practice associations, 4 endoscopy centers, and approximately 500 private practice physicians. The MCR signed the modified National Data Exchange Agreement on March 28, 2013. This is a single agreement that allows participating states to exchange data on cases diagnosed or treated in other areas. Together with states participating in the agreement, and states with individual agreements, the MCR now has reciprocal reporting agreements with 42 states and with the District of Columbia, the Virgin Islands, Puerto Rico and Guam to obtain data on Massachusetts residents diagnosed out of state. Currently the MCR collects information on *in situ* and invasive cancers and benign tumors of the brain and associated tissues. The MCR does not collect information on basal and squamous cell carcinomas of the skin.

The MCR also collects information from reporting hospitals on cases diagnosed and treated in staff physician offices when this information is available. Not all hospitals report this type of case, however, some hospitals report such cases as if the patients had been diagnosed and treated by the hospital directly. Collecting these types of data makes the MCR's overall case ascertainment more complete. Some cancer types that may be reported to the MCR in this manner are melanoma, prostate, colon/rectum, and oral cancers.

In addition, the MCR identifies previously unreported cancer cases through review of death certificate data to further improve case completeness. This process is referred to as death clearance and identifies cancers mentioned on death certificates that were not previously reported to the MCR. In some instances, the MCR obtains additional information on these cases through follow-up activities with hospitals, nursing homes, hospice residences, and physicians' offices. In other instances, a cancer-related cause of death recorded on a Massachusetts death certificate is the only source of information for a cancer case. Thus these "death certificate only" cancer diagnoses are poorly documented and have not been confirmed by review of clinical and pathological information. Such cases are included in this report, but they comprise less than 3% of all cancer cases.

All case reports that provided the basis for this report were coded following the *International Classification of Diseases for Oncology, Third Edition (ICD-O-3)*, which was implemented in North America with cases diagnosed as of January 1, 2001. (1) Please see Appendix A for the classification of cancers by ICD-O3 codes.

Each year, the North American Association of Central Cancer Registries (NAACCR) reviews cancer registry data for quality, completeness, and timeliness. For 2011-2015, the MCR's annual case count was estimated by NAACCR to be more than 95% complete for each year. The MCR has achieved the gold standard for this certification element as well as for six other certification elements for each case year since 1997.

The Massachusetts cancer cases presented in this report are primary cases of cancer diagnosed among Massachusetts residents during 2011-2015 and reported to the MCR as of June 26, 2018. These data include some additional cases diagnosed in 2010-2014 that were not counted in the

previous report, *Cancer Incidence in Massachusetts 2010-2014: City and Town Supplement*. The lag time between this report and the annual statewide report of 2011-2015 cancer cases is due to the fact that data for this city and town report needed to be cleaned for accuracy of residence within Massachusetts. The statewide report presented data at the state level and did not require such accuracy of city and town of residence. The numbers presented in this report may change slightly in future reports, reflecting late reported cases or corrections based on subsequent details from the reporting facilities. Such changes might result in slight differences in numbers and rates in future reports of MCR data, reflecting the nature of population-based cancer registries that receive case reports on an ongoing basis.

Massachusetts cancer cases presented in this report are primary cases of cancer diagnosed among Massachusetts residents during 2011-2015. The Massachusetts data presented include invasive cancers only (except cancer of the urinary bladder, where *in situ* cancers are also included). Invasive cancers have spread beyond the layer of cells where they started and have the potential to spread to other parts of the body. *In situ* cancers are neoplasms diagnosed at the earliest stage, before they have spread, when they are limited to a small number of cells and have not invaded the organ itself. Typically, published incidence rates do not combine invasive and *in situ* cancers due to differences in the biologic significance, survival prognosis and types of treatment of the tumors. Cancer of the urinary bladder is the only exception, due to the specific nature of the diagnostic techniques and treatment patterns.

Presentation of Data

Each city and town in Massachusetts is listed alphabetically in the **TABLES** section. The observed number of cases, the expected number of cases, the standardized incidence ratios, and 95% confidence intervals are presented for twenty-three main types of cancer and for all cancer types combined. The “all cancers combined” category includes the twenty-three main types presented in this report and other malignant neoplasms. This category is meant to provide a summary of the total cancer experience in a community. As different cancers have different causes, this category does not reflect any specific risk factor that may be important for this community.

Observed and Expected Case Counts

The *observed* case count (**Obs**) for a particular type of cancer in a city/town is the actual number of newly diagnosed cases among residents of that city/town for a given time period.

A city/town’s *expected* case count (**Exp**) for a certain type of cancer for this time period is a calculated number based on that city/town’s population distribution² (by sex and among eighteen age groups) for the time period 2011-2015, and the corresponding statewide average annual age-specific incidence rates. The source of the city and town population data for the 2011-2015 period was the US Census American Community Survey (ACS), an ongoing national survey that provides demographic estimates on a yearly basis.²

Standardized Incidence Ratios

A Standardized Incidence Ratio (SIR) is an indirect method of adjustment for age and sex that describes in numerical terms how a city/town's cancer experience in a given time period compares with that of the state as a whole.

- An SIR of *exactly 100* indicates that a city/town's incidence of a certain type of cancer is *equal to that expected* based on statewide average age-specific incidence rates.
- An SIR of *more than 100* indicates that a city/town's incidence of a certain type of cancer is *higher than expected* for that type of cancer based on statewide average annual age-specific incidence rates. For example, an SIR of 105 indicates that a city/town's cancer incidence is 5% higher than expected based on statewide average annual age-specific incidence rates.
- An SIR of *less than 100* indicates that a city/town's incidence of a certain type of cancer is *lower than expected* based on statewide average age-specific incidence rates. For example, an SIR of 85 indicates that a city/town's cancer incidence is 15% lower than expected based on statewide average annual age-specific incidence rates.

Statistical Significance and Interpretation of SIRs

The interpretation of the SIR depends on both how large it is and how stable it is. Stability in this context refers to how much the SIR changes when there are small increases or decreases in the observed or expected number of cases. Two SIRs may have the same size but not the same stability. For example, an SIR of 150 may represent 6 observed cases and 4 expected cases, or 600 observed cases and 400 expected cases. Both represent a 50 percent excess of observed cases. However, in the first instance, one or two fewer cases would change the SIR a great deal, whereas in the second instance, even if there were several fewer cases, the SIR would only change minimally. When the observed and expected numbers of cases are relatively small, their ratio is easily affected by one or two cases. Conversely, when the observed and expected numbers of cases are relatively large, the value of the SIR is stable.

A 95 percent confidence interval (CI) has been presented for each SIR in this report (when the observed number of cases is at least 5), to indicate if the observed number of cases is significantly different from the expected number, or if the difference is most likely due to chance. A confidence interval is a range of values around a measurement that indicates the precision of the measurement. In this report, the 95% confidence interval is the range of estimated SIR values that has a 95% probability of including the true SIR for a specific city or town. If the 95% confidence interval range *does not* include the value 100.0, then the number of observed cases is significantly different from the expected number of cases. "Significantly different" means there is at most a 5% chance that the difference between the number of observed and expected cancer cases is due solely to chance alone. If the confidence interval does contain the value 100.0, there is no significant difference between the observed and expected numbers. Statistically, the width of the interval reflects the size of the population and the number of events; smaller populations and smaller observed numbers of cases yield less precise estimates that have wider confidence intervals. Wide confidence intervals indicate instability, meaning that small changes in the observed or expected number of cases would change the SIR a great deal.

Examples:

- SIR = 137.0; 95% CI (101.6 - 180.6) – the confidence interval does not include 100.0 and the interval is above 100.0, indicating that the number of observed cases is *statistically significantly higher* than the expected number.
- SIR = 71.0; 95% CI (56.2 – 88.4) – the confidence interval does not include 100.0 and the interval is below 100.0, indicating that the number of observed cases is *statistically significantly lower* than the expected number.
- SIR = 108.8 95% CI (71.0-159.4) – the confidence interval DOES include 100.0 indicating that the number of observed cases is *NOT statistically significantly different* from what is expected, and the difference is likely due to chance. When the interval includes 100.0, then the true SIR may be 100.0.

Example of Calculation of an SIR and Its Significance

$$\text{SIR} = \frac{\text{OBSERVED CASES}}{\text{EXPECTED CASES}} \times 100$$

The following example illustrates the method of calculation for a hypothetical town for one type of cancer and one sex for the years 2007-2011:

Age Group	<u>Town X</u> Population (A)	<u>State</u> Age-Specific Incidence Rate (B)	<u>Town X</u> Expected Cases (C) = (A) x (B)	<u>Town X</u> Observed Cases (D)
00-04	74,657	0.0001	7.47	11
05-09	134,957	0.0002	26.99	25
10-14	54,463	0.0005	27.23	30
15-19	25,136	0.0015	37.70	40
20-24	17,012	0.0018	30.62	30
UP TO				
85+	6,337	0.0010	6.34	8
		Total:	136.35	144

$$\text{SIR} = \frac{\text{Observed Cases}}{\text{Expected Cases}} \times 100 = \frac{(\text{column D total})}{(\text{column C total})} \times 100 = \frac{144}{136.35} \times 100 \approx 106$$

Thus the SIR for this type of cancer in Town X is 106, indicating that the incidence of this cancer in Town X is 6% higher than the corresponding statewide average incidence for this cancer. However, the range for the 95% confidence interval (89.1-124.3) (calculation not shown) indicates that the true value may be as low as 89.1 or as high as 124.3 Also, since the range

includes the value 100, it means that the observed number of cases is *not statistically significantly higher or lower* than what is expected.

Whenever the number of observed cases is less than five, the corresponding SIR is neither calculated nor tested for statistical significance. This is indicated with an (nc) (“not calculated”). However, the number of observed and expected cases is shown in these circumstances.

Notes about Data Interpretation

The SIR is a useful indication of the disease categories that have relatively high or low rates for a given community. These statistics, however, should be used with care. Such statistics provide a starting point for further research and investigation into a possible health problem, but they do not by themselves confirm or deny the existence of a particular health problem. Many factors unrelated to disease causation may contribute to an elevated SIR, including demographic factors, changes in diagnostic techniques, and changes in data collection or recording methods over time, as well as the natural variation in disease occurrence.

When reviewing the data tables, it is important to keep in mind that an SIR compares the observed cancer incidence in a particular community with the expected incidence based on statewide average annual age-specific incidence rates. This means that *valid comparisons can only be made between a community and the state as a whole. SIRs for different cities and towns CANNOT and SHOULD NOT be compared to each other.* (Comparisons between two communities would be valid only if there were no differences in the age and sex distributions of the two communities’ populations.)

Another point to keep in mind when reviewing these data is the large number of statistical tests being performed in this report. For each of the 351 cities and towns, we evaluate 18 types of cancer that can occur in both males and females, 3 types that occur only in females and 2 types that occur only in males, resulting in 41 gender/cancer categories. This results in 14,391 possible calculations (351 cities and towns x 41 gender cancer categories). Note that gender/cancer categories with less than 5 observed cases are not evaluated for statistical significance, so the actual numbers of tests is slightly lower than 14,391. This is important for the reader because when multiple significance tests are performed, some will result in a significant finding due to chance alone. Based on the number of calculations in this report, we expect 720 significant findings to be due to chance alone. Half of these would be significant excesses (360) and half would be significant deficits (360). There are statistical techniques that can be used to reduce this number, however use of these techniques leads to the opposite problem – true significant differences that may be missed. We choose to err on the side of caution and identify more significant results, knowing that some will be due to chance alone.

Data Limitations

It should be emphasized that apparent increases or decreases in cancer incidence over time might reflect changes in diagnostic methods or case reporting rather than true changes in cancer incidence. Four other limitations must be considered when interpreting cancer incidence data for Massachusetts cities and towns: under-reporting in areas close to neighboring states; under-reporting for cancers that may not be diagnosed in hospitals; cases being assigned to incorrect cities/towns; and standardized incidence ratios based on small numbers of cases.

Border Areas and Neighboring States

Some areas of Massachusetts appear to have low cancer incidence, but this may be due to loss of Massachusetts resident cases who are diagnosed in neighboring or other states and not reported to the MCR. The MCR has reciprocal reporting agreements with 42 states and with the District of Columbia, the Virgin Islands, Puerto Rico, and Guam.

Cases Diagnosed in Non-Hospital Settings

During the time period covered by this report, the MCR's primary information source for most newly diagnosed cases of cancer was hospitals. In addition the MCR collected information from reporting hospitals on cases diagnosed and treated in staff physician offices, when this information was available. Other reporting sources include dermatologists and dermatopathology laboratories, urologists' offices and a general laboratory. Some types of cancer in this report may be under-reported because they are diagnosed primarily by private physicians, private laboratories, health maintenance organizations, radiotherapy centers that escape identification systems used by hospitals. The most common types of cancer diagnosed or treated outside of the hospital include melanoma and prostate cancer. The exact extent of this under-reporting has not been determined, but cases included in this report represent the great majority of cases statewide and provide an essential basis for evaluating statewide cancer incidence patterns.

City/Town Misassignment

In accordance with standard central cancer registry procedures, each case reported to the MCR ideally should be assigned to the city/town in which the patient lived at the time of diagnosis, based on the address provided by the reporting hospital. In practice, however, a patient may provide the hospital with his/her mailing address (e.g., a post office box located outside the patient's city/town of residence); a business address; a temporary address (e.g., the patient is staying with a relative while receiving treatment and reports the relative's address as his/her own); or a locality or post office name (e.g., "Chestnut Hill" rather than "Boston," "Brookline," or "Newton"). In addition, if a patient has moved since being diagnosed, the hospital may report the patient's current address. Because of the large number of cases reported to the MCR, and because data are reported to the MCR via electronic media, most city/town case assignments are performed by an automated computer process. This simplified matching process may misassign some cases based on the reported locality name. When MCR staff become aware of such misassignments, they manually correct the errors. Furthermore, in order to minimize such errors, cases from fifty geographic localities prone to city/town misassignment are reviewed manually.

Small Numbers of Cases

Standardized incidence ratios based on small numbers of cases result in estimates that are very unstable. This situation is common when the population of a city or town is small or if the particular cancer type is rare. SIRs and statistical significance are not calculated when the number of observed cases for a specific category is less than five. In these instances, the observed and expected cases are presented in the tables *for qualitative comparison only*.

This page intentionally left blank.

TABLES

Abington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	14	14.4	97.5	(53.3-163.6)	Male	12	9.9	121.0	(62.5-211.4)
Female	7	5.9	119.1	(47.7-245.4)	Female	8	8.8	91.0	(39.2-179.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	3.0	nc	(nc-nc)	Male	7	3.2	220.2	(88.2-453.8)
Female	1	3.0	nc	(nc-nc)	Female	3	2.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.5	nc	(nc-nc)	Male	4	8.7	nc	(nc-nc)
Female	59	72.4	81.5	(62.0-105.1)	Female	6	8.4	71.6	(26.2-155.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	2.4	nc	(nc-nc)	Male	7	7.8	89.2	(35.7-183.7)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	22	15.9	138.1	(86.5-209.1)	Female	5	6.2	80.8	(26.1-188.7)
Female	20	16.7	120.0	(73.3-185.4)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	6	4.0	151.7	(55.4-330.2)	Male	42	48.8	86.1	(62.1-116.4)
Female	0	1.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	0	1.3	nc	(nc-nc)	Male	2	2.5	nc	(nc-nc)
Female	2	1.2	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	17	9.4	181.2	(105.5-290.1)	Female	18	17.2	104.7	(62.0-165.5)
Female	7	5.7	123.4	(49.4-254.3)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Leukemia</u>				
Male	3	2.4	nc	(nc-nc)	Male	5	6.0	83.2	(26.8-194.1)
Female	6	0.8	741.1	(270.6-1613.1)	Female	6	4.9	121.7	(44.4-264.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Lung and Bronchus</u>				
Male	6	5.7	105.4	(38.5-229.4)	Male	35	26.5	132.3	(92.2-184.0)
Female	2	2.1	nc	(nc-nc)	Female	41	32.0	128.3	(92.0-174.0)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Acton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	19	21.6	87.9	(52.9-137.3)	Male	17	15.1	112.3	(65.4-179.8)
Female	4	7.9	nc	(nc-nc)	Female	16	12.4	128.9	(73.6-209.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	4.7	128.4	(46.9-279.5)	Male	3	4.8	nc	(nc-nc)
Female	3	3.9	nc	(nc-nc)	Female	4	3.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.8	nc	(nc-nc)	Male	16	13.4	119.8	(68.5-194.6)
Female	118	103.5	114.1	(94.4-136.6)	Female	8	11.6	69.2	(29.8-136.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	3.6	nc	(nc-nc)	Male	10	12.2	81.8	(39.2-150.5)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	24	25.1	95.5	(61.2-142.1)	Female	8	8.6	93.0	(40.0-183.2)
Female	20	24.2	82.8	(50.5-127.8)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	6	6.0	100.8	(36.8-219.4)	Male	79	72.3	109.3	(86.5-136.2)
Female	3	1.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	1	1.8	nc	(nc-nc)	Male	3	3.5	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	7	14.5	48.4	(19.4-99.8)	Female	14	22.7	61.6	(33.7-103.4)
Female	10	7.8	127.9	(61.2-235.2)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Leukemia</u>				
Male	3	3.5	nc	(nc-nc)	Male	8	9.2	86.7	(37.4-170.9)
Female	1	1.1	nc	(nc-nc)	Female	9	6.7	134.3	(61.3-255.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Lung and Bronchus</u>				
Male	6	8.7	68.7	(25.1-149.6)	Male	18	38.9	46.3	(27.4-73.1)
Female	2	2.7	nc	(nc-nc)	Female	27	42.2	64.0	(42.2-93.1)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Acushnet

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	20	13.4	148.8	(90.9-229.9)	Male	4	8.5	nc	(nc-nc)
Female	4	4.3	nc	(nc-nc)	Female	5	5.8	86.3	(27.8-201.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	2.4	nc	(nc-nc)	Male	3	2.7	nc	(nc-nc)
Female	2	1.9	nc	(nc-nc)	Female	4	2.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.4	nc	(nc-nc)	Male	9	7.4	121.0	(55.2-229.7)
Female	50	47.8	104.6	(77.6-137.9)	Female	13	5.9	221.2	(117.7-378.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.5	nc	(nc-nc)	Male	3	6.0	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	18	13.7	131.5	(77.9-207.9)	Female	5	4.1	123.3	(39.7-287.6)
Female	13	12.0	108.0	(57.4-184.7)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	4	3.2	nc	(nc-nc)	Male	44	36.5	120.6	(87.6-162.0)
Female	0	0.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	2	0.9	nc	(nc-nc)	Male	1	1.7	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	5	7.3	68.4	(22.1-159.7)	Female	6	11.0	54.5	(19.9-118.6)
Female	4	3.8	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Leukemia</u>				
Male	3	1.8	nc	(nc-nc)	Male	3	5.4	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	8	3.3	240.9	(103.7-474.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Lung and Bronchus</u>				
Male	4	4.5	nc	(nc-nc)	Male	30	22.8	131.3	(88.6-187.5)
Female	1	1.4	nc	(nc-nc)	Female	22	23.2	95.0	(59.5-143.9)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Adams

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	7	9.9	70.8	(28.4-145.9)	Male	5	6.1	81.6	(26.3-190.5)
Female	3	3.8	nc	(nc-nc)	Female	3	5.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.8	nc	(nc-nc)	Male	2	2.0	nc	(nc-nc)
Female	3	1.6	nc	(nc-nc)	Female	1	1.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	6	5.4	110.7	(40.4-240.9)
Female	35	41.8	83.8	(58.4-116.6)	Female	7	5.1	136.2	(54.6-280.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.3	nc	(nc-nc)	Male	5	4.5	112.0	(36.1-261.4)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	13	10.0	129.8	(69.1-222.0)	Female	1	3.6	nc	(nc-nc)
Female	8	10.7	75.0	(32.3-147.7)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	6	3.6	167.0	(61.0-363.6)
Male	1	2.4	nc	(nc-nc)	Female	7	3.9	178.9	(71.7-368.7)
Female	0	0.7	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	22	29.6	74.3	(46.6-112.5)
Male	2	0.7	nc	(nc-nc)	<u>Stomach</u>				
Female	2	0.6	nc	(nc-nc)	Male	2	2.3	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	3	1.5	nc	(nc-nc)
Male	6	5.5	109.9	(40.1-239.3)	<u>Testis</u>				
Female	2	3.4	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	1.4	nc	(nc-nc)	Male	3	2.3	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	6	7.3	81.7	(29.8-177.8)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	6	3.9	154.7	(56.5-336.6)	Female	6	9.5	63.2	(23.1-137.5)
Female	2	3.0	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	125	123.1	101.6	(84.5-121.0)
Male	1	3.4	nc	(nc-nc)	Female	118	139.8	84.4	(69.9-101.1)
Female	0	1.3	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	20	17.1	116.7	(71.3-180.2)					
Female	20	20.0	100.1	(61.1-154.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Agawam

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	34	35.2	96.7	(66.9-135.1)	Male	20	22.1	90.6	(55.3-140.0)
Female	8	13.7	58.6	(25.2-115.4)	Female	15	18.0	83.5	(46.7-137.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	6.3	78.8	(25.4-183.8)	Male	10	7.1	139.9	(67.0-257.3)
Female	5	5.7	87.2	(28.1-203.4)	Female	7	6.3	111.2	(44.5-229.1)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.2	nc	(nc-nc)	Male	20	19.5	102.5	(62.6-158.4)
Female	141	143.2	98.4	(82.9-116.1)	Female	20	18.3	109.4	(66.8-169.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	6	4.5	132.5	(48.4-288.4)	Male	24	16.3	147.2	(94.3-219.0)
Female					Female	12	8.0	149.6	(77.2-261.3)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	38	36.1	105.2	(74.5-144.5)	Female	7	12.5	56.1	(22.5-115.6)
Female	34	38.8	87.7	(60.7-122.5)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	8	12.9	61.9	(26.6-121.9)
Male	3	8.8	nc	(nc-nc)	Female	17	14.4	118.2	(68.8-189.2)
Female	4	2.6	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	87	106.1	82.0	(65.7-101.2)
Male	3	2.3	nc	(nc-nc)	<u>Stomach</u>				
Female	2	2.1	nc	(nc-nc)	Male	8	8.2	97.9	(42.2-192.9)
<u>Kidney & Renal Pelvis</u>					Female	4	5.5	nc	(nc-nc)
Male	28	19.8	141.2	(93.8-204.0)	<u>Testis</u>				
Female	11	11.6	94.7	(47.2-169.5)	Male	1	4.0	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	7	5.1	136.7	(54.8-281.7)	Male	3	8.4	nc	(nc-nc)
Female	1	1.6	nc	(nc-nc)	Female	20	25.0	80.0	(48.8-123.5)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	16	13.8	115.7	(66.1-188.0)	Female	27	32.6	82.8	(54.5-120.4)
Female	7	10.7	65.3	(26.1-134.5)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	432	442.0	97.7	(88.7-107.4)
Male	13	12.3	106.1	(56.4-181.5)	Female	481	490.0	98.2	(89.6-107.3)
Female	5	4.5	111.3	(35.9-259.8)					
<u>Lung and Bronchus</u>									
Male	72	61.5	117.0	(91.5-147.3)					
Female	88	69.7	126.3	(101.3-155.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Alford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	1.1	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	5	3.3	150.6	(48.5-351.4)	Female	0	0.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	0	1.0	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	3.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	0.6	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
Female	2	0.3	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Leukemia</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Lung and Bronchus</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	1.9	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	1.7	nc	(nc-nc)
<u>Male</u>					<u>Female</u>				
					3				
					8				
					12.8				
					72.7				
					(31.3-143.2)				

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Amesbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	15	16.3	92.1	(51.5-151.9)	Male	6	11.1	53.9	(19.7-117.4)
Female	11	6.8	160.9	(80.2-287.9)	Female	4	9.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	3.4	145.2	(46.8-339.0)	Male	2	3.5	nc	(nc-nc)
Female	4	3.1	nc	(nc-nc)	Female	0	3.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.6	nc	(nc-nc)	Male	17	9.8	172.9	(100.6-276.8)
Female	78	81.0	96.3	(76.1-120.2)	Female	11	9.6	114.9	(57.3-205.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	2.7	nc	(nc-nc)	Male	10	8.7	114.3	(54.7-210.3)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	16	18.0	88.9	(50.8-144.4)	Female	6	6.9	87.3	(31.9-190.1)
Female	20	19.6	101.9	(62.2-157.5)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	7	6.3	111.4	(44.6-229.5)
Male	4	4.4	nc	(nc-nc)	Female	4	7.1	nc	(nc-nc)
Female	2	1.4	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	70	53.8	130.0	(101.4-164.3)
Male	3	1.4	nc	(nc-nc)	<u>Stomach</u>				
Female	0	1.2	nc	(nc-nc)	Male	5	4.0	125.5	(40.5-293.0)
<u>Kidney & Renal Pelvis</u>					Female	1	2.8	nc	(nc-nc)
Male	3	10.5	nc	(nc-nc)	<u>Testis</u>				
Female	7	6.4	110.2	(44.1-227.0)	Male	2	2.7	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	2.6	nc	(nc-nc)	Male	7	5.0	139.6	(55.9-287.7)
Female	0	0.9	nc	(nc-nc)	Female	18	15.1	119.5	(70.8-188.8)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	9	7.0	129.0	(58.9-245.0)	Female	18	18.6	96.6	(57.2-152.7)
Female	5	5.4	91.9	(29.6-214.5)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	234	221.7	105.6	(92.5-120.0)
Male	8	6.4	124.8	(53.7-245.8)	Female	248	265.2	93.5	(82.3-105.9)
Female	0	2.3	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	29	29.1	99.7	(66.8-143.3)					
Female	43	36.6	117.5	(85.1-158.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Amherst

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	17	19.8	85.8	(50.0-137.4)	Male	11	12.7	86.7	(43.2-155.1)
Female	3	7.6	nc	(nc-nc)	Female	12	10.3	116.0	(59.9-202.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	5.2	nc	(nc-nc)	Male	4	4.0	nc	(nc-nc)
Female	1	5.0	nc	(nc-nc)	Female	1	3.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.7	nc	(nc-nc)	Male	9	12.0	74.8	(34.1-142.0)
Female	78	79.7	97.8	(77.3-122.1)	Female	8	10.7	74.9	(32.3-147.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	2.5	nc	(nc-nc)	Male	8	9.5	84.5	(36.4-166.6)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	18	20.5	87.7	(52.0-138.7)	Female	12	7.4	161.4	(83.3-282.0)
Female	23	21.1	108.8	(69.0-163.3)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	2	5.0	nc	(nc-nc)	Male	43	60.1	71.5	(51.8-96.4)
Female	0	1.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	0	2.6	nc	(nc-nc)	Male	0	3.6	nc	(nc-nc)
Female	0	2.6	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	2	11.4	nc	(nc-nc)	Female	17	18.5	91.8	(53.4-146.9)
Female	7	6.6	106.1	(42.5-218.6)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Leukemia</u>				
Male	2	2.9	nc	(nc-nc)	Male	7	9.8	71.1	(28.5-146.5)
Female	0	0.9	nc	(nc-nc)	Female	2	6.8	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Lung and Bronchus</u>				
Male	3	7.1	nc	(nc-nc)	Male	14	35.0	40.0	(21.8-67.1)
Female	0	2.6	nc	(nc-nc)	Female	19	38.8	49.0	(29.5-76.5)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Andover

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	29	39.6	73.3	(49.0-105.2)	Male	27	25.4	106.2	(70.0-154.5)
Female	12	12.5	95.8	(49.4-167.4)	Female	25	18.8	132.9	(86.0-196.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	8	7.4	107.4	(46.3-211.7)	Male	5	8.3	60.5	(19.5-141.3)
Female	5	6.1	81.4	(26.2-189.9)	Female	13	6.0	216.7	(115.3-370.6)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	4	1.4	nc	(nc-nc)	Male	30	22.5	133.5	(90.0-190.5)
Female	170	156.3	108.7	(93.0-126.4)	Female	16	17.9	89.2	(51.0-144.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	5.3	nc	(nc-nc)	Male	17	19.1	88.9	(51.7-142.3)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	28	42.0	66.6	(44.2-96.3)	Female	11	13.1	84.2	(42.0-150.7)
Female	38	37.3	101.9	(72.1-139.9)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	14	14.7	95.3	(52.1-159.9)
Male	8	10.1	79.3	(34.1-156.2)	Female	11	13.1	83.9	(41.8-150.2)
Female	7	2.5	280.6	(112.4-578.2)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	104	119.8	86.8	(71.0-105.2)
Male	1	2.6	nc	(nc-nc)	<u>Stomach</u>				
Female	1	2.2	nc	(nc-nc)	Male	6	9.3	64.2	(23.4-139.7)
<u>Kidney & Renal Pelvis</u>					Female	4	5.2	nc	(nc-nc)
Male	22	23.2	94.7	(59.3-143.4)	<u>Testis</u>				
Female	11	12.0	91.5	(45.6-163.7)	Male	8	4.6	173.1	(74.5-341.1)
<u>Larynx</u>					<u>Thyroid</u>				
Male	3	5.9	nc	(nc-nc)	Male	18	10.1	178.8	(105.9-282.6)
Female	2	1.7	nc	(nc-nc)	Female	45	29.7	151.4	(110.4-202.6)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	18	15.8	114.0	(67.5-180.1)	Female	22	34.7	63.4	(39.7-96.0)
Female	11	10.5	104.6	(52.1-187.2)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	429	505.3	84.9	(77.1-93.3)
Male	7	14.0	50.1	(20.1-103.2)	Female	482	502.8	95.9	(87.5-104.8)
Female	2	4.3	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	38	69.7	54.5	(38.6-74.8)					
Female	41	67.0	61.2	(43.9-83.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Aquinnah

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	4	2.1	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.2	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	1	0.4	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	0	0.1	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	1	1.3	nc	(nc-nc)
Male	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.1	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<u>Testis</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.2	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	3	5.0	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	Female	5	6.6	75.2	(24.2-175.5)
Female	0	0.1	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	0	0.6	nc	(nc-nc)					
Female	0	0.8	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Arlington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	48	47.6	100.9	(74.4-133.8)	Male	24	30.3	79.2	(50.7-117.8)
Female	14	19.7	71.0	(38.8-119.1)	Female	29	26.8	108.1	(72.4-155.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	12	8.9	135.3	(69.8-236.3)	Male	10	9.6	104.6	(50.1-192.4)
Female	11	8.5	129.8	(64.7-232.2)	Female	4	9.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	1.6	nc	(nc-nc)	Male	24	26.9	89.3	(57.2-132.8)
Female	206	207.3	99.4	(86.3-113.9)	Female	34	26.6	127.9	(88.6-178.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	5	6.9	72.5	(23.4-169.2)	Male	16	21.8	73.6	(42.0-119.5)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	45	50.0	90.0	(65.7-120.5)	Female	23	18.3	126.0	(79.9-189.1)
Female	56	57.0	98.3	(74.2-127.6)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	9	11.5	77.9	(35.6-148.0)	Male	141	134.1	105.2	(88.5-124.0)
Female	4	3.8	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	5	3.4	145.1	(46.8-338.6)	Male	9	7.0	128.6	(58.7-244.2)
Female	5	3.3	153.8	(49.6-358.9)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	27	26.7	101.3	(66.7-147.4)	Female	48	46.8	102.5	(75.6-135.9)
Female	14	16.9	82.9	(45.3-139.1)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Leukemia</u>				
Male	6	6.7	89.6	(32.7-195.0)	Male	21	19.1	110.1	(68.1-168.3)
Female	3	2.3	nc	(nc-nc)	Female	11	16.0	68.6	(34.2-122.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Lung and Bronchus</u>				
Male	15	16.1	93.2	(52.1-153.7)	Male	66	81.0	81.5	(63.0-103.6)
Female	4	6.5	nc	(nc-nc)	Female	84	99.4	84.5	(67.4-104.6)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Ashburnham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	6	5.3	112.9	(41.2-245.8)	Male	3	3.9	nc	(nc-nc)
Female	0	2.1	nc	(nc-nc)	Female	3	3.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	1.3	nc	(nc-nc)	Male	2	1.3	nc	(nc-nc)
Female	2	1.1	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.2	nc	(nc-nc)	Male	2	3.5	nc	(nc-nc)
Female	18	29.2	61.7	(36.6-97.6)	Female	0	3.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.0	nc	(nc-nc)	Male	3	3.5	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	4	6.3	nc	(nc-nc)	Female	3	2.4	nc	(nc-nc)
Female	8	6.2	129.2	(55.6-254.7)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	5	2.2	224.4	(72.3-523.7)
Male	1	1.7	nc	(nc-nc)	Female	1	2.2	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	19	22.1	85.9	(51.7-134.2)
Male	1	0.5	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.4	nc	(nc-nc)	Male	2	1.4	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.9	nc	(nc-nc)
Male	3	4.0	nc	(nc-nc)	<u>Testis</u>				
Female	2	2.2	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	1.0	nc	(nc-nc)	Male	1	1.9	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	5	5.6	89.3	(28.8-208.4)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	5	2.4	210.3	(67.8-490.7)	Female	5	6.9	72.9	(23.5-170.1)
Female	3	1.7	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	79	81.5	97.0	(76.8-120.8)
Male	0	2.4	nc	(nc-nc)	Female	63	90.6	69.6	(53.4-89.0)
Female	0	0.8	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	6	10.1	59.3	(21.6-129.0)					
Female	4	11.9	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Ashby

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	3.7	nc	(nc-nc)	Male	4	2.4	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)	Female	4	1.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	0.7	nc	(nc-nc)	Male	2	0.8	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	2.1	nc	(nc-nc)
Female	13	14.6	88.9	(47.3-152.0)	Female	0	1.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.5	nc	(nc-nc)	Male	3	1.9	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	3	4.1	nc	(nc-nc)	Female	2	1.2	nc	(nc-nc)
Female	2	3.3	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	2	0.9	nc	(nc-nc)	Male	7	11.5	60.8	(24.4-125.3)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	1	0.3	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	2.2	nc	(nc-nc)	Female	3	3.4	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Leukemia</u>				
Male	1	0.6	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Lung and Bronchus</u>				
Male	1	1.4	nc	(nc-nc)	Male	3	6.3	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	4	6.3	nc	(nc-nc)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Ashfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	1.8	nc	(nc-nc)	Male	2	1.2	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Female	5	9.3	53.9	(17.4-125.7)	Female	0	1.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	1	2.0	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
Female	2	2.2	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	0	0.5	nc	(nc-nc)	Male	4	6.9	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	1.2	nc	(nc-nc)	Female	4	2.2	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Male</u>				
Male	0	0.3	nc	(nc-nc)	21	25.8	81.4	(50.4-124.4)	
Female	0	0.1	nc	(nc-nc)	<u>Female</u>				
<u>Leukemia</u>					18				
Male	0	0.8	nc	(nc-nc)	30.1	59.7	(35.4-94.4)		
Female	1	0.6	nc	(nc-nc)					
<u>Liver and Intrahepatic Bile Ducts</u>									
Male	1	0.8	nc	(nc-nc)					
Female	0	0.3	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	2	3.4	nc	(nc-nc)					
Female	1	4.3	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Ashland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	17	15.4	110.3	(64.2-176.6)	Male	7	10.6	66.2	(26.5-136.3)
Female	4	5.9	nc	(nc-nc)	Female	5	9.2	54.1	(17.4-126.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	3.4	nc	(nc-nc)	Male	3	3.4	nc	(nc-nc)
Female	3	3.0	nc	(nc-nc)	Female	3	2.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.6	nc	(nc-nc)	Male	8	9.4	85.4	(36.8-168.2)
Female	80	76.1	105.2	(83.4-130.9)	Female	8	8.6	93.2	(40.1-183.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	2.6	nc	(nc-nc)	Male	6	8.4	71.7	(26.2-156.1)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	12	17.3	69.5	(35.9-121.5)	Female	8	6.4	125.5	(54.0-247.2)
Female	21	17.2	121.8	(75.3-186.2)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	3	6.0	nc	(nc-nc)
Male	7	4.2	168.3	(67.4-346.8)	Female	6	6.1	98.4	(35.9-214.1)
Female	3	1.2	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	44	51.5	85.4	(62.0-114.6)
Male	1	1.3	nc	(nc-nc)	<u>Stomach</u>				
Female	2	1.2	nc	(nc-nc)	Male	4	3.8	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	3	2.4	nc	(nc-nc)
Male	4	10.1	nc	(nc-nc)	<u>Testis</u>				
Female	1	5.8	nc	(nc-nc)	Male	2	2.6	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	2.5	nc	(nc-nc)	Male	3	4.8	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	16	15.0	106.5	(60.8-173.0)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	5	6.7	74.9	(24.2-174.9)	Female	15	17.6	85.5	(47.8-141.0)
Female	6	5.1	118.3	(43.2-257.6)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	162	211.6	76.6	(65.2-89.3)
Male	5	6.0	82.8	(26.7-193.3)	Female	238	243.2	97.9	(85.8-111.1)
Female	3	2.1	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	19	27.8	68.2	(41.1-106.6)					
Female	36	32.0	112.6	(78.9-156.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Athol

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	20	14.9	134.2	(82.0-207.3)	Male	7	9.5	73.3	(29.4-151.1)
Female	1	4.6	nc	(nc-nc)	Female	4	6.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	2.7	nc	(nc-nc)	Male	2	3.1	nc	(nc-nc)
Female	0	2.1	nc	(nc-nc)	Female	0	2.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.5	nc	(nc-nc)	Male	3	8.4	nc	(nc-nc)
Female	43	52.5	81.9	(59.3-110.3)	Female	6	6.4	93.7	(34.2-203.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	1.7	nc	(nc-nc)	Male	6	7.2	83.2	(30.4-181.2)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	18	15.2	118.5	(70.2-187.3)	Female	4	4.5	nc	(nc-nc)
Female	16	13.5	118.3	(67.6-192.2)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	5	5.6	89.6	(28.9-209.1)
Male	6	3.9	154.4	(56.4-336.0)	Female	6	4.9	123.4	(45.1-268.6)
Female	0	0.9	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	30	47.4	63.2	(42.7-90.3)
Male	1	1.0	nc	(nc-nc)	<u>Stomach</u>				
Female	1	0.8	nc	(nc-nc)	Male	2	3.5	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	1.9	nc	(nc-nc)
Male	13	8.7	149.8	(79.7-256.2)	<u>Testis</u>				
Female	4	4.2	nc	(nc-nc)	Male	2	1.7	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	2.3	nc	(nc-nc)	Male	4	3.7	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	9	9.6	94.1	(42.9-178.6)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	5.9	nc	(nc-nc)	Female	19	11.9	159.1	(95.7-248.5)
Female	6	3.8	158.1	(57.7-344.1)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	180	192.3	93.6	(80.4-108.3)
Male	6	5.5	109.2	(39.9-237.7)	Female	174	174.9	99.5	(85.2-115.4)
Female	2	1.6	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	33	26.9	122.6	(84.4-172.2)					
Female	32	23.9	134.1	(91.7-189.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Attleboro

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	43	42.0	102.4	(74.1-138.0)	Male	29	28.3	102.6	(68.7-147.3)
Female	19	15.1	126.2	(76.0-197.1)	Female	23	22.8	101.0	(64.0-151.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	10	8.8	113.9	(54.5-209.4)	Male	5	9.0	55.7	(17.9-130.0)
Female	4	7.4	nc	(nc-nc)	Female	7	7.2	97.4	(39.0-200.7)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.5	nc	(nc-nc)	Male	15	25.0	59.9	(33.5-98.8)
Female	197	183.1	107.6	(93.1-123.7)	Female	19	21.5	88.4	(53.2-138.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	6.4	nc	(nc-nc)	Male	22	21.6	101.8	(63.8-154.2)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	51	46.1	110.5	(82.3-145.3)	Female	18	15.5	115.8	(68.6-183.0)
Female	42	44.2	95.1	(68.5-128.5)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	14	11.0	127.4	(69.6-213.7)	Male	23	15.9	144.6	(91.6-216.9)
Female	4	3.0	nc	(nc-nc)	Female	18	15.7	114.9	(68.0-181.6)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	8	3.5	226.6	(97.6-446.5)	Male	133	131.0	101.5	(85.0-120.3)
Female	2	3.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	21	26.3	79.9	(49.5-122.2)	Male	7	10.2	68.9	(27.6-142.0)
Female	9	14.3	63.0	(28.7-119.5)	Female	10	6.2	160.4	(76.8-294.9)
<u>Larynx</u>					<u>Testis</u>				
Male	11	6.4	171.3	(85.4-306.5)	Male	11	7.0	156.6	(78.1-280.3)
Female	3	2.0	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	16	17.8	89.9	(51.3-145.9)	Male	13	12.6	103.5	(55.1-177.1)
Female	10	12.7	78.7	(37.7-144.8)	Female	26	36.5	71.2	(46.5-104.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	11	15.4	71.2	(35.5-127.4)	Female	45	41.1	109.4	(79.8-146.4)
Female	9	5.1	174.9	(79.8-332.0)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	94	74.7	125.9	(101.7-154.1)	Male	577	557.8	103.4	(95.2-112.2)
Female	86	80.2	107.3	(85.8-132.5)	Female	623	598.8	104.0	(96.0-112.5)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Auburn

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	27	20.3	133.1	(87.7-193.6)	Male	19	12.6	151.0	(90.9-235.8)
Female	11	8.3	133.2	(66.4-238.4)	Female	11	10.5	104.5	(52.1-186.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	3.5	141.3	(45.5-329.8)	Male	4	4.1	nc	(nc-nc)
Female	6	3.4	177.8	(64.9-387.0)	Female	8	3.8	213.0	(91.7-419.7)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.7	nc	(nc-nc)	Male	11	11.2	98.5	(49.1-176.2)
Female	86	84.3	102.0	(81.6-125.9)	Female	12	11.0	109.2	(56.4-190.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	2.6	nc	(nc-nc)	Male	10	8.9	112.0	(53.6-206.0)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	19	20.9	90.9	(54.7-142.0)	Female	7	7.3	95.7	(38.4-197.3)
Female	21	23.2	90.5	(56.0-138.3)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	6	7.3	81.7	(29.8-177.9)
Male	5	4.9	102.2	(32.9-238.5)	Female	6	8.6	69.6	(25.4-151.4)
Female	2	1.6	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	57	56.4	101.1	(76.6-131.0)
Male	0	1.2	nc	(nc-nc)	<u>Stomach</u>				
Female	2	1.2	nc	(nc-nc)	Male	2	4.7	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	4	3.3	nc	(nc-nc)
Male	8	11.0	72.8	(31.3-143.4)	<u>Testis</u>				
Female	5	6.9	72.7	(23.4-169.7)	Male	1	2.3	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	8	2.9	280.5	(120.8-552.8)	Male	5	4.7	106.5	(34.3-248.4)
Female	0	0.9	nc	(nc-nc)	Female	9	14.2	63.4	(28.9-120.3)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	4	7.8	nc	(nc-nc)	Female	17	19.0	89.6	(52.2-143.5)
Female	10	6.3	158.3	(75.8-291.2)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	253	247.0	102.4	(90.2-115.8)
Male	7	6.7	104.8	(42.0-216.0)	Female	290	290.0	100.0	(88.8-112.2)
Female	0	2.7	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	32	34.8	92.0	(62.9-129.9)					
Female	49	42.1	116.3	(86.0-153.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Avon

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	8	5.9	135.5	(58.3-266.9)	Male	4	3.6	nc	(nc-nc)
Female	1	2.1	nc	(nc-nc)	Female	2	2.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.0	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	Female	2	1.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.2	nc	(nc-nc)	Male	9	3.2	281.3	(128.4-534.1)
Female	24	22.1	108.6	(69.6-161.6)	Female	2	2.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.7	nc	(nc-nc)	Male	0	2.6	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	7	6.0	116.1	(46.5-239.2)	Female	2	1.9	nc	(nc-nc)
Female	5	5.7	87.1	(28.1-203.2)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	2	1.4	nc	(nc-nc)	Male	9	16.7	53.8	(24.5-102.1)
Female	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	1	0.4	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	2	3.2	nc	(nc-nc)	Female	3	5.2	nc	(nc-nc)
Female	1	1.8	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Leukemia</u>				
Male	1	0.8	nc	(nc-nc)	Male	1	2.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	1.6	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Lung and Bronchus</u>				
Male	2	1.9	nc	(nc-nc)	Male	12	10.0	120.2	(62.0-209.9)
Female	0	0.7	nc	(nc-nc)	Female	14	11.4	122.5	(66.9-205.5)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Ayer

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	9	7.1	127.4	(58.1-241.9)	Male	4	5.1	nc	(nc-nc)
Female	3	2.5	nc	(nc-nc)	Female	4	3.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.6	nc	(nc-nc)	Male	2	1.6	nc	(nc-nc)
Female	2	1.2	nc	(nc-nc)	Female	2	1.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	1	4.5	nc	(nc-nc)
Female	37	29.8	124.2	(87.4-171.2)	Female	3	3.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	1.1	nc	(nc-nc)	Male	4	4.0	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	10	8.0	125.7	(60.2-231.2)	Female	3	2.5	nc	(nc-nc)
Female	14	7.4	189.7	(103.6-318.2)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	5	2.8	178.2	(57.4-415.9)
Male	6	2.0	301.0	(109.9-655.1)	Female	6	2.6	233.9	(85.4-509.1)
Female	0	0.5	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	24	23.9	100.2	(64.2-149.2)
Male	0	0.7	nc	(nc-nc)	<u>Stomach</u>				
Female	1	0.5	nc	(nc-nc)	Male	1	1.8	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	1.0	nc	(nc-nc)
Male	2	4.8	nc	(nc-nc)	<u>Testis</u>				
Female	4	2.3	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	1.2	nc	(nc-nc)	Male	1	2.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	4	6.5	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	4	3.1	nc	(nc-nc)	Female	13	6.4	201.8	(107.4-345.2)
Female	0	2.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	104	99.6	104.4	(85.3-126.5)
Male	4	2.9	nc	(nc-nc)	Female	125	98.5	126.9	(105.6-151.2)
Female	0	0.8	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	19	13.2	144.4	(86.9-225.4)					
Female	19	13.1	145.4	(87.5-227.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Barnstable

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	90	73.2	122.9	(98.8-151.0)	Male	69	43.7	157.9	(122.9-199.9)
Female	28	24.0	116.6	(77.5-168.5)	Female	40	29.8	134.1	(95.8-182.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	16	11.6	137.4	(78.5-223.2)	Male	10	14.3	69.9	(33.5-128.5)
Female	10	9.6	104.3	(49.9-191.8)	Female	14	10.9	128.5	(70.2-215.6)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	5	2.4	206.9	(66.7-482.7)	Male	44	38.4	114.7	(83.3-154.0)
Female	310	246.8	125.6	(112.0-140.4)	Female	42	31.4	133.6	(96.3-180.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	6	7.1	84.9	(31.0-184.8)	Male	34	30.7	110.9	(76.8-155.0)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	56	70.8	79.1	(59.8-102.8)	Female	20	21.4	93.3	(57.0-144.2)
Female	60	64.6	92.9	(70.9-119.6)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	24	17.6	136.2	(87.2-202.6)	Male	29	26.1	111.1	(74.4-159.5)
Female	3	4.7	nc	(nc-nc)	Female	18	24.7	72.8	(43.1-115.1)
<u>Hodgkin Lymphoma</u>					<u>Stomach</u>				
Male	3	3.8	nc	(nc-nc)	Male	15	16.4	91.3	(51.1-150.6)
Female	0	3.1	nc	(nc-nc)	Female	13	9.1	142.1	(75.6-243.1)
<u>Kidney & Renal Pelvis</u>					<u>Testis</u>				
Male	32	37.5	85.3	(58.3-120.4)	Male	4	5.9	nc	(nc-nc)
Female	15	20.4	73.6	(41.1-121.3)	<u>Thyroid</u>				
<u>Larynx</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	5	10.1	49.5	(15.9-115.4)	Female	45	58.1	77.5	(56.5-103.7)
Female	0	2.9	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	33	27.1	121.8	(83.8-171.0)	Male	884	871.9	101.4	(94.8-108.3)
Female	29	18.0	161.5	(108.1-231.9)	Female	872	842.9	103.4	(96.7-110.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	31	23.9	129.6	(88.1-184.0)	Female	45	58.1	77.5	(56.5-103.7)
Female	7	7.9	89.0	(35.7-183.5)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					<u>All Sites / Types</u>				
Male	95	126.7	75.0	(60.6-91.6)	Male	884	871.9	101.4	(94.8-108.3)
Female	107	127.6	83.9	(68.7-101.3)	Female	872	842.9	103.4	(96.7-110.6)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Barre

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	5.7	87.3	(28.1-203.7)	Male	1	3.7	nc	(nc-nc)
Female	2	2.2	nc	(nc-nc)	Female	6	3.2	190.0	(69.4-413.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.2	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	2	1.0	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	3	3.4	nc	(nc-nc)
Female	19	25.5	74.4	(44.8-116.2)	Female	1	3.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.8	nc	(nc-nc)	Male	4	2.9	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	10	6.1	163.0	(78.0-299.7)	Female	3	2.2	nc	(nc-nc)
Female	1	6.7	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	2	2.2	nc	(nc-nc)
Male	1	1.5	nc	(nc-nc)	Female	1	2.4	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	13	18.5	70.2	(37.3-120.0)
Male	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.3	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	0.9	nc	(nc-nc)
Male	0	3.4	nc	(nc-nc)	<u>Testis</u>				
Female	3	2.0	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.9	nc	(nc-nc)	Male	2	1.5	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	4.6	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	2.4	nc	(nc-nc)	Female	6	5.8	103.8	(37.9-225.9)
Female	2	1.8	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	55	75.4	72.9	(54.9-94.9)
Male	0	2.2	nc	(nc-nc)	Female	60	84.9	70.7	(53.9-91.0)
Female	0	0.8	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	7	10.0	69.9	(28.0-144.0)					
Female	6	11.2	53.5	(19.5-116.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Becket

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	3.1	162.7	(52.4-379.7)	Male	1	1.9	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.5	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	1.7	nc	(nc-nc)
Female	8	10.2	78.5	(33.8-154.7)	Female	2	1.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	3	1.4	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	4	3.0	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
Female	2	2.5	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	0	1.1	nc	(nc-nc)
Male	2	0.8	nc	(nc-nc)	Female	2	0.9	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	5	9.5	52.5	(16.9-122.5)
Male	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.4	nc	(nc-nc)
Male	1	1.7	nc	(nc-nc)	<u>Testis</u>				
Female	0	0.8	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.5	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	1.6	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	1.1	nc	(nc-nc)	Female	5	2.4	206.9	(66.7-482.8)
Female	0	0.7	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	33	38.3	86.0	(59.2-120.9)
Male	1	1.1	nc	(nc-nc)	Female	27	33.6	80.3	(52.9-116.8)
Female	0	0.3	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	3	5.6	nc	(nc-nc)					
Female	4	5.0	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Bedford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	23	19.6	117.3	(74.3-176.0)	Male	14	12.0	116.3	(63.5-195.1)
Female	6	5.9	101.3	(37.0-220.4)	Female	11	8.1	136.5	(68.1-244.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	3.3	153.0	(49.3-357.1)	Male	6	3.8	159.6	(58.3-347.4)
Female	0	2.6	nc	(nc-nc)	Female	2	2.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.6	nc	(nc-nc)	Male	15	10.5	143.3	(80.1-236.3)
Female	71	64.1	110.8	(86.5-139.8)	Female	7	8.0	87.6	(35.1-180.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	2.1	nc	(nc-nc)	Male	7	8.1	86.2	(34.5-177.6)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	16	19.9	80.5	(46.0-130.7)	Female	5	5.5	90.4	(29.1-211.0)
Female	14	17.2	81.3	(44.4-136.5)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	4	4.5	nc	(nc-nc)	Male	58	47.8	121.4	(92.2-156.9)
Female	2	1.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	1	1.1	nc	(nc-nc)	Male	2	2.1	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	7	10.0	69.9	(28.0-144.0)	Female	6	13.8	43.4	(15.9-94.5)
Female	1	5.2	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Liver and Intrahepatic Bile Ducts</u>				
Male	1	2.5	nc	(nc-nc)	Male	6	6.1	98.7	(36.0-214.8)
Female	0	0.7	nc	(nc-nc)	Female	1	1.9	nc	(nc-nc)
<u>Leukemia</u>					<u>Lung and Bronchus</u>				
Male	7	7.5	92.8	(37.2-191.2)	Male	24	33.1	72.6	(46.5-108.0)
Female	5	4.8	104.8	(33.8-244.6)	Female	27	30.4	88.9	(58.6-129.3)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Belchertown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	7	14.4	48.8	(19.5-100.5)	Male	6	9.9	60.5	(22.1-131.6)
Female	3	5.0	nc	(nc-nc)	Female	6	7.9	76.0	(27.8-165.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	3.1	195.4	(71.4-425.4)	Male	5	3.2	157.1	(50.6-366.5)
Female	0	2.6	nc	(nc-nc)	Female	4	2.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.5	nc	(nc-nc)	Male	7	8.7	80.3	(32.2-165.5)
Female	70	65.4	107.0	(83.4-135.2)	Female	14	7.3	190.9	(104.3-320.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	2.3	nc	(nc-nc)	Male	6	8.1	74.4	(27.2-162.0)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	15	16.1	93.3	(52.2-153.9)	Female	4	5.4	nc	(nc-nc)
Female	14	14.9	94.3	(51.5-158.2)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	2	4.0	nc	(nc-nc)	Male	51	50.5	101.0	(75.2-132.9)
Female	1	1.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	0	1.1	nc	(nc-nc)	Male	2	2.0	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	7	9.6	73.0	(29.2-150.4)	Female	22	14.7	149.3	(93.5-226.1)
Female	3	5.0	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Leukemia</u>				
Male	2	2.4	nc	(nc-nc)	Male	5	6.1	81.4	(26.2-190.0)
Female	0	0.7	nc	(nc-nc)	Female	3	4.3	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Lung and Bronchus</u>				
Male	2	5.8	nc	(nc-nc)	Male	13	26.7	48.7	(25.9-83.3)
Female	1	1.8	nc	(nc-nc)	Female	20	27.5	72.7	(44.4-112.3)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Bellingham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	14	14.4	97.5	(53.3-163.6)	Male	11	9.9	110.9	(55.3-198.4)
Female	3	5.0	nc	(nc-nc)	Female	9	7.9	114.0	(52.0-216.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	3.1	nc	(nc-nc)	Male	8	3.2	251.3	(108.2-495.2)
Female	5	2.6	195.7	(63.1-456.8)	Female	1	2.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.5	nc	(nc-nc)	Male	19	8.7	218.0	(131.2-340.4)
Female	74	65.4	113.1	(88.8-142.0)	Female	10	7.3	136.4	(65.3-250.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	2.3	nc	(nc-nc)	Male	7	8.1	86.8	(34.8-178.9)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	21	16.1	130.6	(80.8-199.6)	Female	4	5.4	nc	(nc-nc)
Female	17	14.9	114.5	(66.6-183.3)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	8	5.7	141.4	(60.9-278.6)
Male	4	4.0	nc	(nc-nc)	Female	13	5.2	250.1	(133.0-427.7)
Female	2	1.0	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	74	50.5	146.6	(115.1-184.1)
Male	1	1.1	nc	(nc-nc)	<u>Stomach</u>				
Female	1	1.0	nc	(nc-nc)	Male	5	3.6	140.4	(45.2-327.6)
<u>Kidney & Renal Pelvis</u>					Female	1	2.1	nc	(nc-nc)
Male	10	9.6	104.3	(49.9-191.8)	<u>Testis</u>				
Female	5	5.0	99.9	(32.2-233.0)	Male	3	2.0	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	2.4	nc	(nc-nc)	Male	5	4.3	115.4	(37.2-269.2)
Female	0	0.7	nc	(nc-nc)	Female	17	12.9	131.7	(76.7-210.8)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	5	6.1	81.4	(26.2-190.0)	Female	16	14.7	108.6	(62.0-176.4)
Female	7	4.3	164.5	(65.9-338.9)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	250	200.4	124.7	(109.7-141.2)
Male	5	5.8	85.8	(27.7-200.2)	Female	226	208.2	108.6	(94.9-123.7)
Female	0	1.8	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	30	26.7	112.4	(75.8-160.5)					
Female	27	27.5	98.1	(64.6-142.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Belmont

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	24	29.3	81.9	(52.5-121.9)	Male	18	18.3	98.4	(58.3-155.5)
Female	4	10.5	nc	(nc-nc)	Female	7	14.8	47.4	(19.0-97.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	5.2	114.5	(41.8-249.2)	Male	3	5.9	nc	(nc-nc)
Female	2	4.8	nc	(nc-nc)	Female	4	4.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	5	1.0	498.5	(160.7-1163.4)	Male	17	16.2	104.9	(61.1-168.0)
Female	129	118.2	109.1	(91.1-129.7)	Female	9	14.5	62.3	(28.4-118.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	4.0	nc	(nc-nc)	Male	5	13.0	38.4	(12.4-89.6)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	24	30.1	79.6	(51.0-118.5)	Female	14	10.1	138.3	(75.5-232.0)
Female	25	30.5	81.9	(53.0-121.0)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	4	7.1	nc	(nc-nc)	Male	77	82.2	93.7	(73.9-117.1)
Female	5	2.0	244.0	(78.6-569.4)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	2	1.9	nc	(nc-nc)	Male	7	3.7	188.1	(75.4-387.6)
Female	1	1.8	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	12	16.0	74.8	(38.6-130.7)	Female	24	26.2	91.7	(58.7-136.5)
Female	7	9.4	74.4	(29.8-153.2)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Leukemia</u>				
Male	2	4.1	nc	(nc-nc)	Male	5	11.5	43.6	(14.0-101.7)
Female	0	1.3	nc	(nc-nc)	Female	5	8.6	58.1	(18.7-135.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Lung and Bronchus</u>				
Male	5	9.7	51.8	(16.7-120.8)	Male	39	50.1	77.9	(55.4-106.5)
Female	1	3.5	nc	(nc-nc)	Female	41	54.9	74.6	(53.6-101.3)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Berkley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	7.2	nc	(nc-nc)	Male	5	4.8	104.9	(33.8-244.7)
Female	0	1.6	nc	(nc-nc)	Female	5	3.0	164.2	(52.9-383.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.5	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
Female	2	1.0	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	4.2	nc	(nc-nc)
Female	24	25.8	93.0	(59.6-138.4)	Female	6	2.6	227.6	(83.1-495.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	1.0	nc	(nc-nc)	Male	4	3.7	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	10	7.6	131.9	(63.2-242.7)	Female	0	2.1	nc	(nc-nc)
Female	7	5.1	137.4	(55.0-283.0)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	1	1.9	nc	(nc-nc)	Male	15	23.5	63.8	(35.7-105.2)
Female	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	0	0.5	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	4	4.5	nc	(nc-nc)	Female	8	5.7	140.4	(60.5-276.7)
Female	2	1.9	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	1.1	nc	(nc-nc)	Female	73	95.9	76.1	(59.7-95.7)
Female	0	0.2	nc	(nc-nc)	Female	77	77.9	98.9	(78.0-123.6)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	4	3.0	nc	(nc-nc)	<u>All Sites / Types</u>				
Female	3	1.5	nc	(nc-nc)	Male	73	95.9	76.1	(59.7-95.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	2	2.7	nc	(nc-nc)	Female	77	77.9	98.9	(78.0-123.6)
Female	0	0.6	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					<u>All Sites / Types</u>				
Male	13	13.3	97.5	(51.9-166.7)	Male	73	95.9	76.1	(59.7-95.7)
Female	4	9.4	nc	(nc-nc)	Female	77	77.9	98.9	(78.0-123.6)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Berlin

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	4.8	nc	(nc-nc)	Male	6	2.9	210.1	(76.7-457.3)
Female	1	1.3	nc	(nc-nc)	Female	2	1.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.8	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.2	nc	(nc-nc)	Male	0	2.5	nc	(nc-nc)
Female	16	15.0	107.0	(61.1-173.8)	Female	1	1.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.5	nc	(nc-nc)	Male	1	2.0	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	3	4.8	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
Female	3	3.5	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	1	1.7	nc	(nc-nc)
Male	4	1.1	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	11	13.1	84.1	(41.9-150.5)
Male	2	0.3	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.5	nc	(nc-nc)
Male	2	2.4	nc	(nc-nc)	<u>Testis</u>				
Female	1	1.2	nc	(nc-nc)	Male	2	0.4	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.6	nc	(nc-nc)	Male	2	1.0	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	2	2.6	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	1.8	nc	(nc-nc)	Female	4	3.5	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	54	56.6	95.4	(71.6-124.4)
Male	1	1.5	nc	(nc-nc)	Female	40	48.4	82.6	(59.0-112.5)
Female	0	0.4	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	8	8.1	99.0	(42.6-195.0)					
Female	5	6.8	73.0	(23.5-170.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Bernardston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	3.8	nc	(nc-nc)	Male	3	2.2	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)	Female	2	1.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.6	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	5	2.0	255.4	(82.3-596.1)
Female	14	12.3	113.7	(62.1-190.8)	Female	3	1.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.4	nc	(nc-nc)	Male	0	1.5	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	5	3.7	134.8	(43.5-314.7)	Female	1	1.0	nc	(nc-nc)
Female	3	3.0	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	1	1.3	nc	(nc-nc)
Male	1	0.9	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	10	10.2	98.2	(47.0-180.6)
Male	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.4	nc	(nc-nc)
Male	1	1.9	nc	(nc-nc)	<u>Testis</u>				
Female	2	1.0	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	0.5	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	2.0	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	1.4	nc	(nc-nc)	Female	3	2.9	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	35	43.8	79.8	(55.6-111.0)
Male	0	1.2	nc	(nc-nc)	Female	42	40.5	103.8	(74.8-140.3)
Female	1	0.4	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	5	6.3	79.5	(25.6-185.5)					
Female	5	5.8	85.5	(27.6-199.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Beverly

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	49	42.2	116.1	(85.9-153.5)	Male	38	26.9	141.3	(100.0-193.9)
Female	19	16.7	114.1	(68.6-178.1)	Female	27	23.0	117.1	(77.2-170.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	10	8.0	125.2	(59.9-230.2)	Male	10	8.6	116.7	(55.8-214.5)
Female	5	7.6	65.7	(21.2-153.4)	Female	6	7.7	77.5	(28.3-168.7)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	4	1.5	nc	(nc-nc)	Male	26	23.8	109.2	(71.3-160.0)
Female	177	183.9	96.2	(82.6-111.5)	Female	19	22.7	83.6	(50.3-130.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	6	6.0	100.8	(36.8-219.4)	Male	26	19.9	130.5	(85.2-191.2)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	37	43.8	84.5	(59.5-116.5)	Female	12	15.9	75.3	(38.9-131.6)
Female	51	47.5	107.3	(79.9-141.1)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	18	15.6	115.5	(68.4-182.6)
Male	10	10.6	94.0	(45.0-172.8)	Female	19	17.6	108.0	(65.0-168.7)
Female	4	3.3	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	137	128.5	106.6	(89.5-126.1)
Male	1	3.1	nc	(nc-nc)	<u>Stomach</u>				
Female	2	3.0	nc	(nc-nc)	Male	4	9.9	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	3	6.7	nc	(nc-nc)
Male	29	24.2	119.9	(80.3-172.3)	<u>Testis</u>				
Female	13	14.7	88.5	(47.1-151.3)	Male	7	5.8	121.6	(48.7-250.5)
<u>Larynx</u>					<u>Thyroid</u>				
Male	6	6.2	97.5	(35.6-212.2)	Male	20	10.8	185.5	(113.3-286.5)
Female	2	2.1	nc	(nc-nc)	Female	35	33.8	103.5	(72.1-143.9)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	24	17.0	140.8	(90.2-209.5)	Female	33	42.3	78.0	(53.7-109.5)
Female	21	13.4	156.2	(96.7-238.9)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	604	537.3	112.4	(103.6-121.8)
Male	12	14.9	80.7	(41.6-140.9)	Female	633	620.7	102.0	(94.2-110.3)
Female	6	5.5	108.4	(39.6-236.0)					
<u>Lung and Bronchus</u>									
Male	80	73.6	108.8	(86.2-135.4)					
Female	95	86.4	109.9	(88.9-134.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Billerica

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	52	42.3	122.8	(91.7-161.1)	Male	26	28.4	91.7	(59.9-134.4)
Female	18	15.4	117.1	(69.4-185.1)	Female	27	22.0	122.9	(81.0-178.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	10	8.7	114.7	(54.9-211.0)	Male	8	9.1	88.2	(38.0-173.8)
Female	5	7.2	69.3	(22.3-161.7)	Female	9	7.2	125.5	(57.3-238.3)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.5	nc	(nc-nc)	Male	29	25.1	115.6	(77.4-166.0)
Female	195	177.5	109.8	(95.0-126.4)	Female	22	21.3	103.2	(64.6-156.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	6	5.9	100.9	(36.8-219.6)	Male	19	22.0	86.4	(52.0-134.9)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	37	46.6	79.4	(55.9-109.4)	Female	11	15.1	72.8	(36.3-130.2)
Female	59	43.9	134.5	(102.4-173.5)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	11	16.1	68.5	(34.1-122.5)
Male	14	11.2	125.0	(68.3-209.7)	Female	12	16.0	75.0	(38.7-131.0)
Female	1	3.0	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	129	135.9	94.9	(79.2-112.8)
Male	6	3.5	170.8	(62.4-371.7)	<u>Stomach</u>				
Female	2	2.9	nc	(nc-nc)	Male	7	10.2	68.3	(27.4-140.7)
<u>Kidney & Renal Pelvis</u>					Female	8	6.2	129.9	(55.9-255.9)
Male	33	26.5	124.5	(85.7-174.9)	<u>Testis</u>				
Female	7	14.1	49.7	(19.9-102.5)	Male	5	6.9	72.8	(23.5-170.0)
<u>Larynx</u>					<u>Thyroid</u>				
Male	3	6.5	nc	(nc-nc)	Male	16	12.4	129.0	(73.7-209.6)
Female	0	2.0	nc	(nc-nc)	Female	40	33.7	118.7	(84.8-161.6)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	24	17.7	135.8	(87.0-202.1)	Female	43	40.3	106.7	(77.2-143.8)
Female	20	12.6	159.2	(97.2-245.9)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	567	565.4	100.3	(92.2-108.9)
Male	12	15.9	75.6	(39.0-132.0)	Female	644	588.8	109.4	(101.1-118.1)
Female	3	5.1	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	82	75.3	108.9	(86.6-135.1)					
Female	108	82.0	131.8	(108.1-159.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Blackstone

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	11	8.0	137.8	(68.7-246.6)	Male	6	5.6	107.9	(39.4-234.9)
Female	4	3.1	nc	(nc-nc)	Female	6	5.0	119.1	(43.5-259.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	1.7	nc	(nc-nc)	Male	2	1.8	nc	(nc-nc)
Female	1	1.6	nc	(nc-nc)	Female	2	1.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.3	nc	(nc-nc)	Male	4	4.9	nc	(nc-nc)
Female	30	41.7	72.0	(48.6-102.8)	Female	3	4.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.5	nc	(nc-nc)	Male	2	4.6	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	9	9.1	99.1	(45.2-188.1)	Female	6	3.5	173.0	(63.2-376.6)
Female	7	9.5	73.8	(29.5-152.0)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	1	3.2	nc	(nc-nc)
Male	4	2.2	nc	(nc-nc)	Female	3	3.3	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	31	27.9	110.9	(75.4-157.5)
Male	1	0.6	nc	(nc-nc)	<u>Stomach</u>				
Female	2	0.7	nc	(nc-nc)	Male	2	2.0	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	1.3	nc	(nc-nc)
Male	1	5.3	nc	(nc-nc)	<u>Testis</u>				
Female	4	3.1	nc	(nc-nc)	Male	3	1.2	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	1.3	nc	(nc-nc)	Male	1	2.5	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	4	8.3	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	4	3.4	nc	(nc-nc)	Female	5	9.5	52.8	(17.0-123.3)
Female	7	2.7	262.8	(105.3-541.6)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	122	112.0	109.0	(90.5-130.1)
Male	3	3.4	nc	(nc-nc)	Female	124	131.9	94.0	(78.2-112.1)
Female	0	1.1	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	20	14.6	137.1	(83.7-211.8)					
Female	14	16.9	83.0	(45.3-139.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Blandford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	1.4	nc	(nc-nc)	Male	3	1.0	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	7	5.7	123.8	(49.6-255.2)	Female	0	0.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.2	nc	(nc-nc)	Male	2	0.8	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	0	1.6	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
Female	2	1.3	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	1	0.4	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Female	1	0.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male				
Male	0	0.1	nc	(nc-nc)	Female	3	5.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	1	1.0	nc	(nc-nc)	Female	1	0.2	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male				
Male	1	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	2	0.6	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Female				
Male	0	0.6	nc	(nc-nc)	Male	17	20.6	82.5	(48.1-132.2)
Female	0	0.2	nc	(nc-nc)	Female	22	17.8	123.6	(77.4-187.1)
<u>Lung and Bronchus</u>					<u>All Sites / Types</u>				
Male	2	2.6	nc	(nc-nc)					
Female	4	2.4	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Bolton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	4.9	nc	(nc-nc)	Male	2	3.4	nc	(nc-nc)
Female	0	1.4	nc	(nc-nc)	Female	2	2.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.0	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	2	0.8	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	7	3.0	235.8	(94.5-485.9)
Female	29	21.2	137.0	(91.7-196.7)	Female	2	2.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.8	nc	(nc-nc)	Male	5	2.7	184.6	(59.5-430.7)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	4	5.6	nc	(nc-nc)	Female	2	1.7	nc	(nc-nc)
Female	8	4.3	186.6	(80.4-367.8)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	1	1.3	nc	(nc-nc)	Male	15	16.0	94.0	(52.6-155.1)
Female	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	1	0.4	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	5	3.2	155.1	(50.0-362.0)	Female	4	4.9	nc	(nc-nc)
Female	0	1.6	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Leukemia</u>				
Male	1	0.8	nc	(nc-nc)	Male	2	2.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Lung and Bronchus</u>				
Male	1	1.9	nc	(nc-nc)	Male	2	8.7	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	3	7.9	nc	(nc-nc)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Boston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	359	478.0	75.1	(67.5-83.3)	Male	238	320.2	74.3	(65.2-84.4)
Female	146	184.8	79.0	(66.7-92.9)	Female	223	281.6	79.2	(69.1-90.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	84	108.4	77.5	(61.8-95.9)	Male	113	99.9	113.1	(93.2-135.9)
Female	74	98.2	75.4	(59.2-94.6)	Female	128	86.3	148.3	(123.7-176.4)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	20	17.0	117.5	(71.7-181.5)	Male	264	289.1	91.3	(80.6-103.0)
Female	1951	2117.3	92.1	(88.1-96.3)	Female	258	262.3	98.4	(86.7-111.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	95	75.4	126.0	(101.9-154.0)	Male	271	237.4	114.2	(101.0-128.6)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	555	513.5	108.1	(99.3-117.5)	Female	181	187.1	96.7	(83.1-111.9)
Female	545	534.1	102.0	(93.7-111.0)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	174	178.5	97.5	(83.5-113.1)
Male	122	122.7	99.4	(82.6-118.7)	Female	187	191.6	97.6	(84.1-112.6)
Female	26	36.1	72.1	(47.1-105.6)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	1737	1459.5	119.0	(113.5-124.7)
Male	49	54.9	89.2	(66.0-118.0)	<u>Stomach</u>				
Female	39	52.1	74.9	(53.3-102.4)	Male	170	114.0	149.2	(127.6-173.4)
<u>Kidney & Renal Pelvis</u>					Female	123	75.6	162.7	(135.2-194.1)
Male	255	288.7	88.3	(77.8-99.8)	<u>Testis</u>				
Female	167	170.1	98.2	(83.9-114.3)	Male	95	110.4	86.0	(69.6-105.1)
<u>Larynx</u>					<u>Thyroid</u>				
Male	90	71.5	125.8	(101.2-154.7)	Male	140	146.8	95.4	(80.2-112.6)
Female	21	23.0	91.1	(56.4-139.3)	Female	436	462.7	94.2	(85.6-103.5)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	185	212.0	87.3	(75.1-100.8)	Female	447	478.2	93.5	(85.0-102.5)
Female	151	162.4	93.0	(78.7-109.0)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	6566	6345.0	103.5	(101.0-106.0)
Male	254	173.3	146.5	(129.1-165.7)	Female	6881	7198.6	95.6	(93.3-97.9)
Female	99	63.1	157.0	(127.6-191.1)					
<u>Lung and Bronchus</u>									
Male	872	839.4	103.9	(97.1-111.0)					
Female	880	968.2	90.9	(85.0-97.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Bourne

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	41	28.4	144.6	(103.7-196.1)	Male	32	17.2	185.8	(127.1-262.3)
Female	10	10.4	95.9	(45.9-176.3)	Female	16	13.0	123.3	(70.4-200.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	4.7	nc	(nc-nc)	Male	8	5.6	142.4	(61.3-280.7)
Female	3	4.1	nc	(nc-nc)	Female	3	4.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.0	nc	(nc-nc)	Male	12	15.3	78.6	(40.6-137.4)
Female	87	105.8	82.3	(65.9-101.5)	Female	10	13.7	73.1	(35.0-134.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	3.1	nc	(nc-nc)	Male	17	12.1	141.0	(82.1-225.7)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	28	28.1	99.5	(66.1-143.8)	Female	12	9.2	130.4	(67.3-227.8)
Female	29	28.9	100.2	(67.1-144.0)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	8	10.2	78.5	(33.8-154.7)
Male	8	6.8	117.4	(50.6-231.4)	Female	12	11.0	109.5	(56.5-191.3)
Female	2	2.0	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	82	78.9	103.9	(82.7-129.0)
Male	0	1.6	nc	(nc-nc)	<u>Stomach</u>				
Female	0	1.3	nc	(nc-nc)	Male	9	6.4	139.7	(63.8-265.3)
<u>Kidney & Renal Pelvis</u>					Female	6	4.1	146.8	(53.6-319.4)
Male	13	14.8	87.6	(46.6-149.8)	<u>Testis</u>				
Female	10	8.7	115.4	(55.2-212.2)	Male	3	2.6	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	11	4.0	276.7	(138.0-495.2)	Male	5	6.0	83.6	(26.9-195.1)
Female	4	1.2	nc	(nc-nc)	Female	23	16.9	136.1	(86.2-204.2)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	7	10.7	65.3	(26.2-134.6)	Female	22	24.4	90.1	(56.4-136.4)
Female	6	7.9	76.4	(27.9-166.3)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	378	340.7	111.0	(100.0-122.7)
Male	8	9.3	85.8	(36.9-169.0)	Female	345	363.8	94.8	(85.1-105.4)
Female	3	3.4	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	54	49.1	110.0	(82.6-143.5)					
Female	56	53.8	104.2	(78.7-135.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Boxborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	4.9	nc	(nc-nc)	Male	2	3.4	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)	Female	4	2.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.0	nc	(nc-nc)	Male	3	1.1	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.2	nc	(nc-nc)	Male	5	3.0	167.5	(54.0-391.0)
Female	22	21.2	103.6	(64.9-156.9)	Female	1	2.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.8	nc	(nc-nc)	Male	3	2.8	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	3	5.7	nc	(nc-nc)	Female	0	1.7	nc	(nc-nc)
Female	5	4.3	117.1	(37.7-273.2)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	1	1.4	nc	(nc-nc)	Male	16	17.5	91.7	(52.4-148.9)
Female	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	0	0.4	nc	(nc-nc)	Male	2	0.7	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	2	3.3	nc	(nc-nc)	Female	2	4.7	nc	(nc-nc)
Female	0	1.5	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Leukemia</u>				
Male	0	0.8	nc	(nc-nc)	Male	2	2.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	4	1.2	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Lung and Bronchus</u>				
Male	0	2.0	nc	(nc-nc)	Male	6	8.8	68.1	(24.9-148.3)
Female	0	0.5	nc	(nc-nc)	Female	8	7.7	103.7	(44.7-204.4)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Boxford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	8	9.8	82.0	(35.3-161.5)	Male	10	6.6	150.9	(72.3-277.6)
Female	2	3.3	nc	(nc-nc)	Female	11	4.7	233.9	(116.6-418.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.9	nc	(nc-nc)	Male	3	2.1	nc	(nc-nc)
Female	2	1.5	nc	(nc-nc)	Female	1	1.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	4	5.8	nc	(nc-nc)
Female	34	39.7	85.7	(59.3-119.7)	Female	5	4.6	109.8	(35.4-256.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.3	nc	(nc-nc)	Male	0	5.2	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	3	10.7	nc	(nc-nc)	Female	1	3.4	nc	(nc-nc)
Female	8	9.2	86.5	(37.3-170.5)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	0	2.6	nc	(nc-nc)	Male	3	3.8	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	4	3.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.6	nc	(nc-nc)	Male	36	32.4	111.0	(77.8-153.7)
Female	2	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	4	6.3	nc	(nc-nc)	Male	2	2.4	nc	(nc-nc)
Female	2	3.1	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	2	1.6	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	5	3.9	127.1	(41.0-296.7)	Male	2	2.8	nc	(nc-nc)
Female	3	2.6	nc	(nc-nc)	Female	10	7.3	137.3	(65.7-252.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	3.8	nc	(nc-nc)	Female	7	9.2	76.0	(30.4-156.5)
Female	0	1.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	8	17.9	44.8	(19.3-88.2)	Male	99	131.8	75.1	(61.0-91.4)
Female	13	17.7	73.2	(39.0-125.3)	Female	120	128.4	93.5	(77.5-111.8)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Boylston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	5.6	nc	(nc-nc)	Male	4	3.5	nc	(nc-nc)
Female	2	1.8	nc	(nc-nc)	Female	6	2.6	231.9	(84.7-504.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.0	nc	(nc-nc)	Male	2	1.1	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	3	3.1	nc	(nc-nc)
Female	26	20.7	125.8	(82.1-184.3)	Female	0	2.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.7	nc	(nc-nc)	Male	4	2.6	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	5	5.9	85.0	(27.4-198.3)	Female	1	1.8	nc	(nc-nc)
Female	8	5.4	149.1	(64.2-293.7)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	1	1.4	nc	(nc-nc)	Male	16	16.4	97.3	(55.6-158.0)
Female	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	1	0.4	nc	(nc-nc)	Male	2	0.6	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	3	3.2	nc	(nc-nc)	Female	4	4.7	nc	(nc-nc)
Female	1	1.6	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Leukemia</u>				
Male	0	0.8	nc	(nc-nc)	Male	1	2.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	1.5	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Lung and Bronchus</u>				
Male	0	2.0	nc	(nc-nc)	Male	5	9.6	52.1	(16.8-121.6)
Female	1	0.6	nc	(nc-nc)	Female	6	9.2	65.6	(23.9-142.7)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Braintree

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	41	40.5	101.3	(72.7-137.5)	Male	26	25.6	101.5	(66.3-148.8)
Female	17	17.3	98.5	(57.4-157.8)	Female	23	22.5	102.4	(64.9-153.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	7.5	66.5	(21.4-155.2)	Male	7	8.2	85.6	(34.3-176.4)
Female	7	7.2	96.8	(38.8-199.5)	Female	3	7.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.4	nc	(nc-nc)	Male	21	22.7	92.6	(57.3-141.6)
Female	194	175.3	110.6	(95.6-127.4)	Female	20	22.9	87.4	(53.4-135.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	6	5.7	105.7	(38.6-230.0)	Male	20	18.4	108.6	(66.3-167.7)
Female	6	5.7	105.7	(38.6-230.0)	Female	10	9.8	101.6	(48.6-186.8)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	46	41.8	109.9	(80.5-146.6)	Female	16	15.3	104.3	(59.6-169.5)
Female	64	49.2	130.1	(100.2-166.2)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	14	14.7	95.2	(52.0-159.7)
Male	9	9.9	90.7	(41.4-172.2)	Female	19	18.2	104.6	(62.9-163.3)
Female	6	3.3	182.3	(66.6-396.8)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	120	114.1	105.2	(87.2-125.8)
Male	6	2.9	207.7	(75.8-452.0)	<u>Stomach</u>				
Female	4	2.6	nc	(nc-nc)	Male	9	9.4	96.1	(43.9-182.5)
<u>Kidney & Renal Pelvis</u>					Female	7	7.0	100.5	(40.2-207.0)
Male	25	22.5	111.3	(72.0-164.3)	<u>Testis</u>				
Female	12	14.4	83.6	(43.2-146.1)	Male	6	5.5	109.8	(40.1-239.1)
<u>Larynx</u>					<u>Thyroid</u>				
Male	4	5.7	nc	(nc-nc)	Male	10	10.1	99.4	(47.6-182.8)
Female	4	2.0	nc	(nc-nc)	Female	29	31.2	93.0	(62.2-133.5)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	8	16.2	49.5	(21.3-97.4)	Female	48	38.7	123.9	(91.4-164.3)
Female	17	13.7	124.1	(72.3-198.8)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	500	501.4	99.7	(91.2-108.9)
Male	16	13.8	116.2	(66.4-188.7)	Female	651	608.0	107.1	(99.0-115.6)
Female	4	5.5	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	66	69.5	95.0	(73.5-120.9)					
Female	88	86.9	101.3	(81.3-124.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Brewster

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	16	19.7	81.4	(46.5-132.2)	Male	18	11.6	155.0	(91.8-244.9)
Female	6	7.1	84.3	(30.8-183.4)	Female	8	8.1	98.4	(42.4-193.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	2.9	nc	(nc-nc)	Male	3	3.9	nc	(nc-nc)
Female	1	2.5	nc	(nc-nc)	Female	1	3.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.7	nc	(nc-nc)	Male	12	10.1	119.2	(61.5-208.2)
Female	96	67.9	141.3	(114.5-172.6)	Female	17	9.0	189.0	(110.1-302.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.8	nc	(nc-nc)	Male	5	8.1	61.7	(19.9-144.0)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	10	18.7	53.6	(25.7-98.6)	Female	7	5.9	117.9	(47.2-242.8)
Female	15	19.1	78.7	(44.0-129.8)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	4	7.0	nc	(nc-nc)
Male	5	4.8	104.6	(33.7-244.1)	Female	3	7.5	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	55	55.6	98.9	(74.5-128.7)
Male	0	0.8	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.7	nc	(nc-nc)	Male	1	4.4	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	2.7	nc	(nc-nc)
Male	4	10.0	nc	(nc-nc)	<u>Testis</u>				
Female	6	5.7	105.4	(38.5-229.5)	Male	1	1.1	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	2.8	nc	(nc-nc)	Male	2	3.6	nc	(nc-nc)
Female	2	0.8	nc	(nc-nc)	Female	5	9.3	54.0	(17.4-126.1)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	9	7.0	128.7	(58.7-244.4)	Female	16	16.2	98.6	(56.3-160.2)
Female	7	5.1	136.5	(54.7-281.3)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	205	232.3	88.3	(76.6-101.2)
Male	8	6.3	126.4	(54.4-249.1)	Female	239	237.3	100.7	(88.3-114.3)
Female	0	2.2	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	31	35.0	88.6	(60.2-125.7)					
Female	26	36.9	70.4	(46.0-103.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Bridgewater

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	26	27.6	94.1	(61.5-137.9)	Male	16	17.9	89.3	(51.0-145.1)
Female	11	8.0	136.7	(68.1-244.6)	Female	21	11.8	178.2	(110.2-272.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	5.5	nc	(nc-nc)	Male	3	5.7	nc	(nc-nc)
Female	6	4.1	145.5	(53.1-316.7)	Female	3	3.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.0	nc	(nc-nc)	Male	10	16.1	61.9	(29.6-113.9)
Female	87	96.3	90.3	(72.4-111.4)	Female	11	11.4	96.2	(48.0-172.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	3.2	nc	(nc-nc)	Male	13	13.5	96.1	(51.1-164.4)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	35	29.6	118.4	(82.5-164.7)	Female	9	8.2	109.5	(49.9-207.8)
Female	23	23.1	99.4	(63.0-149.1)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	12	10.3	116.3	(60.0-203.1)
Male	6	7.0	85.5	(31.2-186.1)	Female	9	8.3	107.8	(49.2-204.7)
Female	0	1.6	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	74	84.7	87.4	(68.6-109.7)
Male	2	2.3	nc	(nc-nc)	<u>Stomach</u>				
Female	0	1.7	nc	(nc-nc)	Male	5	6.5	76.6	(24.7-178.7)
<u>Kidney & Renal Pelvis</u>					Female	2	3.3	nc	(nc-nc)
Male	13	16.4	79.5	(42.3-136.0)	<u>Testis</u>				
Female	8	7.5	106.2	(45.7-209.2)	Male	2	4.2	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	4.1	nc	(nc-nc)	Male	9	7.6	118.8	(54.2-225.5)
Female	1	1.1	nc	(nc-nc)	Female	28	18.3	153.1	(101.7-221.3)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	8	11.6	69.2	(29.8-136.3)	Female	26	22.2	117.1	(76.4-171.5)
Female	4	6.7	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	333	357.7	93.1	(83.4-103.6)
Male	14	9.9	141.1	(77.1-236.8)	Female	319	316.1	100.9	(90.1-112.6)
Female	1	2.8	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	55	47.6	115.6	(87.1-150.5)					
Female	43	42.9	100.2	(72.5-135.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Brimfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	4.0	nc	(nc-nc)	Male	2	2.8	nc	(nc-nc)
Female	0	1.4	nc	(nc-nc)	Female	1	2.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.8	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	4	2.4	nc	(nc-nc)
Female	15	18.2	82.6	(46.2-136.2)	Female	5	2.0	247.1	(79.6-576.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.6	nc	(nc-nc)	Male	2	2.4	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	1	4.5	nc	(nc-nc)	Female	0	1.5	nc	(nc-nc)
Female	2	3.9	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	2	1.6	nc	(nc-nc)
Male	0	1.2	nc	(nc-nc)	Female	0	1.5	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	8	15.0	53.4	(23.0-105.2)
Male	2	0.3	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.2	nc	(nc-nc)	Male	2	1.0	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	0.6	nc	(nc-nc)
Male	6	2.7	219.2	(80.0-477.1)	<u>Testis</u>				
Female	1	1.4	nc	(nc-nc)	Male	2	0.6	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.7	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	3.2	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	3	1.7	nc	(nc-nc)	Female	3	4.4	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	51	57.1	89.3	(66.5-117.4)
Male	1	1.7	nc	(nc-nc)	Female	41	57.5	71.3	(51.1-96.7)
Female	0	0.5	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	6	7.5	79.8	(29.1-173.7)					
Female	5	7.9	63.0	(20.3-147.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Brockton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	85	86.8	98.0	(78.3-121.2)	Male	27	57.0	47.3	(31.2-68.9)
Female	32	33.0	96.8	(66.2-136.7)	Female	30	48.0	62.5	(42.1-89.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	16	18.0	89.1	(50.9-144.8)	Male	14	18.2	77.0	(42.1-129.2)
Female	21	15.9	131.8	(81.6-201.5)	Female	17	15.4	110.5	(64.4-177.0)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	3.1	nc	(nc-nc)	Male	45	50.9	88.4	(64.5-118.3)
Female	325	379.4	85.7	(76.6-95.5)	Female	40	45.9	87.1	(62.2-118.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	28	12.9	216.5	(143.8-312.8)	Male	41	43.2	94.9	(68.1-128.7)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	111	93.4	118.8	(97.7-143.1)	Female	40	32.8	122.1	(87.2-166.3)
Female	98	95.6	102.5	(83.2-125.0)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	25	22.3	112.1	(72.5-165.5)	Male	265	265.8	99.7	(88.1-112.5)
Female	8	6.5	123.9	(53.3-244.1)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	8	7.2	111.7	(48.1-220.1)	Male	13	13.7	94.8	(50.4-162.1)
Female	6	6.6	91.3	(33.3-198.7)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	72	52.1	138.1	(108.1-173.9)	Female	88	84.6	104.0	(83.4-128.1)
Female	30	30.3	99.1	(66.9-141.5)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Leukemia</u>				
Male	17	13.0	131.1	(76.3-209.9)	Male	26	36.9	70.5	(46.1-103.4)
Female	6	4.2	144.2	(52.7-314.0)	Female	18	27.8	64.7	(38.3-102.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Lung and Bronchus</u>				
Male	46	31.6	145.6	(106.6-194.2)	Male	182	151.0	120.5	(103.7-139.4)
Female	15	11.1	135.6	(75.8-223.6)	Female	205	174.1	117.8	(102.2-135.1)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Brookfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	3.8	132.8	(42.8-309.9)	Male	3	2.5	nc	(nc-nc)
Female	2	1.4	nc	(nc-nc)	Female	3	2.0	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.8	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	2.2	nc	(nc-nc)
Female	12	16.0	74.9	(38.7-130.9)	Female	4	2.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.5	nc	(nc-nc)	Male	0	1.9	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	2	3.9	nc	(nc-nc)	Female	2	1.4	nc	(nc-nc)
Female	4	4.0	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	2	1.0	nc	(nc-nc)	Male	15	13.0	115.5	(64.6-190.5)
Female	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	1	0.3	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	2	2.4	nc	(nc-nc)	Female	2	3.7	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Leukemia</u>				
Male	0	0.6	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Lung and Bronchus</u>				
Male	1	1.5	nc	(nc-nc)	Male	10	7.0	143.0	(68.5-263.1)
Female	2	0.5	nc	(nc-nc)	Female	18	7.6	235.4	(139.4-372.0)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Brookline

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	47	55.9	84.1	(61.8-111.8)	Male	51	35.5	143.6	(106.9-188.8)
Female	16	22.4	71.3	(40.7-115.8)	Female	32	31.2	102.7	(70.2-145.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	8	10.8	74.3	(32.0-146.3)	Male	9	11.4	79.0	(36.1-150.0)
Female	14	10.7	131.4	(71.8-220.6)	Female	7	10.3	67.9	(27.2-139.9)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.9	nc	(nc-nc)	Male	35	31.5	111.0	(77.3-154.3)
Female	222	242.6	91.5	(79.9-104.4)	Female	36	30.5	118.1	(82.7-163.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	7.9	nc	(nc-nc)	Male	29	25.9	112.0	(75.0-160.9)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	30	56.9	52.8	(35.6-75.3)	Female	31	21.3	145.4	(98.8-206.4)
Female	41	62.4	65.7	(47.2-89.2)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	18	20.5	87.6	(51.9-138.5)
Male	4	14.1	nc	(nc-nc)	Female	26	23.5	110.6	(72.2-162.1)
Female	3	4.5	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	155	169.7	91.3	(77.5-106.9)
Male	6	4.6	129.6	(47.3-282.0)	<u>Stomach</u>				
Female	7	5.0	139.0	(55.7-286.5)	Male	10	13.0	76.9	(36.8-141.5)
<u>Kidney & Renal Pelvis</u>					Female	6	8.9	67.7	(24.7-147.3)
Male	31	31.7	97.7	(66.4-138.7)	<u>Testis</u>				
Female	16	19.8	81.0	(46.2-131.5)	Male	12	8.7	137.2	(70.8-239.7)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	8.2	nc	(nc-nc)	Male	16	14.3	112.1	(64.0-182.0)
Female	2	2.8	nc	(nc-nc)	Female	46	46.9	98.2	(71.9-131.0)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	33	22.6	145.8	(100.4-204.8)	Female	46	56.4	81.5	(59.7-108.8)
Female	22	18.6	118.6	(74.3-179.5)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	607	711.1	85.4	(78.7-92.4)
Male	12	19.2	62.4	(32.2-108.9)	Female	740	832.1	88.9	(82.6-95.6)
Female	3	7.4	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	47	98.6	47.7	(35.0-63.4)					
Female	74	118.3	62.5	(49.1-78.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Buckland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	2.5	nc	(nc-nc)	Male	2	1.5	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	Female	2	1.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	0.4	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	4	10.5	nc	(nc-nc)	Female	0	1.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.3	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	2	2.5	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
Female	4	2.5	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	0	0.6	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	7	7.6	91.6	(36.7-188.8)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	3	1.4	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	0	1.0	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	1	1.7	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	0.9	nc	(nc-nc)	Female	0	2.5	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	1	4.4	nc	(nc-nc)	Male	24	31.1	77.3	(49.5-115.0)
Female	7	5.1	137.8	(55.2-284.0)	Female	24	34.8	69.0	(44.2-102.7)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Burlington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	27	33.5	80.7	(53.2-117.4)	Male	19	20.4	93.3	(56.1-145.6)
Female	8	11.3	70.8	(30.5-139.6)	Female	11	15.0	73.2	(36.5-131.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	5.7	88.5	(28.5-206.4)	Male	6	6.5	92.5	(33.8-201.2)
Female	5	4.9	102.4	(33.0-238.9)	Female	4	5.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.1	nc	(nc-nc)	Male	24	17.9	134.0	(85.8-199.3)
Female	131	123.6	105.9	(88.6-125.7)	Female	13	15.1	85.9	(45.7-146.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	3.9	nc	(nc-nc)	Male	10	13.6	73.4	(35.1-135.0)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	27	33.1	81.7	(53.8-118.8)	Female	9	10.5	85.6	(39.1-162.6)
Female	30	31.4	95.6	(64.5-136.5)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	19	11.7	161.8	(97.3-252.6)
Male	3	7.7	nc	(nc-nc)	Female	7	11.7	60.0	(24.0-123.5)
Female	1	2.2	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	75	83.9	89.4	(70.3-112.0)
Male	1	2.1	nc	(nc-nc)	<u>Stomach</u>				
Female	2	1.8	nc	(nc-nc)	Male	6	7.5	79.9	(29.2-174.0)
<u>Kidney & Renal Pelvis</u>					Female	3	4.4	nc	(nc-nc)
Male	16	16.9	94.6	(54.1-153.7)	<u>Testis</u>				
Female	5	10.0	49.9	(16.1-116.6)	Male	3	3.9	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	4.4	nc	(nc-nc)	Male	8	7.3	110.3	(47.5-217.4)
Female	1	1.4	nc	(nc-nc)	Female	31	22.0	141.0	(95.8-200.2)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	16	12.8	125.1	(71.5-203.2)	Female	34	27.6	123.1	(85.2-172.0)
Female	5	8.8	56.7	(18.3-132.4)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	352	390.9	90.0	(80.9-100.0)
Male	8	10.5	76.4	(32.9-150.6)	Female	395	415.1	95.2	(86.0-105.0)
Female	3	3.6	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	39	56.9	68.6	(48.8-93.8)					
Female	60	61.1	98.3	(75.0-126.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Cambridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	52	77.2	67.4	(50.3-88.4)	Male	52	50.3	103.4	(77.2-135.6)
Female	16	29.9	53.6	(30.6-87.0)	Female	52	44.6	116.6	(87.1-153.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	20	17.5	114.5	(69.9-176.8)	Male	15	15.7	95.6	(53.4-157.6)
Female	15	15.9	94.1	(52.6-155.2)	Female	9	13.8	65.1	(29.7-123.6)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	3	2.7	nc	(nc-nc)	Male	47	45.8	102.6	(75.4-136.4)
Female	326	328.6	99.2	(88.7-110.6)	Female	49	41.9	116.9	(86.5-154.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	6	11.5	52.3	(19.1-113.9)	Male	40	35.7	112.1	(80.1-152.6)
Female	6	11.5	52.3	(19.1-113.9)	Female	18	18.5	97.3	(57.7-153.8)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	70	79.1	88.5	(69.0-111.9)	Female	31	29.5	105.2	(71.4-149.3)
Female	64	83.7	76.5	(58.9-97.6)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	28	28.1	99.7	(66.2-144.1)
Male	16	19.3	83.0	(47.4-134.8)	Female	26	30.9	84.2	(55.0-123.4)
Female	10	5.9	170.6	(81.7-313.8)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	255	227.4	112.1	(98.8-126.8)
Male	11	9.8	112.7	(56.2-201.6)	<u>Stomach</u>				
Female	4	9.0	nc	(nc-nc)	Male	12	17.9	66.9	(34.5-116.9)
<u>Kidney & Renal Pelvis</u>					Female	10	12.0	83.5	(40.0-153.6)
Male	33	43.8	75.3	(51.8-105.7)	<u>Testis</u>				
Female	17	26.9	63.2	(36.8-101.2)	Male	24	19.5	122.9	(78.7-182.9)
<u>Larynx</u>					<u>Thyroid</u>				
Male	5	11.1	44.9	(14.5-104.7)	Male	25	22.5	111.0	(71.8-163.9)
Female	0	3.7	nc	(nc-nc)	Female	84	72.4	116.0	(92.5-143.6)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	32	34.0	94.1	(64.4-132.9)	Female	67	76.0	88.1	(68.3-111.9)
Female	16	26.0	61.5	(35.1-99.8)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	928	1000.3	92.8	(86.9-98.9)
Male	19	26.6	71.3	(42.9-111.4)	Female	1020	1139.5	89.5	(84.1-95.2)
Female	10	10.1	98.9	(47.4-182.0)					
<u>Lung and Bronchus</u>									
Male	99	134.8	73.4	(59.7-89.4)					
Female	112	157.4	71.2	(58.6-85.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Canton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	19	27.1	70.2	(42.2-109.6)	Male	21	16.9	124.1	(76.8-189.7)
Female	5	9.5	52.5	(16.9-122.6)	Female	15	13.1	114.5	(64.1-188.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	7	4.8	145.4	(58.2-299.5)	Male	13	5.4	240.2	(127.8-410.8)
Female	6	4.2	142.4	(52.0-309.9)	Female	5	4.4	114.4	(36.9-266.9)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.9	nc	(nc-nc)	Male	13	15.0	86.8	(46.2-148.4)
Female	113	104.6	108.0	(89.0-129.9)	Female	15	12.9	116.2	(65.0-191.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	5	3.5	143.2	(46.2-334.2)	Male	11	12.0	92.0	(45.9-164.6)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	34	27.4	123.9	(85.8-173.2)	Female	9	9.0	100.2	(45.7-190.3)
Female	30	27.3	109.8	(74.1-156.8)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	11	9.8	112.0	(55.9-200.5)
Male	6	6.5	91.6	(33.5-199.4)	Female	8	10.0	80.2	(34.5-158.0)
Female	0	1.9	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	87	76.0	114.5	(91.7-141.3)
Male	2	1.8	nc	(nc-nc)	<u>Stomach</u>				
Female	1	1.6	nc	(nc-nc)	Male	8	6.2	128.7	(55.4-253.6)
<u>Kidney & Renal Pelvis</u>					Female	3	3.8	nc	(nc-nc)
Male	9	14.8	60.9	(27.8-115.7)	<u>Testis</u>				
Female	7	8.4	83.6	(33.5-172.2)	Male	3	3.3	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	3	3.8	nc	(nc-nc)	Male	11	6.4	170.8	(85.1-305.6)
Female	3	1.1	nc	(nc-nc)	Female	31	19.4	159.5	(108.4-226.5)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	16	10.6	151.1	(86.3-245.3)	Female	25	23.2	107.9	(69.8-159.3)
Female	6	7.7	78.0	(28.5-169.7)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	360	331.6	108.6	(97.6-120.4)
Male	4	9.0	nc	(nc-nc)	Female	380	352.3	107.9	(97.3-119.3)
Female	0	3.1	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	46	46.9	98.2	(71.9-131.0)					
Female	55	49.4	111.4	(83.9-145.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Carlisle

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	7.2	69.5	(22.4-162.2)	Male	7	4.7	149.5	(59.9-308.0)
Female	1	2.2	nc	(nc-nc)	Female	7	3.2	220.8	(88.4-454.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.3	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
Female	3	1.0	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	4	4.0	nc	(nc-nc)
Female	32	27.3	117.2	(80.1-165.4)	Female	5	3.1	159.9	(51.5-373.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.9	nc	(nc-nc)	Male	1	3.7	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	3	7.6	nc	(nc-nc)	Female	4	2.3	nc	(nc-nc)
Female	3	6.5	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	2	2.7	nc	(nc-nc)
Male	0	1.9	nc	(nc-nc)	Female	3	2.3	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	24	23.9	100.4	(64.3-149.5)
Male	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.3	nc	(nc-nc)	Male	1	1.7	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	0.9	nc	(nc-nc)
Male	1	4.4	nc	(nc-nc)	<u>Testis</u>				
Female	1	2.1	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	1.1	nc	(nc-nc)	Male	2	1.8	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	2	4.7	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	6	2.8	215.6	(78.7-469.2)	Female	10	6.1	163.9	(78.5-301.5)
Female	1	1.8	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	69	94.6	72.9	(56.7-92.3)
Male	1	2.8	nc	(nc-nc)	Female	82	87.0	94.2	(74.9-116.9)
Female	1	0.8	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	6	13.3	45.3	(16.5-98.5)					
Female	1	11.9	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Carver

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	22	14.9	147.5	(92.4-223.4)	Male	11	9.3	118.2	(58.9-211.5)
Female	9	5.4	165.7	(75.6-314.6)	Female	11	7.3	150.0	(74.8-268.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	2.6	nc	(nc-nc)	Male	6	3.0	199.4	(72.8-434.0)
Female	0	2.4	nc	(nc-nc)	Female	1	2.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.5	nc	(nc-nc)	Male	3	8.2	nc	(nc-nc)
Female	48	61.8	77.7	(57.3-103.0)	Female	7	7.5	93.8	(37.6-193.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	1.9	nc	(nc-nc)	Male	7	6.8	103.5	(41.5-213.3)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	16	15.2	105.4	(60.2-171.2)	Female	1	5.2	nc	(nc-nc)
Female	15	15.2	98.5	(55.1-162.4)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	6	3.7	162.5	(59.4-353.8)	Male	28	44.0	63.6	(42.3-92.0)
Female	1	1.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	1	0.9	nc	(nc-nc)	Male	2	1.6	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	4	8.3	nc	(nc-nc)	Female	18	14.4	125.2	(74.2-197.9)
Female	6	4.9	122.6	(44.8-266.9)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Leukemia</u>				
Male	1	2.2	nc	(nc-nc)	Male	3	5.7	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	3	4.3	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Lung and Bronchus</u>				
Male	1	5.1	nc	(nc-nc)	Male	33	26.2	126.2	(86.8-177.2)
Female	1	1.8	nc	(nc-nc)	Female	44	28.9	152.0	(110.5-204.1)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Charlemont

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	1.8	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Female	2	0.6	nc	(nc-nc)	Female	2	0.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
Female	9	6.3	142.4	(65.0-270.3)	Female	1	0.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.2	nc	(nc-nc)	Male	2	0.8	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	3	1.8	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Female	0	1.6	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	1	0.7	nc	(nc-nc)
Male	1	0.4	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	5	5.3	94.7	(30.5-221.0)
Male	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.1	nc	(nc-nc)	Male	2	0.4	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	0.2	nc	(nc-nc)
Male	0	1.0	nc	(nc-nc)	<u>Testis</u>				
Female	0	0.5	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	0.3	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	0.7	nc	(nc-nc)	Female	3	1.5	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	26	22.0	118.1	(77.1-173.1)
Male	1	0.6	nc	(nc-nc)	Female	26	21.4	121.5	(79.4-178.1)
Female	0	0.2	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	3	3.2	nc	(nc-nc)					
Female	2	3.2	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Charlton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	19	13.4	142.3	(85.6-222.2)	Male	6	8.9	67.5	(24.6-146.9)
Female	5	4.5	111.7	(36.0-260.6)	Female	4	7.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	2.7	nc	(nc-nc)	Male	2	2.8	nc	(nc-nc)
Female	1	2.3	nc	(nc-nc)	Female	4	2.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.5	nc	(nc-nc)	Male	9	7.9	114.1	(52.1-216.6)
Female	50	57.9	86.3	(64.1-113.8)	Female	7	6.6	106.0	(42.5-218.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	2.0	nc	(nc-nc)	Male	4	6.9	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	7	14.9	46.9	(18.8-96.6)	Female	5	4.9	101.6	(32.7-237.0)
Female	16	13.7	116.9	(66.8-189.8)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	9	5.1	177.1	(80.8-336.3)
Male	2	3.5	nc	(nc-nc)	Female	4	4.7	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	33	42.0	78.7	(54.1-110.5)
Male	0	1.0	nc	(nc-nc)	<u>Stomach</u>				
Female	1	0.9	nc	(nc-nc)	Male	0	3.2	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	1.9	nc	(nc-nc)
Male	12	8.3	144.8	(74.7-253.0)	<u>Testis</u>				
Female	3	4.4	nc	(nc-nc)	Male	1	2.0	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	2.0	nc	(nc-nc)	Male	3	3.9	nc	(nc-nc)
Female	3	0.6	nc	(nc-nc)	Female	17	11.5	147.4	(85.8-236.0)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	7	5.6	125.6	(50.3-258.9)	Female	9	13.3	67.9	(31.0-128.9)
Female	3	3.9	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	153	176.5	86.7	(73.5-101.6)
Male	2	5.0	nc	(nc-nc)	Female	177	185.5	95.4	(81.9-110.6)
Female	1	1.6	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	21	23.1	90.9	(56.3-139.0)					
Female	22	23.3	94.6	(59.2-143.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Chatham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	11	15.3	71.9	(35.8-128.7)	Male	25	8.7	288.1	(186.4-425.4)
Female	11	4.8	228.7	(114.0-409.2)	Female	15	5.2	288.5	(161.4-475.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	2.1	nc	(nc-nc)	Male	1	2.9	nc	(nc-nc)
Female	1	1.6	nc	(nc-nc)	Female	2	2.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.5	nc	(nc-nc)	Male	11	7.6	144.5	(72.0-258.6)
Female	40	43.5	92.0	(65.8-125.3)	Female	6	5.9	101.4	(37.0-220.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	1.1	nc	(nc-nc)	Male	8	5.7	140.8	(60.6-277.5)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	18	14.0	128.4	(76.0-202.9)	Female	4	3.8	nc	(nc-nc)
Female	11	12.5	88.3	(44.0-158.0)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	6	5.3	113.4	(41.4-246.9)
Male	3	3.5	nc	(nc-nc)	Female	5	5.0	99.9	(32.2-233.2)
Female	1	0.9	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	39	39.8	98.0	(69.7-134.0)
Male	0	0.6	nc	(nc-nc)	<u>Stomach</u>				
Female	1	0.4	nc	(nc-nc)	Male	1	3.3	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	1.8	nc	(nc-nc)
Male	6	7.2	83.7	(30.6-182.1)	<u>Testis</u>				
Female	3	3.7	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	2.0	nc	(nc-nc)	Male	2	2.4	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	2	5.6	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	9	5.3	170.1	(77.6-322.9)	Female	9	10.3	87.7	(40.0-166.5)
Female	4	3.4	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	175	172.0	101.7	(87.2-118.0)
Male	1	4.5	nc	(nc-nc)	Female	164	154.8	105.9	(90.4-123.5)
Female	3	1.5	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	17	26.4	64.5	(37.5-103.2)					
Female	26	25.4	102.5	(66.9-150.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Chelmsford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	52	40.8	127.4	(95.1-167.0)	Male	21	26.4	79.6	(49.3-121.7)
Female	15	15.8	94.7	(52.9-156.2)	Female	22	21.3	103.4	(64.8-156.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	12	7.6	158.2	(81.6-276.4)	Male	7	8.4	83.2	(33.3-171.5)
Female	5	6.8	73.3	(23.6-171.1)	Female	9	7.4	122.4	(55.8-232.3)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	1.4	nc	(nc-nc)	Male	27	23.2	116.5	(76.8-169.5)
Female	179	174.6	102.5	(88.1-118.7)	Female	10	21.5	46.5	(22.3-85.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	5	5.5	90.6	(29.2-211.5)	Male	22	19.5	112.9	(70.8-171.0)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	39	42.9	91.0	(64.7-124.4)	Female	23	14.9	154.5	(97.9-231.9)
Female	51	44.1	115.5	(86.0-151.9)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	9	10.3	87.3	(39.9-165.8)	Male	19	15.2	125.4	(75.4-195.8)
Female	2	3.1	nc	(nc-nc)	Female	24	16.4	146.7	(94.0-218.3)
<u>Hodgkin Lymphoma</u>					<u>Stomach</u>				
Male	1	2.8	nc	(nc-nc)	Male	5	9.6	52.0	(16.8-121.4)
Female	3	2.4	nc	(nc-nc)	Female	3	6.2	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					<u>Testis</u>				
Male	22	23.6	93.0	(58.3-140.9)	Male	7	5.4	130.4	(52.2-268.7)
Female	13	14.1	92.3	(49.1-157.9)	<u>Thyroid</u>				
<u>Larynx</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	4	6.0	nc	(nc-nc)	Female	47	39.8	118.2	(86.8-157.1)
Female	1	2.0	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Leukemia</u>					<u>Female</u>				
Male	16	16.3	98.1	(56.1-159.4)	Male	531	519.3	102.2	(93.7-111.3)
Female	23	12.4	186.0	(117.9-279.1)	Female	608	584.3	104.1	(96.0-112.7)
<u>Liver and Intrahepatic Bile Ducts</u>									
Male	15	14.5	103.6	(57.9-170.8)					
Female	2	5.2	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	60	71.9	83.4	(63.7-107.4)					
Female	71	84.8	83.7	(65.4-105.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Chelsea

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	18	24.4	73.7	(43.6-116.4)	Male	8	17.2	46.4	(20.0-91.4)
Female	9	8.8	101.7	(46.4-193.1)	Female	11	14.7	74.9	(37.3-134.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	6.2	96.4	(35.2-209.8)	Male	8	5.2	153.1	(65.9-301.6)
Female	6	5.1	117.0	(42.7-254.7)	Female	3	4.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.9	nc	(nc-nc)	Male	14	15.7	89.4	(48.8-149.9)
Female	99	109.3	90.5	(73.6-110.2)	Female	19	13.0	146.0	(87.9-228.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	9	4.3	209.9	(95.8-398.4)	Male	7	12.8	54.5	(21.8-112.3)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	33	28.3	116.6	(80.2-163.7)	Female	5	9.4	53.1	(17.1-123.9)
Female	12	26.6	45.1	(23.3-78.8)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	9	9.2	97.5	(44.5-185.0)
Male	4	6.2	nc	(nc-nc)	Female	16	9.3	172.4	(98.5-280.0)
Female	1	1.8	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	52	71.5	72.7	(54.3-95.3)
Male	3	3.2	nc	(nc-nc)	<u>Stomach</u>				
Female	2	2.6	nc	(nc-nc)	Male	8	6.0	133.6	(57.5-263.3)
<u>Kidney & Renal Pelvis</u>					Female	4	3.8	nc	(nc-nc)
Male	7	15.8	44.3	(17.7-91.2)	<u>Testis</u>				
Female	12	8.6	139.3	(71.9-243.3)	Male	4	7.1	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	3.6	nc	(nc-nc)	Male	13	8.9	145.5	(77.4-248.9)
Female	1	1.1	nc	(nc-nc)	Female	43	25.9	166.3	(120.3-224.0)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	10	11.7	85.6	(41.0-157.5)	Female	16	23.6	67.8	(38.7-110.1)
Female	12	8.4	142.0	(73.3-248.1)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	301	332.2	90.6	(80.7-101.4)
Male	12	8.8	136.1	(70.2-237.7)	Female	396	364.7	108.6	(98.2-119.8)
Female	12	3.0	396.7	(204.7-692.9)					
<u>Lung and Bronchus</u>									
Male	53	41.6	127.5	(95.5-166.8)					
Female	65	46.5	139.8	(107.9-178.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Cheshire

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	5.2	96.0	(30.9-224.0)	Male	6	3.2	189.7	(69.3-412.9)
Female	2	1.5	nc	(nc-nc)	Female	1	2.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.8	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.2	nc	(nc-nc)	Male	1	2.8	nc	(nc-nc)
Female	18	17.3	104.0	(61.6-164.3)	Female	4	2.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.5	nc	(nc-nc)	Male	1	2.3	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	6	5.1	117.8	(43.0-256.3)	Female	3	1.5	nc	(nc-nc)
Female	2	4.1	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	1	1.9	nc	(nc-nc)
Male	0	1.3	nc	(nc-nc)	Female	1	1.5	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	13	15.7	83.0	(44.1-141.9)
Male	1	0.3	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.2	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.6	nc	(nc-nc)
Male	2	2.8	nc	(nc-nc)	<u>Testis</u>				
Female	2	1.4	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.7	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	3.0	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	1.9	nc	(nc-nc)	Female	5	4.1	122.7	(39.5-286.2)
Female	0	1.2	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	55	63.7	86.3	(65.0-112.3)
Male	2	1.8	nc	(nc-nc)	Female	49	57.3	85.5	(63.3-113.1)
Female	0	0.5	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	12	9.2	130.0	(67.1-227.1)					
Female	6	8.5	71.0	(25.9-154.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Chester

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	1.5	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	5	5.5	91.6	(29.5-213.7)	Female	1	0.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	5	1.7	289.7	(93.3-675.9)	Female	1	0.5	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	0	0.4	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male				
Male	0	0.1	nc	(nc-nc)	Female	5	5.3	94.3	(30.4-220.2)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	2	1.0	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male				
Male	0	0.3	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	0	0.6	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Female				
Male	1	0.6	nc	(nc-nc)	Male	20	21.2	94.2	(57.5-145.6)
Female	0	0.1	nc	(nc-nc)	Female	15	16.7	89.7	(50.2-147.9)
<u>Lung and Bronchus</u>					<u>All Sites / Types</u>				
Male	2	2.7	nc	(nc-nc)					
Female	4	1.9	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Chesterfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	1.2	nc	(nc-nc)	Male	2	0.9	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.3	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	0	6.1	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	3	1.5	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
Female	0	1.4	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	1	0.5	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
Female	1	0.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	6	4.8	125.9	(46.0-273.9)
Male	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.1	nc	(nc-nc)	Male	3	0.3	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.2	nc	(nc-nc)
Male	0	0.9	nc	(nc-nc)	<u>Testis</u>				
Female	0	0.5	nc	(nc-nc)	Male	1	0.2	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	0.5	nc	(nc-nc)	Female	2	1.5	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	22	18.0	122.2	(76.6-185.1)
Male	0	0.6	nc	(nc-nc)	Female	11	19.3	57.1	(28.5-102.1)
Female	0	0.2	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	2	2.2	nc	(nc-nc)					
Female	2	2.5	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Chicopee

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	57	65.0	87.6	(66.4-113.5)	Male	21	40.9	51.3	(31.7-78.4)
Female	21	24.1	87.0	(53.8-133.0)	Female	20	31.9	62.7	(38.3-96.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	7	12.1	58.0	(23.2-119.5)	Male	11	13.2	83.3	(41.6-149.1)
Female	11	10.4	106.0	(52.8-189.6)	Female	6	11.1	54.1	(19.8-117.8)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	3	2.3	nc	(nc-nc)	Male	30	36.3	82.7	(55.8-118.1)
Female	260	254.6	102.1	(90.1-115.3)	Female	39	32.4	120.4	(85.6-164.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	11	7.9	139.7	(69.6-249.9)	Male	30	29.6	101.4	(68.4-144.8)
Female					Female	22	14.2	155.0	(97.1-234.6)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	95	66.5	142.8	(115.5-174.5)	Female	28	22.3	125.6	(83.4-181.5)
Female	60	67.7	88.7	(67.7-114.1)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	19	23.8	80.0	(48.1-124.9)
Male	16	16.1	99.1	(56.6-161.0)	Female	24	25.2	95.3	(61.0-141.8)
Female	6	4.7	128.5	(46.9-279.7)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	121	189.5	63.8	(53.0-76.3)
Male	4	4.7	nc	(nc-nc)	<u>Stomach</u>				
Female	1	4.1	nc	(nc-nc)	Male	11	15.1	73.1	(36.4-130.7)
<u>Kidney & Renal Pelvis</u>					Female	9	9.5	94.4	(43.1-179.2)
Male	43	36.2	118.8	(85.9-160.0)	<u>Testis</u>				
Female	28	20.7	135.0	(89.7-195.2)	Male	10	8.6	116.0	(55.5-213.3)
<u>Larynx</u>					<u>Thyroid</u>				
Male	11	9.4	117.6	(58.6-210.4)	Male	13	15.8	82.1	(43.7-140.5)
Female	2	2.9	nc	(nc-nc)	Female	34	44.8	75.9	(52.5-106.0)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	23	25.9	88.9	(56.3-133.4)	Female	54	58.5	92.3	(69.3-120.5)
Female	10	19.0	52.7	(25.2-96.9)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	722	811.6	89.0	(82.6-95.7)
Male	13	22.1	58.7	(31.2-100.4)	Female	866	870.7	99.5	(92.9-106.3)
Female	7	7.9	88.5	(35.5-182.4)					
<u>Lung and Bronchus</u>									
Male	135	113.3	119.2	(99.9-141.1)					
Female	136	125.6	108.3	(90.8-128.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Chilmark

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	1.6	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	2	6.2	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.2	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	1	1.5	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
Female	0	1.4	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	0	0.4	nc	(nc-nc)	Male	2	4.9	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.9	nc	(nc-nc)	Female	0	1.5	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Male</u>				
Male	0	0.2	nc	(nc-nc)	14	19.6	71.6	(39.1-120.1)	
Female	0	0.1	nc	(nc-nc)	<u>Female</u>				
<u>Leukemia</u>					<u>11</u>				
Male	3	0.6	nc	(nc-nc)	19.8	55.5	(27.7-99.4)		
Female	1	0.4	nc	(nc-nc)					
<u>Liver and Intrahepatic Bile Ducts</u>									
Male	1	0.6	nc	(nc-nc)					
Female	0	0.2	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	3	2.7	nc	(nc-nc)					
Female	2	2.8	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Clarksburg

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	2.8	nc	(nc-nc)	Male	2	1.7	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	2	0.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	1.5	nc	(nc-nc)
Female	5	8.8	57.0	(18.4-132.9)	Female	1	1.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	3	1.2	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	1	2.8	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
Female	3	2.2	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	2	0.7	nc	(nc-nc)	Male	8	7.6	105.5	(45.4-207.8)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	1.4	nc	(nc-nc)	Female	1	2.1	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Leukemia</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Lung and Bronchus</u>				
Male	0	0.9	nc	(nc-nc)	Male	5	4.9	101.3	(32.6-236.3)
Female	0	0.3	nc	(nc-nc)	Female	5	4.3	115.5	(37.2-269.5)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Clinton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	27	12.4	217.5	(143.3-316.5)	Male	10	8.3	120.5	(57.7-221.6)
Female	5	5.1	98.4	(31.7-229.6)	Female	12	7.3	165.5	(85.4-289.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	2.6	nc	(nc-nc)	Male	3	2.6	nc	(nc-nc)
Female	3	2.4	nc	(nc-nc)	Female	2	2.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	5	7.4	67.6	(21.8-157.9)
Female	56	57.4	97.6	(73.7-126.7)	Female	9	7.0	127.7	(58.3-242.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	1.9	nc	(nc-nc)	Male	5	6.2	80.0	(25.8-186.7)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	20	13.5	148.1	(90.5-228.8)	Female	7	5.0	140.8	(56.4-290.1)
Female	12	14.7	81.6	(42.1-142.6)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	3	4.7	nc	(nc-nc)
Male	4	3.2	nc	(nc-nc)	Female	4	5.3	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	56	39.0	143.7	(108.6-186.7)
Male	1	1.1	nc	(nc-nc)	<u>Stomach</u>				
Female	0	1.0	nc	(nc-nc)	Male	4	3.0	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	2	2.1	nc	(nc-nc)
Male	13	7.6	170.2	(90.5-291.0)	<u>Testis</u>				
Female	6	4.6	131.0	(47.9-285.2)	Male	1	2.3	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	1.9	nc	(nc-nc)	Male	3	3.8	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	14	11.1	126.5	(69.1-212.2)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	8	5.3	151.0	(65.0-297.5)	Female	16	13.0	123.0	(70.2-199.7)
Female	7	4.2	165.8	(66.4-341.6)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	216	164.7	131.1	(114.2-149.9)
Male	11	4.5	242.5	(120.9-433.9)	Female	216	192.7	112.1	(97.7-128.1)
Female	0	1.7	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	29	21.8	133.1	(89.1-191.2)					
Female	31	26.3	117.9	(80.1-167.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Cohasset

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	9	9.0	100.1	(45.7-190.0)	Male	4	6.0	nc	(nc-nc)
Female	6	3.4	179.0	(65.4-389.5)	Female	15	4.8	314.7	(176.0-519.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.7	nc	(nc-nc)	Male	1	1.9	nc	(nc-nc)
Female	2	1.6	nc	(nc-nc)	Female	0	1.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	6	5.2	114.4	(41.8-249.1)
Female	44	39.4	111.6	(81.1-149.8)	Female	2	4.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.3	nc	(nc-nc)	Male	6	4.4	137.3	(50.1-298.8)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	10	9.5	105.5	(50.5-194.0)	Female	5	3.3	151.6	(48.8-353.7)
Female	4	9.5	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	3	3.4	nc	(nc-nc)
Male	2	2.3	nc	(nc-nc)	Female	2	3.4	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	28	26.4	105.9	(70.3-153.0)
Male	0	0.6	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.5	nc	(nc-nc)	Male	1	2.1	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	1.4	nc	(nc-nc)
Male	6	5.3	113.5	(41.5-247.1)	<u>Testis</u>				
Female	4	3.1	nc	(nc-nc)	Male	2	1.2	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	1.4	nc	(nc-nc)	Male	2	2.4	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	10	7.3	136.6	(65.4-251.3)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	3	3.7	nc	(nc-nc)	Female	7	8.5	82.1	(32.9-169.2)
Female	5	2.7	183.6	(59.2-428.5)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	105	115.5	90.9	(74.4-110.1)
Male	3	3.3	nc	(nc-nc)	Female	132	128.7	102.6	(85.8-121.6)
Female	1	1.1	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	11	16.0	68.9	(34.3-123.2)					
Female	12	18.1	66.4	(34.3-116.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Colrain

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	2.6	nc	(nc-nc)	Male	0	1.6	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	13	8.5	153.6	(81.7-262.7)	Female	0	1.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.3	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	2	2.6	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
Female	4	2.0	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	1	0.6	nc	(nc-nc)	Male	4	7.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	1.4	nc	(nc-nc)	Female	4	2.1	nc	(nc-nc)
Female	2	0.7	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Leukemia</u>				
Male	0	0.4	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Lung and Bronchus</u>				
Male	0	0.9	nc	(nc-nc)	Male	4	4.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	4	3.8	nc	(nc-nc)
<u>Male</u>					<u>Female</u>				
					Male	19	31.8	59.8	(36.0-93.4)
					Female	34	27.5	123.8	(85.7-173.0)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Concord

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	32	27.4	117.0	(80.0-165.1)	Male	27	17.4	155.5	(102.4-226.2)
Female	11	9.7	113.8	(56.7-203.6)	Female	30	12.2	246.4	(166.2-351.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	4.9	103.0	(33.2-240.3)	Male	5	5.6	88.5	(28.5-206.6)
Female	4	3.8	nc	(nc-nc)	Female	4	4.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	1.0	nc	(nc-nc)	Male	15	15.3	98.0	(54.8-161.6)
Female	130	99.3	130.9	(109.3-155.4)	Female	10	12.8	78.1	(37.4-143.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	3.0	nc	(nc-nc)	Male	11	12.9	85.6	(42.7-153.1)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	17	28.6	59.5	(34.6-95.2)	Female	16	8.6	185.4	(105.9-301.1)
Female	30	27.2	110.1	(74.3-157.2)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	1	6.9	nc	(nc-nc)	Male	82	81.0	101.2	(80.5-125.6)
Female	0	1.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	1	1.7	nc	(nc-nc)	Male	3	3.1	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	6	15.7	38.3	(14.0-83.4)	Female	26	22.8	114.2	(74.6-167.4)
Female	11	8.1	136.3	(67.9-243.9)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Leukemia</u>				
Male	1	4.0	nc	(nc-nc)	Male	10	10.6	94.0	(45.0-172.8)
Female	1	1.1	nc	(nc-nc)	Female	3	7.3	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Lung and Bronchus</u>				
Male	7	9.5	74.0	(29.6-152.4)	Male	18	47.7	37.8	(22.4-59.7)
Female	3	3.1	nc	(nc-nc)	Female	29	49.2	59.0	(39.5-84.7)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Conway

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	2.6	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.4	nc	(nc-nc)	Male	2	0.5	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.4	nc	(nc-nc)
Female	7	10.3	68.0	(27.2-140.0)	Female	0	1.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	2	2.8	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
Female	2	2.2	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	0	0.7	nc	(nc-nc)	Male	2	1.0	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	3	8.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	2	1.5	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	1	0.4	nc	(nc-nc)	Male	1	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	1	1.0	nc	(nc-nc)	Male	2	0.6	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	0	1.9	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.9	nc	(nc-nc)	Female	3	2.5	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	3	4.5	nc	(nc-nc)	Male	27	33.1	81.5	(53.7-118.6)
Female	1	4.3	nc	(nc-nc)	Female	18	32.1	56.2	(33.3-88.8)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Cummington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	1.3	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	2	0.7	nc	(nc-nc)
Female	9	5.1	177.0	(80.8-336.1)	Female	1	0.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	3	1.4	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Female	5	1.4	367.6	(118.5-857.8)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	1	0.3	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Stomach</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					<u>Testis</u>				
Male	1	0.7	nc	(nc-nc)	Male	1	0.1	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	<u>Thyroid</u>				
<u>Larynx</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.2	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Leukemia</u>					<u>All Sites / Types</u>				
Male	0	0.5	nc	(nc-nc)	Male	15	15.4	97.3	(54.4-160.6)
Female	0	0.4	nc	(nc-nc)	Female	21	17.2	122.1	(75.5-186.6)
<u>Liver and Intrahepatic Bile Ducts</u>									
Male	0	0.4	nc	(nc-nc)					
Female	1	0.2	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	2	2.2	nc	(nc-nc)					
Female	1	2.4	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Dalton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	8	10.2	78.1	(33.6-154.0)	Male	6	6.2	97.4	(35.6-211.9)
Female	4	3.5	nc	(nc-nc)	Female	4	4.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.7	nc	(nc-nc)	Male	2	2.0	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)	Female	1	1.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	3	5.4	nc	(nc-nc)
Female	24	36.2	66.2	(42.4-98.5)	Female	2	4.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.1	nc	(nc-nc)	Male	0	4.2	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	7	10.2	68.8	(27.6-141.7)	Female	3	3.1	nc	(nc-nc)
Female	8	9.9	80.8	(34.8-159.2)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	1	3.6	nc	(nc-nc)
Male	1	2.4	nc	(nc-nc)	Female	2	3.7	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	22	26.1	84.4	(52.9-127.8)
Male	1	0.6	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.4	nc	(nc-nc)	Male	1	2.3	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	2	1.4	nc	(nc-nc)
Male	2	5.2	nc	(nc-nc)	<u>Testis</u>				
Female	3	3.0	nc	(nc-nc)	Male	2	1.0	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	1.3	nc	(nc-nc)	Male	2	2.1	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	0	5.7	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	4	3.8	nc	(nc-nc)	Female	7	8.2	85.6	(34.3-176.3)
Female	3	2.7	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	91	119.1	76.4	(61.5-93.8)
Male	4	3.2	nc	(nc-nc)	Female	90	123.8	72.7	(58.5-89.4)
Female	0	1.1	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	18	17.3	104.2	(61.7-164.7)					
Female	15	18.3	82.2	(46.0-135.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Danvers

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	33	37.2	88.6	(61.0-124.5)	Male	15	22.8	65.9	(36.8-108.7)
Female	18	13.7	131.8	(78.1-208.3)	Female	15	17.3	86.7	(48.5-143.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	12	6.2	192.3	(99.3-336.0)	Male	2	7.3	nc	(nc-nc)
Female	5	5.5	90.5	(29.2-211.3)	Female	3	6.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.2	nc	(nc-nc)	Male	16	20.1	79.6	(45.5-129.3)
Female	150	136.9	109.6	(92.7-128.6)	Female	21	17.9	117.4	(72.6-179.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	4.3	nc	(nc-nc)	Male	20	15.8	126.9	(77.5-195.9)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	34	37.3	91.2	(63.1-127.4)	Female	13	11.9	108.9	(57.9-186.2)
Female	36	38.7	93.0	(65.2-128.8)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	15	13.3	112.8	(63.1-186.0)
Male	10	8.8	113.4	(54.3-208.5)	Female	12	14.4	83.2	(42.9-145.3)
Female	3	2.6	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	97	100.1	96.9	(78.6-118.3)
Male	2	2.2	nc	(nc-nc)	<u>Stomach</u>				
Female	3	1.9	nc	(nc-nc)	Male	6	8.4	71.1	(25.9-154.7)
<u>Kidney & Renal Pelvis</u>					Female	6	5.5	109.6	(40.0-238.6)
Male	20	19.5	102.6	(62.7-158.5)	<u>Testis</u>				
Female	16	11.2	142.4	(81.3-231.2)	Male	7	4.0	173.9	(69.7-358.3)
<u>Larynx</u>					<u>Thyroid</u>				
Male	4	5.1	nc	(nc-nc)	Male	9	8.3	108.6	(49.5-206.1)
Female	1	1.5	nc	(nc-nc)	Female	31	23.1	134.0	(91.1-190.3)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	9	14.2	63.3	(28.9-120.2)	Female	41	30.4	134.9	(96.8-183.0)
Female	13	10.7	121.7	(64.7-208.1)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	424	444.2	95.5	(86.6-105.0)
Male	7	11.9	58.6	(23.5-120.8)	Female	505	475.2	106.3	(97.2-116.0)
Female	2	4.4	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	63	63.3	99.5	(76.4-127.3)					
Female	65	68.8	94.5	(72.9-120.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Dartmouth

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	53	42.2	125.6	(94.0-164.2)	Male	23	25.8	89.2	(56.5-133.9)
Female	17	15.5	110.0	(64.0-176.1)	Female	11	19.5	56.5	(28.2-101.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	7	7.4	94.5	(37.8-194.6)	Male	5	8.3	60.4	(19.5-140.9)
Female	6	6.5	92.7	(33.8-201.7)	Female	7	7.0	99.9	(40.0-205.9)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.4	nc	(nc-nc)	Male	22	22.9	96.1	(60.2-145.5)
Female	134	155.4	86.2	(72.3-102.1)	Female	17	20.3	83.9	(48.8-134.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	4.8	nc	(nc-nc)	Male	18	18.1	99.2	(58.8-156.8)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	38	42.3	89.8	(63.5-123.2)	Female	9	13.6	66.1	(30.2-125.6)
Female	48	43.6	110.1	(81.2-146.0)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	15	15.1	99.4	(55.6-164.0)
Male	13	10.1	128.8	(68.5-220.3)	Female	7	16.4	42.6	(17.0-87.7)
Female	2	3.0	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	127	117.2	108.3	(90.3-128.9)
Male	3	2.9	nc	(nc-nc)	<u>Stomach</u>				
Female	2	2.3	nc	(nc-nc)	Male	13	9.6	135.7	(72.2-232.0)
<u>Kidney & Renal Pelvis</u>					Female	12	6.1	195.5	(100.9-341.5)
Male	21	22.3	94.1	(58.2-143.9)	<u>Testis</u>				
Female	15	12.7	117.9	(65.9-194.5)	Male	4	4.8	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	8	5.8	138.3	(59.5-272.5)	Male	10	9.4	106.2	(50.8-195.3)
Female	1	1.8	nc	(nc-nc)	Female	36	25.9	138.8	(97.2-192.2)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	15	16.4	91.5	(51.2-150.9)	Female	27	35.3	76.5	(50.4-111.3)
Female	9	12.0	74.8	(34.1-142.0)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	511	510.0	100.2	(91.7-109.3)
Male	14	13.6	102.7	(56.1-172.4)	Female	450	539.7	83.4	(75.9-91.5)
Female	1	4.9	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	72	72.4	99.4	(77.8-125.2)					
Female	50	78.3	63.9	(47.4-84.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Dedham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	32	31.2	102.7	(70.2-145.0)	Male	25	18.9	132.1	(85.5-195.0)
Female	15	12.9	116.3	(65.0-191.8)	Female	21	15.8	132.5	(82.0-202.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	8	5.4	148.3	(63.9-292.3)	Male	7	6.1	115.6	(46.3-238.2)
Female	6	5.1	117.6	(43.0-256.0)	Female	4	5.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.0	nc	(nc-nc)	Male	24	16.9	142.3	(91.2-211.8)
Female	152	123.0	123.6	(104.7-144.9)	Female	18	16.6	108.1	(64.1-170.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	3.8	nc	(nc-nc)	Male	19	12.9	147.1	(88.5-229.8)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	29	31.2	93.0	(62.3-133.5)	Female	6	11.0	54.7	(20.0-119.1)
Female	35	36.5	95.9	(66.8-133.4)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	17	11.0	153.9	(89.6-246.4)
Male	4	7.3	nc	(nc-nc)	Female	17	13.6	125.0	(72.8-200.2)
Female	3	2.4	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	89	82.8	107.5	(86.4-132.3)
Male	0	2.0	nc	(nc-nc)	<u>Stomach</u>				
Female	4	1.8	nc	(nc-nc)	Male	8	7.0	113.7	(49.0-224.1)
<u>Kidney & Renal Pelvis</u>					Female	7	5.1	136.8	(54.8-282.0)
Male	25	16.1	155.3	(100.4-229.2)	<u>Testis</u>				
Female	14	10.3	135.5	(74.0-227.3)	Male	6	3.9	154.9	(56.6-337.2)
<u>Larynx</u>					<u>Thyroid</u>				
Male	5	4.2	119.8	(38.6-279.5)	Male	6	7.0	86.0	(31.4-187.2)
Female	1	1.4	nc	(nc-nc)	Female	25	20.6	121.1	(78.3-178.7)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	12	12.1	99.5	(51.4-173.8)	Female	27	27.1	99.7	(65.7-145.0)
Female	8	10.1	79.5	(34.2-156.6)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	419	370.3	113.2	(102.6-124.5)
Male	11	9.8	112.4	(56.0-201.1)	Female	494	436.5	113.2	(103.4-123.6)
Female	5	4.1	122.7	(39.5-286.3)					
<u>Lung and Bronchus</u>									
Male	49	52.4	93.5	(69.2-123.6)					
Female	81	64.2	126.1	(100.2-156.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Deerfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	4.6	nc	(nc-nc)	Male	6	3.3	179.7	(65.6-391.1)
Female	3	2.3	nc	(nc-nc)	Female	5	3.2	156.6	(50.5-365.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.0	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	3	2.9	nc	(nc-nc)
Female	19	26.4	72.0	(43.3-112.4)	Female	2	3.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.8	nc	(nc-nc)	Male	1	2.8	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	8	5.4	148.3	(63.8-292.2)	Female	1	2.3	nc	(nc-nc)
Female	7	6.5	108.0	(43.3-222.6)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	3	1.9	nc	(nc-nc)
Male	2	1.3	nc	(nc-nc)	Female	3	2.4	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	16	17.0	94.1	(53.7-152.8)
Male	1	0.4	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.4	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.9	nc	(nc-nc)
Male	3	3.3	nc	(nc-nc)	<u>Testis</u>				
Female	0	2.1	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.8	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	4.7	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	1.9	nc	(nc-nc)	Female	9	6.2	145.4	(66.3-276.0)
Female	1	1.8	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	60	66.8	89.8	(68.5-115.6)
Male	0	2.0	nc	(nc-nc)	Female	71	86.8	81.8	(63.9-103.1)
Female	0	0.8	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	4	8.6	nc	(nc-nc)					
Female	9	12.1	74.2	(33.8-140.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Dennis

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	51	32.0	159.6	(118.8-209.9)	Male	37	18.0	205.5	(144.7-283.3)
Female	16	11.6	138.4	(79.1-224.8)	Female	27	12.7	213.3	(140.5-310.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	4.4	nc	(nc-nc)	Male	11	6.0	183.2	(91.3-327.9)
Female	1	4.0	nc	(nc-nc)	Female	5	5.1	97.5	(31.4-227.4)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.0	nc	(nc-nc)	Male	13	15.7	82.7	(44.0-141.4)
Female	116	107.3	108.1	(89.3-129.7)	Female	12	14.4	83.1	(42.9-145.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	2.6	nc	(nc-nc)	Male	14	11.6	120.6	(65.9-202.3)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	23	28.7	80.0	(50.7-120.1)	Female	19	9.4	203.1	(122.2-317.1)
Female	25	29.5	84.8	(54.8-125.1)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	9	11.0	81.8	(37.3-155.3)
Male	12	7.3	164.4	(84.9-287.3)	Female	12	11.9	100.7	(52.0-175.9)
Female	6	2.2	267.4	(97.7-582.1)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	100	83.5	119.7	(97.4-145.6)
Male	1	1.2	nc	(nc-nc)	<u>Stomach</u>				
Female	1	1.1	nc	(nc-nc)	Male	2	6.9	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	2	4.2	nc	(nc-nc)
Male	6	14.8	40.5	(14.8-88.1)	<u>Testis</u>				
Female	7	9.2	76.4	(30.6-157.4)	Male	2	1.5	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	3	4.2	nc	(nc-nc)	Male	3	4.9	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)	Female	13	13.8	94.1	(50.1-160.9)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	10	11.1	90.2	(43.2-165.9)	Female	22	25.8	85.1	(53.3-128.9)
Female	7	8.0	87.4	(35.0-180.2)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	391	358.5	109.1	(98.5-120.4)
Male	8	9.3	85.9	(37.0-169.2)	Female	394	377.3	104.4	(94.4-115.3)
Female	2	3.6	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	48	55.9	85.9	(63.4-113.9)					
Female	63	61.9	101.8	(78.2-130.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Dighton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	10	7.9	126.3	(60.5-232.4)	Male	8	5.3	149.8	(64.5-295.2)
Female	0	2.9	nc	(nc-nc)	Female	3	3.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	1.6	nc	(nc-nc)	Male	1	1.7	nc	(nc-nc)
Female	0	1.3	nc	(nc-nc)	Female	0	1.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	5	4.7	106.8	(34.4-249.3)
Female	26	31.4	82.8	(54.1-121.4)	Female	4	3.9	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.0	nc	(nc-nc)	Male	3	4.1	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	11	8.8	124.4	(62.0-222.7)	Female	3	2.7	nc	(nc-nc)
Female	8	8.2	97.3	(41.9-191.7)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	4	3.0	nc	(nc-nc)
Male	3	2.1	nc	(nc-nc)	Female	3	3.0	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	21	24.4	86.1	(53.3-131.6)
Male	2	0.6	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.5	nc	(nc-nc)	Male	2	1.9	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	1.2	nc	(nc-nc)
Male	5	4.9	101.3	(32.6-236.3)	<u>Testis</u>				
Female	4	2.6	nc	(nc-nc)	Male	2	1.2	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	1.2	nc	(nc-nc)	Male	4	2.3	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	4	5.6	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	3.2	nc	(nc-nc)	Female	9	7.1	127.2	(58.0-241.4)
Female	0	2.4	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	110	104.6	105.1	(86.4-126.7)
Male	3	3.0	nc	(nc-nc)	Female	91	106.3	85.6	(68.9-105.1)
Female	2	1.0	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	10	14.1	70.9	(33.9-130.3)					
Female	15	15.2	98.9	(55.3-163.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Douglas

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	11	8.2	134.8	(67.2-241.2)	Male	12	5.7	211.0	(108.9-368.6)
Female	6	2.3	263.7	(96.3-574.0)	Female	2	4.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.8	nc	(nc-nc)	Male	5	1.9	268.8	(86.6-627.2)
Female	1	1.3	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	5	5.0	99.1	(31.9-231.3)
Female	33	35.3	93.6	(64.4-131.4)	Female	1	3.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	1.3	nc	(nc-nc)	Male	6	4.5	132.7	(48.5-288.9)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	8	9.1	87.4	(37.7-172.3)	Female	3	2.9	nc	(nc-nc)
Female	9	7.0	128.6	(58.7-244.1)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	0	3.2	nc	(nc-nc)
Male	1	2.3	nc	(nc-nc)	Female	0	2.3	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	25	27.5	90.9	(58.8-134.2)
Male	1	0.7	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.5	nc	(nc-nc)	Male	2	2.0	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	1.0	nc	(nc-nc)
Male	6	5.4	111.4	(40.7-242.4)	<u>Testis</u>				
Female	3	2.6	nc	(nc-nc)	Male	3	1.3	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	1.4	nc	(nc-nc)	Male	5	2.5	196.1	(63.2-457.6)
Female	0	0.4	nc	(nc-nc)	Female	8	7.5	107.3	(46.2-211.4)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	3	3.5	nc	(nc-nc)	Female	6	7.9	75.5	(27.6-164.3)
Female	2	2.0	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	123	113.1	108.7	(90.4-129.7)
Male	3	3.3	nc	(nc-nc)	Female	104	106.5	97.7	(79.8-118.3)
Female	0	0.9	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	16	15.0	106.4	(60.8-172.7)					
Female	13	13.2	98.4	(52.3-168.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Dover

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	8.0	nc	(nc-nc)	Male	10	4.9	202.3	(96.9-372.1)
Female	2	2.1	nc	(nc-nc)	Female	3	3.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.4	nc	(nc-nc)	Male	2	1.6	nc	(nc-nc)
Female	2	1.0	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.3	nc	(nc-nc)	Male	7	4.3	161.2	(64.6-332.2)
Female	31	27.7	111.8	(76.0-158.7)	Female	3	3.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.9	nc	(nc-nc)	Male	2	3.5	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	7	8.2	85.7	(34.3-176.5)	Female	2	2.3	nc	(nc-nc)
Female	2	6.2	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	2	2.9	nc	(nc-nc)
Male	1	1.9	nc	(nc-nc)	Female	2	2.1	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	22	22.2	99.1	(62.1-150.0)
Male	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.3	nc	(nc-nc)	Male	0	1.8	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.9	nc	(nc-nc)
Male	5	4.3	115.2	(37.1-268.9)	<u>Testis</u>				
Female	2	2.1	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	1.1	nc	(nc-nc)	Male	4	1.8	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	6	5.2	116.0	(42.3-252.4)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	3.1	nc	(nc-nc)	Female	5	6.2	81.3	(26.2-189.7)
Female	0	1.7	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	88	96.9	90.8	(72.8-111.9)
Male	3	2.6	nc	(nc-nc)	Female	72	86.4	83.4	(65.2-105.0)
Female	0	0.7	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	8	13.9	57.7	(24.8-113.6)					
Female	6	11.4	52.8	(19.3-114.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Dracut

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	35	30.5	114.9	(80.0-159.8)	Male	15	20.3	73.8	(41.3-121.7)
Female	17	10.6	160.5	(93.4-256.9)	Female	17	16.0	106.4	(61.9-170.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	9	6.3	142.3	(64.9-270.1)	Male	9	6.5	138.6	(63.3-263.2)
Female	3	5.2	nc	(nc-nc)	Female	4	5.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.1	nc	(nc-nc)	Male	12	17.9	67.1	(34.6-117.2)
Female	137	129.2	106.1	(89.0-125.4)	Female	12	15.1	79.2	(40.9-138.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	4.4	nc	(nc-nc)	Male	16	15.7	101.6	(58.1-165.1)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	36	32.6	110.4	(77.3-152.9)	Female	11	11.1	99.2	(49.4-177.4)
Female	44	30.6	143.7	(104.4-192.9)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	9	11.6	77.8	(35.5-147.8)
Male	13	8.1	160.4	(85.3-274.3)	Female	12	10.9	110.2	(56.9-192.5)
Female	4	2.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	82	99.2	82.7	(65.8-102.6)
Male	0	2.6	nc	(nc-nc)	<u>Stomach</u>				
Female	3	2.1	nc	(nc-nc)	Male	11	7.3	150.2	(74.9-268.7)
<u>Kidney & Renal Pelvis</u>					Female	5	4.3	116.2	(37.4-271.2)
Male	20	18.9	105.9	(64.6-163.5)	<u>Testis</u>				
Female	16	10.2	157.4	(89.9-255.6)	Male	5	4.9	101.8	(32.8-237.5)
<u>Larynx</u>					<u>Thyroid</u>				
Male	8	4.7	168.9	(72.7-332.8)	Male	8	8.7	92.3	(39.8-181.9)
Female	0	1.4	nc	(nc-nc)	Female	24	25.4	94.5	(60.5-140.6)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	16	12.8	124.9	(71.3-202.8)	Female	27	29.7	90.8	(59.8-132.1)
Female	5	8.9	56.4	(18.2-131.7)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	445	407.5	109.2	(99.3-119.8)
Male	12	11.6	103.6	(53.4-180.9)	Female	472	422.1	111.8	(102.0-122.4)
Female	4	3.7	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	81	55.1	147.1	(116.8-182.8)					
Female	75	57.3	130.9	(103.0-164.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Dudley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	12	11.4	105.0	(54.2-183.4)	Male	5	7.6	65.7	(21.2-153.4)
Female	3	3.3	nc	(nc-nc)	Female	7	5.2	133.4	(53.4-274.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	2.4	nc	(nc-nc)	Male	4	2.5	nc	(nc-nc)
Female	2	1.8	nc	(nc-nc)	Female	2	1.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	5	6.8	73.6	(23.7-171.7)
Female	46	42.8	107.6	(78.8-143.5)	Female	5	4.8	103.9	(33.5-242.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	1.5	nc	(nc-nc)	Male	4	5.7	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	11	12.2	90.4	(45.1-161.8)	Female	3	3.6	nc	(nc-nc)
Female	11	9.9	111.2	(55.4-199.0)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	4	3.0	nc	(nc-nc)	Male	34	35.1	96.8	(67.0-135.3)
Female	3	0.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	1	0.9	nc	(nc-nc)	Male	1	1.7	nc	(nc-nc)
Female	2	0.7	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	16	6.9	232.1	(132.6-377.0)	Female	16	9.7	165.5	(94.6-268.8)
Female	7	3.3	214.8	(86.0-442.5)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	1.8	nc	(nc-nc)	Female	16	9.7	165.5	(94.6-268.8)
Female	1	0.5	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Leukemia</u>					<u>All Sites / Types</u>				
Male	9	4.8	186.8	(85.2-354.6)	Male	155	150.2	103.2	(87.6-120.8)
Female	6	2.9	206.9	(75.6-450.4)	Female	172	137.1	125.4	(107.4-145.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	4.3	nc	(nc-nc)	<u>All Sites / Types</u>				
Female	1	1.2	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					<u>All Sites / Types</u>				
Male	20	20.5	97.4	(59.5-150.5)	<u>All Sites / Types</u>				
Female	26	17.4	149.3	(97.5-218.8)	<u>All Sites / Types</u>				

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Dunstable

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	3.5	nc	(nc-nc)	Male	4	2.3	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)	Female	2	2.0	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	0.7	nc	(nc-nc)	Male	2	0.8	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	2.1	nc	(nc-nc)
Female	14	16.7	83.8	(45.8-140.6)	Female	2	1.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.6	nc	(nc-nc)	Male	0	1.9	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	5	3.9	129.5	(41.7-302.3)	Female	0	1.4	nc	(nc-nc)
Female	1	3.8	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	0	1.3	nc	(nc-nc)
Male	3	0.9	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	10	11.4	87.6	(41.9-161.1)
Male	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	0.5	nc	(nc-nc)
Male	2	2.2	nc	(nc-nc)	<u>Testis</u>				
Female	1	1.2	nc	(nc-nc)	Male	3	0.4	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	0.6	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	2	3.2	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	1.4	nc	(nc-nc)	Female	5	3.7	136.0	(43.8-317.4)
Female	0	1.0	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	42	46.7	89.9	(64.8-121.5)
Male	0	1.3	nc	(nc-nc)	Female	45	51.9	86.8	(63.3-116.1)
Female	0	0.4	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	3	6.2	nc	(nc-nc)					
Female	8	6.5	122.8	(52.9-242.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Duxbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	26	19.3	134.5	(87.8-197.0)	Male	31	12.3	251.8	(171.0-357.4)
Female	2	6.4	nc	(nc-nc)	Female	12	9.2	131.0	(67.6-228.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	3.5	141.2	(45.5-329.6)	Male	9	4.1	221.5	(101.1-420.5)
Female	1	2.9	nc	(nc-nc)	Female	2	3.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.7	nc	(nc-nc)	Male	18	10.9	164.9	(97.7-260.6)
Female	85	77.2	110.1	(88.0-136.2)	Female	6	8.9	67.2	(24.5-146.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	2.5	nc	(nc-nc)	Male	5	9.6	52.3	(16.9-122.0)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	3	20.3	nc	(nc-nc)	Female	9	6.5	138.5	(63.2-263.0)
Female	12	19.0	63.0	(32.5-110.1)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	4	7.3	nc	(nc-nc)
Male	3	5.1	nc	(nc-nc)	Female	8	6.8	118.1	(50.8-232.7)
Female	2	1.3	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	74	62.9	117.6	(92.3-147.6)
Male	1	1.1	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.9	nc	(nc-nc)	Male	2	4.6	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	2.6	nc	(nc-nc)
Male	16	11.5	138.7	(79.2-225.2)	<u>Testis</u>				
Female	3	5.9	nc	(nc-nc)	Male	2	1.9	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	2.9	nc	(nc-nc)	Male	2	4.8	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	Female	8	13.6	58.7	(25.3-115.7)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	8	7.6	104.7	(45.1-206.4)	Female	11	17.5	63.0	(31.4-112.7)
Female	7	5.2	134.8	(54.0-277.7)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	252	251.0	100.4	(88.4-113.6)
Male	1	7.1	nc	(nc-nc)	Female	216	249.5	86.6	(75.4-98.9)
Female	0	2.2	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	27	34.3	78.7	(51.9-114.6)					
Female	22	33.4	65.8	(41.2-99.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

East Bridgewater

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	16	14.1	113.8	(65.0-184.8)	Male	12	9.3	129.0	(66.6-225.3)
Female	2	6.3	nc	(nc-nc)	Female	10	8.6	116.5	(55.8-214.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	2.8	nc	(nc-nc)	Male	1	3.0	nc	(nc-nc)
Female	3	2.8	nc	(nc-nc)	Female	1	2.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.5	nc	(nc-nc)	Male	9	8.2	109.1	(49.8-207.2)
Female	53	71.1	74.5	(55.8-97.5)	Female	11	8.5	128.8	(64.2-230.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	2.2	nc	(nc-nc)	Male	9	7.0	128.8	(58.8-244.5)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	19	15.1	125.9	(75.8-196.6)	Female	7	6.1	115.2	(46.2-237.4)
Female	10	17.6	56.9	(27.2-104.6)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	3	5.3	nc	(nc-nc)
Male	6	3.6	165.2	(60.3-359.6)	Female	7	6.5	108.4	(43.4-223.3)
Female	0	1.2	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	51	43.6	117.0	(87.1-153.8)
Male	0	1.1	nc	(nc-nc)	<u>Stomach</u>				
Female	1	1.0	nc	(nc-nc)	Male	0	3.4	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	3	2.5	nc	(nc-nc)
Male	15	8.6	175.3	(98.1-289.2)	<u>Testis</u>				
Female	5	5.7	87.6	(28.2-204.5)	Male	3	2.1	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	3	2.1	nc	(nc-nc)	Male	2	4.0	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	11	12.7	86.9	(43.3-155.4)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	3	5.8	nc	(nc-nc)	Female	10	16.2	61.9	(29.6-113.9)
Female	4	5.0	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	199	184.0	108.2	(93.7-124.3)
Male	4	5.1	nc	(nc-nc)	Female	179	235.8	75.9	(65.2-87.9)
Female	1	2.1	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	24	25.1	95.5	(61.2-142.1)					
Female	22	34.0	64.7	(40.5-98.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

East Brookfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	3.4	nc	(nc-nc)	Male	1	2.0	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	0.5	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	2	0.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	1.8	nc	(nc-nc)
Female	6	9.8	61.3	(22.4-133.4)	Female	0	1.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	0	1.4	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	3	3.4	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
Female	0	2.2	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	1	1.2	nc	(nc-nc)
Male	2	0.8	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	10	9.4	106.4	(50.9-195.6)
Male	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.3	nc	(nc-nc)
Male	3	1.7	nc	(nc-nc)	<u>Testis</u>				
Female	1	0.8	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	0.5	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	2	1.9	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	1.2	nc	(nc-nc)	Female	5	2.3	214.8	(69.2-501.2)
Female	1	0.6	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	40	39.7	100.8	(72.0-137.3)
Male	2	1.0	nc	(nc-nc)	Female	29	31.3	92.7	(62.1-133.2)
Female	0	0.3	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	5	5.6	89.3	(28.8-208.4)					
Female	7	4.2	166.7	(66.8-343.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

East Longmeadow

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	14	23.0	60.9	(33.3-102.2)	Male	13	13.7	94.9	(50.5-162.3)
Female	5	8.6	58.1	(18.7-135.6)	Female	11	10.9	101.2	(50.5-181.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	3.7	nc	(nc-nc)	Male	4	4.4	nc	(nc-nc)
Female	4	3.5	nc	(nc-nc)	Female	4	3.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.8	nc	(nc-nc)	Male	14	12.1	115.3	(63.0-193.5)
Female	80	86.0	93.0	(73.8-115.8)	Female	11	11.3	97.0	(48.3-173.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	2.6	nc	(nc-nc)	Male	10	9.7	103.6	(49.6-190.6)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	25	22.9	108.9	(70.5-160.8)	Female	11	7.5	145.9	(72.8-261.1)
Female	33	24.2	136.4	(93.8-191.5)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	3	5.4	nc	(nc-nc)	Female	7	8.2	85.9	(34.4-176.9)
Female	2	1.6	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male				
Male	1	1.3	nc	(nc-nc)	Female	52	62.8	82.8	(61.9-108.6)
Female	0	1.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	14	11.8	118.7	(64.9-199.2)	Female	4	5.2	nc	(nc-nc)
Female	5	7.1	70.8	(22.8-165.2)	<u>Testis</u>				
<u>Larynx</u>					Male				
Male	2	3.1	nc	(nc-nc)	Female	6	3.4	174.4	(63.7-379.6)
Female	1	1.0	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	4	8.7	nc	(nc-nc)	Female	3	4.8	nc	(nc-nc)
Female	3	6.7	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Female				
Male	2	7.3	nc	(nc-nc)	Male	22	19.3	113.8	(71.3-172.2)
Female	1	2.8	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	37	38.3	96.7	(68.1-133.2)	Female	231	271.7	85.0	(74.4-96.7)
Female	45	43.4	103.7	(75.6-138.7)	Female	288	298.6	96.5	(85.6-108.3)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Eastham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	14	10.9	128.7	(70.3-216.0)	Male	13	6.1	211.5	(112.5-361.7)
Female	1	3.5	nc	(nc-nc)	Female	6	4.0	148.8	(54.3-323.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	1.5	nc	(nc-nc)	Male	2	2.0	nc	(nc-nc)
Female	0	1.3	nc	(nc-nc)	Female	3	1.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	5	5.3	93.5	(30.1-218.2)
Female	50	34.2	146.2	(108.5-192.7)	Female	6	4.5	133.7	(48.8-291.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.9	nc	(nc-nc)	Male	7	4.2	168.3	(67.4-346.8)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	14	10.0	140.5	(76.7-235.7)	Female	3	3.0	nc	(nc-nc)
Female	9	9.2	97.8	(44.6-185.7)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	3	2.5	nc	(nc-nc)	Male	32	29.7	107.6	(73.6-151.9)
Female	2	0.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	5	5.2	97.0	(31.3-226.4)	Female	3	8.2	nc	(nc-nc)
Female	2	2.9	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Leukemia</u>				
Male	2	1.4	nc	(nc-nc)	Male	7	3.8	185.0	(74.1-381.3)
Female	0	0.4	nc	(nc-nc)	Female	1	2.5	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Lung and Bronchus</u>				
Male	2	3.3	nc	(nc-nc)	Male	28	18.7	149.5	(99.3-216.1)
Female	1	1.1	nc	(nc-nc)	Female	14	19.0	73.7	(40.3-123.7)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Easthampton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	12	19.4	61.7	(31.8-107.8)	Male	10	12.6	79.6	(38.1-146.4)
Female	5	6.8	73.6	(23.7-171.7)	Female	4	9.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	3.6	nc	(nc-nc)	Male	2	4.0	nc	(nc-nc)
Female	3	3.0	nc	(nc-nc)	Female	3	3.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.7	nc	(nc-nc)	Male	15	11.1	135.6	(75.8-223.6)
Female	75	76.2	98.4	(77.4-123.4)	Female	7	9.4	74.4	(29.8-153.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	2.4	nc	(nc-nc)	Male	10	9.3	107.1	(51.3-196.9)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	26	20.3	127.9	(83.6-187.5)	Female	1	6.6	nc	(nc-nc)
Female	18	19.3	93.1	(55.1-147.1)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	7	7.3	96.5	(38.7-198.8)
Male	3	4.9	nc	(nc-nc)	Female	11	7.0	156.2	(77.9-279.5)
Female	1	1.3	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	45	59.5	75.6	(55.2-101.2)
Male	2	1.4	nc	(nc-nc)	<u>Stomach</u>				
Female	0	1.2	nc	(nc-nc)	Male	6	4.6	130.9	(47.8-284.8)
<u>Kidney & Renal Pelvis</u>					Female	2	2.7	nc	(nc-nc)
Male	14	11.3	123.8	(67.6-207.8)	<u>Testis</u>				
Female	6	6.1	98.4	(35.9-214.1)	Male	1	2.6	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	3	2.9	nc	(nc-nc)	Male	1	5.0	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	Female	8	14.0	57.1	(24.6-112.4)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	5	7.6	65.4	(21.1-152.6)	Female	23	17.7	130.0	(82.4-195.1)
Female	4	5.4	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	207	249.3	83.0	(72.1-95.1)
Male	4	7.0	nc	(nc-nc)	Female	244	255.3	95.6	(83.9-108.3)
Female	5	2.3	215.5	(69.5-503.0)					
<u>Lung and Bronchus</u>									
Male	26	34.7	74.9	(48.9-109.8)					
Female	43	35.7	120.5	(87.2-162.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Easton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	28	21.9	128.1	(85.1-185.1)	Male	23	14.6	157.8	(100.0-236.8)
Female	12	7.9	151.3	(78.1-264.3)	Female	10	11.9	84.1	(40.3-154.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	4.6	130.4	(47.6-283.8)	Male	4	4.7	nc	(nc-nc)
Female	4	4.0	nc	(nc-nc)	Female	7	3.8	184.1	(73.8-379.3)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.8	nc	(nc-nc)	Male	10	13.0	77.1	(36.9-141.9)
Female	113	98.7	114.5	(94.3-137.6)	Female	12	11.4	105.3	(54.3-183.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	3.3	nc	(nc-nc)	Male	10	11.4	87.8	(42.0-161.5)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	14	23.7	59.1	(32.3-99.2)	Female	11	8.3	132.9	(66.3-237.9)
Female	26	22.9	113.5	(74.1-166.4)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	4	5.9	nc	(nc-nc)	Male	12	8.3	144.2	(74.4-251.9)
Female	2	1.6	nc	(nc-nc)	Female	12	8.2	147.1	(75.9-256.9)
<u>Hodgkin Lymphoma</u>					<u>Stomach</u>				
Male	3	1.8	nc	(nc-nc)	Male	3	5.3	nc	(nc-nc)
Female	0	1.6	nc	(nc-nc)	Female	3	3.2	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					<u>Testis</u>				
Male	17	13.8	123.4	(71.8-197.5)	Male	1	3.2	nc	(nc-nc)
Female	5	7.6	65.4	(21.1-152.5)	<u>Thyroid</u>				
<u>Larynx</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	2	3.4	nc	(nc-nc)	Female	21	22.3	94.0	(58.2-143.7)
Female	0	1.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	16	9.2	173.0	(98.8-280.9)	Male	324	293.9	110.2	(98.6-122.9)
Female	3	6.6	nc	(nc-nc)	Female	354	318.7	111.1	(99.8-123.3)
<u>Liver and Intrahepatic Bile Ducts</u>									
Male	10	8.3	120.6	(57.7-221.8)					
Female	5	2.7	182.3	(58.8-425.4)					
<u>Lung and Bronchus</u>									
Male	34	39.7	85.6	(59.3-119.7)					
Female	50	43.1	115.9	(86.0-152.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Edgartown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	6	6.8	87.9	(32.1-191.3)	Male	18	4.3	415.6	(246.2-656.8)
Female	2	1.8	nc	(nc-nc)	Female	3	2.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.2	nc	(nc-nc)	Male	2	1.4	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	5	3.8	130.8	(42.1-305.2)
Female	29	19.9	146.0	(97.8-209.8)	Female	1	2.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.6	nc	(nc-nc)	Male	6	3.4	178.4	(65.1-388.3)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	10	7.1	140.1	(67.1-257.7)	Female	0	1.7	nc	(nc-nc)
Female	4	5.1	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	0	2.5	nc	(nc-nc)
Male	2	1.8	nc	(nc-nc)	Female	3	1.9	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	24	21.7	110.7	(70.9-164.8)
Male	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.2	nc	(nc-nc)	Male	2	1.6	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.7	nc	(nc-nc)
Male	2	4.0	nc	(nc-nc)	<u>Testis</u>				
Female	1	1.6	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	1.0	nc	(nc-nc)	Male	3	1.7	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	Female	6	3.2	185.5	(67.8-403.9)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	2.7	nc	(nc-nc)	Female	1	4.7	nc	(nc-nc)
Female	0	1.4	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	101	87.5	115.4	(94.0-140.2)
Male	1	2.5	nc	(nc-nc)	Female	72	66.4	108.5	(84.9-136.7)
Female	1	0.6	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	13	11.7	110.6	(58.9-189.2)					
Female	9	9.6	93.5	(42.7-177.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Egremont

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	2.7	nc	(nc-nc)	Male	0	1.6	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	2	0.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.4	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.4	nc	(nc-nc)
Female	6	7.4	81.5	(29.8-177.4)	Female	1	1.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.2	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	5	2.6	194.2	(62.6-453.3)	Female	2	0.7	nc	(nc-nc)
Female	1	2.1	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	1	1.0	nc	(nc-nc)
Male	0	0.6	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	6	7.7	77.9	(28.5-169.7)
Male	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.3	nc	(nc-nc)
Male	1	1.4	nc	(nc-nc)	<u>Testis</u>				
Female	0	0.6	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	0.9	nc	(nc-nc)	Female	2	1.8	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	22	31.7	69.5	(43.5-105.2)
Male	1	0.9	nc	(nc-nc)	Female	25	25.8	96.9	(62.7-143.1)
Female	0	0.2	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	1	4.6	nc	(nc-nc)					
Female	3	4.0	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Erving

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	2.0	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	4	8.7	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	3	2.2	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
Female	1	2.1	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	1	0.8	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	Female	2	0.8	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	1	6.5	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.3	nc	(nc-nc)
Male	1	1.2	nc	(nc-nc)	<u>Testis</u>				
Female	1	0.7	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	1.6	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.8	nc	(nc-nc)	Female	4	1.9	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	18	26.7	67.3	(39.9-106.4)
Male	1	0.8	nc	(nc-nc)	Female	21	28.7	73.2	(45.3-111.8)
Female	0	0.3	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	5	3.6	140.3	(45.2-327.3)					
Female	3	4.1	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Essex

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	5.1	nc	(nc-nc)	Male	7	3.2	220.2	(88.2-453.8)
Female	1	1.4	nc	(nc-nc)	Female	2	2.0	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.9	nc	(nc-nc)	Male	2	1.1	nc	(nc-nc)
Female	3	0.7	nc	(nc-nc)	Female	2	0.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	3	2.8	nc	(nc-nc)
Female	18	17.5	102.8	(60.9-162.5)	Female	3	2.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.5	nc	(nc-nc)	Male	4	2.4	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	1	5.2	nc	(nc-nc)	Female	4	1.5	nc	(nc-nc)
Female	4	4.0	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	3	1.9	nc	(nc-nc)
Male	2	1.3	nc	(nc-nc)	Female	2	1.5	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	9	16.2	55.6	(25.4-105.6)
Male	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.2	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.6	nc	(nc-nc)
Male	2	2.9	nc	(nc-nc)	<u>Testis</u>				
Female	1	1.4	nc	(nc-nc)	Male	2	0.5	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.8	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	Female	2	3.1	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	3	2.0	nc	(nc-nc)	Female	2	4.1	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	58	64.8	89.5	(68.0-115.7)
Male	0	1.8	nc	(nc-nc)	Female	59	56.5	104.5	(79.5-134.8)
Female	0	0.5	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	10	8.9	112.3	(53.7-206.5)					
Female	9	8.0	112.8	(51.5-214.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Everett

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	32	37.4	85.6	(58.5-120.8)	Male	22	25.0	88.1	(55.2-133.5)
Female	12	13.6	88.0	(45.4-153.7)	Female	9	20.9	43.0	(19.6-81.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	8.0	nc	(nc-nc)	Male	9	7.8	114.7	(52.3-217.7)
Female	4	7.0	nc	(nc-nc)	Female	2	6.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	1.3	nc	(nc-nc)	Male	22	22.2	99.0	(62.0-150.0)
Female	146	161.2	90.6	(76.5-106.5)	Female	17	19.5	87.2	(50.8-139.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	13	5.9	219.1	(116.5-374.7)	Male	18	18.4	98.0	(58.1-154.9)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	40	40.0	99.9	(71.4-136.0)	Female	12	13.9	86.4	(44.6-150.9)
Female	27	40.4	66.8	(44.0-97.2)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	15	13.9	107.8	(60.3-177.8)
Male	11	9.5	115.4	(57.5-206.6)	Female	13	14.2	91.3	(48.6-156.2)
Female	2	2.7	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	88	111.1	79.2	(63.5-97.6)
Male	2	3.5	nc	(nc-nc)	<u>Stomach</u>				
Female	2	3.1	nc	(nc-nc)	Male	16	8.9	179.6	(102.6-291.6)
<u>Kidney & Renal Pelvis</u>					Female	7	5.7	123.5	(49.5-254.5)
Male	26	22.5	115.3	(75.3-169.0)	<u>Testis</u>				
Female	15	12.7	118.0	(66.0-194.6)	Male	7	7.1	98.6	(39.5-203.1)
<u>Larynx</u>					<u>Thyroid</u>				
Male	8	5.6	143.8	(61.9-283.4)	Male	13	11.0	118.0	(62.8-201.8)
Female	5	1.7	294.3	(94.8-686.7)	Female	29	34.3	84.7	(56.7-121.6)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	17	16.1	105.7	(61.5-169.3)	Female	27	35.6	75.9	(50.0-110.5)
Female	11	11.8	92.9	(46.3-166.2)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	470	488.5	96.2	(87.7-105.3)
Male	22	13.4	164.3	(102.9-248.7)	Female	478	537.3	89.0	(81.2-97.3)
Female	6	4.6	130.1	(47.5-283.1)					
<u>Lung and Bronchus</u>									
Male	69	66.3	104.0	(80.9-131.6)					
Female	73	71.0	102.8	(80.6-129.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Fairhaven

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	24	22.5	106.8	(68.4-158.9)	Male	8	13.8	58.0	(25.0-114.2)
Female	20	8.6	232.5	(142.0-359.1)	Female	5	10.7	46.5	(15.0-108.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	3.8	nc	(nc-nc)	Male	7	4.4	157.5	(63.1-324.5)
Female	3	3.4	nc	(nc-nc)	Female	4	3.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.8	nc	(nc-nc)	Male	11	12.1	90.6	(45.2-162.2)
Female	80	85.7	93.4	(74.1-116.2)	Female	15	11.2	134.4	(75.1-221.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	2.6	nc	(nc-nc)	Male	5	9.9	50.3	(16.2-117.4)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	17	22.7	74.8	(43.6-119.8)	Female	14	7.6	184.5	(100.8-309.5)
Female	22	24.0	91.8	(57.5-139.0)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	2	5.5	nc	(nc-nc)	Female	7	9.0	77.6	(31.1-159.9)
Female	2	1.6	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male				
Male	0	1.3	nc	(nc-nc)	Female	62	64.9	95.5	(73.2-122.4)
Female	2	1.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	17	12.1	140.2	(81.6-224.5)	Female	3	5.1	nc	(nc-nc)
Female	7	7.1	98.4	(39.4-202.8)	<u>Testis</u>				
<u>Larynx</u>					Male				
Male	5	3.1	159.3	(51.3-371.7)	Female	3	3.4	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	6	8.5	70.2	(25.6-152.8)	Female	14	14.0	99.7	(54.5-167.3)
Female	10	6.5	153.1	(73.3-281.7)	<u>Uteri Corpus and Uterus, NOS</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Female				
Male	1	7.5	nc	(nc-nc)	Female	18	19.7	91.4	(54.2-144.5)
Female	1	2.8	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	39	38.6	101.1	(71.9-138.2)	Female	286	297.9	96.0	(85.2-107.8)
Female	36	44.2	81.5	(57.1-112.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Fall River

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	101	87.6	115.3	(93.9-140.1)	Male	26	56.4	46.1	(30.1-67.6)
Female	37	38.3	96.7	(68.0-133.2)	Female	24	51.4	46.7	(29.9-69.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	17	17.2	99.1	(57.7-158.7)	Male	12	17.9	66.9	(34.5-116.9)
Female	14	16.7	83.6	(45.7-140.3)	Female	13	17.5	74.1	(39.4-126.7)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	3	3.1	nc	(nc-nc)	Male	48	50.1	95.8	(70.6-127.0)
Female	317	403.6	78.5	(70.1-87.7)	Female	38	51.5	73.7	(52.2-101.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	19	13.0	145.7	(87.7-227.5)	Male	38	41.6	91.4	(64.7-125.5)
Female					Female	22	22.4	98.0	(61.4-148.4)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	108	92.0	117.4	(96.3-141.7)	Female	18	35.3	51.0	(30.2-80.7)
Female	115	109.0	105.6	(87.1-126.7)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	35	32.4	108.1	(75.3-150.3)
Male	18	22.0	81.9	(48.5-129.4)	Female	42	40.1	104.7	(75.4-141.5)
Female	4	7.4	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	278	262.7	105.8	(93.8-119.0)
Male	10	7.0	143.8	(68.8-264.5)	<u>Stomach</u>				
Female	7	6.7	104.2	(41.8-214.7)	Male	34	20.6	165.4	(114.5-231.1)
<u>Kidney & Renal Pelvis</u>					Female	28	15.3	182.5	(121.2-263.8)
Male	56	50.8	110.2	(83.3-143.1)	<u>Testis</u>				
Female	35	32.9	106.5	(74.2-148.1)	Male	12	13.4	89.9	(46.4-157.0)
<u>Larynx</u>					<u>Thyroid</u>				
Male	17	12.8	132.7	(77.3-212.6)	Male	16	23.1	69.2	(39.5-112.4)
Female	8	4.6	175.2	(75.4-345.2)	Female	91	73.9	123.2	(99.2-151.3)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	35	35.9	97.4	(67.9-135.5)	Female	93	90.4	102.9	(83.0-126.0)
Female	34	30.7	110.7	(76.6-154.6)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	1256	1119.3	112.2	(106.1-118.6)
Male	36	30.5	117.9	(82.5-163.2)	Female	1277	1384.9	92.2	(87.2-97.4)
Female	10	12.4	80.8	(38.7-148.6)					
<u>Lung and Bronchus</u>									
Male	258	153.3	168.3	(148.4-190.2)					
Female	200	197.5	101.3	(87.7-116.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Falmouth

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	47	57.2	82.1	(60.3-109.2)	Male	36	33.5	107.4	(75.2-148.7)
Female	13	20.9	62.1	(33.0-106.2)	Female	33	24.2	136.5	(93.9-191.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	14	8.6	162.2	(88.6-272.2)	Male	8	11.0	73.0	(31.4-143.9)
Female	10	7.6	131.2	(62.8-241.3)	Female	10	9.3	107.1	(51.3-197.0)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.9	nc	(nc-nc)	Male	32	29.3	109.1	(74.6-154.1)
Female	204	199.8	102.1	(88.6-117.1)	Female	13	26.5	49.1	(26.1-84.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	5.3	nc	(nc-nc)	Male	28	23.0	121.8	(80.9-176.1)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	52	54.6	95.2	(71.1-124.8)	Female	22	17.5	125.5	(78.6-190.0)
Female	52	55.8	93.2	(69.6-122.2)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	12	13.4	89.5	(46.2-156.4)	Male	14	20.2	69.3	(37.9-116.4)
Female	5	4.0	124.6	(40.1-290.7)	Female	14	21.8	64.2	(35.1-107.8)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	2.6	nc	(nc-nc)	Male	183	157.1	116.5	(100.2-134.6)
Female	2	2.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	29	28.6	101.5	(68.0-145.8)	Male	10	12.7	78.7	(37.7-144.7)
Female	15	16.9	88.9	(49.7-146.7)	Female	3	7.9	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	13	7.7	168.3	(89.5-287.8)	Male	4	3.8	nc	(nc-nc)
Female	2	2.4	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	29	20.7	140.4	(94.0-201.6)	Male	8	10.5	76.5	(32.9-150.7)
Female	6	15.1	39.6	(14.5-86.3)	Female	15	28.8	52.1	(29.1-85.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	17	17.7	96.1	(56.0-153.9)	Female	33	46.5	70.9	(48.8-99.6)
Female	3	6.5	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	74	99.3	74.5	(58.5-93.5)	Male	665	667.4	99.6	(92.2-107.5)
Female	118	110.2	107.1	(88.6-128.2)	Female	644	699.6	92.1	(85.1-99.4)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Fitchburg

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	52	39.9	130.4	(97.4-171.0)	Male	17	25.8	66.0	(38.4-105.6)
Female	20	13.8	145.1	(88.6-224.1)	Female	15	19.2	78.2	(43.7-129.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	8.0	nc	(nc-nc)	Male	4	8.2	nc	(nc-nc)
Female	13	6.6	198.4	(105.5-339.2)	Female	6	6.3	94.8	(34.6-206.4)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	1.4	nc	(nc-nc)	Male	13	22.9	56.8	(30.2-97.2)
Female	147	151.5	97.0	(82.0-114.1)	Female	15	18.7	80.1	(44.8-132.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	8	5.0	160.1	(68.9-315.5)	Male	22	18.7	117.5	(73.6-178.0)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	40	41.8	95.6	(68.3-130.2)	Female	12	13.2	90.7	(46.8-158.5)
Female	45	39.5	114.0	(83.1-152.5)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	17	14.7	115.9	(67.5-185.6)
Male	6	9.9	60.4	(22.0-131.4)	Female	9	14.3	62.8	(28.6-119.2)
Female	2	2.6	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	84	115.1	73.0	(58.2-90.3)
Male	2	3.3	nc	(nc-nc)	<u>Stomach</u>				
Female	1	2.7	nc	(nc-nc)	Male	12	9.3	128.4	(66.2-224.2)
<u>Kidney & Renal Pelvis</u>					Female	6	5.5	108.6	(39.7-236.5)
Male	27	22.9	117.9	(77.7-171.6)	<u>Testis</u>				
Female	16	12.3	129.8	(74.2-210.9)	Male	6	6.2	96.0	(35.1-209.0)
<u>Larynx</u>					<u>Thyroid</u>				
Male	4	5.8	nc	(nc-nc)	Male	8	10.5	75.9	(32.7-149.5)
Female	2	1.7	nc	(nc-nc)	Female	32	29.1	110.1	(75.3-155.4)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	14	16.6	84.4	(46.1-141.5)	Female	29	33.5	86.5	(57.9-124.2)
Female	17	11.6	147.0	(85.6-235.4)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	478	505.9	94.5	(86.2-103.3)
Male	16	13.8	115.9	(66.2-188.3)	Female	534	514.3	103.8	(95.2-113.0)
Female	6	4.5	133.5	(48.7-290.5)					
<u>Lung and Bronchus</u>									
Male	86	69.8	123.1	(98.5-152.1)					
Female	76	72.7	104.6	(82.4-130.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Florida

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	0.8	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	3	3.9	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	1	0.9	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	1	0.3	nc	(nc-nc)
Male	1	0.2	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	1	2.8	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.1	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	<u>Testis</u>				
Female	0	0.3	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	0.1	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.3	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	10	10.9	92.1	(44.1-169.5)
Male	0	0.3	nc	(nc-nc)	Female	8	12.6	63.5	(27.3-125.2)
Female	0	0.1	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	0	1.5	nc	(nc-nc)					
Female	2	1.8	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Foxborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	16	21.3	75.1	(42.9-121.9)	Male	24	13.2	182.3	(116.7-271.2)
Female	1	7.2	nc	(nc-nc)	Female	11	9.9	111.1	(55.4-198.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	8	3.7	216.7	(93.3-427.0)	Male	2	4.2	nc	(nc-nc)
Female	3	3.2	nc	(nc-nc)	Female	3	3.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.7	nc	(nc-nc)	Male	11	11.7	93.9	(46.8-168.0)
Female	98	80.1	122.3	(99.3-149.1)	Female	7	9.8	71.2	(28.5-146.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	2.6	nc	(nc-nc)	Male	8	9.4	85.4	(36.8-168.4)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	20	22.0	91.1	(55.6-140.7)	Female	6	6.9	87.1	(31.8-189.6)
Female	20	20.4	98.0	(59.8-151.4)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	4	7.7	nc	(nc-nc)
Male	6	5.1	116.9	(42.7-254.4)	Female	6	7.5	80.3	(29.3-174.8)
Female	0	1.4	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	63	58.3	108.1	(83.0-138.2)
Male	5	1.4	364.5	(117.5-850.5)	<u>Stomach</u>				
Female	0	1.2	nc	(nc-nc)	Male	8	4.9	163.8	(70.5-322.8)
<u>Kidney & Renal Pelvis</u>					Female	3	2.9	nc	(nc-nc)
Male	19	11.4	166.7	(100.3-260.3)	<u>Testis</u>				
Female	8	6.4	124.6	(53.7-245.6)	Male	3	2.6	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	2.9	nc	(nc-nc)	Male	7	5.0	139.2	(55.8-286.8)
Female	0	0.9	nc	(nc-nc)	Female	20	14.5	137.5	(84.0-212.4)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	10	8.3	121.2	(58.0-222.9)	Female	18	18.2	98.8	(58.5-156.2)
Female	6	5.8	103.6	(37.8-225.6)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	274	257.9	106.3	(94.1-119.6)
Male	3	7.0	nc	(nc-nc)	Female	278	268.2	103.6	(91.8-116.6)
Female	1	2.4	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	34	35.6	95.6	(66.2-133.5)					
Female	42	37.8	111.2	(80.1-150.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Framingham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	65	67.5	96.2	(74.3-122.7)	Male	48	44.0	109.1	(80.4-144.6)
Female	26	26.1	99.8	(65.2-146.2)	Female	29	36.9	78.5	(52.6-112.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	8	13.5	59.2	(25.5-116.6)	Male	12	13.9	86.4	(44.6-151.0)
Female	8	12.3	65.1	(28.0-128.3)	Female	6	12.1	49.5	(18.1-107.8)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	2.4	nc	(nc-nc)	Male	40	39.1	102.3	(73.1-139.3)
Female	280	287.4	97.4	(86.4-109.5)	Female	28	35.8	78.2	(51.9-113.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	22	9.8	223.5	(140.0-338.3)	Male	31	32.4	95.7	(65.0-135.8)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	61	71.3	85.5	(65.4-109.8)	Female	26	25.1	103.7	(67.7-152.0)
Female	82	75.8	108.2	(86.0-134.3)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	30	25.1	119.6	(80.7-170.8)
Male	10	17.0	58.8	(28.1-108.1)	Female	30	27.4	109.4	(73.8-156.1)
Female	4	5.0	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	194	201.5	96.3	(83.2-110.8)
Male	3	5.6	nc	(nc-nc)	<u>Stomach</u>				
Female	8	5.1	156.1	(67.2-307.6)	Male	22	15.9	138.2	(86.6-209.3)
<u>Kidney & Renal Pelvis</u>					Female	6	10.7	56.2	(20.5-122.4)
Male	55	39.4	139.5	(105.1-181.6)	<u>Testis</u>				
Female	20	23.1	86.4	(52.8-133.5)	Male	9	11.2	80.4	(36.7-152.6)
<u>Larynx</u>					<u>Thyroid</u>				
Male	4	9.9	nc	(nc-nc)	Male	22	18.6	118.4	(74.2-179.2)
Female	4	3.2	nc	(nc-nc)	Female	70	56.3	124.4	(97.0-157.2)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	20	28.1	71.2	(43.5-110.0)	Female	63	64.1	98.2	(75.5-125.7)
Female	19	22.0	86.5	(52.0-135.0)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	816	867.7	94.0	(87.7-100.7)
Male	29	24.0	121.0	(81.0-173.8)	Female	955	976.6	97.8	(91.7-104.2)
Female	8	8.7	92.1	(39.7-181.5)					
<u>Lung and Bronchus</u>									
Male	101	117.3	86.1	(70.1-104.6)					
Female	124	133.6	92.8	(77.2-110.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Franklin

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	28	29.5	94.8	(63.0-137.1)	Male	22	20.0	109.8	(68.8-166.2)
Female	9	10.8	83.6	(38.2-158.7)	Female	19	16.6	114.1	(68.7-178.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	6.3	79.9	(25.8-186.5)	Male	10	6.3	157.8	(75.5-290.2)
Female	5	5.5	90.9	(29.3-212.2)	Female	6	5.1	117.7	(43.0-256.3)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.1	nc	(nc-nc)	Male	19	17.7	107.0	(64.4-167.2)
Female	148	135.3	109.4	(92.5-128.5)	Female	15	15.5	96.7	(54.1-159.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	8	4.9	164.3	(70.8-323.8)	Male	18	15.5	115.9	(68.7-183.2)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	30	32.7	91.7	(61.8-130.8)	Female	15	11.3	132.4	(74.0-218.4)
Female	23	32.4	71.1	(45.0-106.6)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	15	11.3	132.9	(74.3-219.2)
Male	8	7.8	102.7	(44.2-202.4)	Female	7	11.2	62.6	(25.1-129.1)
Female	2	2.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	96	93.9	102.3	(82.8-124.9)
Male	3	2.4	nc	(nc-nc)	<u>Stomach</u>				
Female	4	2.2	nc	(nc-nc)	Male	12	7.2	167.1	(86.2-291.8)
<u>Kidney & Renal Pelvis</u>					Female	5	4.6	109.8	(35.4-256.2)
Male	15	18.8	79.8	(44.6-131.7)	<u>Testis</u>				
Female	18	10.4	173.3	(102.7-274.0)	Male	11	4.7	234.8	(117.0-420.1)
<u>Larynx</u>					<u>Thyroid</u>				
Male	7	4.6	153.8	(61.6-316.8)	Male	16	9.0	178.7	(102.1-290.2)
Female	0	1.4	nc	(nc-nc)	Female	40	27.6	145.2	(103.7-197.7)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	15	12.7	118.3	(66.2-195.2)	Female	43	29.4	146.4	(105.9-197.2)
Female	4	9.3	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	407	396.1	102.8	(93.0-113.2)
Male	6	11.1	53.9	(19.7-117.3)	Female	436	436.4	99.9	(90.7-109.7)
Female	0	3.7	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	38	52.6	72.3	(51.1-99.2)					
Female	38	56.8	66.9	(47.3-91.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Freetown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	9	11.5	78.4	(35.8-148.8)	Male	4	7.3	nc	(nc-nc)
Female	1	3.1	nc	(nc-nc)	Female	4	4.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	2.1	nc	(nc-nc)	Male	1	2.4	nc	(nc-nc)
Female	1	1.5	nc	(nc-nc)	Female	3	1.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	4	6.5	nc	(nc-nc)
Female	48	39.2	122.4	(90.3-162.3)	Female	4	4.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	1.3	nc	(nc-nc)	Male	7	5.5	126.3	(50.6-260.3)
<u>Colon / Rectum</u>					Female	2	2.0	nc	(nc-nc)
Male	7	12.2	57.4	(23.0-118.2)	<u>Ovary</u>				
Female	4	8.9	nc	(nc-nc)	Female	2	3.3	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	2.9	nc	(nc-nc)	Male	0	4.2	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	6	3.2	188.8	(69.0-411.0)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.8	nc	(nc-nc)	Male	38	34.4	110.5	(78.2-151.7)
Female	0	0.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	2.7	nc	(nc-nc)
Male	4	6.7	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
Female	2	3.0	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	1.4	nc	(nc-nc)
Male	1	1.6	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.4	nc	(nc-nc)	Male	4	3.0	nc	(nc-nc)
<u>Leukemia</u>					Female	9	7.5	119.8	(54.7-227.4)
Male	1	4.6	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	2.5	nc	(nc-nc)	Female	10	9.0	110.9	(53.1-204.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	4.0	nc	(nc-nc)	Male	117	145.4	80.4	(66.5-96.4)
Female	1	1.1	nc	(nc-nc)	Female	147	125.7	116.9	(98.8-137.4)
<u>Lung and Bronchus</u>									
Male	16	19.6	81.5	(46.6-132.4)					
Female	23	17.2	133.7	(84.7-200.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Gardner

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	13	23.4	55.5	(29.5-94.9)	Male	4	14.8	nc	(nc-nc)
Female	11	8.6	127.3	(63.5-227.8)	Female	11	11.3	97.0	(48.3-173.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	4.4	114.9	(37.0-268.1)	Male	3	4.8	nc	(nc-nc)
Female	5	3.7	135.4	(43.6-316.0)	Female	2	4.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.8	nc	(nc-nc)	Male	11	13.2	83.4	(41.6-149.2)
Female	59	89.7	65.8	(50.1-84.9)	Female	9	11.6	77.7	(35.5-147.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	2.8	nc	(nc-nc)	Male	11	10.6	103.7	(51.7-185.6)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	30	24.3	123.3	(83.1-176.0)	Female	9	7.9	114.1	(52.1-216.6)
Female	25	24.2	103.1	(66.7-152.2)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	8	8.5	93.7	(40.4-184.7)
Male	11	5.8	190.9	(95.2-341.6)	Female	5	9.0	55.6	(17.9-129.7)
Female	0	1.7	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	43	65.7	65.5	(47.4-88.2)
Male	2	1.7	nc	(nc-nc)	<u>Stomach</u>				
Female	3	1.4	nc	(nc-nc)	Male	2	5.4	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	6	3.4	175.5	(64.1-382.0)
Male	15	13.0	115.5	(64.6-190.5)	<u>Testis</u>				
Female	9	7.4	122.3	(55.8-232.1)	Male	3	3.3	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	3	3.3	nc	(nc-nc)	Male	2	5.9	nc	(nc-nc)
Female	2	1.0	nc	(nc-nc)	Female	11	15.9	69.4	(34.6-124.2)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	13	9.3	139.3	(74.1-238.2)	Female	21	20.5	102.3	(63.3-156.4)
Female	12	6.9	174.2	(89.9-304.3)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	269	290.2	92.7	(81.9-104.5)
Male	11	7.9	139.3	(69.4-249.3)	Female	290	308.7	93.9	(83.4-105.4)
Female	4	2.9	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	60	40.2	149.4	(114.0-192.3)					
Female	53	44.3	119.6	(89.6-156.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Georgetown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	6	8.7	69.0	(25.2-150.3)	Male	6	5.8	103.6	(37.8-225.5)
Female	2	2.9	nc	(nc-nc)	Female	4	4.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.8	nc	(nc-nc)	Male	0	1.9	nc	(nc-nc)
Female	1	1.5	nc	(nc-nc)	Female	2	1.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	7	5.1	136.8	(54.8-281.8)
Female	31	38.9	79.6	(54.1-113.0)	Female	2	4.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.3	nc	(nc-nc)	Male	1	4.5	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	6	9.6	62.6	(22.8-136.2)	Female	0	3.2	nc	(nc-nc)
Female	6	8.6	69.5	(25.4-151.3)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	5	3.3	151.7	(48.9-354.0)
Male	1	2.3	nc	(nc-nc)	Female	3	3.0	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	32	28.3	113.2	(77.4-159.8)
Male	1	0.7	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.5	nc	(nc-nc)	Male	2	2.1	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	1.2	nc	(nc-nc)
Male	4	5.5	nc	(nc-nc)	<u>Testis</u>				
Female	2	3.0	nc	(nc-nc)	Male	2	1.3	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	1.3	nc	(nc-nc)	Male	3	2.5	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	5	7.3	68.5	(22.1-160.0)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	2	3.6	nc	(nc-nc)	Female	10	9.0	110.9	(53.1-203.9)
Female	2	2.5	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	98	116.1	84.4	(68.5-102.9)
Male	2	3.2	nc	(nc-nc)	Female	97	122.4	79.3	(64.3-96.7)
Female	1	1.0	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	7	15.7	44.7	(17.9-92.0)					
Female	11	16.2	68.0	(33.9-121.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Gill

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	2.2	nc	(nc-nc)	Male	0	1.4	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.4	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
Female	6	7.6	78.5	(28.7-170.8)	Female	1	0.9	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.2	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	1	2.3	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
Female	0	1.7	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	0	0.6	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male				
Male	1	0.2	nc	(nc-nc)	Female	4	7.0	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	0	1.3	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male				
Male	0	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	0	0.8	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Female				
Male	0	0.8	nc	(nc-nc)	Male	2	1.9	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	10	3.9	256.8	(123.0-472.4)	Female	23	28.5	80.7	(51.1-121.0)
Female	4	3.3	nc	(nc-nc)	Female	22	24.6	89.4	(56.0-135.3)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Gloucester

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	43	40.0	107.6	(77.9-144.9)	Male	26	24.8	104.9	(68.5-153.7)
Female	27	14.8	182.5	(120.2-265.5)	Female	28	19.5	143.9	(95.6-207.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	6.9	nc	(nc-nc)	Male	9	8.2	110.2	(50.3-209.2)
Female	4	6.3	nc	(nc-nc)	Female	3	6.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	1.4	nc	(nc-nc)	Male	26	22.0	118.4	(77.3-173.5)
Female	175	161.3	108.5	(93.0-125.8)	Female	24	20.0	120.0	(76.9-178.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	4.8	nc	(nc-nc)	Male	27	18.9	142.9	(94.1-207.8)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	37	40.4	91.6	(64.5-126.3)	Female	22	13.9	158.6	(99.3-240.1)
Female	51	41.4	123.3	(91.8-162.1)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	27	14.8	182.0	(119.9-264.8)
Male	12	10.3	116.7	(60.2-203.9)	Female	12	15.5	77.6	(40.1-135.6)
Female	1	2.9	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	115	128.6	89.4	(73.8-107.3)
Male	4	2.4	nc	(nc-nc)	<u>Stomach</u>				
Female	3	2.1	nc	(nc-nc)	Male	9	9.3	97.2	(44.3-184.4)
<u>Kidney & Renal Pelvis</u>					Female	2	5.8	nc	(nc-nc)
Male	27	22.6	119.5	(78.7-173.9)	<u>Testis</u>				
Female	15	13.0	115.6	(64.7-190.7)	Male	5	3.8	131.6	(42.4-307.0)
<u>Larynx</u>					<u>Thyroid</u>				
Male	8	6.0	134.2	(57.8-264.4)	Male	11	9.0	122.2	(60.9-218.6)
Female	3	1.8	nc	(nc-nc)	Female	32	26.7	119.7	(81.8-168.9)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	20	15.3	130.3	(79.6-201.2)	Female	27	37.8	71.4	(47.1-103.9)
Female	13	11.5	113.0	(60.1-193.3)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	553	508.4	108.8	(99.9-118.2)
Male	9	14.5	62.0	(28.3-117.8)	Female	606	541.0	112.0	(103.3-121.3)
Female	5	4.9	101.2	(32.6-236.2)					
<u>Lung and Bronchus</u>									
Male	90	70.4	127.8	(102.8-157.1)					
Female	95	77.8	122.0	(98.7-149.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Goshen

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	1.3	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	5	5.8	86.8	(28.0-202.5)	Female	0	0.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	2	0.8	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	1	1.5	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	0	0.4	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	3	4.8	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	0	0.9	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	0	0.2	nc	(nc-nc)	Male	1	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	0	0.5	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	0.5	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	1	2.4	nc	(nc-nc)	Male	12	18.3	65.5	(33.8-114.5)
Female	0	2.3	nc	(nc-nc)	Female	10	18.2	54.8	(26.2-100.8)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Gosnold

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
					Female	0	0.0	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)					
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)					
<u>Kidney & Renal Pelvis</u>					<u>Stomach</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)					
<u>Leukemia</u>					<u>Thyroid</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.0	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)					
<u>Lung and Bronchus</u>					<u>All Sites / Types</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	1.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	2.3	nc	(nc-nc)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Grafton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	21	16.1	130.1	(80.5-198.8)	Male	11	11.2	98.4	(49.1-176.1)
Female	4	5.8	nc	(nc-nc)	Female	11	9.1	120.3	(60.0-215.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	7	3.5	199.2	(79.8-410.5)	Male	2	3.5	nc	(nc-nc)
Female	5	3.0	168.4	(54.3-392.9)	Female	3	2.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.6	nc	(nc-nc)	Male	7	9.9	70.5	(28.3-145.3)
Female	74	74.4	99.5	(78.1-124.9)	Female	7	8.4	83.4	(33.4-171.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	2.7	nc	(nc-nc)	Male	15	8.8	171.3	(95.8-282.6)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	7	18.4	38.0	(15.2-78.3)	Female	2	6.2	nc	(nc-nc)
Female	18	17.0	105.9	(62.8-167.4)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	3	4.3	nc	(nc-nc)	Male	3	6.3	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)	Female	2	5.9	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.4	nc	(nc-nc)	Male	63	51.9	121.4	(93.3-155.4)
Female	1	1.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	14	10.5	133.2	(72.8-223.5)	Male	1	4.0	nc	(nc-nc)
Female	5	5.7	87.3	(28.1-203.7)	Female	2	2.4	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	9	2.5	356.6	(162.7-676.9)	Male	1	3.0	nc	(nc-nc)
Female	2	0.8	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	9	7.0	127.7	(58.3-242.4)	Male	5	5.2	95.8	(30.9-223.5)
Female	12	4.9	243.7	(125.8-425.7)	Female	15	15.4	97.6	(54.6-161.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	3	6.2	nc	(nc-nc)	Female	14	16.5	84.8	(46.3-142.2)
Female	1	2.0	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	31	28.4	109.0	(74.1-154.7)	Male	226	220.0	102.7	(89.7-117.0)
Female	31	31.7	97.9	(66.5-138.9)	Female	237	238.5	99.4	(87.1-112.9)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Granby

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	6.1	nc	(nc-nc)	Male	2	4.3	nc	(nc-nc)
Female	4	2.5	nc	(nc-nc)	Female	3	3.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.3	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	2	1.2	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	5	3.7	133.9	(43.2-312.6)
Female	23	29.0	79.3	(50.2-118.9)	Female	3	3.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.0	nc	(nc-nc)	Male	3	3.6	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	10	6.8	147.6	(70.6-271.4)	Female	2	2.5	nc	(nc-nc)
Female	8	7.2	110.7	(47.7-218.2)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	2	2.5	nc	(nc-nc)
Male	4	1.8	nc	(nc-nc)	Female	0	2.7	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	19	22.6	84.2	(50.7-131.5)
Male	1	0.5	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.4	nc	(nc-nc)	Male	2	1.5	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	1.0	nc	(nc-nc)
Male	4	4.1	nc	(nc-nc)	<u>Testis</u>				
Female	8	2.3	350.9	(151.1-691.4)	Male	2	0.8	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	1.1	nc	(nc-nc)	Male	1	1.9	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	5.6	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	4	2.6	nc	(nc-nc)	Female	6	6.7	89.2	(32.6-194.2)
Female	1	2.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	89	87.2	102.1	(82.0-125.6)
Male	2	2.7	nc	(nc-nc)	Female	82	96.3	85.1	(67.7-105.6)
Female	2	0.8	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	14	11.5	121.9	(66.6-204.5)					
Female	12	12.8	93.6	(48.3-163.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Granville

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	2.3	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	2	0.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.4	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	4	1.3	nc	(nc-nc)
Female	7	7.4	94.4	(37.8-194.5)	Female	0	0.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	1	2.3	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
Female	2	1.7	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male 0 0.6 nc (nc-nc)				
Male	0	0.6	nc	(nc-nc)	Female 0 0.6 nc (nc-nc)				
Female	0	0.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male 8 7.2 111.3 (47.9-219.2)				
Male	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.1	nc	(nc-nc)	Male 0 0.5 nc (nc-nc)				
<u>Kidney & Renal Pelvis</u>					Female 0 0.2 nc (nc-nc)				
Male	2	1.3	nc	(nc-nc)	<u>Testis</u>				
Female	1	0.6	nc	(nc-nc)	Male 0 0.2 nc (nc-nc)				
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.3	nc	(nc-nc)	Male 0 0.6 nc (nc-nc)				
Female	0	0.1	nc	(nc-nc)	Female 2 1.3 nc (nc-nc)				
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	0.9	nc	(nc-nc)	Female 6 1.7 350.8 (128.1-763.6)				
Female	0	0.5	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male 27 29.0 93.0 (61.2-135.3)				
Male	0	0.8	nc	(nc-nc)	Female 28 23.3 120.0 (79.7-173.4)				
Female	0	0.2	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	3	4.0	nc	(nc-nc)					
Female	4	3.1	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Great Barrington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	11	9.2	119.6	(59.6-214.0)	Male	9	5.7	159.1	(72.6-301.9)
Female	5	3.9	128.8	(41.5-300.5)	Female	3	4.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.6	nc	(nc-nc)	Male	4	1.8	nc	(nc-nc)
Female	5	1.5	333.0	(107.3-777.0)	Female	2	1.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.3	nc	(nc-nc)	Male	5	5.0	100.0	(32.2-233.5)
Female	45	37.7	119.5	(87.2-159.9)	Female	3	5.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	1.1	nc	(nc-nc)	Male	5	4.1	123.1	(39.7-287.2)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	7	9.1	76.6	(30.7-157.7)	Female	3	3.3	nc	(nc-nc)
Female	9	10.6	85.1	(38.8-161.6)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	3	2.3	nc	(nc-nc)	Male	27	26.6	101.4	(66.8-147.5)
Female	0	0.8	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	0	0.6	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	4	5.0	nc	(nc-nc)	Female	6	8.9	67.2	(24.5-146.2)
Female	2	3.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Leukemia</u>				
Male	3	1.3	nc	(nc-nc)	Male	2	3.6	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	3	2.9	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Lung and Bronchus</u>				
Male	2	3.1	nc	(nc-nc)	Male	14	16.0	87.8	(47.9-147.3)
Female	1	1.2	nc	(nc-nc)	Female	23	19.7	116.8	(74.0-175.2)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Greenfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	15	21.8	68.7	(38.4-113.2)	Male	10	13.7	72.8	(34.8-133.8)
Female	7	8.1	86.6	(34.7-178.4)	Female	7	10.6	66.1	(26.5-136.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	4.0	151.4	(55.3-329.5)	Male	5	4.5	111.9	(36.1-261.2)
Female	5	3.4	146.6	(47.3-342.2)	Female	4	3.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.8	nc	(nc-nc)	Male	6	12.2	49.2	(18.0-107.0)
Female	66	83.6	79.0	(61.1-100.5)	Female	7	10.8	64.7	(25.9-133.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	2.6	nc	(nc-nc)	Male	13	10.2	127.8	(68.0-218.6)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	25	22.1	113.1	(73.1-166.9)	Female	6	7.3	81.8	(29.9-178.1)
Female	27	22.9	118.1	(77.8-171.8)	<u>Pancreas</u>				
<u>Esophagus</u>					Male 8 8.1 98.6 (42.5-194.4)				
Male	4	5.6	nc	(nc-nc)	Female 9 8.5 105.3 (48.0-199.9)				
Female	3	1.6	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male 40 67.7 59.1 (42.2-80.4)				
Male	5	1.5	343.2	(110.6-801.0)	<u>Stomach</u>				
Female	2	1.3	nc	(nc-nc)	Male 3 5.1 nc (nc-nc)				
<u>Kidney & Renal Pelvis</u>					Female 2 3.2 nc (nc-nc)				
Male	9	12.3	73.0	(33.3-138.5)	<u>Testis</u>				
Female	7	6.8	102.7	(41.1-211.6)	Male 2 2.6 nc (nc-nc)				
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	3.3	nc	(nc-nc)	Male 4 5.2 nc (nc-nc)				
Female	1	0.9	nc	(nc-nc)	Female 3 14.6 nc (nc-nc)				
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	7	8.6	81.3	(32.6-167.6)	Female 23 19.3 119.2 (75.5-178.8)				
Female	5	6.4	77.9	(25.1-181.8)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male 227 277.2 81.9 (71.6-93.3)				
Male	6	7.8	76.9	(28.1-167.4)	Female 276 288.2 95.8 (84.8-107.8)				
Female	5	2.7	187.2	(60.3-436.9)					
<u>Lung and Bronchus</u>									
Male	34	38.5	88.4	(61.2-123.5)					
Female	49	40.9	119.9	(88.7-158.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Groton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	10	11.5	86.8	(41.6-159.7)	Male	5	7.8	64.0	(20.6-149.4)
Female	2	3.9	nc	(nc-nc)	Female	5	6.1	82.0	(26.4-191.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	2.3	nc	(nc-nc)	Male	1	2.5	nc	(nc-nc)
Female	0	1.9	nc	(nc-nc)	Female	1	1.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.4	nc	(nc-nc)	Male	4	6.9	nc	(nc-nc)
Female	45	50.8	88.5	(64.6-118.5)	Female	7	5.7	122.7	(49.2-252.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	1.8	nc	(nc-nc)	Male	5	6.3	79.4	(25.6-185.2)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	15	13.1	114.7	(64.1-189.2)	Female	2	4.3	nc	(nc-nc)
Female	12	11.8	101.8	(52.5-177.9)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	3	4.5	nc	(nc-nc)
Male	3	3.1	nc	(nc-nc)	Female	3	4.1	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	29	38.4	75.5	(50.6-108.4)
Male	0	0.8	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.7	nc	(nc-nc)	Male	2	2.8	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	2	1.6	nc	(nc-nc)
Male	7	7.5	93.7	(37.6-193.1)	<u>Testis</u>				
Female	3	3.9	nc	(nc-nc)	Male	5	1.5	326.7	(105.3-762.3)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	1.8	nc	(nc-nc)	Male	6	3.4	175.1	(63.9-381.1)
Female	0	0.5	nc	(nc-nc)	Female	9	9.8	91.5	(41.8-173.7)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	3	4.8	nc	(nc-nc)	Female	10	11.4	87.5	(41.9-160.9)
Female	0	3.3	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	123	156.5	78.6	(65.3-93.8)
Male	0	4.5	nc	(nc-nc)	Female	128	161.5	79.3	(66.1-94.2)
Female	1	1.4	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	9	20.4	44.1	(20.1-83.8)					
Female	13	21.1	61.7	(32.8-105.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Groveland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	6	9.3	64.7	(23.6-140.8)	Male	5	5.8	86.7	(27.9-202.3)
Female	3	2.9	nc	(nc-nc)	Female	12	3.9	304.8	(157.3-532.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.6	nc	(nc-nc)	Male	0	1.9	nc	(nc-nc)
Female	0	1.3	nc	(nc-nc)	Female	1	1.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	9	5.1	176.0	(80.3-334.2)
Female	34	34.2	99.4	(68.8-138.9)	Female	4	3.9	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	1.0	nc	(nc-nc)	Male	2	4.1	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	3	9.4	nc	(nc-nc)	Female	3	2.9	nc	(nc-nc)
Female	5	8.0	62.6	(20.2-146.2)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	2	2.3	nc	(nc-nc)	Male	5	3.4	147.3	(47.5-343.7)
Female	1	0.6	nc	(nc-nc)	Female	3	3.0	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.6	nc	(nc-nc)	Male	30	27.1	110.6	(74.6-157.9)
Female	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	2	5.1	nc	(nc-nc)	Male	3	2.1	nc	(nc-nc)
Female	3	2.7	nc	(nc-nc)	Female	4	1.1	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	1	1.4	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	1	3.6	nc	(nc-nc)	Male	6	2.1	285.9	(104.4-622.2)
Female	2	2.2	nc	(nc-nc)	Female	5	5.7	87.7	(28.3-204.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	3.1	nc	(nc-nc)	Female	6	8.1	74.2	(27.1-161.5)
Female	1	1.0	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	8	16.5	48.5	(20.9-95.6)	Male	94	114.8	81.9	(66.2-100.2)
Female	16	15.8	101.1	(57.7-164.2)	Female	113	110.6	102.2	(84.2-122.9)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hadley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	6	7.2	83.3	(30.4-181.4)	Male	2	4.2	nc	(nc-nc)
Female	1	3.4	nc	(nc-nc)	Female	1	4.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.1	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	0	1.3	nc	(nc-nc)	Female	0	1.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	2	3.7	nc	(nc-nc)
Female	28	32.4	86.4	(57.4-124.9)	Female	4	4.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.0	nc	(nc-nc)	Male	8	2.9	273.6	(117.8-539.2)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	6	7.0	85.7	(31.3-186.6)	Female	3	2.9	nc	(nc-nc)
Female	8	9.4	85.4	(36.8-168.2)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	1	1.7	nc	(nc-nc)	Female	2	2.5	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male				
Male	0	0.4	nc	(nc-nc)	Female	19	19.5	97.5	(58.7-152.3)
Female	0	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	3	3.6	nc	(nc-nc)	Female	1	1.6	nc	(nc-nc)
Female	3	2.7	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male				
Male	0	0.9	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	2	2.6	nc	(nc-nc)	Female	1	1.4	nc	(nc-nc)
Female	3	2.6	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Female				
Male	0	2.2	nc	(nc-nc)	Female	12	7.5	159.3	(82.2-278.2)
Female	1	1.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	7	12.2	57.5	(23.0-118.5)	Female	69	84.1	82.1	(63.8-103.8)
Female	7	17.0	41.1	(16.5-84.7)	Female	81	114.8	70.6	(56.0-87.7)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Halifax

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	6	8.2	72.8	(26.6-158.4)	Male	4	5.4	nc	(nc-nc)
Female	1	3.1	nc	(nc-nc)	Female	5	4.3	115.4	(37.2-269.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.6	nc	(nc-nc)	Male	2	1.7	nc	(nc-nc)
Female	2	1.4	nc	(nc-nc)	Female	1	1.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	5	4.8	104.0	(33.5-242.8)
Female	40	35.4	112.8	(80.6-153.7)	Female	6	4.3	138.5	(50.6-301.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.2	nc	(nc-nc)	Male	5	3.9	127.2	(41.0-296.9)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	15	8.8	170.3	(95.3-281.0)	Female	2	3.0	nc	(nc-nc)
Female	11	8.9	124.0	(61.8-221.9)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	3	2.1	nc	(nc-nc)	Female	7	3.1	229.2	(91.8-472.3)
Female	1	0.6	nc	(nc-nc)	Female				
<u>Hodgkin Lymphoma</u>					Male				
Male	0	0.6	nc	(nc-nc)	Female	3	3.1	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<u>Prostate</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	9	4.9	185.3	(84.5-351.8)	Female				
Female	5	2.8	177.9	(57.3-415.1)	<u>Stomach</u>				
<u>Larynx</u>					Male				
Male	1	1.2	nc	(nc-nc)	Female				
Female	1	0.4	nc	(nc-nc)	<u>Testis</u>				
<u>Leukemia</u>					Male				
Male	4	3.3	nc	(nc-nc)	Female				
Female	2	2.5	nc	(nc-nc)	<u>Thyroid</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male				
Male	5	2.9	173.8	(56.0-405.6)	Female				
Female	3	1.0	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
<u>Lung and Bronchus</u>					Female				
Male	19	14.6	129.8	(78.1-202.7)	17				
Female	17	16.4	103.4	(60.2-165.5)	7.7				
					220.8				
					(128.6-353.6)				
					<u>All Sites / Types</u>				
					Male				
					130				
					104.9				
					123.9				
					144				
					116.9				
					123.1				
					(103.6-147.2)				
					(103.9-145.0)				

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hamilton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	8.8	nc	(nc-nc)	Male	5	5.8	86.6	(27.9-202.0)
Female	5	3.0	167.2	(53.9-390.3)	Female	9	4.3	210.9	(96.3-400.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.8	nc	(nc-nc)	Male	2	1.9	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)	Female	0	1.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	2	5.1	nc	(nc-nc)
Female	41	35.2	116.4	(83.5-158.0)	Female	10	4.1	241.7	(115.7-444.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.1	nc	(nc-nc)	Male	3	4.3	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	2	9.5	nc	(nc-nc)	Female	1	3.0	nc	(nc-nc)
Female	11	8.7	126.5	(63.1-226.4)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	2	2.3	nc	(nc-nc)	Female	1	3.1	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male				
Male	1	0.7	nc	(nc-nc)	Female	24	26.7	90.0	(57.7-134.0)
Female	0	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	6	5.3	113.3	(41.4-246.7)	Female	0	1.2	nc	(nc-nc)
Female	3	2.8	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male				
Male	0	1.3	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	4	3.6	nc	(nc-nc)	Female	5	2.4	208.6	(67.2-486.9)
Female	3	2.4	nc	(nc-nc)	Female	7	6.4	109.8	(44.0-226.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	3.1	nc	(nc-nc)	Female	6	8.0	75.1	(27.4-163.5)
Female	0	1.0	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	8	15.6	51.2	(22.0-100.8)	Female	79	114.2	69.2	(54.8-86.2)
Female	13	16.0	81.3	(43.2-139.0)	Female	125	115.3	108.4	(90.2-129.1)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hampden

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	6	8.8	68.5	(25.0-149.1)	Male	1	5.3	nc	(nc-nc)
Female	0	2.6	nc	(nc-nc)	Female	1	3.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.4	nc	(nc-nc)	Male	1	1.8	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)	Female	2	1.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	7	4.7	149.5	(59.9-308.1)
Female	26	27.9	93.2	(60.9-136.6)	Female	2	3.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.9	nc	(nc-nc)	Male	1	3.7	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	2	8.5	nc	(nc-nc)	Female	2	2.4	nc	(nc-nc)
Female	5	7.3	68.1	(21.9-158.9)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	1	2.1	nc	(nc-nc)	Male	22	25.0	87.9	(55.1-133.1)
Female	0	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	0	0.4	nc	(nc-nc)	Male	6	0.6	1007.6	(367.9-2193.2)
Female	0	0.4	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	5	4.6	108.7	(35.0-253.6)	Female	5	6.3	79.2	(25.5-184.9)
Female	0	2.2	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Male</u>				
Male	0	1.3	nc	(nc-nc)	70	105.6	66.3	(51.7-83.8)	
Female	0	0.3	nc	(nc-nc)	<u>Female</u>				
<u>Leukemia</u>					69				
Male	2	3.2	nc	(nc-nc)	93.4	73.8	(57.5-93.5)		
Female	1	2.0	nc	(nc-nc)	<u>Liver and Intrahepatic Bile Ducts</u>				
Male	3	2.9	nc	(nc-nc)	<u>Lung and Bronchus</u>				
Female	0	0.8	nc	(nc-nc)	Male	6	15.6	38.5	(14.0-83.7)
<u>Lung and Bronchus</u>					Female	9	13.3	67.6	(30.8-128.3)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hancock

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	1.0	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
Female	2	3.5	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	0	1.0	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	0	0.3	nc	(nc-nc)	Male	3	3.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.6	nc	(nc-nc)	Female	2	0.8	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Male</u>				
Male	0	0.2	nc	(nc-nc)	9	12.7	71.1	(32.5-135.1)	
Female	0	0.0	nc	(nc-nc)	<u>Female</u>				
<u>Leukemia</u>					11				
Male	0	0.4	nc	(nc-nc)	11.4	96.5	(48.1-172.6)		
Female	0	0.2	nc	(nc-nc)					
<u>Liver and Intrahepatic Bile Ducts</u>									
Male	1	0.4	nc	(nc-nc)					
Female	0	0.1	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	0	1.8	nc	(nc-nc)					
Female	3	1.6	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hanover

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	17	13.1	129.4	(75.4-207.2)	Male	23	8.9	259.5	(164.5-389.5)
Female	6	5.4	111.9	(40.8-243.5)	Female	6	7.8	77.0	(28.1-167.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	2.8	nc	(nc-nc)	Male	2	2.8	nc	(nc-nc)
Female	2	2.6	nc	(nc-nc)	Female	4	2.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.5	nc	(nc-nc)	Male	4	7.9	nc	(nc-nc)
Female	82	64.1	128.0	(101.8-158.9)	Female	8	7.5	106.2	(45.7-209.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	2.2	nc	(nc-nc)	Male	6	6.8	87.6	(32.0-190.7)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	18	14.2	126.4	(74.9-199.8)	Female	6	5.4	111.9	(40.9-243.5)
Female	16	15.4	104.2	(59.5-169.2)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	1	5.0	nc	(nc-nc)
Male	5	3.5	141.4	(45.6-330.1)	Female	2	5.6	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	53	42.9	123.5	(92.5-161.6)
Male	0	1.0	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.9	nc	(nc-nc)	Male	1	3.2	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	2.2	nc	(nc-nc)
Male	4	8.4	nc	(nc-nc)	<u>Testis</u>				
Female	5	5.0	99.9	(32.2-233.0)	Male	2	2.1	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	2.0	nc	(nc-nc)	Male	6	4.0	151.0	(55.1-328.6)
Female	0	0.7	nc	(nc-nc)	Female	13	12.1	107.1	(57.0-183.2)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	10	5.7	176.6	(84.6-324.8)	Female	18	14.5	123.9	(73.4-195.7)
Female	2	4.4	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	184	177.1	103.9	(89.4-120.1)
Male	2	5.0	nc	(nc-nc)	Female	214	209.5	102.1	(88.9-116.8)
Female	0	1.8	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	17	23.6	72.1	(42.0-115.5)					
Female	31	28.7	108.1	(73.4-153.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hanson

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	10	10.7	93.2	(44.6-171.5)	Male	6	7.3	82.6	(30.2-179.7)
Female	4	3.3	nc	(nc-nc)	Female	4	5.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	2.2	nc	(nc-nc)	Male	1	2.4	nc	(nc-nc)
Female	0	1.7	nc	(nc-nc)	Female	2	1.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	2	6.4	nc	(nc-nc)
Female	37	44.6	83.0	(58.4-114.4)	Female	3	4.9	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.5	nc	(nc-nc)	Male	11	5.8	189.3	(94.3-338.7)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	13	11.7	111.5	(59.3-190.7)	Female	4	3.6	nc	(nc-nc)
Female	9	9.5	95.0	(43.3-180.3)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	1	3.0	nc	(nc-nc)	Male	4	4.2	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	1	3.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.8	nc	(nc-nc)	Male	31	37.4	83.0	(56.4-117.8)
Female	0	0.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	3	7.0	nc	(nc-nc)	Male	1	2.6	nc	(nc-nc)
Female	8	3.4	236.2	(101.7-465.4)	Female	0	1.4	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	0	1.8	nc	(nc-nc)	Male	3	1.5	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	1	4.5	nc	(nc-nc)	Male	2	3.1	nc	(nc-nc)
Female	4	2.8	nc	(nc-nc)	Female	6	8.7	69.3	(25.3-150.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	4	4.3	nc	(nc-nc)	Female	9	10.2	87.8	(40.1-166.7)
Female	2	1.2	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	25	19.9	125.7	(81.3-185.6)	Male	137	147.7	92.7	(77.9-109.6)
Female	26	18.9	137.7	(89.9-201.8)	Female	137	140.0	97.9	(82.2-115.7)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hardwick

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	4.9	nc	(nc-nc)	Male	4	3.1	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	Female	1	1.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.9	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
Female	2	0.5	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	2	2.7	nc	(nc-nc)
Female	13	13.3	97.8	(52.0-167.3)	Female	1	1.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.4	nc	(nc-nc)	Male	1	2.3	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	5	4.9	101.8	(32.8-237.5)	Female	0	1.1	nc	(nc-nc)
Female	3	2.9	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	3	1.8	nc	(nc-nc)
Male	2	1.3	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	6	16.3	36.8	(13.4-80.2)
Male	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	0.4	nc	(nc-nc)
Male	2	2.9	nc	(nc-nc)	<u>Testis</u>				
Female	0	1.0	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.8	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	2.4	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	1.9	nc	(nc-nc)	Female	4	3.2	nc	(nc-nc)
Female	2	0.8	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	44	63.3	69.5	(50.5-93.3)
Male	2	1.8	nc	(nc-nc)	Female	43	42.2	101.8	(73.7-137.2)
Female	0	0.4	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	10	9.0	110.6	(53.0-203.5)					
Female	9	5.8	156.2	(71.3-296.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Harvard

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	9.1	54.9	(17.7-128.1)	Male	3	6.1	nc	(nc-nc)
Female	0	1.8	nc	(nc-nc)	Female	3	2.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.8	nc	(nc-nc)	Male	4	2.0	nc	(nc-nc)
Female	3	0.9	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.3	nc	(nc-nc)	Male	7	5.3	130.9	(52.4-269.8)
Female	28	24.7	113.5	(75.4-164.1)	Female	3	2.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.8	nc	(nc-nc)	Male	5	4.8	104.0	(33.5-242.6)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	3	9.9	nc	(nc-nc)	Female	2	2.0	nc	(nc-nc)
Female	10	5.4	184.9	(88.5-340.1)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	3	2.5	nc	(nc-nc)	Male	22	31.0	70.9	(44.4-107.4)
Female	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	0	0.6	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	2	5.8	nc	(nc-nc)	Female	4	5.6	nc	(nc-nc)
Female	1	1.9	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Leukemia</u>				
Male	1	1.5	nc	(nc-nc)	Male	4	3.6	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	1.5	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Lung and Bronchus</u>				
Male	1	3.5	nc	(nc-nc)	Male	5	16.5	30.3	(9.8-70.8)
Female	0	0.6	nc	(nc-nc)	Female	8	10.0	80.1	(34.5-157.8)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Harwich

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	29	23.3	124.5	(83.4-178.9)	Male	26	13.3	194.8	(127.2-285.4)
Female	7	8.5	82.4	(33.0-169.8)	Female	17	9.8	173.8	(101.2-278.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	3.4	nc	(nc-nc)	Male	8	4.4	180.8	(77.9-356.3)
Female	5	3.1	158.9	(51.2-370.9)	Female	7	3.8	184.0	(73.7-379.2)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.8	nc	(nc-nc)	Male	18	11.7	153.3	(90.8-242.3)
Female	109	81.7	133.4	(109.5-160.9)	Female	7	10.8	64.6	(25.9-133.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	2.2	nc	(nc-nc)	Male	8	8.8	90.4	(38.9-178.2)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	25	21.5	116.0	(75.1-171.3)	Female	4	7.1	nc	(nc-nc)
Female	37	22.3	165.8	(116.7-228.6)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	6	8.1	74.2	(27.1-161.5)
Male	6	5.4	111.4	(40.7-242.5)	Female	8	8.8	91.2	(39.3-179.7)
Female	0	1.6	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	90	62.1	144.8	(116.5-178.0)
Male	3	1.0	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.9	nc	(nc-nc)	Male	7	5.1	137.3	(55.0-282.9)
<u>Kidney & Renal Pelvis</u>					Female	1	3.2	nc	(nc-nc)
Male	12	11.2	107.2	(55.3-187.3)	<u>Testis</u>				
Female	5	6.9	72.7	(23.4-169.7)	Male	0	1.5	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	3	3.1	nc	(nc-nc)	Male	7	4.0	174.1	(69.8-358.8)
Female	1	1.0	nc	(nc-nc)	Female	5	11.5	43.3	(14.0-101.1)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	10	8.3	120.9	(57.9-222.3)	Female	20	19.2	104.0	(63.5-160.6)
Female	7	6.1	113.9	(45.6-234.8)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	336	266.0	126.3	(113.2-140.6)
Male	6	6.9	86.4	(31.5-188.0)	Female	327	284.5	114.9	(102.8-128.1)
Female	3	2.7	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	44	40.1	109.6	(79.6-147.2)					
Female	46	44.8	102.7	(75.1-136.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hatfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	5.3	94.2	(30.4-219.9)	Male	4	3.3	nc	(nc-nc)
Female	3	1.6	nc	(nc-nc)	Female	1	2.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	0.9	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	Female	2	0.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	1	2.9	nc	(nc-nc)
Female	21	18.9	111.3	(68.9-170.1)	Female	3	2.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.6	nc	(nc-nc)	Male	0	2.4	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	5	5.3	94.9	(30.6-221.5)	Female	3	1.6	nc	(nc-nc)
Female	9	4.5	200.5	(91.5-380.6)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	1	1.3	nc	(nc-nc)	Male	16	16.3	98.1	(56.0-159.3)
Female	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	1	0.3	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	6	3.0	201.9	(73.7-439.5)	Female	5	4.3	115.4	(37.2-269.3)
Female	6	1.5	400.0	(146.1-870.7)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Leukemia</u>				
Male	0	0.8	nc	(nc-nc)	Male	2	2.0	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Lung and Bronchus</u>				
Male	0	1.9	nc	(nc-nc)	Male	9	9.8	92.2	(42.1-175.0)
Female	1	0.5	nc	(nc-nc)	Female	8	9.0	88.8	(38.2-174.9)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Haverhill

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	54	61.0	88.5	(66.5-115.5)	Male	29	39.9	72.7	(48.7-104.5)
Female	33	21.5	153.6	(105.7-215.7)	Female	17	32.2	52.8	(30.7-84.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	14	12.1	115.4	(63.0-193.6)	Male	8	12.6	63.5	(27.3-125.0)
Female	16	10.5	152.1	(86.9-247.0)	Female	10	10.2	98.2	(47.0-180.7)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	3	2.1	nc	(nc-nc)	Male	36	35.6	101.2	(70.9-140.2)
Female	242	255.2	94.8	(83.3-107.6)	Female	39	30.4	128.5	(91.4-175.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	9	8.8	102.1	(46.6-193.8)	Male	27	30.0	90.0	(59.3-131.0)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	64	65.9	97.2	(74.8-124.1)	Female	18	22.0	81.9	(48.5-129.4)
Female	71	63.5	111.8	(87.3-141.0)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	23	22.8	101.1	(64.1-151.7)
Male	13	15.5	84.1	(44.7-143.8)	Female	28	22.5	124.2	(82.5-179.6)
Female	8	4.2	188.9	(81.3-372.3)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	156	183.1	85.2	(72.4-99.7)
Male	6	5.0	120.5	(44.0-262.3)	<u>Stomach</u>				
Female	4	4.3	nc	(nc-nc)	Male	18	14.5	124.5	(73.7-196.8)
<u>Kidney & Renal Pelvis</u>					Female	7	8.9	79.0	(31.7-162.8)
Male	36	35.9	100.2	(70.1-138.7)	<u>Testis</u>				
Female	23	20.1	114.4	(72.5-171.7)	Male	7	9.8	71.3	(28.6-146.9)
<u>Larynx</u>					<u>Thyroid</u>				
Male	12	8.9	134.4	(69.4-234.7)	Male	16	17.0	94.3	(53.9-153.2)
Female	5	2.8	179.0	(57.7-417.8)	Female	61	50.6	120.5	(92.1-154.8)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	22	25.4	86.8	(54.4-131.4)	Female	69	57.6	119.8	(93.2-151.6)
Female	22	18.4	119.6	(74.9-181.1)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	723	787.2	91.8	(85.3-98.8)
Male	16	22.2	72.2	(41.3-117.3)	Female	895	843.6	106.1	(99.2-113.3)
Female	6	7.4	81.6	(29.8-177.6)					
<u>Lung and Bronchus</u>									
Male	116	104.3	111.2	(91.9-133.4)					
Female	134	112.5	119.1	(99.8-141.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hawley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	0.7	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	3	2.0	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	0	0.7	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	2	0.3	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	1	2.3	nc	(nc-nc)
Male	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.1	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<u>Testis</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.3	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	6	9.2	65.5	(23.9-142.6)
Male	0	0.2	nc	(nc-nc)	Female	3	6.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	1	1.4	nc	(nc-nc)					
Female	0	0.9	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Heath

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	1.1	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	1	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
Female	2	3.6	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	0	1.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	0	0.3	nc	(nc-nc)	Male	2	3.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	1	0.0	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.6	nc	(nc-nc)	Female	3	0.9	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Male</u>				
Male	0	0.2	nc	(nc-nc)	Obs	12	14.0	85.9	(44.4-150.1)
Female	0	0.0	nc	(nc-nc)	Female	11	11.5	95.4	(47.5-170.7)
<u>Leukemia</u>					<u>Female</u>				
Male	1	0.4	nc	(nc-nc)					
Female	0	0.2	nc	(nc-nc)					
<u>Liver and Intrahepatic Bile Ducts</u>									
Male	0	0.4	nc	(nc-nc)					
Female	0	0.1	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	3	1.9	nc	(nc-nc)					
Female	1	1.7	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hingham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	32	31.5	101.6	(69.5-143.4)	Male	34	19.1	178.4	(123.5-249.3)
Female	12	11.8	101.6	(52.4-177.5)	Female	31	14.8	208.9	(141.9-296.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	8	5.2	154.0	(66.3-303.6)	Male	7	6.1	115.5	(46.3-238.0)
Female	5	4.7	105.7	(34.1-246.7)	Female	5	5.4	92.4	(29.8-215.6)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.0	nc	(nc-nc)	Male	14	16.7	83.6	(45.7-140.3)
Female	108	119.5	90.4	(74.1-109.1)	Female	21	15.5	135.5	(83.8-207.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	3.6	nc	(nc-nc)	Male	14	13.3	105.4	(57.6-176.9)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	35	31.8	110.2	(76.7-153.2)	Female	9	10.5	85.8	(39.2-163.0)
Female	36	33.8	106.6	(74.6-147.5)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	9	11.2	80.4	(36.7-152.7)
Male	2	7.3	nc	(nc-nc)	Female	14	12.6	111.4	(60.8-186.8)
Female	7	2.3	311.1	(124.6-640.9)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	93	83.8	110.9	(89.5-135.9)
Male	2	1.7	nc	(nc-nc)	<u>Stomach</u>				
Female	1	1.4	nc	(nc-nc)	Male	12	7.1	168.6	(87.0-294.5)
<u>Kidney & Renal Pelvis</u>					Female	1	4.7	nc	(nc-nc)
Male	16	16.3	97.9	(55.9-159.0)	<u>Testis</u>				
Female	7	9.8	71.5	(28.6-147.3)	Male	6	3.1	193.1	(70.5-420.2)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	4.2	nc	(nc-nc)	Male	4	6.8	nc	(nc-nc)
Female	0	1.4	nc	(nc-nc)	Female	22	19.4	113.3	(71.0-171.6)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	14	12.0	116.6	(63.7-195.6)	Female	19	26.9	70.6	(42.5-110.2)
Female	14	9.3	151.3	(82.6-253.9)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	368	372.3	98.8	(89.0-109.5)
Male	2	9.9	nc	(nc-nc)	Female	395	412.8	95.7	(86.5-105.6)
Female	1	3.8	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	28	52.9	52.9	(35.2-76.5)					
Female	46	59.6	77.2	(56.5-103.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hinsdale

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	2.7	nc	(nc-nc)	Male	0	1.8	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.5	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	3	1.6	nc	(nc-nc)
Female	15	9.9	152.0	(85.0-250.8)	Female	2	1.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	0	1.4	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	3	3.0	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
Female	4	2.4	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	1	1.1	nc	(nc-nc)
Male	1	0.7	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	10	8.8	113.0	(54.1-207.8)
Male	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.3	nc	(nc-nc)
Male	3	1.7	nc	(nc-nc)	<u>Testis</u>				
Female	0	0.8	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	4	1.8	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	1.1	nc	(nc-nc)	Female	2	2.3	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	34	36.2	93.9	(65.0-131.3)
Male	0	1.1	nc	(nc-nc)	Female	41	31.9	128.6	(92.3-174.4)
Female	0	0.3	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	5	4.8	103.6	(33.4-241.9)					
Female	6	4.4	136.5	(49.8-297.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Holbrook

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	17	13.6	125.2	(72.9-200.5)	Male	5	8.6	57.9	(18.7-135.1)
Female	7	4.7	148.2	(59.4-305.4)	Female	1	6.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	2.5	nc	(nc-nc)	Male	4	2.8	nc	(nc-nc)
Female	4	2.1	nc	(nc-nc)	Female	6	2.2	275.6	(100.6-599.9)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.5	nc	(nc-nc)	Male	10	7.6	131.8	(63.1-242.3)
Female	55	54.3	101.3	(76.3-131.9)	Female	10	6.4	155.1	(74.2-285.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	1.7	nc	(nc-nc)	Male	6	6.2	96.8	(35.3-210.7)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	18	14.1	127.5	(75.5-201.5)	Female	10	4.6	216.4	(103.6-397.9)
Female	19	13.3	143.3	(86.2-223.7)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	3	4.9	nc	(nc-nc)
Male	7	3.3	210.4	(84.3-433.4)	Female	5	4.8	103.8	(33.4-242.2)
Female	0	0.9	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	41	37.8	108.4	(77.8-147.1)
Male	1	1.0	nc	(nc-nc)	<u>Stomach</u>				
Female	1	0.8	nc	(nc-nc)	Male	3	3.2	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	1.9	nc	(nc-nc)
Male	12	7.5	159.5	(82.3-278.6)	<u>Testis</u>				
Female	4	4.3	nc	(nc-nc)	Male	1	1.8	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	1.9	nc	(nc-nc)	Male	1	3.3	nc	(nc-nc)
Female	2	0.6	nc	(nc-nc)	Female	6	9.9	60.7	(22.2-132.2)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	5	5.3	93.5	(30.1-218.1)	Female	10	12.3	81.4	(39.0-149.7)
Female	6	3.6	165.1	(60.3-359.5)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	177	167.9	105.5	(90.5-122.2)
Male	6	4.6	129.0	(47.1-280.9)	Female	195	178.8	109.0	(94.3-125.5)
Female	1	1.6	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	20	23.5	85.0	(51.9-131.2)					
Female	32	25.7	124.4	(85.1-175.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Holden

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	14	19.8	70.7	(38.6-118.7)	Male	19	12.9	147.2	(88.6-229.9)
Female	14	6.8	206.3	(112.7-346.1)	Female	13	9.9	130.8	(69.6-223.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	3.9	nc	(nc-nc)	Male	7	4.2	168.3	(67.4-346.9)
Female	4	3.2	nc	(nc-nc)	Female	3	3.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.7	nc	(nc-nc)	Male	11	11.4	96.2	(47.9-172.1)
Female	93	80.4	115.7	(93.4-141.8)	Female	8	9.6	83.6	(36.0-164.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	2.7	nc	(nc-nc)	Male	14	9.9	141.6	(77.3-237.6)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	18	21.2	84.8	(50.2-134.0)	Female	7	6.9	101.9	(40.8-210.0)
Female	14	19.8	70.7	(38.6-118.6)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	12	7.5	161.0	(83.1-281.2)
Male	7	5.1	136.6	(54.7-281.4)	Female	8	7.1	113.0	(48.7-222.8)
Female	2	1.3	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	65	61.7	105.4	(81.3-134.3)
Male	0	1.4	nc	(nc-nc)	<u>Stomach</u>				
Female	1	1.2	nc	(nc-nc)	Male	1	4.7	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	5	2.8	179.6	(57.9-419.0)
Male	8	11.8	67.7	(29.1-133.3)	<u>Testis</u>				
Female	5	6.3	79.4	(25.6-185.4)	Male	3	2.6	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	3	3.0	nc	(nc-nc)	Male	7	5.3	133.1	(53.3-274.3)
Female	0	0.9	nc	(nc-nc)	Female	11	15.2	72.2	(36.0-129.3)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	7	8.1	86.6	(34.7-178.4)	Female	32	18.2	175.5	(120.1-247.8)
Female	7	5.6	125.4	(50.2-258.3)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	252	257.5	97.9	(86.1-110.7)
Male	7	7.3	95.3	(38.2-196.4)	Female	296	264.0	112.1	(99.7-125.7)
Female	3	2.3	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	22	34.7	63.3	(39.7-95.9)					
Female	36	35.8	100.6	(70.5-139.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Holland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	3.0	nc	(nc-nc)	Male	2	2.1	nc	(nc-nc)
Female	2	0.8	nc	(nc-nc)	Female	0	1.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.6	nc	(nc-nc)	Male	2	0.7	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.8	nc	(nc-nc)
Female	9	10.6	84.6	(38.6-160.7)	Female	2	1.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.4	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	2	3.3	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
Female	1	2.4	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	2	1.2	nc	(nc-nc)
Male	1	0.8	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	5	10.3	48.4	(15.6-113.1)
Male	1	0.2	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.2	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.3	nc	(nc-nc)
Male	3	2.0	nc	(nc-nc)	<u>Testis</u>				
Female	0	0.8	nc	(nc-nc)	Male	2	0.4	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.5	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	4	2.2	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	1.2	nc	(nc-nc)	Female	3	2.4	nc	(nc-nc)
Female	3	0.7	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	35	41.4	84.6	(58.9-117.7)
Male	0	1.2	nc	(nc-nc)	Female	35	33.3	105.0	(73.1-146.0)
Female	0	0.3	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	6	5.7	105.6	(38.6-229.9)					
Female	6	4.3	139.4	(50.9-303.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Holliston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	22	14.7	150.1	(94.0-227.3)	Male	11	9.8	112.4	(56.0-201.1)
Female	2	5.1	nc	(nc-nc)	Female	12	7.7	155.7	(80.4-272.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	2.9	204.0	(74.5-444.1)	Male	6	3.1	191.1	(69.8-416.1)
Female	3	2.5	nc	(nc-nc)	Female	0	2.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.5	nc	(nc-nc)	Male	12	8.7	138.6	(71.5-242.0)
Female	68	64.0	106.3	(82.5-134.7)	Female	8	7.2	110.4	(47.5-217.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	2.2	nc	(nc-nc)	Male	6	7.8	77.3	(28.2-168.3)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	15	16.1	93.0	(52.0-153.5)	Female	4	5.4	nc	(nc-nc)
Female	14	15.1	92.7	(50.6-155.5)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	4	3.9	nc	(nc-nc)	Male	49	49.0	100.0	(74.0-132.3)
Female	2	1.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	1	1.1	nc	(nc-nc)	Male	4	2.0	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	12	9.3	129.3	(66.8-225.9)	Female	20	14.5	138.2	(84.4-213.4)
Female	5	4.9	101.7	(32.8-237.4)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Leukemia</u>				
Male	2	2.3	nc	(nc-nc)	Male	8	6.1	131.7	(56.7-259.5)
Female	0	0.7	nc	(nc-nc)	Female	4	4.3	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Lung and Bronchus</u>				
Male	2	5.6	nc	(nc-nc)	Male	19	26.1	72.8	(43.8-113.7)
Female	4	1.8	nc	(nc-nc)	Female	19	27.0	70.3	(42.3-109.7)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Holyoke

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	29	39.2	74.0	(49.5-106.2)	Male	13	24.7	52.7	(28.0-90.1)
Female	10	15.6	64.2	(30.7-118.0)	Female	13	21.2	61.5	(32.7-105.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	8	7.6	105.6	(45.5-208.0)	Male	3	7.7	nc	(nc-nc)
Female	5	7.0	71.8	(23.1-167.6)	Female	4	7.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.3	nc	(nc-nc)	Male	17	22.1	77.0	(44.8-123.3)
Female	136	162.6	83.6	(70.2-98.9)	Female	19	20.8	91.4	(55.0-142.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	6	5.5	109.5	(40.0-238.4)	Male	21	17.4	120.7	(74.7-184.6)
<u>Colon / Rectum</u>					Female	10	9.1	110.0	(52.7-202.3)
Male	40	40.9	97.9	(69.9-133.3)	<u>Ovary</u>				
Female	43	44.9	95.8	(69.3-129.0)	Female	14	14.3	97.8	(53.4-164.2)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	9.3	53.9	(17.4-125.9)	Male	14	14.1	99.2	(54.2-166.5)
Female	0	3.0	nc	(nc-nc)	Female	20	16.4	121.9	(74.4-188.2)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	5	3.1	163.5	(52.7-381.5)	Male	96	103.6	92.6	(75.0-113.1)
Female	6	2.9	206.6	(75.4-449.6)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	8	9.0	88.9	(38.3-175.3)
Male	24	21.3	112.9	(72.3-168.0)	Female	9	6.3	143.0	(65.2-271.4)
Female	12	13.3	90.1	(46.5-157.3)	<u>Testis</u>				
<u>Larynx</u>					Male	3	5.8	nc	(nc-nc)
Male	9	5.3	169.7	(77.4-322.1)	<u>Thyroid</u>				
Female	3	1.8	nc	(nc-nc)	Male	1	9.7	nc	(nc-nc)
<u>Leukemia</u>					Female	27	31.3	86.4	(56.9-125.7)
Male	10	16.3	61.3	(29.4-112.8)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	11	12.8	85.6	(42.7-153.2)	Female	42	35.6	118.0	(85.1-159.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	19	12.9	147.1	(88.5-229.8)	Male	444	478.1	92.9	(84.4-101.9)
Female	4	5.0	nc	(nc-nc)	Female	523	563.1	92.9	(85.1-101.2)
<u>Lung and Bronchus</u>									
Male	69	65.7	105.0	(81.7-132.9)					
Female	73	79.4	92.0	(72.1-115.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hopedale

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	7	6.2	113.4	(45.4-233.7)	Male	2	3.8	nc	(nc-nc)
Female	3	2.4	nc	(nc-nc)	Female	4	3.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.1	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)	Female	2	1.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	3	3.4	nc	(nc-nc)
Female	27	26.1	103.3	(68.1-150.4)	Female	1	3.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.9	nc	(nc-nc)	Male	3	2.7	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	7	6.7	104.9	(42.0-216.2)	Female	1	2.2	nc	(nc-nc)
Female	9	7.1	127.3	(58.1-241.6)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	2	2.2	nc	(nc-nc)
Male	2	1.4	nc	(nc-nc)	Female	1	2.5	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	22	15.7	140.0	(87.7-212.0)
Male	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
Female	1	0.4	nc	(nc-nc)	Male	3	1.4	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	1.0	nc	(nc-nc)
Male	2	3.3	nc	(nc-nc)	<u>Testis</u>				
Female	2	2.1	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	0.8	nc	(nc-nc)	Male	2	1.5	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	7	5.0	139.4	(55.9-287.3)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	2.5	nc	(nc-nc)	Female	7	5.6	124.6	(49.9-256.7)
Female	1	2.0	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	86	73.7	116.7	(93.4-144.2)
Male	3	2.0	nc	(nc-nc)	Female	89	88.3	100.8	(80.9-124.0)
Female	0	0.8	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	16	9.6	166.6	(95.1-270.5)					
Female	13	11.9	109.0	(58.0-186.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hopkinton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	14	12.2	114.8	(62.7-192.7)	Male	9	8.8	102.0	(46.5-193.6)
Female	11	4.6	240.3	(119.8-430.0)	Female	10	7.9	126.6	(60.6-232.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	2.9	nc	(nc-nc)	Male	1	2.8	nc	(nc-nc)
Female	4	2.6	nc	(nc-nc)	Female	0	2.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.5	nc	(nc-nc)	Male	7	7.8	89.3	(35.8-183.9)
Female	67	65.1	102.9	(79.8-130.7)	Female	5	7.0	71.3	(23.0-166.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	2.5	nc	(nc-nc)	Male	10	7.2	138.5	(66.3-254.7)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	18	14.6	123.1	(72.9-194.5)	Female	4	5.3	nc	(nc-nc)
Female	12	14.5	82.9	(42.8-144.8)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	4	4.8	nc	(nc-nc)
Male	2	3.4	nc	(nc-nc)	Female	8	4.8	168.2	(72.4-331.5)
Female	1	0.9	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	59	41.7	141.6	(107.8-182.7)
Male	0	1.1	nc	(nc-nc)	<u>Stomach</u>				
Female	3	1.0	nc	(nc-nc)	Male	2	3.1	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	2.0	nc	(nc-nc)
Male	3	8.6	nc	(nc-nc)	<u>Testis</u>				
Female	1	4.8	nc	(nc-nc)	Male	4	2.4	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	2.0	nc	(nc-nc)	Male	9	4.4	205.6	(93.8-390.2)
Female	0	0.6	nc	(nc-nc)	Female	13	13.9	93.2	(49.6-159.4)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	5.5	nc	(nc-nc)	Female	10	14.0	71.6	(34.3-131.7)
Female	1	4.2	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	177	174.2	101.6	(87.2-117.7)
Male	3	5.1	nc	(nc-nc)	Female	188	202.0	93.1	(80.2-107.4)
Female	0	1.6	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	14	21.9	63.8	(34.9-107.1)					
Female	23	24.6	93.7	(59.4-140.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hubbardston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	4.5	nc	(nc-nc)	Male	1	3.0	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)	Female	1	2.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.9	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
Female	2	0.7	nc	(nc-nc)	Female	2	0.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	5	2.7	185.3	(59.7-432.5)
Female	13	18.6	70.0	(37.2-119.6)	Female	2	2.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.7	nc	(nc-nc)	Male	1	2.4	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	0	5.1	nc	(nc-nc)	Female	3	1.5	nc	(nc-nc)
Female	4	3.9	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	1	1.2	nc	(nc-nc)	Male	1	1.7	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	2	1.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.4	nc	(nc-nc)	Male	13	14.2	91.8	(48.9-157.1)
Female	1	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	3	2.8	nc	(nc-nc)	Male	2	1.1	nc	(nc-nc)
Female	2	1.4	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	0	0.7	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	2	1.9	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)	Female	5	3.9	129.0	(41.6-301.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	1.7	nc	(nc-nc)	Female	3	4.2	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	6	7.8	77.0	(28.1-167.5)	Male	46	59.8	76.9	(56.3-102.6)
Female	9	6.9	130.9	(59.7-248.4)	Female	61	56.7	107.6	(82.3-138.3)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hudson

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	21	21.5	97.8	(60.5-149.4)	Male	13	14.0	92.9	(49.4-158.9)
Female	8	8.4	95.8	(41.2-188.7)	Female	7	11.5	60.6	(24.3-124.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	4.2	142.7	(52.1-310.7)	Male	4	4.5	nc	(nc-nc)
Female	5	3.7	133.4	(43.0-311.2)	Female	4	3.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.8	nc	(nc-nc)	Male	6	12.3	48.7	(17.8-105.9)
Female	96	95.9	100.1	(81.1-122.3)	Female	10	11.4	87.8	(42.0-161.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	3.1	nc	(nc-nc)	Male	14	10.5	132.8	(72.6-222.9)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	26	22.6	115.3	(75.3-168.9)	Female	9	8.1	111.1	(50.7-211.0)
Female	34	23.1	147.0	(101.8-205.4)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	2	5.6	nc	(nc-nc)	Male	66	69.0	95.7	(74.0-121.8)
Female	0	1.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	0	1.6	nc	(nc-nc)	Male	2	3.0	nc	(nc-nc)
Female	2	1.4	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	11	13.0	84.7	(42.2-151.5)	Female	23	22.0	104.7	(66.4-157.2)
Female	9	7.6	117.7	(53.7-223.4)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Leukemia</u>				
Male	2	3.3	nc	(nc-nc)	Male	7	8.7	80.4	(32.2-165.7)
Female	2	1.1	nc	(nc-nc)	Female	2	6.6	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Lung and Bronchus</u>				
Male	4	7.7	nc	(nc-nc)	Male	33	39.0	84.6	(58.2-118.8)
Female	3	2.8	nc	(nc-nc)	Female	35	45.6	76.8	(53.5-106.8)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hull

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	15	15.3	98.1	(54.9-161.9)	Male	14	9.6	145.7	(79.6-244.6)
Female	8	5.9	136.6	(58.8-269.2)	Female	14	7.7	181.1	(98.9-303.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	2.6	nc	(nc-nc)	Male	4	3.2	nc	(nc-nc)
Female	4	2.4	nc	(nc-nc)	Female	2	2.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.5	nc	(nc-nc)	Male	3	8.4	nc	(nc-nc)
Female	61	65.3	93.4	(71.5-120.0)	Female	11	7.9	138.6	(69.1-247.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	1.9	nc	(nc-nc)	Male	9	7.3	123.8	(56.5-235.1)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	17	15.3	110.8	(64.5-177.5)	Female	5	5.6	88.9	(28.6-207.4)
Female	17	15.9	107.1	(62.3-171.4)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	4	4.0	nc	(nc-nc)	Male	36	49.2	73.2	(51.3-101.4)
Female	0	1.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	4	0.8	nc	(nc-nc)	Male	4	1.3	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	13	8.7	148.7	(79.1-254.3)	Female	20	15.7	127.5	(77.8-196.9)
Female	5	5.3	94.9	(30.6-221.5)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Leukemia</u>				
Male	3	2.4	nc	(nc-nc)	Male	4	5.8	nc	(nc-nc)
Female	4	0.8	nc	(nc-nc)	Female	2	4.4	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Lung and Bronchus</u>				
Male	11	5.7	194.2	(96.8-347.6)	Male	21	27.8	75.5	(46.7-115.4)
Female	0	2.0	nc	(nc-nc)	Female	36	31.9	112.7	(78.9-156.0)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Huntington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	2.4	nc	(nc-nc)	Male	2	1.6	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.5	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	1.4	nc	(nc-nc)
Female	10	9.5	104.9	(50.2-192.9)	Female	4	1.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.3	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	3	2.5	nc	(nc-nc)	Female	2	0.8	nc	(nc-nc)
Female	3	2.0	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	0	0.9	nc	(nc-nc)
Male	2	0.7	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	4	8.2	nc	(nc-nc)
Male	1	0.2	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.3	nc	(nc-nc)
Male	4	1.5	nc	(nc-nc)	<u>Testis</u>				
Female	1	0.7	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	3	0.4	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	2	1.8	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	1.0	nc	(nc-nc)	Female	1	2.3	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	37	32.1	115.3	(81.2-158.9)
Male	1	0.9	nc	(nc-nc)	Female	33	29.8	110.9	(76.3-155.7)
Female	0	0.3	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	7	4.3	162.0	(64.9-333.9)					
Female	5	4.1	122.0	(39.3-284.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Ipswich

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	20	17.5	114.1	(69.7-176.3)	Male	20	11.4	175.9	(107.4-271.7)
Female	10	6.8	146.6	(70.2-269.6)	Female	9	8.9	101.0	(46.1-191.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	3.2	nc	(nc-nc)	Male	1	3.7	nc	(nc-nc)
Female	2	2.8	nc	(nc-nc)	Female	1	3.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.6	nc	(nc-nc)	Male	15	10.0	149.8	(83.8-247.2)
Female	91	73.0	124.6	(100.3-153.0)	Female	11	9.2	119.6	(59.6-214.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	2.2	nc	(nc-nc)	Male	7	8.8	79.7	(31.9-164.2)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	17	18.6	91.4	(53.2-146.4)	Female	3	6.3	nc	(nc-nc)
Female	15	19.3	77.6	(43.4-127.9)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	9	4.6	196.5	(89.7-373.1)	Male	62	56.7	109.3	(83.8-140.1)
Female	2	1.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	0	1.1	nc	(nc-nc)	Male	5	2.0	247.1	(79.6-576.7)
Female	2	0.9	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	5	10.6	47.4	(15.3-110.5)	Female	15	17.0	88.4	(49.5-145.9)
Female	7	5.8	119.7	(48.0-246.6)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Leukemia</u>				
Male	2	2.7	nc	(nc-nc)	Male	5	6.9	72.3	(23.3-168.8)
Female	0	0.8	nc	(nc-nc)	Female	2	5.2	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Lung and Bronchus</u>				
Male	6	6.5	93.0	(34.0-202.5)	Male	21	31.4	66.8	(41.4-102.2)
Female	2	2.3	nc	(nc-nc)	Female	25	35.0	71.5	(46.2-105.5)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Kingston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	14	14.3	97.7	(53.4-164.0)	Male	20	9.1	218.8	(133.6-337.9)
Female	6	5.6	108.0	(39.4-235.1)	Female	12	7.6	156.9	(81.0-274.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	2.6	nc	(nc-nc)	Male	4	2.9	nc	(nc-nc)
Female	6	2.5	244.0	(89.1-531.1)	Female	2	2.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.5	nc	(nc-nc)	Male	8	8.1	98.9	(42.6-194.9)
Female	54	60.9	88.6	(66.6-115.7)	Female	6	7.6	79.4	(29.0-172.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	5	2.1	235.3	(75.8-549.2)	Male	4	6.7	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	12	15.1	79.6	(41.1-139.1)	Female	2	5.2	nc	(nc-nc)
Female	9	16.4	54.8	(25.0-104.0)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	8	5.3	151.0	(65.0-297.6)
Male	3	3.5	nc	(nc-nc)	Female	9	5.9	153.2	(69.9-290.9)
Female	4	1.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	44	40.9	107.6	(78.2-144.5)
Male	0	0.9	nc	(nc-nc)	<u>Stomach</u>				
Female	2	0.9	nc	(nc-nc)	Male	3	3.3	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					<u>Testis</u>				
Male	10	8.1	123.8	(59.3-227.6)	Female	1	2.3	nc	(nc-nc)
Female	2	4.8	nc	(nc-nc)	<u>Thyroid</u>				
<u>Larynx</u>					Male	4	1.7	nc	(nc-nc)
Male	2	2.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.7	nc	(nc-nc)	Male	6	3.5	169.1	(61.7-368.0)
<u>Leukemia</u>					Female	12	11.5	104.5	(53.9-182.5)
Male	9	5.7	157.5	(71.9-299.0)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	4.5	nc	(nc-nc)	Female	16	13.1	122.4	(69.9-198.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	5.0	nc	(nc-nc)	Male	198	178.8	110.8	(95.9-127.3)
Female	1	1.8	nc	(nc-nc)	Female	205	205.2	99.9	(86.7-114.5)
<u>Lung and Bronchus</u>									
Male	29	24.7	117.6	(78.7-168.9)					
Female	28	28.1	99.7	(66.2-144.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Lakeville

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	15	12.1	124.0	(69.4-204.6)	Male	9	8.2	110.0	(50.2-208.8)
Female	5	3.9	129.0	(41.6-301.0)	Female	5	6.1	82.2	(26.5-191.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	2.4	nc	(nc-nc)	Male	3	2.6	nc	(nc-nc)
Female	2	2.0	nc	(nc-nc)	Female	2	1.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	4	7.2	nc	(nc-nc)
Female	47	51.6	91.1	(67.0-121.2)	Female	5	5.7	87.3	(28.1-203.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.7	nc	(nc-nc)	Male	6	6.6	91.5	(33.4-199.1)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	9	13.3	67.9	(31.0-128.9)	Female	3	4.3	nc	(nc-nc)
Female	11	11.4	96.3	(48.0-172.2)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	4	3.3	nc	(nc-nc)	Male	38	41.6	91.4	(64.7-125.4)
Female	0	0.8	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	2	0.9	nc	(nc-nc)	Male	2	1.6	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	5	7.8	64.1	(20.7-149.7)	Female	13	12.0	108.1	(57.5-184.9)
Female	2	3.9	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Leukemia</u>				
Male	2	1.9	nc	(nc-nc)	Male	3	5.0	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	2	3.3	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Lung and Bronchus</u>				
Male	5	4.8	104.4	(33.6-243.5)	Male	15	22.0	68.1	(38.1-112.4)
Female	3	1.4	nc	(nc-nc)	Female	20	21.1	95.0	(58.0-146.7)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Lancaster

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	7	9.3	75.2	(30.1-154.9)	Male	5	5.9	84.6	(27.3-197.3)
Female	6	2.5	238.4	(87.1-518.9)	Female	4	3.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.8	nc	(nc-nc)	Male	1	1.9	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.3	nc	(nc-nc)	Male	6	5.3	113.2	(41.4-246.5)
Female	31	30.4	102.0	(69.3-144.8)	Female	5	3.5	140.9	(45.4-328.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.0	nc	(nc-nc)	Male	3	4.3	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	7	9.4	74.6	(29.9-153.8)	Female	3	2.6	nc	(nc-nc)
Female	6	7.3	81.8	(29.9-178.0)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	2	2.4	nc	(nc-nc)	Male	28	28.7	97.7	(64.9-141.1)
Female	0	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	0	0.8	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	2	5.3	nc	(nc-nc)	Female	2	6.9	nc	(nc-nc)
Female	2	2.4	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Leukemia</u>				
Male	2	1.4	nc	(nc-nc)	Male	4	3.8	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	2.1	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Lung and Bronchus</u>				
Male	0	3.2	nc	(nc-nc)	Male	6	16.5	36.3	(13.2-79.0)
Female	1	0.9	nc	(nc-nc)	Female	13	13.5	96.5	(51.3-165.1)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Lanesborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	2.7	nc	(nc-nc)	Male	4	1.9	nc	(nc-nc)
Female	2	1.3	nc	(nc-nc)	Female	3	1.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.6	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	5	1.7	292.5	(94.3-682.6)
Female	12	14.3	83.8	(43.3-146.4)	Female	1	1.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.4	nc	(nc-nc)	Male	2	1.7	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	1	3.1	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
Female	3	3.7	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	1	1.1	nc	(nc-nc)
Male	2	0.8	nc	(nc-nc)	Female	3	1.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	11	10.8	101.4	(50.5-181.4)
Male	1	0.2	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.2	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.5	nc	(nc-nc)
Male	1	1.9	nc	(nc-nc)	<u>Testis</u>				
Female	2	1.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	0.5	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	4	2.5	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	2	1.2	nc	(nc-nc)	Female	2	3.2	nc	(nc-nc)
Female	3	1.0	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	48	40.5	118.5	(87.4-157.2)
Male	0	1.2	nc	(nc-nc)	Female	42	47.5	88.5	(63.8-119.6)
Female	1	0.4	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	8	5.3	151.2	(65.1-298.0)					
Female	4	6.6	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Lawrence

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	51	51.0	100.1	(74.5-131.6)	Male	6	35.9	16.7	(6.1-36.4)
Female	16	21.1	75.9	(43.4-123.3)	Female	9	34.3	26.2	(12.0-49.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	9	12.8	70.3	(32.1-133.4)	Male	13	11.2	116.2	(61.8-198.7)
Female	7	12.0	58.5	(23.5-120.6)	Female	23	10.2	226.5	(143.5-339.9)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.9	nc	(nc-nc)	Male	25	32.3	77.4	(50.1-114.3)
Female	190	268.5	70.8	(61.1-81.6)	Female	33	31.1	106.3	(73.1-149.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	17	10.0	170.8	(99.4-273.5)	Male	25	28.2	88.6	(57.3-130.8)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	63	58.4	108.0	(83.0-138.1)	Female	13	22.9	56.8	(30.2-97.1)
Female	42	63.9	65.7	(47.3-88.8)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	7	13.8	50.8	(20.4-104.8)	Male	17	19.7	86.2	(50.2-138.0)
Female	7	4.2	166.6	(66.7-343.2)	Female	13	22.1	58.9	(31.4-100.8)
<u>Hodgkin Lymphoma</u>					<u>Stomach</u>				
Male	4	5.9	nc	(nc-nc)	Male	16	12.6	126.8	(72.4-205.9)
Female	10	5.5	183.1	(87.7-336.8)	Female	14	9.0	155.9	(85.2-261.6)
<u>Kidney & Renal Pelvis</u>					<u>Testis</u>				
Male	26	34.0	76.4	(49.9-111.9)	Male	11	11.9	92.3	(46.0-165.1)
Female	29	20.7	139.8	(93.6-200.7)	<u>Thyroid</u>				
<u>Larynx</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	12	8.0	149.2	(77.0-260.6)	Female	48	58.9	81.5	(60.1-108.0)
Female	2	2.8	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	21	24.2	86.7	(53.7-132.6)	Male	710	712.2	99.7	(92.5-107.3)
Female	21	19.5	107.5	(66.5-164.3)	Female	740	875.4	84.5	(78.6-90.9)
<u>Liver and Intrahepatic Bile Ducts</u>									
Male	38	19.8	191.7	(135.6-263.1)					
Female	16	7.4	215.6	(123.2-350.2)					
<u>Lung and Bronchus</u>									
Male	93	90.8	102.4	(82.7-125.5)					
Female	101	110.7	91.2	(74.3-110.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Lee

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	16	8.9	179.9	(102.8-292.2)	Male	4	5.3	nc	(nc-nc)
Female	1	3.0	nc	(nc-nc)	Female	5	3.9	129.8	(41.8-303.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.4	nc	(nc-nc)	Male	1	1.7	nc	(nc-nc)
Female	2	1.3	nc	(nc-nc)	Female	0	1.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	1	4.6	nc	(nc-nc)
Female	30	31.8	94.3	(63.6-134.6)	Female	4	4.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.9	nc	(nc-nc)	Male	3	3.6	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	9	8.6	104.2	(47.5-197.8)	Female	2	2.8	nc	(nc-nc)
Female	11	8.1	135.5	(67.5-242.4)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	4	2.1	nc	(nc-nc)	Male	3	3.1	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	1	3.1	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.5	nc	(nc-nc)	Male	19	24.1	78.9	(47.5-123.3)
Female	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	6	4.5	133.4	(48.7-290.4)	Male	0	2.0	nc	(nc-nc)
Female	3	2.6	nc	(nc-nc)	Female	5	1.2	429.7	(138.5-1002.7)
<u>Larynx</u>					<u>Testis</u>				
Male	2	1.2	nc	(nc-nc)	Male	2	0.8	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	2	3.3	nc	(nc-nc)	Male	4	1.7	nc	(nc-nc)
Female	1	2.3	nc	(nc-nc)	Female	4	5.3	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	2	2.8	nc	(nc-nc)	Female	7	7.4	94.3	(37.8-194.2)
Female	1	1.0	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	17	15.2	111.5	(64.9-178.6)	Male	105	104.4	100.5	(82.2-121.7)
Female	24	16.0	149.8	(95.9-222.9)	Female	110	107.7	102.1	(83.9-123.1)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Leicester

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	12	12.5	95.8	(49.4-167.3)	Male	11	8.3	133.3	(66.5-238.6)
Female	4	5.1	nc	(nc-nc)	Female	12	6.8	176.5	(91.1-308.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	2.5	nc	(nc-nc)	Male	3	2.7	nc	(nc-nc)
Female	2	2.2	nc	(nc-nc)	Female	2	2.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.5	nc	(nc-nc)	Male	2	7.3	nc	(nc-nc)
Female	39	56.5	69.0	(49.1-94.3)	Female	4	6.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	1.7	nc	(nc-nc)	Male	10	6.4	156.5	(74.9-287.8)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	7	13.3	52.6	(21.1-108.4)	Female	6	4.9	122.4	(44.7-266.4)
Female	11	14.0	78.7	(39.2-140.8)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	6	3.3	179.2	(65.4-390.1)	Male	37	40.7	90.8	(64.0-125.2)
Female	0	1.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	0	0.9	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	6	7.6	78.8	(28.8-171.5)	Female	12	13.0	92.5	(47.7-161.5)
Female	6	4.6	131.2	(47.9-285.5)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Leukemia</u>				
Male	3	2.0	nc	(nc-nc)	Male	12	5.1	235.3	(121.4-411.0)
Female	0	0.6	nc	(nc-nc)	Female	6	3.9	154.2	(56.3-335.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Lung and Bronchus</u>				
Male	1	4.9	nc	(nc-nc)	Male	10	22.6	44.3	(21.2-81.4)
Female	2	1.7	nc	(nc-nc)	Female	21	27.7	75.9	(47.0-116.1)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Lenox

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	14	10.8	129.3	(70.6-217.0)	Male	7	5.9	119.4	(47.8-246.1)
Female	2	4.3	nc	(nc-nc)	Female	8	4.6	174.4	(75.1-343.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.4	nc	(nc-nc)	Male	4	1.9	nc	(nc-nc)
Female	4	1.4	nc	(nc-nc)	Female	1	1.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	6	5.1	116.5	(42.5-253.6)
Female	35	36.4	96.1	(66.9-133.7)	Female	4	5.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.9	nc	(nc-nc)	Male	5	3.7	136.6	(44.0-318.7)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	14	10.0	140.6	(76.8-235.9)	Female	5	3.3	152.0	(49.0-354.6)
Female	17	11.9	143.3	(83.4-229.5)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	4	3.6	nc	(nc-nc)
Male	1	2.3	nc	(nc-nc)	Female	5	4.7	107.5	(34.6-250.8)
Female	0	0.8	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	24	25.2	95.4	(61.1-141.9)
Male	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.3	nc	(nc-nc)	Male	0	2.3	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	1.7	nc	(nc-nc)
Male	5	4.6	109.5	(35.3-255.6)	<u>Testis</u>				
Female	5	3.1	159.1	(51.3-371.4)	Male	0	0.6	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	1.3	nc	(nc-nc)	Male	0	1.6	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	2	4.7	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	2	3.7	nc	(nc-nc)	Female	5	8.2	61.2	(19.7-142.8)
Female	3	3.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	108	114.8	94.1	(77.2-113.6)
Male	2	2.9	nc	(nc-nc)	Female	127	133.8	94.9	(79.1-112.9)
Female	2	1.3	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	11	17.2	64.0	(31.9-114.4)					
Female	16	21.0	76.3	(43.6-123.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Leominster

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	63	47.2	133.3	(102.5-170.6)	Male	22	29.7	74.0	(46.4-112.1)
Female	27	15.7	171.7	(113.1-249.9)	Female	19	22.7	83.9	(50.5-131.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	8.5	70.2	(25.6-152.8)	Male	10	9.5	105.7	(50.6-194.3)
Female	9	7.3	122.7	(56.0-232.9)	Female	4	7.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	1.6	nc	(nc-nc)	Male	21	26.3	79.8	(49.4-122.0)
Female	169	179.3	94.3	(80.6-109.6)	Female	24	21.8	109.9	(70.4-163.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	7	6.1	114.8	(46.0-236.5)	Male	23	21.2	108.5	(68.7-162.8)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	44	49.0	89.8	(65.2-120.6)	Female	29	15.5	187.1	(125.3-268.7)
Female	37	46.0	80.4	(56.6-110.8)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	18	17.1	105.1	(62.3-166.2)
Male	14	11.4	122.4	(66.9-205.4)	Female	21	16.4	127.9	(79.1-195.5)
Female	2	3.0	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	127	130.9	97.0	(80.9-115.4)
Male	2	3.3	nc	(nc-nc)	<u>Stomach</u>				
Female	3	3.0	nc	(nc-nc)	Male	11	10.9	100.8	(50.3-180.5)
<u>Kidney & Renal Pelvis</u>					Female	1	6.4	nc	(nc-nc)
Male	34	25.9	131.1	(90.8-183.2)	<u>Testis</u>				
Female	15	14.3	105.1	(58.8-173.4)	Male	4	6.3	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	11	6.6	167.0	(83.2-298.8)	Male	13	11.6	112.1	(59.6-191.8)
Female	0	2.0	nc	(nc-nc)	Female	27	34.8	77.6	(51.1-112.9)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	18	18.7	96.4	(57.1-152.4)	Female	41	39.8	102.9	(73.9-139.6)
Female	14	13.1	107.1	(58.5-179.7)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	579	580.2	99.8	(91.8-108.3)
Male	10	15.7	63.6	(30.4-116.9)	Female	602	599.3	100.5	(92.6-108.8)
Female	5	5.3	94.9	(30.6-221.4)					
<u>Lung and Bronchus</u>									
Male	82	80.7	101.7	(80.9-126.2)					
Female	88	81.8	107.6	(86.3-132.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Leverett

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	3.6	nc	(nc-nc)	Male	1	2.2	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	Female	3	1.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.6	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	2	0.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	4	1.9	nc	(nc-nc)
Female	11	11.2	97.8	(48.8-175.1)	Female	1	1.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	2	3.5	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
Female	1	2.5	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	3	1.3	nc	(nc-nc)
Male	0	0.9	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	4	11.2	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.4	nc	(nc-nc)
Male	3	1.9	nc	(nc-nc)	<u>Testis</u>				
Female	2	0.9	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.5	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	1.9	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	1.3	nc	(nc-nc)	Female	4	2.7	nc	(nc-nc)
Female	2	0.7	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	30	44.3	67.8	(45.7-96.7)
Male	0	1.2	nc	(nc-nc)	Female	34	36.5	93.2	(64.6-130.3)
Female	0	0.3	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	5	6.4	78.2	(25.2-182.6)					
Female	4	5.4	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Lexington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	26	42.5	61.2	(40.0-89.7)	Male	26	26.3	98.9	(64.6-144.9)
Female	3	15.4	nc	(nc-nc)	Female	24	20.6	116.8	(74.8-173.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	7.3	nc	(nc-nc)	Male	12	8.5	141.3	(72.9-246.9)
Female	6	6.6	91.0	(33.2-198.2)	Female	8	7.1	112.6	(48.5-221.9)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	4	1.5	nc	(nc-nc)	Male	19	23.2	81.8	(49.2-127.7)
Female	183	168.0	108.9	(93.7-125.9)	Female	21	20.8	101.1	(62.6-154.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	5.3	nc	(nc-nc)	Male	18	18.9	95.1	(56.4-150.4)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	37	43.5	85.1	(59.9-117.2)	Female	15	14.4	104.4	(58.4-172.2)
Female	28	44.5	62.9	(41.8-90.9)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	16	15.4	103.9	(59.4-168.8)
Male	5	10.3	48.4	(15.6-112.8)	Female	18	16.3	110.5	(65.4-174.6)
Female	1	3.0	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	129	120.5	107.0	(89.3-127.2)
Male	2	2.4	nc	(nc-nc)	<u>Stomach</u>				
Female	1	2.1	nc	(nc-nc)	Male	1	9.8	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	2	6.2	nc	(nc-nc)
Male	15	23.2	64.7	(36.2-106.7)	<u>Testis</u>				
Female	5	13.4	37.3	(12.0-87.0)	Male	6	4.3	139.3	(50.9-303.1)
<u>Larynx</u>					<u>Thyroid</u>				
Male	3	5.9	nc	(nc-nc)	Male	11	9.8	112.0	(55.8-200.4)
Female	0	1.9	nc	(nc-nc)	Female	34	28.9	117.7	(81.5-164.4)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	17	16.4	104.0	(60.5-166.5)	Female	32	37.4	85.6	(58.5-120.9)
Female	10	12.3	81.5	(39.0-149.9)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	416	518.7	80.2	(72.7-88.3)
Male	4	14.1	nc	(nc-nc)	Female	483	564.1	85.6	(78.2-93.6)
Female	5	5.0	99.6	(32.1-232.3)					
<u>Lung and Bronchus</u>									
Male	29	72.6	39.9	(26.7-57.4)					
Female	40	79.5	50.3	(35.9-68.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Leyden

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	0.9	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	2	4.1	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	1	1.0	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	0	0.3	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male				
Male	1	0.1	nc	(nc-nc)	Female	1	3.4	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	0	0.6	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male				
Male	0	0.2	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	0	0.4	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Female				
Male	0	0.4	nc	(nc-nc)	Male	9	12.5	72.2	(32.9-137.0)
Female	0	0.1	nc	(nc-nc)	Female	16	12.5	127.7	(73.0-207.4)
<u>Lung and Bronchus</u>					<u>All Sites / Types</u>				
Male	0	1.6	nc	(nc-nc)					
Female	2	1.6	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Lincoln

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	9.9	nc	(nc-nc)	Male	7	6.0	117.6	(47.1-242.4)
Female	8	3.0	262.3	(113.0-516.9)	Female	7	4.1	171.2	(68.6-352.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	1.6	372.3	(135.9-810.4)	Male	3	1.9	nc	(nc-nc)
Female	0	1.3	nc	(nc-nc)	Female	0	1.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	4	5.3	nc	(nc-nc)
Female	44	31.9	137.9	(100.2-185.2)	Female	2	4.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.0	nc	(nc-nc)	Male	6	4.0	150.9	(55.1-328.5)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	7	9.8	71.4	(28.6-147.1)	Female	4	2.9	nc	(nc-nc)
Female	8	8.9	89.7	(38.6-176.7)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	5	3.5	143.1	(46.1-334.0)
Male	1	2.3	nc	(nc-nc)	Female	4	3.2	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	42	24.3	173.1	(124.8-234.0)
Male	1	0.5	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.5	nc	(nc-nc)	Male	0	2.2	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	1.2	nc	(nc-nc)
Male	1	4.9	nc	(nc-nc)	<u>Testis</u>				
Female	4	2.6	nc	(nc-nc)	Male	3	1.0	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	1.3	nc	(nc-nc)	Male	3	2.1	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	6	5.7	105.9	(38.7-230.6)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	7	3.8	186.2	(74.6-383.7)	Female	13	7.2	179.5	(95.5-307.0)
Female	5	2.6	195.9	(63.1-457.3)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	118	114.1	103.4	(85.6-123.8)
Male	2	3.1	nc	(nc-nc)	Female	129	109.9	117.3	(98.0-139.4)
Female	1	1.0	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	6	16.3	36.7	(13.4-80.0)					
Female	9	15.1	59.6	(27.2-113.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Littleton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	13	9.2	142.0	(75.5-242.9)	Male	6	6.4	93.6	(34.2-203.7)
Female	1	3.9	nc	(nc-nc)	Female	4	5.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	2.0	nc	(nc-nc)	Male	1	2.0	nc	(nc-nc)
Female	1	1.7	nc	(nc-nc)	Female	0	1.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	8	5.6	142.3	(61.3-280.3)
Female	49	45.1	108.6	(80.4-143.6)	Female	5	5.4	93.1	(30.0-217.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.4	nc	(nc-nc)	Male	8	5.1	156.3	(67.3-307.9)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	6	10.3	58.0	(21.2-126.2)	Female	6	3.9	155.2	(56.7-337.7)
Female	8	11.3	70.9	(30.5-139.7)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	8	3.6	221.8	(95.5-437.1)
Male	1	2.5	nc	(nc-nc)	Female	4	4.1	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	35	30.7	114.0	(79.4-158.5)
Male	3	0.7	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.6	nc	(nc-nc)	Male	1	2.3	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	1.6	nc	(nc-nc)
Male	2	6.0	nc	(nc-nc)	<u>Testis</u>				
Female	4	3.6	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	1.5	nc	(nc-nc)	Male	3	2.8	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	8	8.2	97.8	(42.1-192.8)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	6	3.9	153.3	(56.0-333.8)	Female	12	10.3	116.8	(60.3-204.1)
Female	3	3.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	131	126.7	103.4	(86.4-122.7)
Male	1	3.8	nc	(nc-nc)	Female	132	149.0	88.6	(74.1-105.1)
Female	1	1.3	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	17	16.7	101.8	(59.3-163.0)					
Female	14	20.8	67.4	(36.8-113.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Longmeadow

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	14	22.0	63.7	(34.8-106.9)	Male	16	13.3	120.4	(68.7-195.5)
Female	6	7.9	75.7	(27.6-164.7)	Female	12	10.2	117.3	(60.6-205.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	3.5	nc	(nc-nc)	Male	2	4.2	nc	(nc-nc)
Female	5	3.3	151.1	(48.7-352.7)	Female	1	3.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.7	nc	(nc-nc)	Male	11	11.7	94.4	(47.1-168.9)
Female	88	82.1	107.2	(86.0-132.1)	Female	11	10.4	105.5	(52.6-188.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	2.6	nc	(nc-nc)	Male	7	9.5	73.8	(29.5-152.0)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	14	22.3	62.7	(34.2-105.2)	Female	6	7.1	84.0	(30.7-182.8)
Female	13	23.2	56.0	(29.8-95.7)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	4	7.9	nc	(nc-nc)
Male	2	5.2	nc	(nc-nc)	Female	5	8.5	58.7	(18.9-137.0)
Female	1	1.5	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	50	61.0	81.9	(60.8-108.0)
Male	1	1.2	nc	(nc-nc)	<u>Stomach</u>				
Female	2	1.0	nc	(nc-nc)	Male	4	5.0	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	2	3.2	nc	(nc-nc)
Male	11	11.5	95.3	(47.5-170.6)	<u>Testis</u>				
Female	4	6.6	nc	(nc-nc)	Male	3	2.0	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	3.0	nc	(nc-nc)	Male	6	4.7	128.1	(46.8-278.7)
Female	0	0.9	nc	(nc-nc)	Female	8	13.8	57.8	(24.9-114.0)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	10	8.2	121.5	(58.2-223.5)	Female	13	18.0	72.1	(38.4-123.4)
Female	2	6.3	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	214	262.6	81.5	(70.9-93.2)
Male	4	7.1	nc	(nc-nc)	Female	236	281.4	83.9	(73.5-95.3)
Female	7	2.5	278.8	(111.7-574.5)					
<u>Lung and Bronchus</u>									
Male	26	37.1	70.1	(45.8-102.7)					
Female	23	39.6	58.0	(36.8-87.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Lowell

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	81	82.9	97.7	(77.6-121.5)	Male	25	57.6	43.4	(28.1-64.0)
Female	35	32.1	108.9	(75.8-151.4)	Female	28	48.8	57.4	(38.1-82.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	13	19.5	66.8	(35.5-114.2)	Male	19	18.0	105.3	(63.4-164.5)
Female	12	16.6	72.1	(37.2-126.0)	Female	19	15.1	126.1	(75.9-196.9)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	3.0	nc	(nc-nc)	Male	34	51.6	65.9	(45.6-92.1)
Female	329	378.4	86.9	(77.8-96.9)	Female	36	45.5	79.1	(55.4-109.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	20	13.4	149.5	(91.3-230.8)	Male	59	45.3	130.2	(99.1-167.9)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	92	93.9	98.0	(79.0-120.1)	Female	32	32.9	97.3	(66.5-137.3)
Female	107	94.3	113.5	(93.0-137.1)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	20	22.3	89.8	(54.8-138.7)	Male	30	32.0	93.7	(63.2-133.7)
Female	6	6.3	95.7	(35.0-208.4)	Female	33	33.4	98.9	(68.1-138.9)
<u>Hodgkin Lymphoma</u>					<u>Stomach</u>				
Male	14	9.0	156.1	(85.3-262.0)	Male	23	20.4	112.8	(71.5-169.2)
Female	5	7.7	65.0	(21.0-151.8)	Female	33	13.3	249.0	(171.4-349.7)
<u>Kidney & Renal Pelvis</u>					<u>Testis</u>				
Male	67	54.1	123.9	(96.0-157.3)	Male	14	18.0	77.9	(42.5-130.7)
Female	30	30.1	99.7	(67.3-142.4)	<u>Thyroid</u>				
<u>Larynx</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	15	13.1	114.8	(64.2-189.3)	Female	69	84.4	81.8	(63.6-103.5)
Female	7	4.1	171.3	(68.6-353.0)	<u>All Sites / Types</u>				
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	36	37.6	95.8	(67.1-132.7)	Male	1110	1144.8	97.0	(91.3-102.8)
Female	32	28.2	113.5	(77.6-160.2)	Female	1234	1263.9	97.6	(92.3-103.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	60	32.4	185.4	(141.5-238.7)	<u>All Sites / Types</u>				
Female	15	11.0	136.4	(76.3-225.0)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					<u>All Sites / Types</u>				
Male	175	147.1	119.0	(102.0-138.0)	<u>All Sites / Types</u>				
Female	188	168.9	111.3	(96.0-128.4)	<u>All Sites / Types</u>				

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Ludlow

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	28	26.7	105.0	(69.8-151.8)	Male	11	17.0	64.6	(32.2-115.6)
Female	5	10.3	48.4	(15.6-112.9)	Female	13	13.3	97.7	(52.0-167.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	4.9	nc	(nc-nc)	Male	4	5.5	nc	(nc-nc)
Female	2	4.2	nc	(nc-nc)	Female	7	4.7	148.5	(59.5-306.1)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.9	nc	(nc-nc)	Male	15	15.0	99.7	(55.8-164.5)
Female	99	107.7	92.0	(74.7-112.0)	Female	16	13.7	116.6	(66.6-189.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	6	3.3	182.8	(66.7-397.9)	Male	6	12.8	47.0	(17.2-102.3)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	27	27.7	97.5	(64.2-141.8)	Female	8	9.4	85.5	(36.8-168.5)
Female	30	29.0	103.5	(69.8-147.8)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	10	9.9	101.1	(48.4-186.0)
Male	3	6.8	nc	(nc-nc)	Female	10	10.8	92.6	(44.3-170.2)
Female	2	2.0	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	50	81.2	61.5	(45.7-81.1)
Male	3	1.8	nc	(nc-nc)	<u>Stomach</u>				
Female	1	1.4	nc	(nc-nc)	Male	8	6.3	127.9	(55.1-252.0)
<u>Kidney & Renal Pelvis</u>					Female	5	4.1	121.6	(39.2-283.9)
Male	22	15.3	143.7	(90.0-217.6)	<u>Testis</u>				
Female	5	8.8	57.0	(18.4-133.0)	Male	1	3.3	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	5	3.9	126.8	(40.9-296.0)	Male	4	6.7	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)	Female	8	18.1	44.3	(19.1-87.2)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	6	10.5	57.0	(20.8-124.0)	Female	27	24.6	109.8	(72.3-159.7)
Female	7	8.0	87.2	(34.9-179.6)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	282	339.4	83.1	(73.7-93.4)
Male	10	9.6	103.7	(49.6-190.7)	Female	318	367.8	86.5	(77.2-96.5)
Female	2	3.3	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	35	46.7	74.9	(52.2-104.2)					
Female	32	53.4	59.9	(41.0-84.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Lunenburg

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	11	12.7	86.5	(43.1-154.7)	Male	10	8.1	122.9	(58.8-226.0)
Female	7	4.5	154.9	(62.1-319.3)	Female	2	6.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	2.3	nc	(nc-nc)	Male	5	2.6	192.5	(62.0-449.1)
Female	3	2.1	nc	(nc-nc)	Female	1	2.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	6	7.2	83.1	(30.3-180.9)
Female	64	54.9	116.6	(89.8-148.9)	Female	6	6.5	92.8	(33.9-202.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	1.8	nc	(nc-nc)	Male	6	6.1	98.1	(35.8-213.5)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	10	13.7	72.8	(34.8-133.8)	Female	2	4.6	nc	(nc-nc)
Female	15	13.1	114.6	(64.1-189.0)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	4	4.7	nc	(nc-nc)
Male	2	3.2	nc	(nc-nc)	Female	2	4.7	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	35	37.5	93.3	(65.0-129.8)
Male	3	0.8	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.8	nc	(nc-nc)	Male	2	3.0	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	1.9	nc	(nc-nc)
Male	7	7.4	94.8	(38.0-195.4)	<u>Testis</u>				
Female	3	4.2	nc	(nc-nc)	Male	3	1.6	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	4	1.8	nc	(nc-nc)	Male	5	3.3	150.8	(48.6-351.9)
Female	0	0.6	nc	(nc-nc)	Female	12	10.0	120.3	(62.1-210.1)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	8	5.0	158.7	(68.3-312.7)	Female	16	12.7	126.1	(72.0-204.8)
Female	6	3.7	163.7	(59.8-356.3)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	165	160.6	102.8	(87.7-119.7)
Male	3	4.4	nc	(nc-nc)	Female	171	177.6	96.3	(82.4-111.8)
Female	2	1.6	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	23	21.6	106.5	(67.5-159.8)					
Female	18	23.8	75.6	(44.8-119.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Lynn

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	84	72.8	115.4	(92.0-142.8)	Male	41	49.5	82.8	(59.4-112.4)
Female	26	27.6	94.2	(61.5-138.0)	Female	37	42.2	87.7	(61.7-120.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	19	16.3	116.5	(70.1-182.0)	Male	31	15.6	199.2	(135.3-282.8)
Female	20	14.4	139.0	(84.9-214.7)	Female	18	13.1	137.7	(81.6-217.6)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	5	2.6	189.1	(60.9-441.3)	Male	49	44.2	110.8	(82.0-146.5)
Female	307	329.9	93.1	(82.9-104.1)	Female	49	39.4	124.4	(92.1-164.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	16	11.6	138.0	(78.9-224.2)	Male	44	37.8	116.5	(84.6-156.4)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	117	80.9	144.6	(119.6-173.3)	Female	25	28.5	87.6	(56.7-129.3)
Female	112	81.3	137.8	(113.5-165.9)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	35	27.7	126.5	(88.1-175.9)
Male	15	19.0	79.0	(44.2-130.4)	Female	25	28.7	87.0	(56.3-128.5)
Female	4	5.4	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	284	225.3	126.1	(111.8-141.6)
Male	6	7.2	83.0	(30.3-180.7)	<u>Stomach</u>				
Female	3	6.4	nc	(nc-nc)	Male	20	17.7	113.3	(69.2-175.0)
<u>Kidney & Renal Pelvis</u>					Female	16	11.4	140.1	(80.0-227.5)
Male	40	45.6	87.7	(62.6-119.4)	<u>Testis</u>				
Female	29	26.1	111.0	(74.3-159.4)	Male	11	14.7	74.6	(37.2-133.5)
<u>Larynx</u>					<u>Thyroid</u>				
Male	12	11.1	107.8	(55.7-188.4)	Male	20	22.6	88.4	(53.9-136.5)
Female	5	3.6	140.5	(45.3-327.8)	Female	61	68.4	89.2	(68.3-114.6)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	44	32.1	137.2	(99.7-184.2)	Female	80	73.7	108.5	(86.0-135.0)
Female	29	24.5	118.4	(79.3-170.0)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	1209	975.5	123.9	(117.0-131.1)
Male	53	27.0	196.5	(147.2-257.0)	Female	1190	1095.0	108.7	(102.6-115.0)
Female	21	9.5	221.0	(136.7-337.8)					
<u>Lung and Bronchus</u>									
Male	197	128.0	153.9	(133.2-177.0)					
Female	179	145.4	123.1	(105.7-142.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Lynnfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	13	18.3	70.9	(37.7-121.2)	Male	26	11.1	233.8	(152.7-342.6)
Female	6	5.4	110.4	(40.3-240.4)	Female	12	7.4	161.6	(83.4-282.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	3.0	nc	(nc-nc)	Male	3	3.6	nc	(nc-nc)
Female	5	2.4	210.9	(68.0-492.3)	Female	5	2.5	196.6	(63.4-458.8)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.6	nc	(nc-nc)	Male	13	9.8	132.6	(70.6-226.8)
Female	67	61.4	109.2	(84.6-138.7)	Female	14	7.4	189.5	(103.5-318.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.9	nc	(nc-nc)	Male	5	7.9	63.3	(20.4-147.8)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	12	18.6	64.5	(33.3-112.6)	Female	8	5.2	153.0	(65.9-301.5)
Female	21	15.5	135.4	(83.8-206.9)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	4	6.6	nc	(nc-nc)
Male	1	4.4	nc	(nc-nc)	Female	5	5.7	87.9	(28.3-205.1)
Female	1	1.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	40	50.4	79.3	(56.7-108.0)
Male	0	1.0	nc	(nc-nc)	<u>Stomach</u>				
Female	2	0.8	nc	(nc-nc)	Male	2	4.2	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	3	2.2	nc	(nc-nc)
Male	8	9.6	83.1	(35.8-163.7)	<u>Testis</u>				
Female	5	4.9	102.4	(33.0-239.0)	Male	7	1.7	403.6	(161.7-831.6)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	2.5	nc	(nc-nc)	Male	7	4.0	175.5	(70.3-361.7)
Female	0	0.7	nc	(nc-nc)	Female	17	10.7	158.5	(92.3-253.8)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	12	6.9	174.5	(90.1-304.8)	Female	15	13.9	107.5	(60.1-177.4)
Female	3	4.3	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	190	219.1	86.7	(74.8-99.9)
Male	2	5.9	nc	(nc-nc)	Female	226	203.5	111.0	(97.0-126.5)
Female	0	1.8	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	14	31.0	45.2	(24.7-75.9)					
Female	25	28.7	87.1	(56.3-128.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Malden

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	30	48.4	61.9	(41.8-88.4)	Male	10	33.4	30.0	(14.4-55.1)
Female	19	19.2	99.0	(59.6-154.7)	Female	12	29.1	41.3	(21.3-72.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	10.8	46.1	(14.9-107.6)	Male	10	10.4	95.8	(45.9-176.2)
Female	8	9.7	82.8	(35.7-163.2)	Female	4	9.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	3	1.8	nc	(nc-nc)	Male	47	29.8	157.5	(115.7-209.5)
Female	200	222.5	89.9	(77.9-103.2)	Female	23	27.1	84.7	(53.7-127.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	15	8.0	188.5	(105.4-310.9)	Male	29	25.2	115.1	(77.1-165.4)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	65	53.1	122.4	(94.4-156.0)	Female	16	19.4	82.6	(47.2-134.1)
Female	67	56.2	119.1	(92.3-151.3)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	19	18.5	102.8	(61.9-160.5)
Male	21	12.8	164.4	(101.7-251.2)	Female	20	20.0	99.8	(60.9-154.1)
Female	8	3.7	214.1	(92.2-422.0)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	144	152.2	94.6	(79.8-111.4)
Male	3	5.2	nc	(nc-nc)	<u>Stomach</u>				
Female	5	4.7	107.5	(34.6-250.8)	Male	20	11.8	169.9	(103.8-262.5)
<u>Kidney & Renal Pelvis</u>					Female	12	7.9	151.7	(78.3-265.0)
Male	32	30.5	104.9	(71.7-148.1)	<u>Testis</u>				
Female	20	17.7	112.8	(68.9-174.2)	Male	6	10.8	55.8	(20.4-121.4)
<u>Larynx</u>					<u>Thyroid</u>				
Male	5	7.5	66.3	(21.4-154.8)	Male	13	15.6	83.2	(44.3-142.3)
Female	2	2.4	nc	(nc-nc)	Female	56	47.1	119.0	(89.9-154.5)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	18	21.3	84.6	(50.1-133.8)	Female	41	49.8	82.4	(59.1-111.8)
Female	16	16.6	96.3	(55.0-156.4)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	655	655.5	99.9	(92.4-107.9)
Male	29	18.4	157.7	(105.6-226.6)	Female	728	748.3	97.3	(90.3-104.6)
Female	16	6.5	244.8	(139.8-397.5)					
<u>Lung and Bronchus</u>									
Male	114	86.3	132.1	(109.0-158.7)					
Female	99	100.1	98.9	(80.4-120.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Manchester by the Sea

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	9.3	nc	(nc-nc)	Male	8	5.4	146.9	(63.2-289.5)
Female	1	2.8	nc	(nc-nc)	Female	5	3.7	136.6	(44.0-318.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.4	nc	(nc-nc)	Male	2	1.8	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.3	nc	(nc-nc)	Male	6	4.8	125.4	(45.8-273.0)
Female	32	31.1	102.9	(70.4-145.3)	Female	2	3.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.9	nc	(nc-nc)	Male	4	3.8	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	4	9.0	nc	(nc-nc)	Female	2	2.6	nc	(nc-nc)
Female	9	7.7	117.3	(53.5-222.6)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	1	3.3	nc	(nc-nc)
Male	3	2.2	nc	(nc-nc)	Female	5	2.9	172.7	(55.6-402.9)
Female	2	0.6	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	23	25.7	89.6	(56.8-134.5)
Male	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.4	nc	(nc-nc)	Male	0	2.1	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	1.1	nc	(nc-nc)
Male	3	4.7	nc	(nc-nc)	<u>Testis</u>				
Female	1	2.5	nc	(nc-nc)	Male	2	0.6	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	1.2	nc	(nc-nc)	Male	0	1.8	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	7	5.0	138.8	(55.6-286.0)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	3.4	nc	(nc-nc)	Female	4	7.2	nc	(nc-nc)
Female	2	2.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	80	108.8	73.5	(58.3-91.5)
Male	1	2.9	nc	(nc-nc)	Female	89	102.8	86.5	(69.5-106.5)
Female	0	0.9	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	7	15.9	44.2	(17.7-91.0)					
Female	8	15.0	53.4	(23.0-105.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Mansfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	23	17.3	132.7	(84.1-199.2)	Male	20	12.5	160.4	(97.9-247.8)
Female	1	5.9	nc	(nc-nc)	Female	20	10.7	187.1	(114.2-288.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	8	4.2	192.5	(82.9-379.3)	Male	5	3.9	128.4	(41.4-299.8)
Female	6	3.5	170.7	(62.3-371.6)	Female	1	2.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.7	nc	(nc-nc)	Male	14	11.2	125.5	(68.5-210.5)
Female	99	87.5	113.1	(91.9-137.7)	Female	3	9.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	3.3	nc	(nc-nc)	Male	7	10.1	69.4	(27.8-142.9)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	24	20.6	116.6	(74.7-173.5)	Female	10	7.2	138.0	(66.1-253.8)
Female	27	19.1	141.6	(93.3-206.1)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	5	6.9	72.8	(23.5-169.9)
Male	1	4.8	nc	(nc-nc)	Female	4	6.1	nc	(nc-nc)
Female	2	1.2	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	62	58.7	105.5	(80.9-135.3)
Male	0	1.8	nc	(nc-nc)	<u>Stomach</u>				
Female	2	1.5	nc	(nc-nc)	Male	2	4.4	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	4	2.6	nc	(nc-nc)
Male	11	12.1	91.1	(45.4-163.1)	<u>Testis</u>				
Female	4	6.4	nc	(nc-nc)	Male	8	3.7	216.9	(93.4-427.4)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	2.8	nc	(nc-nc)	Male	13	6.2	208.9	(111.1-357.2)
Female	1	0.9	nc	(nc-nc)	Female	15	19.5	77.1	(43.1-127.2)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	8	7.9	101.1	(43.5-199.2)	Female	12	18.7	64.1	(33.1-112.0)
Female	8	5.6	143.8	(61.9-283.4)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	276	246.5	112.0	(99.1-126.0)
Male	10	7.0	142.2	(68.1-261.6)	Female	279	269.9	103.4	(91.6-116.2)
Female	3	2.2	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	37	30.9	119.6	(84.2-164.8)					
Female	28	32.3	86.6	(57.6-125.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Marblehead

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	25	30.1	83.1	(53.8-122.7)	Male	41	18.3	224.0	(160.7-303.9)
Female	7	10.4	67.4	(27.0-138.9)	Female	24	13.8	174.2	(111.5-259.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	5.0	nc	(nc-nc)	Male	7	6.0	116.6	(46.7-240.3)
Female	4	4.4	nc	(nc-nc)	Female	8	4.8	166.0	(71.5-327.2)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.0	nc	(nc-nc)	Male	14	16.1	87.0	(47.5-145.9)
Female	113	115.7	97.7	(80.5-117.5)	Female	15	14.0	107.2	(59.9-176.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	3.5	nc	(nc-nc)	Male	12	13.0	92.0	(47.5-160.8)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	23	29.8	77.2	(48.9-115.8)	Female	5	9.8	50.9	(16.4-118.8)
Female	22	29.1	75.6	(47.3-114.4)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	8	10.8	73.7	(31.8-145.3)
Male	9	7.3	122.7	(56.0-233.0)	Female	15	10.8	138.9	(77.7-229.1)
Female	2	2.0	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	84	85.6	98.1	(78.2-121.5)
Male	0	1.5	nc	(nc-nc)	<u>Stomach</u>				
Female	4	1.4	nc	(nc-nc)	Male	6	6.8	87.6	(32.0-190.7)
<u>Kidney & Renal Pelvis</u>					Female	1	4.1	nc	(nc-nc)
Male	12	16.0	74.9	(38.6-130.8)	<u>Testis</u>				
Female	7	9.2	75.9	(30.4-156.3)	Male	3	2.4	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	4.2	nc	(nc-nc)	Male	7	6.3	110.9	(44.4-228.5)
Female	1	1.3	nc	(nc-nc)	Female	17	19.4	87.6	(51.0-140.3)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	12	11.3	105.9	(54.7-185.1)	Female	22	26.4	83.3	(52.2-126.2)
Female	9	8.0	112.4	(51.3-213.3)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	323	363.4	88.9	(79.5-99.1)
Male	2	10.0	nc	(nc-nc)	Female	357	383.5	93.1	(83.7-103.3)
Female	1	3.4	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	28	52.4	53.4	(35.5-77.2)					
Female	39	55.4	70.4	(50.1-96.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Marion

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	7	7.9	89.0	(35.7-183.4)	Male	11	4.7	235.4	(117.4-421.3)
Female	5	3.0	167.3	(53.9-390.3)	Female	2	3.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.3	nc	(nc-nc)	Male	2	1.6	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)	Female	0	1.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	10	4.2	239.8	(114.8-441.0)
Female	31	29.3	105.6	(71.8-150.0)	Female	3	3.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	0.8	nc	(nc-nc)	Male	1	3.3	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	11	7.6	144.3	(72.0-258.3)	Female	0	2.5	nc	(nc-nc)
Female	10	8.3	120.5	(57.7-221.7)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	2	2.8	nc	(nc-nc)
Male	1	1.9	nc	(nc-nc)	Female	3	3.2	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	14	22.9	61.2	(33.5-102.8)
Male	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.3	nc	(nc-nc)	Male	0	1.8	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	1.2	nc	(nc-nc)
Male	4	4.1	nc	(nc-nc)	<u>Testis</u>				
Female	3	2.4	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	3	1.1	nc	(nc-nc)	Male	3	1.6	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	6	4.5	134.4	(49.1-292.5)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	6	2.9	206.7	(75.5-449.9)	Female	7	6.7	104.4	(41.8-215.1)
Female	4	2.3	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	99	94.4	104.9	(85.2-127.7)
Male	0	2.5	nc	(nc-nc)	Female	108	101.9	106.0	(86.9-128.0)
Female	1	0.9	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	10	13.6	73.4	(35.1-134.9)					
Female	16	15.1	106.1	(60.6-172.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Marlborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	36	39.6	90.8	(63.6-125.8)	Male	26	26.5	98.3	(64.2-144.0)
Female	12	13.4	89.6	(46.3-156.6)	Female	13	19.8	65.6	(34.9-112.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	7	8.1	86.0	(34.5-177.2)	Male	9	8.4	107.7	(49.2-204.5)
Female	10	6.5	154.3	(73.9-283.7)	Female	7	6.3	110.9	(44.4-228.4)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.4	nc	(nc-nc)	Male	16	23.3	68.6	(39.2-111.3)
Female	152	158.0	96.2	(81.5-112.8)	Female	26	18.9	137.5	(89.8-201.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	9	5.5	163.3	(74.5-310.1)	Male	19	19.9	95.4	(57.4-149.0)
<u>Colon / Rectum</u>					Female	20	8.4	237.6	(145.1-367.0)
Male	43	43.0	100.0	(72.3-134.7)	<u>Ovary</u>				
Female	44	38.6	114.0	(82.8-153.0)	Female	16	13.5	118.3	(67.6-192.2)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	10	10.2	97.8	(46.8-179.9)	Male	14	14.9	94.0	(51.3-157.7)
Female	5	2.6	190.5	(61.4-444.5)	Female	15	13.8	108.3	(60.6-178.7)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	7	3.4	208.2	(83.4-428.9)	Male	102	120.6	84.6	(69.0-102.7)
Female	3	2.8	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	4	9.5	nc	(nc-nc)
Male	15	24.1	62.2	(34.8-102.7)	Female	7	5.4	129.9	(52.0-267.6)
Female	13	12.5	103.9	(55.3-177.7)	<u>Testis</u>				
<u>Larynx</u>					Male	3	6.8	nc	(nc-nc)
Male	6	6.0	100.3	(36.6-218.2)	<u>Thyroid</u>				
Female	1	1.7	nc	(nc-nc)	Male	13	11.5	113.2	(60.2-193.6)
<u>Leukemia</u>					Female	38	31.4	120.9	(85.5-165.9)
Male	12	16.6	72.1	(37.2-125.9)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	14	11.2	125.0	(68.3-209.7)	Female	36	35.8	100.6	(70.4-139.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	14	14.5	96.3	(52.6-161.6)	Male	445	519.6	85.6	(77.9-94.0)
Female	7	4.6	152.7	(61.2-314.6)	Female	569	522.5	108.9	(100.1-118.2)
<u>Lung and Bronchus</u>									
Male	56	70.0	80.0	(60.4-103.9)					
Female	76	71.3	106.6	(84.0-133.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Marshfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	24	29.0	82.8	(53.0-123.2)	Male	31	19.1	162.4	(110.3-230.5)
Female	10	9.7	103.1	(49.4-189.7)	Female	29	14.4	201.1	(134.6-288.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	11	5.6	196.6	(98.0-351.8)	Male	10	6.2	162.1	(77.6-298.1)
Female	4	4.7	nc	(nc-nc)	Female	4	4.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.0	nc	(nc-nc)	Male	10	16.8	59.5	(28.5-109.5)
Female	145	121.4	119.5	(100.8-140.6)	Female	13	13.9	93.4	(49.7-159.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	3.9	nc	(nc-nc)	Male	17	15.0	113.2	(65.9-181.3)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	23	31.3	73.4	(46.5-110.2)	Female	8	10.2	78.7	(33.9-155.1)
Female	27	27.6	97.9	(64.5-142.4)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	12	11.1	108.5	(56.0-189.6)
Male	7	7.7	91.0	(36.5-187.6)	Female	10	10.0	100.5	(48.1-184.8)
Female	0	2.0	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	102	95.1	107.2	(87.4-130.2)
Male	0	2.0	nc	(nc-nc)	<u>Stomach</u>				
Female	3	1.7	nc	(nc-nc)	Male	5	7.0	71.8	(23.1-167.6)
<u>Kidney & Renal Pelvis</u>					Female	4	3.9	nc	(nc-nc)
Male	20	17.9	111.6	(68.2-172.4)	<u>Testis</u>				
Female	6	9.4	63.9	(23.3-139.2)	Male	5	3.6	140.6	(45.3-328.2)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	4.5	nc	(nc-nc)	Male	8	7.8	102.4	(44.1-201.8)
Female	1	1.4	nc	(nc-nc)	Female	17	22.4	75.9	(44.2-121.6)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	15	11.8	127.5	(71.3-210.2)	Female	21	28.3	74.3	(46.0-113.6)
Female	5	7.9	63.4	(20.4-147.9)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	392	384.5	102.0	(92.1-112.6)
Male	13	11.0	118.5	(63.0-202.7)	Female	414	389.2	106.4	(96.4-117.1)
Female	0	3.4	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	49	51.9	94.4	(69.8-124.8)					
Female	71	53.3	133.3	(104.1-168.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Mashpee

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	25	24.6	101.7	(65.8-150.2)	Male	17	14.4	118.4	(68.9-189.5)
Female	6	8.8	68.5	(25.0-149.1)	Female	16	10.5	152.9	(87.4-248.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	3.8	nc	(nc-nc)	Male	10	4.8	209.5	(100.3-385.3)
Female	1	3.4	nc	(nc-nc)	Female	2	4.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.8	nc	(nc-nc)	Male	18	12.6	143.0	(84.7-226.0)
Female	96	89.4	107.3	(86.9-131.1)	Female	10	11.4	88.0	(42.1-161.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	2.4	nc	(nc-nc)	Male	14	9.8	143.4	(78.3-240.6)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	16	23.1	69.2	(39.5-112.4)	Female	4	7.7	nc	(nc-nc)
Female	19	23.2	81.7	(49.2-127.7)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	10	8.6	115.9	(55.5-213.1)
Male	5	5.8	85.5	(27.6-199.6)	Female	8	9.0	89.2	(38.4-175.7)
Female	0	1.7	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	60	67.7	88.7	(67.7-114.1)
Male	2	1.1	nc	(nc-nc)	<u>Stomach</u>				
Female	1	1.0	nc	(nc-nc)	Male	4	5.5	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	3.3	nc	(nc-nc)
Male	7	12.2	57.2	(22.9-117.8)	<u>Testis</u>				
Female	7	7.4	94.3	(37.8-194.2)	Male	3	1.7	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	3	3.4	nc	(nc-nc)	Male	3	4.5	nc	(nc-nc)
Female	2	1.0	nc	(nc-nc)	Female	7	13.1	53.4	(21.4-109.9)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	8	8.9	90.3	(38.9-177.9)	Female	18	20.9	86.0	(50.9-135.9)
Female	11	6.4	171.6	(85.6-307.1)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	275	286.8	95.9	(84.9-107.9)
Male	5	7.7	65.3	(21.0-152.4)	Female	302	304.4	99.2	(88.3-111.1)
Female	1	2.8	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	40	43.0	93.1	(66.5-126.8)					
Female	57	47.6	119.9	(90.8-155.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Mattapoisett

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	12	8.4	142.4	(73.5-248.8)	Male	4	5.3	nc	(nc-nc)
Female	3	2.9	nc	(nc-nc)	Female	2	3.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.5	nc	(nc-nc)	Male	0	1.7	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)	Female	0	1.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.3	nc	(nc-nc)	Male	1	4.6	nc	(nc-nc)
Female	37	33.5	110.5	(77.8-152.3)	Female	4	4.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.0	nc	(nc-nc)	Male	13	4.0	328.8	(174.9-562.4)
<u>Colon / Rectum</u>					Female	2	1.8	nc	(nc-nc)
Male	13	8.6	151.7	(80.7-259.5)	<u>Ovary</u>				
Female	3	8.0	nc	(nc-nc)	Female	3	2.8	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	2.2	nc	(nc-nc)	Male	4	3.1	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	2	3.0	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.5	nc	(nc-nc)	Male	35	26.6	131.5	(91.6-182.9)
Female	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	2.0	nc	(nc-nc)
Male	4	4.9	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
Female	0	2.7	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.8	nc	(nc-nc)
Male	0	1.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.4	nc	(nc-nc)	Male	2	2.0	nc	(nc-nc)
<u>Leukemia</u>					Female	5	5.6	89.9	(29.0-209.7)
Male	1	3.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	4	2.2	nc	(nc-nc)	Female	9	7.8	115.3	(52.6-219.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	2.9	nc	(nc-nc)	Male	123	106.9	115.0	(95.6-137.2)
Female	3	1.0	nc	(nc-nc)	Female	99	109.8	90.2	(73.3-109.8)
<u>Lung and Bronchus</u>									
Male	15	15.0	99.7	(55.8-164.5)					
Female	14	16.1	86.9	(47.5-145.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Maynard

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	9	13.8	65.4	(29.9-124.2)	Male	10	8.8	113.9	(54.6-209.6)
Female	4	3.6	nc	(nc-nc)	Female	5	5.5	91.0	(29.3-212.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	2.5	nc	(nc-nc)	Male	0	2.8	nc	(nc-nc)
Female	0	1.7	nc	(nc-nc)	Female	1	1.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.5	nc	(nc-nc)	Male	3	7.8	nc	(nc-nc)
Female	37	43.8	84.6	(59.5-116.6)	Female	3	5.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.4	nc	(nc-nc)	Male	6	6.4	94.1	(34.3-204.7)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	17	14.1	120.7	(70.3-193.3)	Female	3	3.8	nc	(nc-nc)
Female	15	10.5	142.6	(79.7-235.2)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	4	5.1	nc	(nc-nc)
Male	2	3.5	nc	(nc-nc)	Female	5	3.7	133.9	(43.2-312.5)
Female	1	0.7	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	22	40.3	54.6	(34.2-82.6)
Male	1	0.9	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.7	nc	(nc-nc)	Male	1	3.2	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	1.5	nc	(nc-nc)
Male	2	7.7	nc	(nc-nc)	<u>Testis</u>				
Female	4	3.5	nc	(nc-nc)	Male	0	1.6	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	2.0	nc	(nc-nc)	Male	3	3.3	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	9	8.5	105.8	(48.3-200.8)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	3	5.5	nc	(nc-nc)	Female	5	10.4	48.0	(15.5-112.0)
Female	6	3.0	199.0	(72.7-433.2)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	109	172.8	63.1	(51.8-76.1)
Male	2	4.9	nc	(nc-nc)	Female	139	143.7	96.8	(81.3-114.3)
Female	2	1.3	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	12	24.2	49.6	(25.6-86.6)					
Female	20	19.2	104.2	(63.6-161.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Medfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	8	12.8	62.6	(26.9-123.3)	Male	14	8.7	161.1	(88.0-270.3)
Female	4	3.8	nc	(nc-nc)	Female	5	6.3	79.6	(25.7-185.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	2.6	232.7	(85.0-506.6)	Male	2	2.8	nc	(nc-nc)
Female	3	2.0	nc	(nc-nc)	Female	4	1.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.5	nc	(nc-nc)	Male	5	7.7	65.0	(20.9-151.7)
Female	39	53.6	72.8	(51.8-99.5)	Female	4	5.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.9	nc	(nc-nc)	Male	6	6.7	88.9	(32.5-193.5)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	16	14.3	111.8	(63.9-181.6)	Female	4	4.4	nc	(nc-nc)
Female	10	12.0	83.6	(40.0-153.8)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	4	5.0	nc	(nc-nc)
Male	4	3.4	nc	(nc-nc)	Female	2	3.9	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	53	40.0	132.5	(99.3-173.3)
Male	1	0.9	nc	(nc-nc)	<u>Stomach</u>				
Female	1	0.7	nc	(nc-nc)	Male	2	3.1	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	2	1.6	nc	(nc-nc)
Male	7	8.1	86.9	(34.8-179.1)	<u>Testis</u>				
Female	3	4.0	nc	(nc-nc)	Male	0	1.7	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	2.0	nc	(nc-nc)	Male	3	3.8	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	6	10.7	56.2	(20.5-122.3)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	3	5.3	nc	(nc-nc)	Female	10	11.7	85.6	(41.0-157.5)
Female	3	3.3	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	155	170.3	91.0	(77.3-106.5)
Male	0	4.9	nc	(nc-nc)	Female	123	165.6	74.3	(61.7-88.6)
Female	1	1.4	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	11	22.7	48.5	(24.2-86.9)					
Female	14	20.7	67.5	(36.9-113.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Medford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	56	57.1	98.0	(74.0-127.3)	Male	17	36.0	47.3	(27.5-75.7)
Female	22	21.9	100.4	(62.9-152.0)	Female	17	30.6	55.6	(32.4-89.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	12	10.9	109.8	(56.7-191.8)	Male	11	11.4	96.8	(48.3-173.3)
Female	10	10.1	98.8	(47.3-181.8)	Female	9	10.1	89.1	(40.6-169.1)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	1.9	nc	(nc-nc)	Male	30	32.0	93.7	(63.2-133.8)
Female	233	234.0	99.6	(87.2-113.2)	Female	29	29.9	96.9	(64.9-139.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	6	7.8	77.4	(28.3-168.4)	Male	24	25.3	94.9	(60.8-141.2)
Female					Female	13	13.1	99.4	(52.9-170.0)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	62	58.6	105.8	(81.1-135.7)	Female	19	20.7	91.7	(55.2-143.2)
Female	70	61.7	113.4	(88.4-143.3)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	17	20.6	82.6	(48.1-132.3)
Male	14	13.8	101.6	(55.5-170.4)	Female	22	22.7	96.8	(60.7-146.6)
Female	8	4.2	189.5	(81.6-373.4)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	148	159.3	92.9	(78.6-109.2)
Male	5	4.8	104.6	(33.7-244.2)	<u>Stomach</u>				
Female	5	4.7	107.3	(34.6-250.4)	Male	13	13.1	98.9	(52.6-169.1)
<u>Kidney & Renal Pelvis</u>					Female	9	8.7	103.0	(47.0-195.5)
Male	28	31.1	89.9	(59.8-130.0)	<u>Testis</u>				
Female	21	19.2	109.6	(67.8-167.5)	Male	10	9.4	106.8	(51.1-196.5)
<u>Larynx</u>					<u>Thyroid</u>				
Male	7	8.0	87.6	(35.1-180.5)	Male	13	14.3	91.0	(48.4-155.7)
Female	3	2.6	nc	(nc-nc)	Female	44	45.6	96.4	(70.0-129.4)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	30	23.1	130.0	(87.7-185.6)	Female	55	53.5	102.8	(77.5-133.9)
Female	23	18.0	127.9	(81.1-192.0)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	685	706.1	97.0	(89.9-104.6)
Male	27	18.9	142.7	(94.0-207.6)	Female	834	805.9	103.5	(96.6-110.8)
Female	6	7.3	82.1	(30.0-178.8)					
<u>Lung and Bronchus</u>									
Male	105	98.4	106.8	(87.3-129.2)					
Female	142	113.9	124.7	(105.0-147.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Medway

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	11	11.2	98.2	(49.0-175.8)	Male	9	7.8	116.0	(52.9-220.2)
Female	3	4.6	nc	(nc-nc)	Female	5	7.1	70.6	(22.8-164.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	2.5	nc	(nc-nc)	Male	2	2.5	nc	(nc-nc)
Female	3	2.3	nc	(nc-nc)	Female	2	2.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.4	nc	(nc-nc)	Male	11	6.9	158.8	(79.1-284.1)
Female	63	56.9	110.7	(85.1-141.7)	Female	10	6.6	151.4	(72.5-278.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	2.0	nc	(nc-nc)	Male	1	6.3	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	16	13.1	122.1	(69.7-198.3)	Female	7	4.8	145.5	(58.3-299.8)
Female	10	14.4	69.7	(33.4-128.1)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	5	4.4	114.6	(36.9-267.5)
Male	4	3.1	nc	(nc-nc)	Female	2	4.9	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	55	37.2	148.0	(111.5-192.7)
Male	1	0.9	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.9	nc	(nc-nc)	Male	2	2.8	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	2.0	nc	(nc-nc)
Male	7	7.5	93.6	(37.5-192.9)	<u>Testis</u>				
Female	5	4.4	114.9	(37.0-268.2)	Male	2	1.8	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	1.8	nc	(nc-nc)	Male	6	3.5	169.8	(62.0-369.5)
Female	0	0.6	nc	(nc-nc)	Female	10	11.3	88.7	(42.5-163.2)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	4	4.8	nc	(nc-nc)	Female	15	12.3	121.7	(68.1-200.7)
Female	6	4.0	150.7	(55.0-327.9)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	179	154.7	115.7	(99.4-133.9)
Male	5	4.4	112.7	(36.3-263.0)	Female	189	184.5	102.4	(88.4-118.1)
Female	3	1.6	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	19	19.9	95.3	(57.3-148.8)					
Female	23	23.4	98.4	(62.4-147.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Melrose

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	13	29.5	44.1	(23.5-75.4)	Male	16	19.1	83.8	(47.9-136.2)
Female	8	11.2	71.2	(30.6-140.2)	Female	20	15.7	127.3	(77.7-196.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	5.8	nc	(nc-nc)	Male	7	6.1	115.1	(46.1-237.1)
Female	7	5.0	138.8	(55.6-286.0)	Female	2	5.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.0	nc	(nc-nc)	Male	21	16.9	124.1	(76.8-189.6)
Female	134	125.5	106.7	(89.4-126.4)	Female	22	15.5	142.1	(89.0-215.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	4.2	nc	(nc-nc)	Male	11	14.2	77.4	(38.6-138.5)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	43	31.2	137.9	(99.8-185.8)	Female	5	10.8	46.2	(14.9-107.8)
Female	40	32.0	125.2	(89.4-170.5)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	16	10.9	146.4	(83.7-237.8)
Male	9	7.5	120.0	(54.8-227.8)	Female	13	11.7	111.2	(59.1-190.1)
Female	1	2.2	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	79	90.2	87.6	(69.3-109.2)
Male	1	2.3	nc	(nc-nc)	<u>Stomach</u>				
Female	2	1.9	nc	(nc-nc)	Male	9	7.0	129.2	(59.0-245.3)
<u>Kidney & Renal Pelvis</u>					Female	3	4.5	nc	(nc-nc)
Male	14	17.4	80.4	(43.9-134.9)	<u>Testis</u>				
Female	6	10.1	59.3	(21.7-129.1)	Male	3	4.6	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	7	4.3	161.8	(64.8-333.5)	Male	8	8.1	99.0	(42.6-195.0)
Female	1	1.4	nc	(nc-nc)	Female	23	23.3	98.6	(62.5-147.9)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	20	12.1	165.7	(101.2-255.9)	Female	35	28.7	122.0	(85.0-169.7)
Female	9	9.1	98.6	(45.0-187.2)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	361	379.9	95.0	(85.5-105.4)
Male	7	10.4	67.3	(26.9-138.6)	Female	438	421.6	103.9	(94.4-114.1)
Female	5	3.8	132.6	(42.7-309.4)					
<u>Lung and Bronchus</u>									
Male	41	51.4	79.8	(57.3-108.3)					
Female	60	59.3	101.2	(77.3-130.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Mendon

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	6.5	nc	(nc-nc)	Male	3	4.4	nc	(nc-nc)
Female	1	1.6	nc	(nc-nc)	Female	4	2.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.3	nc	(nc-nc)	Male	0	1.4	nc	(nc-nc)
Female	2	1.0	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.2	nc	(nc-nc)	Male	5	3.9	128.1	(41.3-299.1)
Female	18	25.6	70.4	(41.7-111.3)	Female	4	2.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.9	nc	(nc-nc)	Male	4	3.7	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	6	7.4	81.6	(29.8-177.5)	Female	2	2.1	nc	(nc-nc)
Female	6	5.0	120.1	(43.9-261.4)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	0	1.8	nc	(nc-nc)	Male	18	24.0	74.9	(44.4-118.4)
Female	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	0	0.5	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	5	4.4	114.8	(37.0-268.0)	Female	8	5.9	135.2	(58.2-266.4)
Female	1	1.9	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Leukemia</u>				
Male	0	1.1	nc	(nc-nc)	Male	4	2.7	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	1.5	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Lung and Bronchus</u>				
Male	0	2.7	nc	(nc-nc)	Male	8	11.7	68.4	(29.4-134.7)
Female	1	0.6	nc	(nc-nc)	Female	10	9.3	107.4	(51.4-197.6)
<u>Male</u>					<u>Female</u>				
					64				
					80				
					91.1				
					76.7				
					70.2				
					104.3				
					(54.1-89.7)				
					(82.7-129.9)				

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Merrimac

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	9	7.3	122.5	(55.9-232.5)	Male	3	4.8	nc	(nc-nc)
Female	4	2.5	nc	(nc-nc)	Female	4	3.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.4	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	3	4.2	nc	(nc-nc)
Female	26	31.8	81.6	(53.3-119.6)	Female	3	3.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.1	nc	(nc-nc)	Male	4	3.7	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	8	7.8	102.2	(44.0-201.4)	Female	4	2.7	nc	(nc-nc)
Female	6	7.3	82.6	(30.2-179.8)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	1	1.9	nc	(nc-nc)	Male	3	2.8	nc	(nc-nc)
Female	2	0.5	nc	(nc-nc)	Female	2	2.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.5	nc	(nc-nc)	Male	18	24.0	75.0	(44.4-118.5)
Female	2	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	1	4.5	nc	(nc-nc)	Male	3	1.8	nc	(nc-nc)
Female	2	2.4	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	2	1.1	nc	(nc-nc)	Male	3	0.9	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	4	3.0	nc	(nc-nc)	Male	1	2.0	nc	(nc-nc)
Female	1	2.0	nc	(nc-nc)	Female	6	6.0	99.9	(36.5-217.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	2.7	nc	(nc-nc)	Female	1	7.3	nc	(nc-nc)
Female	3	0.9	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	16	13.3	120.7	(69.0-196.1)	Male	90	96.7	93.1	(74.9-114.5)
Female	24	13.6	176.9	(113.3-263.2)	Female	103	101.3	101.7	(83.0-123.3)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Methuen

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	53	49.5	107.1	(80.2-140.0)	Male	24	32.3	74.3	(47.6-110.5)
Female	23	18.2	126.1	(79.9-189.2)	Female	20	26.0	76.9	(46.9-118.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	12	9.8	122.7	(63.3-214.4)	Male	7	10.3	68.0	(27.2-140.1)
Female	10	8.4	118.4	(56.7-217.7)	Female	8	8.5	93.9	(40.4-185.1)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	4	1.8	nc	(nc-nc)	Male	36	28.7	125.5	(87.9-173.8)
Female	186	208.7	89.1	(76.8-102.9)	Female	24	25.3	94.9	(60.8-141.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	6	6.9	86.9	(31.7-189.0)	Male	25	24.3	102.7	(66.5-151.6)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	48	52.6	91.2	(67.2-120.9)	Female	21	18.0	116.7	(72.2-178.4)
Female	44	52.1	84.4	(61.3-113.3)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	12	18.6	64.5	(33.3-112.7)
Male	9	12.7	70.9	(32.3-134.6)	Female	23	18.9	121.9	(77.2-182.8)
Female	3	3.6	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	158	152.5	103.6	(88.1-121.1)
Male	6	3.9	155.4	(56.7-338.2)	<u>Stomach</u>				
Female	0	3.4	nc	(nc-nc)	Male	12	11.7	102.1	(52.7-178.4)
<u>Kidney & Renal Pelvis</u>					Female	9	7.3	122.9	(56.1-233.4)
Male	36	29.3	122.9	(86.1-170.2)	<u>Testis</u>				
Female	20	16.6	120.1	(73.4-185.6)	Male	12	7.2	165.8	(85.6-289.7)
<u>Larynx</u>					<u>Thyroid</u>				
Male	10	7.4	134.5	(64.4-247.5)	Male	18	13.4	134.3	(79.5-212.2)
Female	6	2.3	258.0	(94.2-561.7)	Female	45	39.6	113.6	(82.9-152.0)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	26	20.4	127.2	(83.1-186.4)	Female	50	47.3	105.6	(78.4-139.3)
Female	15	14.8	101.0	(56.5-166.6)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	663	642.1	103.3	(95.5-111.4)
Male	15	18.0	83.2	(46.5-137.2)	Female	733	695.0	105.5	(98.0-113.4)
Female	6	6.1	98.1	(35.8-213.5)					
<u>Lung and Bronchus</u>									
Male	101	86.7	116.6	(94.9-141.6)					
Female	133	96.9	137.2	(114.9-162.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Middleborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	37	25.4	145.9	(102.7-201.1)	Male	17	16.6	102.1	(59.5-163.5)
Female	10	9.3	107.7	(51.6-198.1)	Female	15	13.2	113.8	(63.7-187.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	7	5.1	136.3	(54.6-280.8)	Male	5	5.4	92.5	(29.8-215.8)
Female	6	4.2	141.5	(51.7-308.1)	Female	6	4.4	137.7	(50.3-299.7)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.9	nc	(nc-nc)	Male	17	14.8	115.1	(67.0-184.2)
Female	109	108.3	100.6	(82.6-121.4)	Female	11	12.9	85.5	(42.6-153.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	3.6	nc	(nc-nc)	Male	15	13.1	114.7	(64.2-189.3)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	26	27.3	95.1	(62.1-139.3)	Female	10	9.2	109.2	(52.3-200.8)
Female	24	26.4	91.0	(58.3-135.4)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	13	9.6	134.7	(71.7-230.4)
Male	10	6.7	148.3	(71.0-272.8)	Female	12	9.7	124.3	(64.2-217.1)
Female	3	1.8	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	86	84.7	101.5	(81.2-125.4)
Male	1	1.8	nc	(nc-nc)	<u>Stomach</u>				
Female	2	1.7	nc	(nc-nc)	Male	6	6.1	98.3	(35.9-214.0)
<u>Kidney & Renal Pelvis</u>					Female	1	3.7	nc	(nc-nc)
Male	23	15.8	145.8	(92.4-218.7)	<u>Testis</u>				
Female	6	8.5	70.2	(25.6-152.8)	Male	4	3.4	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	3	4.0	nc	(nc-nc)	Male	8	6.9	115.8	(49.9-228.2)
Female	5	1.2	412.4	(132.9-962.5)	Female	25	20.2	123.8	(80.1-182.7)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	11	10.5	105.1	(52.4-188.1)	Female	33	24.7	133.6	(92.0-187.6)
Female	10	7.4	134.9	(64.6-248.2)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	393	338.9	116.0	(104.8-128.0)
Male	12	9.6	125.4	(64.7-219.1)	Female	412	356.8	115.5	(104.6-127.2)
Female	6	3.1	193.9	(70.8-422.0)					
<u>Lung and Bronchus</u>									
Male	67	45.6	146.8	(113.8-186.4)					
Female	80	50.1	159.7	(126.6-198.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Middlefield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	1.0	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	1	3.1	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	2	1.0	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	0	0.3	nc	(nc-nc)	Male	1	3.6	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	0.6	nc	(nc-nc)	Female	2	0.8	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Male</u>				
Male	0	0.2	nc	(nc-nc)	7	13.3	52.7	(21.1-108.6)	
Female	0	0.0	nc	(nc-nc)	<u>Female</u>				
<u>Leukemia</u>					<u>8</u>				
Male	0	0.4	nc	(nc-nc)	9.7	82.9	(35.7-163.3)		
Female	0	0.2	nc	(nc-nc)					
<u>Liver and Intrahepatic Bile Ducts</u>									
Male	0	0.4	nc	(nc-nc)					
Female	1	0.1	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	0	1.9	nc	(nc-nc)					
Female	1	1.3	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Middleton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	17	11.0	154.2	(89.8-246.9)	Male	8	7.4	107.5	(46.3-211.8)
Female	3	3.0	nc	(nc-nc)	Female	4	4.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	2.3	216.6	(69.8-505.6)	Male	2	2.3	nc	(nc-nc)
Female	3	1.4	nc	(nc-nc)	Female	2	1.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	12	6.6	181.0	(93.4-316.2)
Female	38	35.5	107.0	(75.7-146.9)	Female	8	4.2	192.3	(82.8-378.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.1	nc	(nc-nc)	Male	5	5.9	85.1	(27.4-198.7)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	11	12.3	89.6	(44.7-160.4)	Female	0	3.0	nc	(nc-nc)
Female	11	8.4	130.9	(65.3-234.3)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	2	2.9	nc	(nc-nc)	Male	35	36.4	96.3	(67.0-133.9)
Female	0	0.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	0	1.0	nc	(nc-nc)	Male	2	2.0	nc	(nc-nc)
Female	2	0.5	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	3	7.0	nc	(nc-nc)	Female	15	8.2	183.6	(102.7-302.9)
Female	4	2.8	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Leukemia</u>				
Male	3	1.7	nc	(nc-nc)	Male	5	4.7	107.3	(34.6-250.5)
Female	0	0.4	nc	(nc-nc)	Female	2	2.4	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Lung and Bronchus</u>				
Male	2	4.2	nc	(nc-nc)	Male	17	19.4	87.7	(51.1-140.5)
Female	1	1.0	nc	(nc-nc)	Female	21	16.8	125.1	(77.4-191.2)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Milford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	42	26.3	159.5	(114.9-215.6)	Male	15	17.8	84.2	(47.1-138.9)
Female	17	9.8	173.0	(100.7-277.0)	Female	13	14.6	89.0	(47.3-152.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	5.5	90.1	(29.0-210.3)	Male	2	5.7	nc	(nc-nc)
Female	5	4.8	104.8	(33.8-244.6)	Female	10	4.7	213.7	(102.3-393.0)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.0	nc	(nc-nc)	Male	22	15.8	138.9	(87.0-210.3)
Female	114	116.9	97.5	(80.4-117.1)	Female	18	13.9	129.2	(76.6-204.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	5	4.0	125.4	(40.4-292.7)	Male	18	13.6	131.9	(78.1-208.5)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	32	29.2	109.6	(75.0-154.7)	Female	9	10.0	90.0	(41.1-170.9)
Female	29	28.6	101.3	(67.8-145.4)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	10	10.0	99.8	(47.8-183.5)
Male	8	6.9	115.8	(49.8-228.1)	Female	9	10.3	87.6	(40.0-166.2)
Female	2	2.0	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	97	82.2	118.0	(95.7-144.0)
Male	5	2.3	220.8	(71.2-515.2)	<u>Stomach</u>				
Female	1	2.0	nc	(nc-nc)	Male	11	6.4	172.2	(85.8-308.1)
<u>Kidney & Renal Pelvis</u>					Female	0	4.0	nc	(nc-nc)
Male	24	16.5	145.3	(93.1-216.2)	<u>Testis</u>				
Female	12	9.2	130.7	(67.5-228.3)	Male	2	4.6	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	4.0	nc	(nc-nc)	Male	6	8.0	75.0	(27.4-163.4)
Female	1	1.3	nc	(nc-nc)	Female	21	22.9	91.8	(56.8-140.4)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	11	11.2	98.1	(48.9-175.6)	Female	22	26.7	82.4	(51.6-124.7)
Female	9	8.3	108.5	(49.5-205.9)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	402	351.0	114.5	(103.6-126.3)
Male	9	9.8	91.8	(41.9-174.3)	Female	412	385.5	106.9	(96.8-117.7)
Female	4	3.4	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	50	46.4	107.8	(80.0-142.2)					
Female	71	51.7	137.4	(107.3-173.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Millbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	22	16.2	135.9	(85.1-205.8)	Male	10	10.3	96.6	(46.3-177.7)
Female	2	5.1	nc	(nc-nc)	Female	8	7.3	109.8	(47.3-216.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	3.0	nc	(nc-nc)	Male	5	3.3	151.2	(48.7-352.9)
Female	2	2.4	nc	(nc-nc)	Female	6	2.4	249.4	(91.1-542.9)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.6	nc	(nc-nc)	Male	14	9.1	153.6	(83.9-257.7)
Female	64	59.6	107.4	(82.7-137.1)	Female	4	7.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	2.0	nc	(nc-nc)	Male	10	7.7	129.1	(61.8-237.4)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	12	16.8	71.4	(36.8-124.7)	Female	7	5.1	136.5	(54.7-281.2)
Female	12	14.6	82.2	(42.4-143.6)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	6	6.0	99.6	(36.4-216.8)
Male	7	4.1	170.3	(68.2-350.9)	Female	9	5.3	170.4	(77.7-323.4)
Female	3	1.0	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	54	50.8	106.2	(79.8-138.6)
Male	2	1.1	nc	(nc-nc)	<u>Stomach</u>				
Female	2	0.9	nc	(nc-nc)	Male	2	3.8	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	3	2.0	nc	(nc-nc)
Male	10	9.5	105.3	(50.4-193.6)	<u>Testis</u>				
Female	7	4.8	147.3	(59.0-303.6)	Male	1	1.9	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	6	2.4	250.7	(91.6-545.7)	Male	10	4.1	242.1	(115.9-445.2)
Female	1	0.7	nc	(nc-nc)	Female	13	11.1	117.0	(62.3-200.2)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	10	6.4	155.5	(74.4-286.0)	Female	12	13.7	87.6	(45.2-153.0)
Female	6	4.1	145.0	(52.9-315.6)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	253	207.7	121.8	(107.3-137.8)
Male	5	5.7	87.5	(28.2-204.2)	Female	210	196.8	106.7	(92.8-122.2)
Female	1	1.7	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	49	28.7	170.7	(126.3-225.7)					
Female	32	27.6	116.0	(79.3-163.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Millis

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	8	6.1	130.3	(56.1-256.7)	Male	4	4.5	nc	(nc-nc)
Female	4	2.8	nc	(nc-nc)	Female	6	4.4	137.6	(50.2-299.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	1.5	nc	(nc-nc)	Male	0	1.4	nc	(nc-nc)
Female	0	1.4	nc	(nc-nc)	Female	1	1.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	2	4.1	nc	(nc-nc)
Female	39	36.2	107.7	(76.6-147.2)	Female	6	4.1	146.2	(53.4-318.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	1.2	nc	(nc-nc)	Male	6	3.8	156.4	(57.1-340.3)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	8	7.5	106.8	(46.0-210.4)	Female	1	3.1	nc	(nc-nc)
Female	8	8.3	96.0	(41.3-189.2)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	2	1.8	nc	(nc-nc)	Male	30	22.9	131.0	(88.4-187.0)
Female	0	0.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	1	0.6	nc	(nc-nc)	Male	2	1.2	nc	(nc-nc)
Female	3	0.6	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	6	4.5	131.9	(48.2-287.1)	Female	8	8.3	95.8	(41.3-188.9)
Female	4	2.8	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Leukemia</u>				
Male	0	1.1	nc	(nc-nc)	Male	3	2.8	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	4	2.4	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Lung and Bronchus</u>				
Male	1	2.7	nc	(nc-nc)	Male	9	11.4	78.7	(35.9-149.4)
Female	1	1.0	nc	(nc-nc)	Female	23	15.7	146.5	(92.8-219.8)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Millville

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	2.1	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
Female	2	1.2	nc	(nc-nc)	Female	0	1.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.5	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	15	14.6	103.0	(57.6-170.0)	Female	1	1.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.5	nc	(nc-nc)	Male	3	1.4	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	1	2.7	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
Female	1	3.5	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	1	0.9	nc	(nc-nc)
Male	1	0.6	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	11	7.9	138.4	(69.0-247.7)
Male	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.2	nc	(nc-nc)	Male	3	0.6	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.5	nc	(nc-nc)
Male	0	1.6	nc	(nc-nc)	<u>Testis</u>				
Female	1	1.1	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.4	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	2.8	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	1.0	nc	(nc-nc)	Female	2	3.2	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	40	32.1	124.8	(89.1-169.9)
Male	2	1.0	nc	(nc-nc)	Female	38	47.2	80.4	(56.9-110.4)
Female	1	0.4	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	7	3.9	180.3	(72.2-371.5)					
Female	9	6.4	140.6	(64.2-267.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Milton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	17	29.1	58.5	(34.0-93.6)	Male	35	18.3	191.7	(133.5-266.6)
Female	7	10.9	64.2	(25.7-132.3)	Female	24	15.0	160.4	(102.7-238.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	5.4	nc	(nc-nc)	Male	7	5.8	120.7	(48.4-248.7)
Female	6	4.9	121.4	(44.3-264.2)	Female	10	5.0	200.0	(95.7-367.8)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.0	nc	(nc-nc)	Male	21	16.1	130.1	(80.5-198.9)
Female	153	118.3	129.4	(109.7-151.6)	Female	10	14.8	67.6	(32.4-124.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	4.0	nc	(nc-nc)	Male	7	13.2	53.2	(21.3-109.6)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	25	30.1	83.2	(53.8-122.8)	Female	18	10.2	176.3	(104.4-278.7)
Female	29	31.3	92.5	(62.0-132.9)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	12	10.5	113.9	(58.8-198.9)
Male	8	7.1	113.0	(48.7-222.7)	Female	11	11.5	96.0	(47.8-171.7)
Female	4	2.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	93	82.0	113.5	(91.6-139.0)
Male	2	2.0	nc	(nc-nc)	<u>Stomach</u>				
Female	4	1.8	nc	(nc-nc)	Male	6	6.7	89.3	(32.6-194.4)
<u>Kidney & Renal Pelvis</u>					Female	4	4.4	nc	(nc-nc)
Male	16	16.1	99.2	(56.7-161.2)	<u>Testis</u>				
Female	11	9.5	115.8	(57.7-207.1)	Male	0	3.6	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	4.0	nc	(nc-nc)	Male	6	7.1	84.2	(30.8-183.4)
Female	0	1.3	nc	(nc-nc)	Female	34	21.9	155.0	(107.4-216.7)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	14	11.8	119.1	(65.1-199.9)	Female	27	26.2	103.0	(67.9-149.9)
Female	8	8.8	90.6	(39.0-178.5)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	351	359.0	97.8	(87.8-108.6)
Male	8	9.7	82.7	(35.6-162.9)	Female	451	401.1	112.5	(102.3-123.3)
Female	1	3.5	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	38	49.9	76.1	(53.9-104.5)					
Female	48	56.2	85.5	(63.0-113.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Monroe

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
					Female	0	0.0	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)					
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)					
<u>Kidney & Renal Pelvis</u>					<u>Stomach</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)					
<u>Leukemia</u>					<u>Thyroid</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.0	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)					
<u>Lung and Bronchus</u>					<u>All Sites / Types</u>				
Male	0	0.2	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	2.2	nc	(nc-nc)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Monson

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	9	11.0	82.1	(37.5-155.9)	Male	4	7.1	nc	(nc-nc)
Female	1	3.4	nc	(nc-nc)	Female	1	5.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	2.0	nc	(nc-nc)	Male	1	2.3	nc	(nc-nc)
Female	2	1.7	nc	(nc-nc)	Female	1	1.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	5	6.2	80.2	(25.8-187.1)
Female	50	44.5	112.3	(83.3-148.0)	Female	7	4.9	142.0	(56.9-292.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	1.4	nc	(nc-nc)	Male	1	5.5	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	11	11.6	94.8	(47.2-169.6)	Female	0	3.7	nc	(nc-nc)
Female	5	9.7	51.8	(16.7-120.9)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	3	2.9	nc	(nc-nc)	Male	3	4.1	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	3	3.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.7	nc	(nc-nc)	Male	33	35.3	93.5	(64.3-131.3)
Female	0	0.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	5	6.6	75.8	(24.4-176.8)	Male	0	2.6	nc	(nc-nc)
Female	0	3.4	nc	(nc-nc)	Female	2	1.4	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	2	1.7	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	4	4.3	nc	(nc-nc)	Male	2	2.8	nc	(nc-nc)
Female	1	2.7	nc	(nc-nc)	Female	4	8.1	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	3	4.0	nc	(nc-nc)	Female	6	10.5	57.1	(20.8-124.3)
Female	1	1.2	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	16	19.7	81.2	(46.4-131.8)	Male	112	142.9	78.4	(64.5-94.3)
Female	14	18.6	75.3	(41.1-126.3)	Female	114	139.6	81.7	(67.4-98.1)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Montague

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	10	10.3	97.4	(46.6-179.1)	Male	8	6.4	125.0	(53.8-246.2)
Female	3	4.1	nc	(nc-nc)	Female	1	5.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	1.8	275.6	(88.8-643.2)	Male	4	2.1	nc	(nc-nc)
Female	1	1.7	nc	(nc-nc)	Female	0	1.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	6	5.7	106.1	(38.8-231.0)
Female	38	44.5	85.4	(60.4-117.3)	Female	3	5.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	1.4	nc	(nc-nc)	Male	3	4.7	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	7	10.4	67.2	(26.9-138.5)	Female	6	3.9	154.8	(56.5-337.0)
Female	12	11.8	101.6	(52.4-177.5)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	2	3.8	nc	(nc-nc)
Male	8	2.6	311.6	(134.2-614.0)	Female	2	4.4	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	17	31.1	54.7	(31.8-87.6)
Male	0	0.7	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.6	nc	(nc-nc)	Male	2	2.4	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	1.7	nc	(nc-nc)
Male	5	5.7	87.5	(28.2-204.2)	<u>Testis</u>				
Female	4	3.6	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	1.5	nc	(nc-nc)	Male	1	2.4	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	3	7.6	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	5	4.0	125.7	(40.5-293.3)	Female	9	10.4	86.4	(39.4-164.1)
Female	6	3.2	184.9	(67.5-402.6)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	121	128.5	94.2	(78.1-112.5)
Male	5	3.5	141.4	(45.6-330.0)	Female	124	150.8	82.2	(68.4-98.0)
Female	0	1.4	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	19	17.9	106.2	(63.9-165.9)					
Female	20	21.3	93.7	(57.2-144.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Monterey

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	1.8	nc	(nc-nc)	Male	3	1.1	nc	(nc-nc)
Female	2	0.5	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	6	5.0	120.4	(44.0-262.1)	Female	0	0.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	0	1.7	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Female	0	1.3	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	0	0.4	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	3	5.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	1	0.9	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	1	0.3	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	1	0.6	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.6	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	1	3.0	nc	(nc-nc)	Male	13	21.3	61.0	(32.4-104.3)
Female	0	2.6	nc	(nc-nc)	Female	11	17.1	64.2	(32.0-114.9)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Montgomery

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	1.1	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	1	4.4	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	2	1.2	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	1	0.4	nc	(nc-nc)
Male	1	0.3	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	8	3.6	222.3	(95.7-438.0)
Male	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					<u>Testis</u>				
Male	0	0.7	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	<u>Thyroid</u>				
<u>Larynx</u>					Male	1	0.1	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Leukemia</u>					Female	0	0.8	nc	(nc-nc)
Male	2	0.4	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.3	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.4	nc	(nc-nc)	Male	16	14.4	110.8	(63.3-179.9)
Female	0	0.1	nc	(nc-nc)	Female	6	14.2	42.2	(15.4-91.9)
<u>Lung and Bronchus</u>									
Male	0	2.0	nc	(nc-nc)					
Female	0	1.9	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Mount Washington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
					Female	0	0.1	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	1	0.3	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	2	0.3	nc	(nc-nc)					
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)					
<u>Kidney & Renal Pelvis</u>					<u>Stomach</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)					
<u>Leukemia</u>					<u>Thyroid</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	0.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)					
<u>Lung and Bronchus</u>					<u>All Sites / Types</u>				
Male	0	0.6	nc	(nc-nc)	Male	2	4.0	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	3	4.4	nc	(nc-nc)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Nahant

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	6	5.4	111.5	(40.7-242.6)	Male	6	3.2	189.4	(69.1-412.2)
Female	0	2.1	nc	(nc-nc)	Female	7	2.7	257.9	(103.3-531.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.8	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
Female	2	0.9	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	2	2.8	nc	(nc-nc)
Female	19	21.5	88.4	(53.2-138.1)	Female	3	2.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	0.6	nc	(nc-nc)	Male	0	2.3	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	6	5.1	116.8	(42.7-254.3)	Female	0	1.9	nc	(nc-nc)
Female	7	6.1	114.7	(45.9-236.3)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	0	1.3	nc	(nc-nc)	Male	3	1.9	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	2	2.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.3	nc	(nc-nc)	Male	24	16.0	149.7	(95.9-222.8)
Female	1	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	1	2.8	nc	(nc-nc)	Male	3	1.2	nc	(nc-nc)
Female	0	1.7	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	1	0.7	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	3	2.0	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
Female	1	1.7	nc	(nc-nc)	Female	3	3.5	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	1.8	nc	(nc-nc)	Female	4	4.9	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	13	9.3	140.0	(74.5-239.4)	Male	80	64.6	123.9	(98.3-154.2)
Female	7	10.5	66.8	(26.7-137.6)	Female	67	74.3	90.2	(69.9-114.5)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Nantucket

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	8	11.5	69.4	(29.9-136.7)	Male	15	7.7	194.8	(109.0-321.4)
Female	4	3.4	nc	(nc-nc)	Female	16	5.1	314.3	(179.6-510.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	2.4	nc	(nc-nc)	Male	7	2.5	281.2	(112.6-579.3)
Female	2	1.7	nc	(nc-nc)	Female	0	1.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	4	6.8	nc	(nc-nc)
Female	54	41.2	131.2	(98.5-171.1)	Female	5	4.8	103.8	(33.4-242.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	1.4	nc	(nc-nc)	Male	9	5.8	155.0	(70.7-294.2)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	10	12.3	81.3	(38.9-149.6)	Female	4	3.5	nc	(nc-nc)
Female	16	9.8	163.5	(93.4-265.6)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	3	3.1	nc	(nc-nc)	Male	31	36.5	85.0	(57.7-120.6)
Female	4	0.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	3	1.0	nc	(nc-nc)	Male	1	2.0	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	4	7.1	nc	(nc-nc)	Female	9	9.5	94.6	(43.2-179.6)
Female	0	3.3	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Leukemia</u>				
Male	1	1.8	nc	(nc-nc)	Male	7	4.8	147.2	(59.0-303.3)
Female	0	0.5	nc	(nc-nc)	Female	5	2.9	174.5	(56.2-407.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Lung and Bronchus</u>				
Male	2	4.2	nc	(nc-nc)	Male	16	20.8	76.8	(43.9-124.7)
Female	0	1.2	nc	(nc-nc)	Female	20	18.5	108.3	(66.1-167.3)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Natick

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	28	34.3	81.7	(54.3-118.1)	Male	21	22.4	93.6	(57.9-143.0)
Female	15	13.2	113.5	(63.5-187.2)	Female	19	19.5	97.7	(58.8-152.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	6.9	72.7	(23.4-169.7)	Male	5	7.1	70.1	(22.6-163.6)
Female	7	6.3	111.3	(44.6-229.4)	Female	5	6.2	80.3	(25.9-187.3)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	4	1.2	nc	(nc-nc)	Male	18	19.9	90.3	(53.5-142.7)
Female	127	160.0	79.4	(66.2-94.4)	Female	15	18.6	80.7	(45.2-133.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	5.4	nc	(nc-nc)	Male	19	16.7	113.6	(68.4-177.4)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	37	36.4	101.6	(71.5-140.1)	Female	19	13.5	140.9	(84.8-220.1)
Female	48	37.9	126.5	(93.3-167.8)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	14	12.8	109.4	(59.8-183.6)
Male	9	8.7	102.9	(47.0-195.4)	Female	12	13.6	88.3	(45.6-154.3)
Female	4	2.6	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	102	104.6	97.5	(79.5-118.3)
Male	2	2.8	nc	(nc-nc)	<u>Stomach</u>				
Female	0	2.4	nc	(nc-nc)	Male	9	8.1	110.7	(50.5-210.2)
<u>Kidney & Renal Pelvis</u>					Female	2	5.3	nc	(nc-nc)
Male	23	20.5	112.2	(71.1-168.3)	<u>Testis</u>				
Female	10	12.6	79.5	(38.1-146.2)	Male	8	5.4	147.7	(63.6-291.1)
<u>Larynx</u>					<u>Thyroid</u>				
Male	6	5.1	117.9	(43.1-256.6)	Male	12	9.5	125.7	(64.9-219.5)
Female	4	1.7	nc	(nc-nc)	Female	30	30.7	97.7	(65.9-139.4)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	15	14.3	105.1	(58.8-173.3)	Female	39	36.0	108.4	(77.0-148.1)
Female	5	10.9	45.9	(14.8-107.0)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	423	444.6	95.1	(86.3-104.6)
Male	9	12.2	73.8	(33.7-140.2)	Female	474	520.9	91.0	(83.0-99.6)
Female	3	4.5	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	47	60.4	77.8	(57.2-103.5)					
Female	62	72.0	86.1	(66.0-110.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Needham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	43	37.7	114.2	(82.6-153.8)	Male	36	23.2	155.4	(108.8-215.2)
Female	16	13.4	119.6	(68.3-194.3)	Female	22	17.9	123.1	(77.1-186.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	7	6.6	106.5	(42.6-219.4)	Male	10	7.4	134.5	(64.4-247.4)
Female	11	5.7	191.6	(95.5-342.8)	Female	6	6.1	97.7	(35.7-212.7)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.3	nc	(nc-nc)	Male	25	20.5	122.2	(79.1-180.4)
Female	177	143.5	123.4	(105.9-142.9)	Female	24	17.9	134.1	(85.9-199.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	4.6	nc	(nc-nc)	Male	7	16.5	42.4	(17.0-87.4)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	26	38.2	68.1	(44.5-99.8)	Female	11	12.4	88.9	(44.3-159.1)
Female	44	38.8	113.3	(82.3-152.1)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	7	13.6	51.6	(20.7-106.2)
Male	9	9.1	99.1	(45.2-188.2)	Female	16	14.2	112.3	(64.2-182.4)
Female	2	2.6	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	120	105.6	113.7	(94.2-135.9)
Male	2	2.2	nc	(nc-nc)	<u>Stomach</u>				
Female	2	1.9	nc	(nc-nc)	Male	3	8.6	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	2	5.5	nc	(nc-nc)
Male	20	20.3	98.6	(60.2-152.4)	<u>Testis</u>				
Female	14	11.5	121.7	(66.5-204.2)	Male	4	4.0	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	3	5.2	nc	(nc-nc)	Male	12	8.6	139.7	(72.1-244.0)
Female	0	1.6	nc	(nc-nc)	Female	32	25.3	126.5	(86.5-178.6)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	13	14.7	88.3	(47.0-151.1)	Female	33	31.9	103.4	(71.1-145.2)
Female	15	10.8	139.5	(78.0-230.0)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	426	457.2	93.2	(84.5-102.5)
Male	7	12.4	56.5	(22.6-116.3)	Female	513	486.4	105.5	(96.5-115.0)
Female	4	4.3	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	40	64.1	62.4	(44.6-84.9)					
Female	38	67.9	56.0	(39.6-76.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

New Ashford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	0.5	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
Female	3	1.5	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	1	0.5	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	1	1.5	nc	(nc-nc)
Male	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.1	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Testis</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.2	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	4	5.9	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	Female	5	5.1	97.6	(31.4-227.7)
Female	0	0.0	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	0	0.8	nc	(nc-nc)					
Female	0	0.7	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

New Bedford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	96	97.6	98.3	(79.6-120.1)	Male	25	62.2	40.2	(26.0-59.3)
Female	25	39.4	63.5	(41.1-93.8)	Female	17	52.6	32.3	(18.8-51.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	10	18.6	53.7	(25.7-98.8)	Male	20	19.8	101.0	(61.6-155.9)
Female	11	17.3	63.5	(31.7-113.7)	Female	15	18.0	83.5	(46.7-137.8)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	3.4	nc	(nc-nc)	Male	46	55.3	83.2	(60.9-110.9)
Female	340	406.9	83.6	(74.9-92.9)	Female	48	52.6	91.3	(67.3-121.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	17	13.2	128.9	(75.0-206.3)	Male	46	45.0	102.1	(74.8-136.2)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	120	101.4	118.3	(98.1-141.5)	Female	30	36.0	83.4	(56.3-119.1)
Female	104	113.1	92.0	(75.1-111.4)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	24	24.1	99.5	(63.7-148.1)	Male	37	35.8	103.4	(72.8-142.6)
Female	9	7.6	118.9	(54.3-225.8)	Female	50	41.7	119.9	(89.0-158.1)
<u>Hodgkin Lymphoma</u>					<u>Stomach</u>				
Male	8	7.6	105.4	(45.4-207.8)	Male	38	22.7	167.4	(118.5-229.8)
Female	5	6.9	72.2	(23.3-168.5)	Female	19	15.9	119.2	(71.7-186.1)
<u>Kidney & Renal Pelvis</u>					<u>Testis</u>				
Male	57	54.9	103.8	(78.6-134.5)	Male	9	14.6	61.6	(28.1-116.9)
Female	40	33.3	120.1	(85.8-163.6)	<u>Thyroid</u>				
<u>Larynx</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	32	13.9	229.5	(157.0-324.0)	Female	73	91.2	80.1	(62.8-100.7)
Female	6	4.6	130.3	(47.6-283.7)	<u>All Sites / Types</u>				
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	35	39.6	88.4	(61.6-123.0)	Male	1349	1224.5	110.2	(104.4-116.2)
Female	21	32.2	65.2	(40.3-99.6)	Female	1274	1410.9	90.3	(85.4-95.4)
<u>Liver and Intrahepatic Bile Ducts</u>									
Male	59	33.5	176.3	(134.2-227.5)					
Female	15	12.8	117.2	(65.5-193.3)					
<u>Lung and Bronchus</u>									
Male	257	168.1	152.9	(134.8-172.8)					
Female	204	198.5	102.8	(89.2-117.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

New Braintree

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	1.1	nc	(nc-nc)	Male	3	0.8	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	4	4.9	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	2	0.7	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	1	1.3	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Female	3	1.2	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	1	0.3	nc	(nc-nc)	Male	6	4.2	143.1	(52.3-311.5)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	0.8	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Leukemia</u>				
Male	1	0.2	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Lung and Bronchus</u>				
Male	0	0.5	nc	(nc-nc)	Male	2	2.0	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	2	2.2	nc	(nc-nc)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

New Marlborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	2.7	nc	(nc-nc)	Male	2	1.7	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	2	1.0	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.4	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
Female	9	9.0	99.5	(45.4-188.9)	Female	1	1.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	1	2.7	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
Female	3	2.1	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	1	0.7	nc	(nc-nc)	Male	2	8.6	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	1.5	nc	(nc-nc)	Female	1	2.2	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Male</u>				
Male	1	0.4	nc	(nc-nc)	18	34.2	52.6	(31.2-83.2)	
Female	0	0.1	nc	(nc-nc)	<u>Female</u>				
<u>Leukemia</u>					22				
Male	0	1.0	nc	(nc-nc)	29.3	75.0	(47.0-113.5)		
Female	0	0.6	nc	(nc-nc)					
<u>Liver and Intrahepatic Bile Ducts</u>									
Male	0	1.0	nc	(nc-nc)					
Female	0	0.3	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	1	4.8	nc	(nc-nc)					
Female	3	4.3	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

New Salem

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	1.4	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	0.8	nc	(nc-nc)
Female	3	5.4	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.2	nc	(nc-nc)	Male	2	0.7	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	0	1.5	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Female	4	1.3	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	0	0.4	nc	(nc-nc)	Male	4	5.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	0.9	nc	(nc-nc)	Female	2	1.3	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Male</u>				
Male	0	0.2	nc	(nc-nc)	14	19.0	73.6	(40.2-123.5)	
Female	0	0.1	nc	(nc-nc)	<u>Female</u>				
<u>Leukemia</u>					<u>15</u>				
Male	0	0.6	nc	(nc-nc)	17.8	84.1	(47.0-138.8)		
Female	1	0.4	nc	(nc-nc)					
<u>Liver and Intrahepatic Bile Ducts</u>									
Male	0	0.6	nc	(nc-nc)					
Female	0	0.2	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	1	2.5	nc	(nc-nc)					
Female	1	2.6	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Newbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	10	8.2	122.3	(58.5-224.9)	Male	17	5.3	318.8	(185.6-510.4)
Female	3	3.1	nc	(nc-nc)	Female	4	4.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	1.5	nc	(nc-nc)	Male	3	1.8	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)	Female	2	1.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	4	4.7	nc	(nc-nc)
Female	37	37.9	97.5	(68.7-134.4)	Female	6	4.4	137.9	(50.3-300.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.2	nc	(nc-nc)	Male	2	4.2	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	11	8.6	127.4	(63.5-228.0)	Female	4	3.2	nc	(nc-nc)
Female	2	8.3	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	3	3.2	nc	(nc-nc)
Male	2	2.2	nc	(nc-nc)	Female	1	3.1	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	41	27.7	148.2	(106.3-201.1)
Male	1	0.5	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.5	nc	(nc-nc)	Male	0	2.0	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	1.2	nc	(nc-nc)
Male	4	5.0	nc	(nc-nc)	<u>Testis</u>				
Female	5	3.0	169.0	(54.5-394.3)	Male	0	0.8	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	1.3	nc	(nc-nc)	Male	2	2.1	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	7	6.7	105.1	(42.1-216.6)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	2	3.2	nc	(nc-nc)	Female	12	9.2	131.0	(67.6-228.9)
Female	3	2.4	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	123	108.7	113.1	(94.0-135.0)
Male	0	3.2	nc	(nc-nc)	Female	104	121.4	85.7	(70.0-103.8)
Female	1	1.1	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	11	15.0	73.6	(36.7-131.6)					
Female	10	17.2	58.1	(27.8-106.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Newburyport

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	21	21.3	98.8	(61.1-151.0)	Male	20	14.0	143.4	(87.5-221.4)
Female	5	8.9	56.0	(18.0-130.7)	Female	15	11.9	125.7	(70.3-207.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	4.1	nc	(nc-nc)	Male	1	4.6	nc	(nc-nc)
Female	3	3.8	nc	(nc-nc)	Female	5	4.2	119.3	(38.4-278.3)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	3	0.8	nc	(nc-nc)	Male	14	12.4	113.3	(61.9-190.1)
Female	96	99.6	96.4	(78.1-117.7)	Female	9	12.1	74.2	(33.8-140.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	3.0	nc	(nc-nc)	Male	9	11.1	81.1	(37.0-154.0)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	25	22.9	109.1	(70.6-161.1)	Female	3	8.6	nc	(nc-nc)
Female	21	24.9	84.4	(52.2-129.0)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	3	5.7	nc	(nc-nc)	Male	90	72.0	125.0	(100.5-153.6)
Female	0	1.8	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	1	1.4	nc	(nc-nc)	Male	1	2.5	nc	(nc-nc)
Female	2	1.2	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	6	13.2	45.4	(16.6-98.9)	Female	26	23.6	110.3	(72.1-161.7)
Female	3	8.0	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Leukemia</u>				
Male	1	3.4	nc	(nc-nc)	Male	11	8.5	129.2	(64.4-231.2)
Female	0	1.2	nc	(nc-nc)	Female	1	6.9	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Lung and Bronchus</u>				
Male	5	8.2	60.7	(19.6-141.6)	Male	25	38.2	65.4	(42.3-96.5)
Female	3	3.0	nc	(nc-nc)	Female	36	47.5	75.8	(53.1-104.9)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Newton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	111	102.0	108.8	(89.5-131.0)	Male	68	63.4	107.2	(83.3-135.9)
Female	46	35.6	129.1	(94.5-172.2)	Female	68	49.4	137.8	(107.0-174.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	22	18.3	120.3	(75.4-182.2)	Male	28	20.5	136.3	(90.5-197.0)
Female	18	16.3	110.2	(65.3-174.2)	Female	16	16.7	96.1	(54.9-156.0)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	3	3.5	nc	(nc-nc)	Male	64	56.3	113.6	(87.5-145.1)
Female	447	399.4	111.9	(101.8-122.8)	Female	54	48.9	110.4	(82.9-144.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	8	13.0	61.7	(26.6-121.5)	Male	28	45.7	61.3	(40.7-88.6)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	100	103.9	96.2	(78.3-117.0)	Female	47	34.3	136.9	(100.6-182.1)
Female	82	102.1	80.3	(63.9-99.7)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	9	25.1	35.9	(16.4-68.1)	Male	332	294.3	112.8	(101.0-125.6)
Female	6	7.0	85.5	(31.2-186.0)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	10	6.6	151.3	(72.4-278.2)	Male	13	11.8	110.4	(58.7-188.9)
Female	8	5.9	135.1	(58.2-266.2)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	51	56.0	91.1	(67.8-119.8)	Female	87	91.1	95.5	(76.5-117.8)
Female	27	31.8	84.8	(55.9-123.4)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Leukemia</u>				
Male	9	14.5	62.1	(28.3-117.9)	Male	34	40.0	85.0	(58.9-118.8)
Female	0	4.4	nc	(nc-nc)	Female	27	29.0	93.0	(61.3-135.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Lung and Bronchus</u>				
Male	22	34.2	64.3	(40.3-97.3)	Male	113	176.1	64.2	(52.9-77.1)
Female	9	11.9	75.5	(34.4-143.2)	Female	148	185.6	79.7	(67.4-93.7)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Norfolk

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	8	13.2	60.8	(26.2-119.8)	Male	24	9.4	255.4	(163.6-380.0)
Female	1	2.8	nc	(nc-nc)	Female	4	4.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	2.9	nc	(nc-nc)	Male	3	3.0	nc	(nc-nc)
Female	2	1.5	nc	(nc-nc)	Female	0	1.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.5	nc	(nc-nc)	Male	6	8.3	72.4	(26.5-157.7)
Female	41	39.1	105.0	(75.3-142.4)	Female	2	4.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.4	nc	(nc-nc)	Male	6	7.7	77.4	(28.3-168.6)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	9	15.1	59.6	(27.2-113.1)	Female	1	3.2	nc	(nc-nc)
Female	6	8.4	71.8	(26.2-156.3)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	2	5.3	nc	(nc-nc)
Male	5	3.8	131.6	(42.4-307.2)	Female	3	2.9	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	38	47.6	79.8	(56.5-109.5)
Male	1	1.2	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.6	nc	(nc-nc)	Male	5	3.3	150.2	(48.4-350.5)
<u>Kidney & Renal Pelvis</u>					Female	0	1.2	nc	(nc-nc)
Male	12	9.1	131.3	(67.8-229.4)	<u>Testis</u>				
Female	4	2.9	nc	(nc-nc)	Male	0	2.4	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	3	2.3	nc	(nc-nc)	Male	2	4.4	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	10	7.7	129.9	(62.2-239.0)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	5	5.7	87.8	(28.3-204.9)	Female	7	9.1	76.9	(30.8-158.4)
Female	2	2.5	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	155	189.1	82.0	(69.6-95.9)
Male	3	5.6	nc	(nc-nc)	Female	105	121.3	86.6	(70.8-104.8)
Female	1	1.0	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	16	24.4	65.7	(37.5-106.6)					
Female	13	15.2	85.4	(45.4-146.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

North Adams

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	19	16.6	114.5	(68.9-178.8)	Male	4	10.3	nc	(nc-nc)
Female	10	6.3	159.8	(76.5-293.9)	Female	6	8.0	74.9	(27.4-163.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	2.9	nc	(nc-nc)	Male	4	3.3	nc	(nc-nc)
Female	1	2.7	nc	(nc-nc)	Female	1	2.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.6	nc	(nc-nc)	Male	10	9.1	110.5	(52.9-203.2)
Female	50	63.9	78.2	(58.0-103.1)	Female	7	8.2	85.3	(34.2-175.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	2.0	nc	(nc-nc)	Male	10	7.3	137.0	(65.6-251.9)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	24	16.6	144.4	(92.5-214.9)	Female	7	5.6	125.1	(50.1-257.9)
Female	17	17.6	96.4	(56.1-154.4)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	0	6.0	nc	(nc-nc)
Male	7	4.0	172.9	(69.3-356.2)	Female	7	6.6	106.0	(42.5-218.4)
Female	1	1.2	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	38	47.2	80.4	(56.9-110.4)
Male	0	1.1	nc	(nc-nc)	<u>Stomach</u>				
Female	1	1.0	nc	(nc-nc)	Male	5	3.8	131.6	(42.4-307.2)
<u>Kidney & Renal Pelvis</u>					Female	2	2.5	nc	(nc-nc)
Male	7	9.0	78.1	(31.3-160.9)	<u>Testis</u>				
Female	3	5.2	nc	(nc-nc)	Male	1	1.9	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	2.3	nc	(nc-nc)	Male	6	3.8	157.6	(57.5-343.0)
Female	3	0.7	nc	(nc-nc)	Female	11	10.9	100.7	(50.2-180.2)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	5	6.4	77.6	(25.0-181.1)	Female	12	14.5	83.0	(42.8-145.0)
Female	3	4.9	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	203	203.2	99.9	(86.6-114.6)
Male	10	5.6	179.6	(86.0-330.3)	Female	209	220.9	94.6	(82.2-108.4)
Female	3	2.0	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	28	29.0	96.7	(64.2-139.8)					
Female	41	32.1	127.8	(91.7-173.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

North Andover

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	32	28.8	111.2	(76.1-157.0)	Male	20	18.9	105.8	(64.6-163.4)
Female	6	11.4	52.6	(19.2-114.5)	Female	15	16.2	92.4	(51.7-152.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	5.8	103.8	(37.9-225.9)	Male	6	6.0	100.3	(36.6-218.2)
Female	6	5.2	115.5	(42.2-251.3)	Female	8	5.4	149.1	(64.2-293.9)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.0	nc	(nc-nc)	Male	20	16.8	118.8	(72.5-183.4)
Female	128	131.1	97.6	(81.5-116.1)	Female	14	15.8	88.5	(48.4-148.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	4.4	nc	(nc-nc)	Male	11	14.5	76.0	(37.9-136.0)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	24	31.6	76.0	(48.7-113.0)	Female	11	11.2	98.2	(49.0-175.7)
Female	37	33.7	109.7	(77.2-151.2)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	6	10.8	55.5	(20.3-120.8)
Male	8	7.3	108.9	(46.9-214.7)	Female	12	12.0	99.7	(51.5-174.2)
Female	0	2.2	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	90	87.7	102.6	(82.5-126.1)
Male	2	2.2	nc	(nc-nc)	<u>Stomach</u>				
Female	5	1.9	266.4	(85.8-621.6)	Male	5	6.9	72.7	(23.4-169.7)
<u>Kidney & Renal Pelvis</u>					Female	7	4.7	148.9	(59.6-306.8)
Male	12	17.3	69.5	(35.9-121.5)	<u>Testis</u>				
Female	7	10.3	67.8	(27.2-139.8)	Male	5	4.3	116.5	(37.5-271.9)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	4.3	nc	(nc-nc)	Male	12	8.1	148.8	(76.8-259.9)
Female	0	1.4	nc	(nc-nc)	Female	22	24.5	89.6	(56.2-135.7)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	14	12.0	116.8	(63.8-195.9)	Female	25	29.0	86.2	(55.8-127.2)
Female	11	9.3	117.9	(58.8-210.9)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	351	374.1	93.8	(84.3-104.2)
Male	6	10.5	56.9	(20.8-123.8)	Female	397	434.7	91.3	(82.6-100.8)
Female	3	3.8	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	37	49.2	75.1	(52.9-103.6)					
Female	49	59.1	82.9	(61.3-109.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

North Attleborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	28	22.6	124.0	(82.4-179.2)	Male	15	16.3	91.8	(51.3-151.4)
Female	8	9.1	87.9	(37.8-173.2)	Female	20	14.3	139.4	(85.1-215.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	5.3	112.5	(41.1-245.0)	Male	8	5.2	154.7	(66.6-304.7)
Female	6	4.7	127.6	(46.6-277.8)	Female	6	4.4	136.8	(50.0-297.8)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.9	nc	(nc-nc)	Male	16	14.5	110.4	(63.1-179.3)
Female	117	116.3	100.6	(83.2-120.5)	Female	16	13.2	121.1	(69.1-196.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	4.2	nc	(nc-nc)	Male	14	13.3	105.5	(57.6-177.0)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	31	26.4	117.2	(79.6-166.4)	Female	4	9.8	nc	(nc-nc)
Female	22	27.4	80.3	(50.3-121.6)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	11	9.0	122.0	(60.8-218.4)
Male	9	6.4	140.7	(64.2-267.0)	Female	11	9.5	115.5	(57.6-206.7)
Female	1	1.8	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	79	78.8	100.2	(79.3-124.9)
Male	1	2.2	nc	(nc-nc)	<u>Stomach</u>				
Female	1	1.9	nc	(nc-nc)	Male	3	5.7	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	4	3.8	nc	(nc-nc)
Male	12	15.9	75.6	(39.0-132.0)	<u>Testis</u>				
Female	9	8.9	100.8	(46.0-191.3)	Male	5	4.5	110.1	(35.5-257.0)
<u>Larynx</u>					<u>Thyroid</u>				
Male	3	3.8	nc	(nc-nc)	Male	6	8.0	74.6	(27.2-162.4)
Female	1	1.2	nc	(nc-nc)	Female	25	23.8	105.2	(68.0-155.2)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	5	10.1	49.3	(15.9-115.0)	Female	21	25.8	81.4	(50.3-124.4)
Female	4	7.9	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	334	324.4	103.0	(92.2-114.6)
Male	9	9.3	96.4	(44.0-183.0)	Female	350	374.5	93.5	(83.9-103.8)
Female	3	3.2	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	39	41.7	93.6	(66.6-128.0)					
Female	41	48.6	84.3	(60.5-114.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

North Brookfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	5.3	nc	(nc-nc)	Male	4	3.5	nc	(nc-nc)
Female	1	1.9	nc	(nc-nc)	Female	0	2.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.0	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	Female	2	0.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	1	3.1	nc	(nc-nc)
Female	16	20.7	77.2	(44.1-125.5)	Female	4	2.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	0.7	nc	(nc-nc)	Male	2	2.7	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	6	5.6	106.2	(38.8-231.2)	Female	2	1.8	nc	(nc-nc)
Female	5	5.3	94.2	(30.4-219.8)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	4	2.0	nc	(nc-nc)
Male	2	1.4	nc	(nc-nc)	Female	2	1.9	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	18	16.1	111.9	(66.3-176.8)
Male	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
Female	1	0.3	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	0.8	nc	(nc-nc)
Male	2	3.2	nc	(nc-nc)	<u>Testis</u>				
Female	1	1.7	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	0.8	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	2	3.8	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	3	2.2	nc	(nc-nc)	Female	6	4.6	130.4	(47.6-283.9)
Female	1	1.5	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	71	69.0	102.9	(80.4-129.8)
Male	2	2.0	nc	(nc-nc)	Female	63	69.2	91.0	(69.9-116.4)
Female	2	0.6	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	10	9.6	104.1	(49.9-191.5)					
Female	6	9.7	61.6	(22.5-134.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

North Reading

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	14	16.2	86.7	(47.3-145.4)	Male	11	10.8	101.5	(50.6-181.7)
Female	7	5.6	125.4	(50.2-258.3)	Female	9	8.5	105.8	(48.3-200.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	3.3	nc	(nc-nc)	Male	2	3.5	nc	(nc-nc)
Female	5	2.7	186.0	(59.9-434.1)	Female	1	2.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.6	nc	(nc-nc)	Male	10	9.6	104.2	(49.9-191.6)
Female	82	71.7	114.4	(91.0-142.0)	Female	4	8.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	2.4	nc	(nc-nc)	Male	3	8.4	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	14	17.5	79.9	(43.6-134.0)	Female	4	6.0	nc	(nc-nc)
Female	14	16.4	85.3	(46.6-143.2)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	6	6.2	97.1	(35.4-211.3)
Male	8	4.3	185.6	(79.9-365.7)	Female	7	5.7	122.3	(49.0-252.1)
Female	0	1.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	50	52.1	95.9	(71.2-126.4)
Male	1	1.2	nc	(nc-nc)	<u>Stomach</u>				
Female	1	1.1	nc	(nc-nc)	Male	3	3.9	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	2.3	nc	(nc-nc)
Male	10	10.1	98.9	(47.4-182.0)	<u>Testis</u>				
Female	3	5.5	nc	(nc-nc)	Male	1	2.3	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	2.6	nc	(nc-nc)	Male	6	4.6	129.7	(47.4-282.3)
Female	1	0.8	nc	(nc-nc)	Female	18	13.7	131.6	(78.0-208.0)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	8	6.7	119.5	(51.5-235.5)	Female	18	16.2	111.0	(65.7-175.4)
Female	4	4.6	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	189	215.9	87.6	(75.5-101.0)
Male	5	6.2	80.8	(26.0-188.5)	Female	219	227.9	96.1	(83.8-109.7)
Female	2	1.9	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	15	29.2	51.4	(28.8-84.8)					
Female	24	30.8	78.0	(50.0-116.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Northampton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	41	29.7	138.3	(99.2-187.6)	Male	13	18.8	69.3	(36.9-118.5)
Female	11	11.4	96.9	(48.3-173.4)	Female	9	15.9	56.7	(25.9-107.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	5.5	108.5	(39.6-236.1)	Male	1	6.1	nc	(nc-nc)
Female	4	5.4	nc	(nc-nc)	Female	7	5.4	130.0	(52.1-267.8)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.1	nc	(nc-nc)	Male	18	16.8	107.3	(63.6-169.6)
Female	166	127.3	130.4	(111.3-151.8)	Female	16	15.8	101.5	(58.0-164.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	5	4.0	123.9	(39.9-289.2)	Male	15	13.9	107.9	(60.4-178.0)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	29	30.5	95.2	(63.7-136.7)	Female	17	11.1	152.6	(88.8-244.3)
Female	37	32.5	113.7	(80.0-156.7)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	10	11.0	91.1	(43.6-167.5)
Male	8	7.5	106.2	(45.7-209.3)	Female	11	11.9	92.4	(46.1-165.4)
Female	4	2.2	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	54	91.4	59.1	(44.4-77.1)
Male	1	2.2	nc	(nc-nc)	<u>Stomach</u>				
Female	1	2.2	nc	(nc-nc)	Male	6	6.9	86.7	(31.7-188.8)
<u>Kidney & Renal Pelvis</u>					Female	4	4.6	nc	(nc-nc)
Male	12	16.9	71.1	(36.7-124.1)	<u>Testis</u>				
Female	9	10.2	88.4	(40.4-167.9)	Male	7	4.0	175.4	(70.3-361.5)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	4.4	nc	(nc-nc)	Male	4	7.4	nc	(nc-nc)
Female	3	1.5	nc	(nc-nc)	Female	10	23.3	42.9	(20.6-79.0)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	13	11.8	110.5	(58.8-188.9)	Female	44	29.7	148.2	(107.7-198.9)
Female	7	9.3	75.2	(30.1-154.9)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	314	377.7	83.1	(74.2-92.9)
Male	5	10.5	47.7	(15.4-111.3)	Female	454	428.0	106.1	(96.5-116.3)
Female	3	3.9	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	44	51.8	84.9	(61.7-114.0)					
Female	44	59.0	74.6	(54.2-100.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Northborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	21	16.2	129.5	(80.2-198.0)	Male	12	10.7	111.6	(57.6-195.0)
Female	7	5.8	121.1	(48.5-249.4)	Female	8	8.1	98.2	(42.3-193.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	3.2	nc	(nc-nc)	Male	4	3.5	nc	(nc-nc)
Female	1	2.6	nc	(nc-nc)	Female	5	2.7	185.0	(59.6-431.8)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.6	nc	(nc-nc)	Male	10	9.5	104.7	(50.1-192.6)
Female	73	66.0	110.6	(86.7-139.0)	Female	5	8.0	62.5	(20.2-145.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	2.2	nc	(nc-nc)	Male	8	8.3	96.4	(41.5-190.0)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	11	17.9	61.6	(30.7-110.2)	Female	3	5.7	nc	(nc-nc)
Female	15	16.8	89.3	(49.9-147.2)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	6	6.2	97.4	(35.6-212.1)
Male	8	4.2	190.9	(82.2-376.3)	Female	6	6.0	99.5	(36.3-216.6)
Female	0	1.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	50	50.3	99.5	(73.8-131.1)
Male	1	1.2	nc	(nc-nc)	<u>Stomach</u>				
Female	0	1.0	nc	(nc-nc)	Male	2	3.9	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	2	2.3	nc	(nc-nc)
Male	10	10.0	100.4	(48.0-184.6)	<u>Testis</u>				
Female	4	5.2	nc	(nc-nc)	Male	3	2.3	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	2.5	nc	(nc-nc)	Male	3	4.5	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	8	12.2	65.8	(28.3-129.6)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	10	6.6	151.8	(72.7-279.1)	Female	15	14.9	100.7	(56.3-166.1)
Female	7	4.7	149.7	(60.0-308.5)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	196	212.6	92.2	(79.7-106.1)
Male	4	5.9	nc	(nc-nc)	Female	209	219.2	95.3	(82.8-109.2)
Female	2	1.9	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	13	28.6	45.4	(24.1-77.6)					
Female	30	30.3	98.9	(66.7-141.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Northbridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	18	15.9	113.5	(67.2-179.4)	Male	9	10.7	84.1	(38.4-159.7)
Female	5	6.3	79.7	(25.7-186.1)	Female	8	8.9	89.7	(38.6-176.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	3.2	nc	(nc-nc)	Male	8	3.4	232.6	(100.2-458.4)
Female	2	3.0	nc	(nc-nc)	Female	3	2.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.6	nc	(nc-nc)	Male	9	9.4	95.6	(43.6-181.5)
Female	58	70.6	82.1	(62.4-106.2)	Female	12	8.7	137.9	(71.2-240.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	2.4	nc	(nc-nc)	Male	8	8.4	94.9	(40.9-187.1)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	9	17.6	51.1	(23.3-97.0)	Female	4	6.0	nc	(nc-nc)
Female	26	18.3	142.1	(92.8-208.3)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	5	6.1	81.9	(26.4-191.2)
Male	1	4.3	nc	(nc-nc)	Female	7	6.5	106.9	(42.8-220.3)
Female	1	1.2	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	50	51.9	96.4	(71.5-127.1)
Male	3	1.2	nc	(nc-nc)	<u>Stomach</u>				
Female	2	1.1	nc	(nc-nc)	Male	5	3.9	129.1	(41.6-301.2)
<u>Kidney & Renal Pelvis</u>					Female	3	2.6	nc	(nc-nc)
Male	14	10.1	138.9	(75.9-233.0)	<u>Testis</u>				
Female	6	5.6	107.1	(39.1-233.1)	Male	1	2.3	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	3	2.5	nc	(nc-nc)	Male	4	4.6	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	Female	12	13.6	88.2	(45.5-154.1)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	4	6.6	nc	(nc-nc)	Female	18	15.4	116.7	(69.1-184.5)
Female	5	5.2	95.6	(30.8-223.1)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	194	213.6	90.8	(78.5-104.5)
Male	2	6.1	nc	(nc-nc)	Female	224	236.5	94.7	(82.7-108.0)
Female	2	2.1	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	27	28.6	94.5	(62.3-137.6)					
Female	30	32.3	93.0	(62.7-132.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Northfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	3.9	nc	(nc-nc)	Male	4	2.5	nc	(nc-nc)
Female	2	1.2	nc	(nc-nc)	Female	4	1.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.7	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	2.2	nc	(nc-nc)
Female	12	13.9	86.6	(44.7-151.3)	Female	1	1.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.5	nc	(nc-nc)	Male	4	1.9	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	3	4.1	nc	(nc-nc)	Female	2	1.2	nc	(nc-nc)
Female	2	3.4	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	0	1.5	nc	(nc-nc)
Male	0	1.0	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	5	12.6	39.8	(12.8-92.8)
Male	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	0.5	nc	(nc-nc)
Male	3	2.3	nc	(nc-nc)	<u>Testis</u>				
Female	3	1.1	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	0.6	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	2.6	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	1.6	nc	(nc-nc)	Female	4	3.2	nc	(nc-nc)
Female	2	1.0	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	35	50.7	69.1	(48.1-96.1)
Male	0	1.4	nc	(nc-nc)	Female	41	45.5	90.1	(64.7-122.3)
Female	0	0.4	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	4	6.8	nc	(nc-nc)					
Female	4	6.1	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Norton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	13	18.7	69.6	(37.0-119.0)	Male	14	12.6	111.3	(60.8-186.7)
Female	9	6.0	149.6	(68.3-284.0)	Female	16	9.0	176.8	(101.0-287.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	3.9	128.6	(41.5-300.2)	Male	4	4.0	nc	(nc-nc)
Female	2	3.1	nc	(nc-nc)	Female	3	2.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.7	nc	(nc-nc)	Male	7	11.1	62.9	(25.2-129.5)
Female	77	74.2	103.7	(81.8-129.6)	Female	12	8.6	138.8	(71.6-242.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	2.5	nc	(nc-nc)	Male	8	10.0	80.2	(34.5-158.1)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	24	20.6	116.6	(74.7-173.4)	Female	8	6.4	126.0	(54.2-248.2)
Female	22	17.7	124.6	(78.1-188.7)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	9	7.2	125.6	(57.3-238.5)
Male	5	5.0	99.4	(32.0-231.9)	Female	10	6.2	161.2	(77.2-296.5)
Female	1	1.2	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	54	62.3	86.7	(65.1-113.1)
Male	2	1.5	nc	(nc-nc)	<u>Stomach</u>				
Female	0	1.2	nc	(nc-nc)	Male	5	4.6	109.9	(35.4-256.4)
<u>Kidney & Renal Pelvis</u>					Female	4	2.5	nc	(nc-nc)
Male	15	11.9	126.0	(70.5-207.8)	<u>Testis</u>				
Female	7	5.8	121.3	(48.6-249.9)	Male	2	2.8	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	2.9	nc	(nc-nc)	Male	6	5.5	109.1	(39.8-237.4)
Female	2	0.8	nc	(nc-nc)	Female	15	14.3	104.6	(58.5-172.6)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	11	7.9	139.4	(69.5-249.5)	Female	24	16.9	141.9	(90.9-211.1)
Female	6	5.1	118.2	(43.1-257.2)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	248	253.3	97.9	(86.1-110.9)
Male	6	7.2	83.3	(30.4-181.3)	Female	272	241.1	112.8	(99.8-127.1)
Female	1	2.1	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	34	33.6	101.1	(70.0-141.3)					
Female	30	32.1	93.4	(63.0-133.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Norwell

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	14	13.4	104.7	(57.2-175.6)	Male	9	8.5	105.8	(48.3-200.9)
Female	4	4.5	nc	(nc-nc)	Female	16	6.2	258.2	(147.5-419.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	7	2.4	287.0	(115.0-591.3)	Male	1	2.7	nc	(nc-nc)
Female	4	2.0	nc	(nc-nc)	Female	6	2.1	289.9	(105.9-631.1)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.5	nc	(nc-nc)	Male	5	7.5	66.7	(21.5-155.7)
Female	54	51.8	104.2	(78.3-136.0)	Female	9	6.1	146.9	(67.0-278.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.7	nc	(nc-nc)	Male	5	6.3	80.0	(25.8-186.7)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	11	14.1	78.0	(38.9-139.7)	Female	6	4.4	137.9	(50.4-300.2)
Female	11	13.0	84.5	(42.1-151.2)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	7	4.9	142.2	(57.0-292.9)
Male	4	3.3	nc	(nc-nc)	Female	4	4.7	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	37	38.4	96.3	(67.8-132.7)
Male	2	0.8	nc	(nc-nc)	<u>Stomach</u>				
Female	1	0.6	nc	(nc-nc)	Male	2	3.1	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	2	1.8	nc	(nc-nc)
Male	4	7.6	nc	(nc-nc)	<u>Testis</u>				
Female	4	4.1	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	1.9	nc	(nc-nc)	Male	3	3.3	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	4	9.1	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	5	5.3	94.1	(30.3-219.7)	Female	16	11.4	139.8	(79.8-227.0)
Female	4	3.6	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	153	166.9	91.7	(77.7-107.4)
Male	7	4.6	152.0	(60.9-313.1)	Female	182	169.8	107.2	(92.2-123.9)
Female	1	1.5	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	13	23.2	56.1	(29.8-95.9)					
Female	14	23.8	58.9	(32.1-98.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Norwood

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	11	32.4	34.0	(16.9-60.8)	Male	36	20.4	176.8	(123.8-244.7)
Female	7	13.2	53.0	(21.3-109.3)	Female	20	17.3	115.8	(70.7-178.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	6.0	99.9	(36.5-217.5)	Male	8	6.5	123.6	(53.2-243.5)
Female	8	5.5	144.4	(62.2-284.5)	Female	7	6.0	116.7	(46.8-240.6)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.1	nc	(nc-nc)	Male	18	18.0	100.2	(59.3-158.3)
Female	143	136.3	104.9	(88.4-123.6)	Female	19	17.6	108.2	(65.1-169.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	5	4.4	114.9	(37.0-268.0)	Male	16	14.3	112.2	(64.1-182.3)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	49	33.3	147.2	(108.9-194.6)	Female	11	11.9	92.4	(46.1-165.4)
Female	51	37.4	136.4	(101.6-179.4)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	20	11.6	172.3	(105.2-266.1)
Male	8	7.8	102.6	(44.2-202.1)	Female	20	13.8	145.1	(88.6-224.2)
Female	3	2.5	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	78	87.7	88.9	(70.3-110.9)
Male	2	2.4	nc	(nc-nc)	<u>Stomach</u>				
Female	3	2.1	nc	(nc-nc)	Male	9	7.5	120.8	(55.1-229.3)
<u>Kidney & Renal Pelvis</u>					Female	4	5.2	nc	(nc-nc)
Male	12	17.7	68.0	(35.1-118.7)	<u>Testis</u>				
Female	15	11.2	134.2	(75.1-221.4)	Male	9	4.7	191.1	(87.2-362.7)
<u>Larynx</u>					<u>Thyroid</u>				
Male	6	4.5	134.1	(49.0-292.0)	Male	13	8.0	162.6	(86.5-278.1)
Female	3	1.5	nc	(nc-nc)	Female	25	24.3	103.0	(66.6-152.0)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	14	12.9	108.5	(59.2-182.0)	Female	32	30.2	106.0	(72.5-149.6)
Female	11	10.4	105.7	(52.7-189.2)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	430	395.7	108.7	(98.6-119.5)
Male	12	10.5	114.1	(58.9-199.4)	Female	522	469.5	111.2	(101.8-121.1)
Female	3	4.2	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	58	55.7	104.0	(79.0-134.5)					
Female	93	68.1	136.5	(110.2-167.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Oak Bluffs

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	10	8.0	124.5	(59.6-229.0)	Male	8	4.9	162.6	(70.0-320.4)
Female	1	2.3	nc	(nc-nc)	Female	7	3.0	236.6	(94.8-487.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.3	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	4	4.3	nc	(nc-nc)
Female	24	24.2	99.3	(63.6-147.7)	Female	1	3.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.8	nc	(nc-nc)	Male	4	3.4	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	8	7.7	104.0	(44.8-204.9)	Female	2	2.1	nc	(nc-nc)
Female	5	6.6	76.1	(24.5-177.5)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	4	2.9	nc	(nc-nc)
Male	0	2.0	nc	(nc-nc)	Female	1	2.5	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	16	23.0	69.5	(39.7-112.8)
Male	1	0.4	nc	(nc-nc)	<u>Stomach</u>				
Female	1	0.3	nc	(nc-nc)	Male	1	1.8	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	0.9	nc	(nc-nc)
Male	3	4.3	nc	(nc-nc)	<u>Testis</u>				
Female	1	1.9	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	1.2	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	4	4.1	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	3.0	nc	(nc-nc)	Female	5	5.5	91.5	(29.5-213.6)
Female	1	1.8	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	84	97.3	86.3	(68.9-106.9)
Male	2	2.7	nc	(nc-nc)	Female	79	82.6	95.6	(75.7-119.2)
Female	0	0.7	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	12	14.6	82.1	(42.3-143.3)					
Female	13	12.0	108.6	(57.8-185.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Oakham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	2.1	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	2	1.0	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	2	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	8	8.0	100.0	(43.1-197.1)	Female	2	0.9	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	0	2.3	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
Female	1	1.8	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	1	0.8	nc	(nc-nc)
Male	0	0.6	nc	(nc-nc)	Female	2	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	8	7.3	109.6	(47.2-215.9)
Male	1	0.1	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.3	nc	(nc-nc)
Male	1	1.3	nc	(nc-nc)	<u>Testis</u>				
Female	0	0.6	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.3	nc	(nc-nc)	Male	2	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	4	1.6	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.8	nc	(nc-nc)	Female	1	1.9	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	26	28.6	90.9	(59.4-133.2)
Male	2	0.9	nc	(nc-nc)	Female	27	25.3	106.7	(70.3-155.3)
Female	0	0.2	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	7	3.8	185.5	(74.3-382.1)					
Female	1	3.3	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Orange

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	8	9.1	88.1	(37.9-173.6)	Male	1	5.9	nc	(nc-nc)
Female	3	3.0	nc	(nc-nc)	Female	3	4.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.7	nc	(nc-nc)	Male	0	1.9	nc	(nc-nc)
Female	5	1.4	348.9	(112.4-814.3)	Female	2	1.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	5	5.3	95.1	(30.6-221.9)
Female	32	37.9	84.4	(57.7-119.1)	Female	6	4.3	141.0	(51.5-307.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.2	nc	(nc-nc)	Male	7	4.5	155.0	(62.1-319.3)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	5	9.6	52.1	(16.8-121.6)	Female	2	3.2	nc	(nc-nc)
Female	8	8.7	92.5	(39.8-182.2)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	4	3.4	nc	(nc-nc)
Male	4	2.4	nc	(nc-nc)	Female	3	3.1	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	25	28.8	86.7	(56.1-127.9)
Male	1	0.6	nc	(nc-nc)	<u>Stomach</u>				
Female	1	0.5	nc	(nc-nc)	Male	0	2.2	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	1.2	nc	(nc-nc)
Male	6	5.4	110.1	(40.2-239.7)	<u>Testis</u>				
Female	1	2.9	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	1.4	nc	(nc-nc)	Male	2	2.3	nc	(nc-nc)
Female	2	0.4	nc	(nc-nc)	Female	5	6.9	72.3	(23.3-168.7)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	4	3.6	nc	(nc-nc)	Female	10	8.8	113.7	(54.4-209.0)
Female	1	2.5	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	110	118.7	92.7	(76.2-111.7)
Male	3	3.4	nc	(nc-nc)	Female	117	120.5	97.1	(80.3-116.3)
Female	1	1.0	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	21	16.4	128.0	(79.2-195.7)					
Female	17	16.2	105.1	(61.2-168.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Orleans

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	12	15.5	77.2	(39.8-134.9)	Male	21	8.6	242.8	(150.3-371.2)
Female	6	5.0	118.9	(43.4-258.9)	Female	9	5.5	163.8	(74.7-310.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	2.1	nc	(nc-nc)	Male	3	2.9	nc	(nc-nc)
Female	2	1.7	nc	(nc-nc)	Female	2	2.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.5	nc	(nc-nc)	Male	13	7.5	172.5	(91.8-295.1)
Female	66	46.5	142.1	(109.9-180.7)	Female	7	6.3	111.3	(44.6-229.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.1	nc	(nc-nc)	Male	5	5.5	90.8	(29.3-212.0)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	14	13.7	102.1	(55.7-171.2)	Female	6	4.1	146.9	(53.7-319.8)
Female	12	13.1	91.3	(47.1-159.5)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	5	5.3	94.2	(30.4-219.8)
Male	1	3.6	nc	(nc-nc)	Female	8	5.3	151.9	(65.4-299.4)
Female	0	1.0	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	36	40.8	88.3	(61.9-122.3)
Male	0	0.5	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.4	nc	(nc-nc)	Male	1	3.4	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	2	1.8	nc	(nc-nc)
Male	4	7.1	nc	(nc-nc)	<u>Testis</u>				
Female	1	4.0	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	2.0	nc	(nc-nc)	Male	2	2.3	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	3	5.9	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	7	5.2	133.4	(53.4-274.9)	Female	7	11.2	62.7	(25.1-129.2)
Female	2	3.5	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	160	172.9	92.5	(78.7-108.0)
Male	5	4.4	113.7	(36.7-265.4)	Female	180	164.0	109.7	(94.3-127.0)
Female	0	1.6	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	10	27.3	36.6	(17.5-67.3)					
Female	18	26.6	67.7	(40.1-107.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Otis

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	2.8	nc	(nc-nc)	Male	2	1.8	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.5	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
Female	13	8.5	153.2	(81.5-262.1)	Female	3	1.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	1	2.8	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
Female	2	2.1	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	0	1.1	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	5	8.8	56.8	(18.3-132.6)
Male	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.3	nc	(nc-nc)
Male	0	1.6	nc	(nc-nc)	<u>Testis</u>				
Female	0	0.7	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	2	1.4	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	1.1	nc	(nc-nc)	Female	2	1.9	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	18	35.6	50.5	(29.9-79.8)
Male	0	1.0	nc	(nc-nc)	Female	29	28.3	102.4	(68.5-147.0)
Female	0	0.3	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	5	5.2	96.1	(31.0-224.3)					
Female	5	4.3	117.0	(37.7-273.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Oxford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	19	11.1	171.4	(103.1-267.7)	Male	11	7.9	139.8	(69.7-250.2)
Female	6	4.8	124.6	(45.5-271.2)	Female	10	7.4	136.0	(65.1-250.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	2.6	nc	(nc-nc)	Male	8	2.5	314.9	(135.6-620.6)
Female	1	2.4	nc	(nc-nc)	Female	5	2.3	217.5	(70.1-507.7)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	11	7.0	157.3	(78.4-281.5)
Female	57	58.5	97.4	(73.7-126.1)	Female	9	6.9	130.2	(59.4-247.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	2.0	nc	(nc-nc)	Male	10	6.5	153.1	(73.3-281.6)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	10	12.8	78.4	(37.5-144.2)	Female	9	5.0	179.8	(82.0-341.3)
Female	18	14.2	126.7	(75.1-200.3)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	5	4.4	112.9	(36.4-263.5)
Male	4	3.2	nc	(nc-nc)	Female	6	5.0	120.1	(43.9-261.4)
Female	2	0.9	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	43	41.3	104.1	(75.3-140.2)
Male	0	1.0	nc	(nc-nc)	<u>Stomach</u>				
Female	1	1.0	nc	(nc-nc)	Male	1	2.8	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	3	2.0	nc	(nc-nc)
Male	6	7.9	76.4	(27.9-166.2)	<u>Testis</u>				
Female	9	4.6	196.9	(89.8-373.7)	Male	4	2.1	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	5	1.9	262.1	(84.5-611.7)	Male	8	3.8	212.3	(91.4-418.3)
Female	1	0.6	nc	(nc-nc)	Female	14	11.7	119.6	(65.3-200.6)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	10	4.9	202.9	(97.1-373.1)	Female	22	13.2	166.5	(104.3-252.2)
Female	6	4.1	145.0	(53.0-315.6)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	203	161.0	126.1	(109.3-144.7)
Male	7	4.7	148.8	(59.6-306.7)	Female	230	191.7	120.0	(105.0-136.5)
Female	2	1.7	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	29	20.7	140.4	(94.0-201.6)					
Female	25	25.3	98.7	(63.9-145.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Palmer

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	17	13.3	128.0	(74.5-205.0)	Male	13	8.8	148.5	(79.0-254.0)
Female	8	5.4	149.1	(64.2-293.9)	Female	7	7.2	96.8	(38.8-199.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	7	2.6	269.5	(108.0-555.3)	Male	2	2.8	nc	(nc-nc)
Female	1	2.4	nc	(nc-nc)	Female	1	2.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.5	nc	(nc-nc)	Male	6	7.7	77.9	(28.4-169.6)
Female	63	59.5	105.8	(81.3-135.4)	Female	8	7.3	110.0	(47.4-216.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.8	nc	(nc-nc)	Male	6	6.7	89.0	(32.5-193.7)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	12	14.3	83.9	(43.3-146.5)	Female	8	5.1	157.4	(67.8-310.2)
Female	13	14.9	87.0	(46.3-148.8)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	4	5.0	nc	(nc-nc)
Male	3	3.5	nc	(nc-nc)	Female	7	5.7	123.8	(49.6-255.1)
Female	2	1.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	32	42.1	76.1	(52.0-107.4)
Male	1	1.0	nc	(nc-nc)	<u>Stomach</u>				
Female	1	0.9	nc	(nc-nc)	Male	6	3.2	188.7	(68.9-410.7)
<u>Kidney & Renal Pelvis</u>					Female	3	2.1	nc	(nc-nc)
Male	14	8.1	173.3	(94.7-290.8)	<u>Testis</u>				
Female	6	4.8	125.9	(46.0-274.0)	Male	2	1.9	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	4	2.0	nc	(nc-nc)	Male	1	3.6	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	Female	7	10.3	67.7	(27.1-139.5)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	5	5.4	92.7	(29.9-216.4)	Female	8	14.0	57.3	(24.7-113.0)
Female	4	4.2	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	183	174.6	104.8	(90.2-121.1)
Male	5	4.9	101.2	(32.6-236.1)	Female	186	199.4	93.3	(80.4-107.7)
Female	2	1.8	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	29	23.8	121.7	(81.5-174.8)					
Female	20	28.5	70.1	(42.8-108.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Paxton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	8	5.8	137.2	(59.1-270.4)	Male	5	3.7	135.3	(43.6-315.6)
Female	2	1.7	nc	(nc-nc)	Female	2	2.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.1	nc	(nc-nc)	Male	3	1.2	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.2	nc	(nc-nc)	Male	1	3.3	nc	(nc-nc)
Female	19	21.0	90.5	(54.5-141.4)	Female	2	2.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.7	nc	(nc-nc)	Male	2	2.9	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	1	6.1	nc	(nc-nc)	Female	0	1.8	nc	(nc-nc)
Female	3	4.9	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	4	2.2	nc	(nc-nc)
Male	3	1.5	nc	(nc-nc)	Female	1	1.8	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	22	18.4	119.3	(74.8-180.7)
Male	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.3	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.7	nc	(nc-nc)
Male	4	3.4	nc	(nc-nc)	<u>Testis</u>				
Female	1	1.6	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	0.9	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	3.8	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	5	2.3	213.7	(68.9-498.6)	Female	7	5.0	141.2	(56.6-290.9)
Female	1	1.4	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	79	75.0	105.3	(83.4-131.2)
Male	2	2.1	nc	(nc-nc)	Female	52	68.1	76.4	(57.0-100.2)
Female	0	0.6	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	5	10.3	48.8	(15.7-113.8)					
Female	4	9.4	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Peabody

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	100	73.3	136.4	(110.9-165.8)	Male	41	43.9	93.3	(66.9-126.6)
Female	38	28.0	135.6	(96.0-186.2)	Female	33	34.3	96.1	(66.1-134.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	7	12.0	58.1	(23.3-119.8)	Male	21	14.3	147.4	(91.2-225.3)
Female	15	10.9	137.1	(76.7-226.1)	Female	14	12.5	111.7	(61.0-187.4)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	2.4	nc	(nc-nc)	Male	41	38.9	105.5	(75.7-143.1)
Female	294	269.0	109.3	(97.2-122.5)	Female	60	36.2	165.8	(126.5-213.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	11	8.2	134.3	(67.0-240.4)	Male	28	30.0	93.2	(61.9-134.7)
Female					Female	17	15.5	109.5	(63.8-175.3)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	63	72.0	87.5	(67.2-112.0)	Female	20	23.9	83.8	(51.2-129.5)
Female	79	78.9	100.2	(79.3-124.8)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	26	25.9	100.4	(65.6-147.1)
Male	14	17.2	81.3	(44.4-136.4)	Female	27	29.7	91.0	(60.0-132.5)
Female	3	5.3	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	200	194.0	103.1	(89.3-118.4)
Male	4	4.2	nc	(nc-nc)	<u>Stomach</u>				
Female	4	3.9	nc	(nc-nc)	Male	17	16.4	103.5	(60.2-165.7)
<u>Kidney & Renal Pelvis</u>					Female	8	11.1	71.8	(30.9-141.6)
Male	36	37.1	97.0	(68.0-134.4)	<u>Testis</u>				
Female	14	22.4	62.5	(34.1-104.9)	Male	7	7.3	95.9	(38.4-197.6)
<u>Larynx</u>					<u>Thyroid</u>				
Male	18	9.8	183.3	(108.5-289.6)	Male	12	15.2	79.2	(40.9-138.3)
Female	1	3.1	nc	(nc-nc)	Female	50	44.4	112.6	(83.6-148.5)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	30	27.7	108.4	(73.1-154.7)	Female	45	60.3	74.6	(54.4-99.9)
Female	29	21.5	134.9	(90.3-193.7)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	898	861.4	104.3	(97.5-111.3)
Male	16	23.2	69.1	(39.5-112.2)	Female	1022	950.2	107.6	(101.1-114.4)
Female	12	8.8	135.9	(70.1-237.3)					
<u>Lung and Bronchus</u>									
Male	124	124.1	99.9	(83.1-119.1)					
Female	153	139.7	109.5	(92.8-128.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Pelham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	2.0	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	3	0.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	4	7.8	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	3	2.0	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
Female	0	2.0	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	0	0.5	nc	(nc-nc)	Male	3	6.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	1.1	nc	(nc-nc)	Female	2	1.9	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.3	nc	(nc-nc)	Male	18	25.1	71.7	(42.5-113.3)
Female	0	0.1	nc	(nc-nc)	Female	16	26.1	61.3	(35.0-99.6)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.8	nc	(nc-nc)	<u>All Sites / Types</u>				
Female	0	0.5	nc	(nc-nc)	Male	18	25.1	71.7	(42.5-113.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	0.7	nc	(nc-nc)	Female	16	26.1	61.3	(35.0-99.6)
Female	1	0.2	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					<u>All Sites / Types</u>				
Male	2	3.5	nc	(nc-nc)	Male	18	25.1	71.7	(42.5-113.3)
Female	3	3.8	nc	(nc-nc)	Female	16	26.1	61.3	(35.0-99.6)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Pembroke

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	19	17.8	107.0	(64.4-167.1)	Male	11	12.1	90.7	(45.2-162.2)
Female	6	6.1	98.1	(35.8-213.5)	Female	15	9.6	156.3	(87.4-257.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	3.7	134.1	(43.2-312.9)	Male	2	3.9	nc	(nc-nc)
Female	2	3.1	nc	(nc-nc)	Female	2	3.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.7	nc	(nc-nc)	Male	13	10.7	121.6	(64.7-207.9)
Female	76	79.4	95.8	(75.4-119.9)	Female	7	9.1	77.2	(30.9-159.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	2.7	nc	(nc-nc)	Male	11	9.8	111.8	(55.7-200.1)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	28	19.7	141.9	(94.3-205.1)	Female	5	6.7	74.9	(24.1-174.9)
Female	18	18.2	99.1	(58.7-156.7)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	7	4.9	141.6	(56.7-291.8)	Male	59	61.5	95.9	(73.0-123.7)
Female	0	1.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	0	1.5	nc	(nc-nc)	Male	5	2.8	178.3	(57.5-416.2)
Female	2	1.2	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	17	11.6	146.1	(85.0-233.9)	Female	19	18.3	103.6	(62.3-161.8)
Female	7	6.1	115.6	(46.3-238.2)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Leukemia</u>				
Male	3	2.9	nc	(nc-nc)	Male	7	7.5	93.9	(37.6-193.5)
Female	0	0.9	nc	(nc-nc)	Female	6	5.1	116.8	(42.6-254.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Lung and Bronchus</u>				
Male	2	7.1	nc	(nc-nc)	Male	39	32.2	121.3	(86.2-165.8)
Female	1	2.2	nc	(nc-nc)	Female	42	32.9	127.8	(92.1-172.7)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Pepperell

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	11	12.0	91.7	(45.7-164.1)	Male	4	8.1	nc	(nc-nc)
Female	3	4.0	nc	(nc-nc)	Female	5	6.3	78.9	(25.4-184.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	2.5	nc	(nc-nc)	Male	1	2.7	nc	(nc-nc)
Female	2	2.1	nc	(nc-nc)	Female	1	2.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	5	7.2	69.6	(22.4-162.3)
Female	49	53.1	92.2	(68.2-121.9)	Female	3	5.9	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.8	nc	(nc-nc)	Male	6	6.6	91.2	(33.3-198.4)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	15	13.4	111.7	(62.5-184.2)	Female	5	4.4	113.0	(36.4-263.8)
Female	16	11.9	134.4	(76.8-218.3)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	6	4.7	128.9	(47.1-280.7)
Male	5	3.3	151.5	(48.8-353.5)	Female	2	4.1	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	23	40.6	56.6	(35.9-84.9)
Male	0	0.9	nc	(nc-nc)	<u>Stomach</u>				
Female	1	0.8	nc	(nc-nc)	Male	3	2.9	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	1.7	nc	(nc-nc)
Male	7	7.8	89.6	(35.9-184.7)	<u>Testis</u>				
Female	6	4.0	148.5	(54.2-323.1)	Male	2	1.7	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	3	1.9	nc	(nc-nc)	Male	6	3.5	169.6	(61.9-369.3)
Female	0	0.6	nc	(nc-nc)	Female	9	10.5	86.1	(39.3-163.4)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	4	5.0	nc	(nc-nc)	Female	16	12.0	133.5	(76.3-216.8)
Female	4	3.4	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	142	164.0	86.6	(72.9-102.0)
Male	2	4.7	nc	(nc-nc)	Female	151	167.7	90.1	(76.3-105.6)
Female	0	1.4	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	24	21.7	110.6	(70.8-164.6)					
Female	16	21.9	73.1	(41.8-118.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Peru

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	1.0	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.0	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	1	3.8	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	2	1.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	0	0.3	nc	(nc-nc)	Male	3	3.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	0.6	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Female</u>				
Male	0	0.2	nc	(nc-nc)	Male	10	13.4	74.8	(35.8-137.6)
Female	0	0.0	nc	(nc-nc)	Female	2	11.8	nc	(nc-nc)
<u>Leukemia</u>					<u>Male</u>				
Male	0	0.4	nc	(nc-nc)	<u>Female</u>				
Female	0	0.2	nc	(nc-nc)	<u>Male</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Female</u>				
Male	1	0.4	nc	(nc-nc)	<u>Male</u>				
Female	0	0.1	nc	(nc-nc)	<u>Female</u>				
<u>Lung and Bronchus</u>					<u>Male</u>				
Male	0	1.8	nc	(nc-nc)	<u>Female</u>				
Female	0	1.4	nc	(nc-nc)	<u>Male</u>				

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Petersham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	1.8	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.3	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	0.9	nc	(nc-nc)
Female	5	6.6	76.0	(24.5-177.3)	Female	0	0.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	3	1.9	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Female	1	1.7	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	1	0.4	nc	(nc-nc)	Male	5	5.1	98.8	(31.8-230.6)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.9	nc	(nc-nc)	Female	2	1.5	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Leukemia</u>				
Male	0	0.2	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
Female	1	0.1	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Lung and Bronchus</u>				
Male	1	0.6	nc	(nc-nc)	Male	1	2.9	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	Female	1	3.1	nc	(nc-nc)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Phillipston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	1.5	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.3	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	1.0	nc	(nc-nc)
Female	3	8.2	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	2	1.8	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
Female	0	1.7	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	1	0.5	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male				
Male	0	0.1	nc	(nc-nc)	Female	2	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Male	9	5.9	153.0	(69.8-290.4)
<u>Kidney & Renal Pelvis</u>					<u>Stomach</u>				
Male	0	1.1	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	0	0.3	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	0	0.7	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Female				
Male	0	0.7	nc	(nc-nc)	Male	1	1.9	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	4	2.8	nc	(nc-nc)	Female	26	22.5	115.7	(75.5-169.5)
Female	3	3.1	nc	(nc-nc)	Female	15	25.3	59.3	(33.1-97.8)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Pittsfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	72	55.8	129.1	(101.0-162.5)	Male	29	34.4	84.3	(56.4-121.1)
Female	24	20.4	117.5	(75.2-174.8)	Female	21	26.7	78.6	(48.6-120.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	13	9.8	132.5	(70.5-226.6)	Male	8	11.1	72.1	(31.0-142.0)
Female	6	8.6	69.5	(25.4-151.4)	Female	2	9.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.9	nc	(nc-nc)	Male	30	30.4	98.7	(66.6-140.9)
Female	206	214.1	96.2	(83.5-110.3)	Female	27	27.2	99.2	(65.3-144.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	5	6.6	75.9	(24.5-177.2)	Male	33	24.9	132.8	(91.4-186.5)
Female					Female	12	11.9	100.5	(51.8-175.5)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	61	56.5	108.0	(82.6-138.8)	Female	16	18.7	85.5	(48.8-138.8)
Female	85	57.2	148.7	(118.8-183.8)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	20	20.2	99.0	(60.4-152.9)
Male	24	13.7	175.6	(112.5-261.3)	Female	25	21.3	117.3	(75.9-173.1)
Female	5	3.9	126.6	(40.8-295.5)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	157	162.5	96.6	(82.1-113.0)
Male	5	3.6	139.5	(45.0-325.6)	<u>Stomach</u>				
Female	1	3.2	nc	(nc-nc)	Male	14	12.8	109.4	(59.8-183.6)
<u>Kidney & Renal Pelvis</u>					Female	8	8.1	99.1	(42.7-195.2)
Male	33	30.4	108.7	(74.8-152.7)	<u>Testis</u>				
Female	25	17.5	142.9	(92.4-210.9)	Male	8	6.4	124.5	(53.6-245.3)
<u>Larynx</u>					<u>Thyroid</u>				
Male	9	7.9	114.4	(52.2-217.3)	Male	10	12.7	78.5	(37.6-144.3)
Female	1	2.5	nc	(nc-nc)	Female	33	37.1	89.0	(61.3-125.0)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	23	21.7	106.1	(67.3-159.3)	Female	67	49.1	136.4	(105.7-173.3)
Female	10	16.1	62.3	(29.8-114.6)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	746	686.6	108.7	(101.0-116.7)
Male	20	18.7	107.0	(65.3-165.3)	Female	771	732.7	105.2	(97.9-112.9)
Female	6	6.7	90.0	(32.9-195.9)					
<u>Lung and Bronchus</u>									
Male	117	96.3	121.5	(100.4-145.6)					
Female	131	106.3	123.3	(103.1-146.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Plainfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	1.0	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	4	3.4	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	1	1.0	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	1	0.3	nc	(nc-nc)	Male	1	3.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	0.6	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Male</u>				
Male	0	0.2	nc	(nc-nc)	7	12.8	54.7	(21.9-112.7)	
Female	0	0.0	nc	(nc-nc)	<u>Female</u>				
<u>Leukemia</u>					<u>13</u>				
Male	0	0.4	nc	(nc-nc)	11.0	118.2	(62.9-202.1)		
Female	0	0.2	nc	(nc-nc)	<u>Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Male</u>				
Male	0	0.4	nc	(nc-nc)	5	1.6	320.4	(103.3-747.8)	
Female	0	0.1	nc	(nc-nc)	<u>Female</u>				
<u>Lung and Bronchus</u>					<u>5</u>				
Male	0	1.8	nc	(nc-nc)	<u>118.2</u>				
Female	5	1.6	320.4	(103.3-747.8)	<u>(62.9-202.1)</u>				

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Plainville

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	9	7.7	116.3	(53.1-220.7)	Male	7	5.5	127.1	(50.9-262.0)
Female	2	3.2	nc	(nc-nc)	Female	3	4.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.7	nc	(nc-nc)	Male	4	1.8	nc	(nc-nc)
Female	0	1.5	nc	(nc-nc)	Female	2	1.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.3	nc	(nc-nc)	Male	7	4.9	143.3	(57.4-295.3)
Female	39	37.3	104.5	(74.3-142.8)	Female	1	4.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.3	nc	(nc-nc)	Male	3	4.5	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	10	9.2	108.9	(52.1-200.3)	Female	4	3.2	nc	(nc-nc)
Female	8	9.3	86.2	(37.1-169.9)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	6	3.1	195.0	(71.2-424.4)
Male	1	2.2	nc	(nc-nc)	Female	2	3.2	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	32	27.3	117.3	(80.2-165.6)
Male	1	0.7	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.6	nc	(nc-nc)	Male	0	2.0	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	1.3	nc	(nc-nc)
Male	12	5.4	222.8	(115.0-389.2)	<u>Testis</u>				
Female	3	3.0	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	1.3	nc	(nc-nc)	Male	1	2.7	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	7	7.4	94.9	(38.0-195.6)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	5	3.4	148.8	(47.9-347.2)	Female	9	8.3	107.9	(49.2-204.9)
Female	6	2.6	226.9	(82.8-493.9)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	139	110.4	125.9	(105.9-148.7)
Male	2	3.1	nc	(nc-nc)	Female	119	123.1	96.7	(80.1-115.7)
Female	0	1.1	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	23	14.0	164.7	(104.4-247.2)					
Female	17	16.5	102.7	(59.8-164.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Plymouth

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	67	68.6	97.6	(75.6-124.0)	Male	76	44.6	170.2	(134.1-213.1)
Female	27	24.9	108.3	(71.4-157.6)	Female	50	34.4	145.3	(107.9-191.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	12	13.1	91.6	(47.3-160.0)	Male	10	14.5	68.9	(33.0-126.8)
Female	11	11.1	99.3	(49.5-177.7)	Female	11	11.8	93.4	(46.5-167.0)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	2.5	nc	(nc-nc)	Male	50	39.4	126.8	(94.1-167.2)
Female	305	288.0	105.9	(94.4-118.5)	Female	27	34.3	78.7	(51.8-114.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	6	9.0	66.7	(24.4-145.2)	Male	34	34.2	99.3	(68.8-138.8)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	60	71.8	83.6	(63.8-107.6)	Female	33	24.4	135.0	(92.9-189.6)
Female	56	70.0	80.0	(60.4-103.9)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	18	18.1	99.5	(58.9-157.3)	Male	27	26.0	104.0	(68.5-151.3)
Female	1	5.0	nc	(nc-nc)	Female	21	26.0	80.8	(50.0-123.6)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	4.9	nc	(nc-nc)	Male	229	225.1	101.8	(89.0-115.8)
Female	2	3.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	43	41.6	103.4	(74.8-139.3)	Male	14	16.3	85.7	(46.8-143.8)
Female	22	22.8	96.4	(60.4-145.9)	Female	12	9.8	122.2	(63.1-213.5)
<u>Larynx</u>					<u>Testis</u>				
Male	9	10.6	84.6	(38.6-160.5)	Male	9	8.8	102.3	(46.7-194.1)
Female	1	3.3	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	28	27.5	101.7	(67.6-147.0)	Male	22	18.1	121.7	(76.2-184.2)
Female	16	19.6	81.6	(46.6-132.5)	Female	72	50.2	143.4	(112.2-180.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	30	25.2	118.9	(80.2-169.7)	Female	79	67.3	117.3	(92.9-146.3)
Female	7	8.4	83.6	(33.5-172.3)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	127	124.5	102.0	(85.0-121.4)	Male	961	903.4	106.4	(99.8-113.3)
Female	148	134.8	109.8	(92.8-129.0)	Female	1006	947.9	106.1	(99.7-112.9)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Plympton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	3.8	132.4	(42.7-308.9)	Male	1	2.4	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	Female	1	1.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	0.7	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	2.2	nc	(nc-nc)
Female	14	12.7	110.0	(60.1-184.7)	Female	1	1.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.4	nc	(nc-nc)	Male	2	1.9	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	3	3.9	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
Female	4	2.7	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	3	1.4	nc	(nc-nc)
Male	1	1.0	nc	(nc-nc)	Female	2	1.0	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	15	12.8	117.5	(65.7-193.8)
Male	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.4	nc	(nc-nc)
Male	3	2.3	nc	(nc-nc)	<u>Testis</u>				
Female	3	1.0	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.6	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
Female	1	0.1	nc	(nc-nc)	Female	1	2.4	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	2	1.5	nc	(nc-nc)	Female	2	3.1	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	46	50.1	91.9	(67.3-122.6)
Male	2	1.4	nc	(nc-nc)	Female	49	40.1	122.1	(90.3-161.4)
Female	0	0.4	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	2	6.9	nc	(nc-nc)					
Female	7	5.4	129.6	(51.9-267.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Princeton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	3.5	141.2	(45.5-329.5)	Male	6	2.5	240.4	(87.8-523.2)
Female	0	1.2	nc	(nc-nc)	Female	3	1.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	0.8	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	3	2.2	nc	(nc-nc)
Female	21	17.0	123.5	(76.4-188.7)	Female	1	1.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.5	nc	(nc-nc)	Male	11	2.2	508.0	(253.2-908.9)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	5	4.1	122.8	(39.6-286.5)	Female	5	1.4	359.5	(115.9-838.9)
Female	2	3.4	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	3	1.1	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male				
Male	0	0.3	nc	(nc-nc)	Female	11	13.8	79.8	(39.8-142.8)
Female	1	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	4	2.5	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Female	2	1.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male				
Male	2	0.6	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	1	1.5	nc	(nc-nc)	Female	3	3.1	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Female				
Male	1	1.6	nc	(nc-nc)	Male	63	51.9	121.5	(93.3-155.4)
Female	0	0.5	nc	(nc-nc)	Female	50	52.3	95.6	(70.9-126.0)
<u>Lung and Bronchus</u>					<u>All Sites / Types</u>				
Male	1	6.7	nc	(nc-nc)					
Female	3	7.0	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Provincetown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	6.2	nc	(nc-nc)	Male	3	3.7	nc	(nc-nc)
Female	7	2.1	329.5	(132.0-679.0)	Female	5	2.4	205.2	(66.1-478.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.0	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	2	3.3	nc	(nc-nc)
Female	23	21.0	109.8	(69.6-164.7)	Female	1	2.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.5	nc	(nc-nc)	Male	7	2.8	246.5	(98.7-507.8)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	4	6.3	nc	(nc-nc)	Female	4	1.8	nc	(nc-nc)
Female	11	5.5	199.6	(99.5-357.1)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	0	1.6	nc	(nc-nc)	Male	2	2.2	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	4	2.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Stomach</u>				
Male	1	0.3	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					<u>Testis</u>				
Male	5	3.4	146.0	(47.1-340.8)	Male	0	0.5	nc	(nc-nc)
Female	1	1.8	nc	(nc-nc)	<u>Thyroid</u>				
<u>Larynx</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.9	nc	(nc-nc)	Female	4	5.2	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Leukemia</u>					<u>Female</u>				
Male	3	2.2	nc	(nc-nc)	Male	66	76.7	86.1	(66.6-109.5)
Female	2	1.5	nc	(nc-nc)	Female	88	72.0	122.3	(98.1-150.7)
<u>Liver and Intrahepatic Bile Ducts</u>									
Male	1	2.1	nc	(nc-nc)					
Female	0	0.7	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	11	10.9	101.3	(50.5-181.2)					
Female	11	11.4	96.3	(48.0-172.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Quincy

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	100	95.9	104.3	(84.9-126.9)	Male	57	62.1	91.8	(69.6-119.0)
Female	35	36.0	97.2	(67.7-135.2)	Female	55	50.0	110.0	(82.9-143.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	19	18.8	100.8	(60.7-157.4)	Male	14	19.7	71.1	(38.9-119.4)
Female	17	16.2	105.0	(61.1-168.1)	Female	14	16.6	84.5	(46.1-141.7)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	5	3.4	149.1	(48.1-348.0)	Male	50	55.1	90.7	(67.3-119.5)
Female	400	389.7	102.6	(92.8-113.2)	Female	57	49.0	116.4	(88.2-150.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	21	12.8	164.7	(101.9-251.8)	Male	61	45.2	135.0	(103.3-173.4)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	125	100.6	124.3	(103.5-148.1)	Female	34	34.3	99.0	(68.6-138.4)
Female	103	102.4	100.6	(82.1-122.0)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	23	24.0	95.9	(60.8-143.9)	Male	257	281.8	91.2	(80.4-103.1)
Female	8	6.9	115.7	(49.8-227.9)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	10	8.2	122.5	(58.7-225.4)	Male	17	16.2	105.2	(61.3-168.5)
Female	10	7.1	140.5	(67.3-258.4)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	53	55.1	96.2	(72.1-125.9)	Female	87	89.0	97.8	(78.3-120.6)
Female	34	31.7	107.1	(74.2-149.7)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Leukemia</u>				
Male	18	14.0	128.4	(76.1-202.9)	Male	23	39.2	58.6	(37.1-88.0)
Female	4	4.4	nc	(nc-nc)	Female	30	29.2	102.6	(69.2-146.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Lung and Bronchus</u>				
Male	57	33.6	169.6	(128.4-219.7)	Male	237	167.4	141.6	(124.1-160.8)
Female	17	11.9	142.5	(83.0-228.2)	Female	241	188.2	128.0	(112.4-145.3)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Randolph

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	33	34.7	95.0	(65.4-133.4)	Male	12	22.4	53.5	(27.6-93.5)
Female	11	14.1	78.0	(38.9-139.6)	Female	13	19.6	66.4	(35.3-113.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	8	6.7	119.3	(51.4-235.0)	Male	8	7.2	111.4	(48.0-219.5)
Female	5	6.3	79.0	(25.4-184.3)	Female	7	6.6	105.7	(42.3-217.7)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.2	nc	(nc-nc)	Male	12	19.9	60.2	(31.1-105.2)
Female	145	157.0	92.4	(78.0-108.7)	Female	22	19.5	113.1	(70.8-171.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	5.1	nc	(nc-nc)	Male	9	17.1	52.7	(24.0-100.0)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	35	37.1	94.2	(65.6-131.1)	Female	11	13.6	81.0	(40.4-145.0)
Female	46	40.1	114.8	(84.0-153.1)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	10	12.9	77.2	(37.0-142.1)
Male	8	8.9	90.2	(38.8-177.7)	Female	10	14.7	67.9	(32.5-124.9)
Female	2	2.8	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	101	107.4	94.1	(76.6-114.3)
Male	2	2.7	nc	(nc-nc)	<u>Stomach</u>				
Female	2	2.5	nc	(nc-nc)	Male	10	8.2	122.0	(58.4-224.3)
<u>Kidney & Renal Pelvis</u>					Female	6	5.7	106.1	(38.7-230.9)
Male	29	20.5	141.6	(94.8-203.3)	<u>Testis</u>				
Female	8	12.6	63.7	(27.4-125.5)	Male	0	5.0	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	7	5.1	136.8	(54.8-282.0)	Male	13	9.2	141.4	(75.2-241.7)
Female	1	1.8	nc	(nc-nc)	Female	35	28.9	121.1	(84.3-168.4)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	11	14.1	77.9	(38.8-139.3)	Female	41	36.3	113.0	(81.1-153.3)
Female	2	11.3	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	391	448.5	87.2	(78.8-96.3)
Male	15	12.5	119.9	(67.1-197.8)	Female	461	527.4	87.4	(79.6-95.8)
Female	1	4.7	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	44	60.2	73.1	(53.1-98.1)					
Female	52	73.7	70.6	(52.7-92.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Raynham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	13	14.5	89.5	(47.6-153.1)	Male	11	9.6	114.6	(57.2-205.1)
Female	6	5.7	105.7	(38.6-230.0)	Female	11	7.8	141.1	(70.4-252.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	2.9	nc	(nc-nc)	Male	4	3.1	nc	(nc-nc)
Female	2	2.5	nc	(nc-nc)	Female	2	2.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.5	nc	(nc-nc)	Male	12	8.4	143.0	(73.8-249.8)
Female	69	63.2	109.3	(85.0-138.3)	Female	7	7.8	89.9	(36.0-185.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	2.0	nc	(nc-nc)	Male	5	7.5	67.0	(21.6-156.4)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	26	15.7	165.9	(108.4-243.1)	Female	9	5.4	166.5	(76.0-316.1)
Female	17	15.9	107.1	(62.3-171.5)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	5	5.5	90.8	(29.3-211.8)
Male	6	3.8	157.8	(57.6-343.4)	Female	5	5.8	85.6	(27.6-199.7)
Female	1	1.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	48	46.6	102.9	(75.9-136.5)
Male	1	1.1	nc	(nc-nc)	<u>Stomach</u>				
Female	1	1.0	nc	(nc-nc)	Male	3	3.5	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	2.2	nc	(nc-nc)
Male	12	8.9	135.5	(69.9-236.7)	<u>Testis</u>				
Female	6	5.1	118.2	(43.2-257.3)	Male	4	2.0	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	3	2.2	nc	(nc-nc)	Male	6	3.9	153.2	(55.9-333.5)
Female	1	0.7	nc	(nc-nc)	Female	24	11.5	208.2	(133.4-309.9)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	2	6.0	nc	(nc-nc)	Female	16	14.3	112.1	(64.1-182.1)
Female	4	4.5	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	213	191.8	111.1	(96.6-127.0)
Male	6	5.5	108.4	(39.6-236.0)	Female	238	211.5	112.5	(98.7-127.8)
Female	2	1.9	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	23	26.0	88.5	(56.1-132.7)					
Female	26	30.4	85.4	(55.8-125.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Reading

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	26	25.7	101.2	(66.1-148.2)	Male	14	16.7	83.8	(45.8-140.6)
Female	11	10.3	106.8	(53.2-191.1)	Female	15	14.3	104.9	(58.7-173.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	5.0	nc	(nc-nc)	Male	4	5.3	nc	(nc-nc)
Female	6	4.6	130.2	(47.5-283.4)	Female	2	4.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.9	nc	(nc-nc)	Male	17	14.8	114.6	(66.7-183.5)
Female	129	112.7	114.5	(95.6-136.0)	Female	8	14.0	57.0	(24.6-112.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	3.8	nc	(nc-nc)	Male	14	12.7	110.1	(60.2-184.8)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	32	27.6	116.0	(79.3-163.8)	Female	14	9.7	143.8	(78.6-241.3)
Female	27	29.9	90.4	(59.6-131.5)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	5	6.6	75.9	(24.5-177.1)	Male	66	79.4	83.2	(64.3-105.8)
Female	2	2.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	1	1.9	nc	(nc-nc)	Male	6	3.7	161.0	(58.8-350.5)
Female	2	1.7	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	16	15.3	104.5	(59.7-169.7)	Female	24	25.1	95.7	(61.3-142.4)
Female	8	9.0	88.7	(38.2-174.7)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Leukemia</u>				
Male	1	3.8	nc	(nc-nc)	Male	13	10.6	123.1	(65.5-210.4)
Female	0	1.2	nc	(nc-nc)	Female	9	8.4	106.8	(48.7-202.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Lung and Bronchus</u>				
Male	11	9.3	117.9	(58.8-211.0)	Male	32	44.5	72.0	(49.2-101.6)
Female	4	3.4	nc	(nc-nc)	Female	37	52.5	70.4	(49.6-97.1)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Rehoboth

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	14.9	nc	(nc-nc)	Male	8	9.5	84.2	(36.3-166.0)
Female	5	3.7	134.3	(43.3-313.4)	Female	6	5.9	102.0	(37.2-222.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	2.7	nc	(nc-nc)	Male	3	3.1	nc	(nc-nc)
Female	2	2.0	nc	(nc-nc)	Female	1	1.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.5	nc	(nc-nc)	Male	9	8.4	107.0	(48.8-203.2)
Female	51	49.1	103.8	(77.3-136.5)	Female	7	5.5	127.8	(51.2-263.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.7	nc	(nc-nc)	Male	0	7.2	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	9	15.7	57.2	(26.1-108.7)	Female	4	4.1	nc	(nc-nc)
Female	9	10.8	83.7	(38.2-158.8)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	1	3.8	nc	(nc-nc)	Male	35	45.9	76.2	(53.1-106.0)
Female	0	0.8	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	0	1.0	nc	(nc-nc)	Male	2	1.8	nc	(nc-nc)
Female	2	0.7	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	7	8.6	81.0	(32.5-166.9)	Female	16	11.7	137.3	(78.4-223.0)
Female	5	3.8	132.9	(42.8-310.2)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	2.2	nc	(nc-nc)	Female	16	11.7	137.3	(78.4-223.0)
Female	2	0.5	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	5	5.9	84.8	(27.3-197.9)	Male	124	190.2	65.2	(54.2-77.7)
Female	2	3.2	nc	(nc-nc)	Female	154	156.0	98.7	(83.8-115.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	2	5.4	nc	(nc-nc)	<u>All Sites / Types</u>				
Female	1	1.4	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					<u>All Sites / Types</u>				
Male	24	25.8	92.9	(59.5-138.2)	<u>All Sites / Types</u>				
Female	17	20.4	83.3	(48.5-133.4)	<u>All Sites / Types</u>				

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Revere

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	52	52.2	99.5	(74.3-130.5)	Male	18	34.9	51.6	(30.5-81.5)
Female	18	19.8	90.9	(53.8-143.7)	Female	20	27.4	73.1	(44.6-112.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	7	10.9	64.2	(25.7-132.4)	Male	7	10.9	64.1	(25.7-132.1)
Female	12	8.9	135.2	(69.8-236.1)	Female	10	9.1	109.4	(52.4-201.2)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.8	nc	(nc-nc)	Male	30	30.9	97.0	(65.4-138.5)
Female	190	216.0	87.9	(75.9-101.4)	Female	25	27.0	92.7	(60.0-136.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	5	7.0	71.2	(22.9-166.0)	Male	21	25.8	81.4	(50.4-124.5)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	60	56.4	106.4	(81.2-137.0)	Female	13	18.8	69.2	(36.8-118.3)
Female	45	55.5	81.0	(59.1-108.4)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	9	13.3	67.7	(30.9-128.5)	Male	23	19.5	117.9	(74.7-176.9)
Female	2	3.9	nc	(nc-nc)	Female	16	20.5	77.9	(44.5-126.5)
<u>Hodgkin Lymphoma</u>					<u>Stomach</u>				
Male	6	4.9	123.3	(45.0-268.3)	Male	20	12.5	160.3	(97.9-247.5)
Female	10	3.7	267.7	(128.2-492.3)	Female	11	7.9	139.5	(69.6-249.7)
<u>Kidney & Renal Pelvis</u>					<u>Testis</u>				
Male	35	31.4	111.4	(77.6-154.9)	Male	7	10.2	68.4	(27.4-141.0)
Female	24	17.5	136.9	(87.7-203.7)	<u>Thyroid</u>				
<u>Larynx</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	6	7.8	77.1	(28.2-167.8)	Female	37	49.7	74.4	(52.4-102.5)
Female	5	2.5	203.5	(65.6-474.9)	<u>All Sites / Types</u>				
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	26	22.0	118.1	(77.1-173.0)	Male	659	682.7	96.5	(89.3-104.2)
Female	17	16.0	106.3	(61.9-170.1)	Female	734	733.4	100.1	(93.0-107.6)
<u>Liver and Intrahepatic Bile Ducts</u>									
Male	24	18.8	127.8	(81.8-190.1)					
Female	7	6.6	106.5	(42.7-219.5)					
<u>Lung and Bronchus</u>									
Male	136	91.8	148.2	(124.3-175.3)					
Female	141	104.3	135.1	(113.7-159.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Richmond

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	3.3	nc	(nc-nc)	Male	0	1.9	nc	(nc-nc)
Female	2	1.0	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.5	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.7	nc	(nc-nc)
Female	7	10.1	69.6	(27.9-143.5)	Female	1	1.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	0	1.4	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	1	3.1	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
Female	2	2.6	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	0	1.2	nc	(nc-nc)
Male	1	0.8	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	12	9.9	121.2	(62.6-211.7)
Male	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.4	nc	(nc-nc)
Male	1	1.7	nc	(nc-nc)	<u>Testis</u>				
Female	0	0.8	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.5	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	1.4	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	1.2	nc	(nc-nc)	Female	0	2.4	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	19	39.6	48.0	(28.9-75.0)
Male	0	1.1	nc	(nc-nc)	Female	17	34.1	49.9	(29.0-79.9)
Female	0	0.3	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	3	5.8	nc	(nc-nc)					
Female	0	5.2	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Rochester

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	6.0	83.3	(26.9-194.4)	Male	3	4.0	nc	(nc-nc)
Female	3	1.8	nc	(nc-nc)	Female	0	2.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.2	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	Female	2	0.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	3	3.5	nc	(nc-nc)
Female	26	23.3	111.5	(72.8-163.4)	Female	2	2.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.8	nc	(nc-nc)	Male	4	3.2	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	4	6.5	nc	(nc-nc)	Female	1	2.0	nc	(nc-nc)
Female	10	5.5	182.7	(87.4-335.9)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	3	2.3	nc	(nc-nc)
Male	1	1.7	nc	(nc-nc)	Female	2	1.9	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	26	20.7	125.4	(81.9-183.8)
Male	0	0.5	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.3	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	0.8	nc	(nc-nc)
Male	6	3.8	156.4	(57.1-340.4)	<u>Testis</u>				
Female	2	1.8	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	1.0	nc	(nc-nc)	Male	1	1.7	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	3	4.5	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	2	2.5	nc	(nc-nc)	Female	4	5.4	nc	(nc-nc)
Female	2	1.6	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	81	81.8	99.1	(78.7-123.1)
Male	3	2.4	nc	(nc-nc)	Female	73	74.6	97.9	(76.7-123.1)
Female	0	0.7	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	9	11.0	81.8	(37.3-155.4)					
Female	6	9.3	64.2	(23.4-139.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Rockland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	26	18.5	140.3	(91.6-205.6)	Male	16	12.0	132.8	(75.9-215.7)
Female	9	7.2	124.8	(57.0-236.9)	Female	14	9.8	142.2	(77.7-238.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	3.7	162.5	(59.3-353.7)	Male	4	3.9	nc	(nc-nc)
Female	4	3.2	nc	(nc-nc)	Female	1	3.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.7	nc	(nc-nc)	Male	10	10.8	93.0	(44.5-171.0)
Female	82	80.8	101.5	(80.8-126.0)	Female	18	9.8	183.2	(108.5-289.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	2.5	nc	(nc-nc)	Male	11	9.0	122.1	(60.9-218.5)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	26	19.6	132.6	(86.6-194.3)	Female	7	6.9	101.0	(40.4-208.0)
Female	25	20.1	124.4	(80.5-183.7)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	10	4.8	208.7	(99.9-383.9)	Male	60	57.8	103.8	(79.2-133.6)
Female	1	1.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	1	1.5	nc	(nc-nc)	Male	2	3.0	nc	(nc-nc)
Female	2	1.1	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	17	11.0	155.2	(90.3-248.5)	Female	23	18.8	122.2	(77.4-183.3)
Female	15	6.5	231.0	(129.2-381.0)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Leukemia</u>				
Male	4	2.8	nc	(nc-nc)	Male	9	7.5	119.4	(54.5-226.7)
Female	0	0.9	nc	(nc-nc)	Female	8	5.7	139.6	(60.1-275.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Lung and Bronchus</u>				
Male	5	6.7	74.5	(24.0-173.9)	Male	32	32.8	97.5	(66.6-137.6)
Female	4	2.4	nc	(nc-nc)	Female	50	38.7	129.3	(96.0-170.5)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Rockport

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	14	12.3	113.4	(62.0-190.4)	Male	5	7.4	68.0	(21.9-158.7)
Female	2	5.0	nc	(nc-nc)	Female	7	5.8	120.5	(48.3-248.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.9	nc	(nc-nc)	Male	2	2.5	nc	(nc-nc)
Female	3	1.8	nc	(nc-nc)	Female	3	2.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.4	nc	(nc-nc)	Male	3	6.4	nc	(nc-nc)
Female	50	47.9	104.3	(77.4-137.5)	Female	4	6.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.3	nc	(nc-nc)	Male	5	5.3	93.8	(30.2-218.8)
<u>Colon / Rectum</u>					Female	5	2.8	181.0	(58.3-422.3)
Male	9	11.9	75.6	(34.5-143.5)	<u>Ovary</u>				
Female	6	13.6	44.2	(16.1-96.2)	Female	5	4.2	119.5	(38.5-278.9)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	3.1	nc	(nc-nc)	Male	2	4.4	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	Female	3	5.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.6	nc	(nc-nc)	Male	39	37.1	105.2	(74.8-143.8)
Female	2	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	2.8	nc	(nc-nc)
Male	10	6.5	154.0	(73.7-283.3)	Female	0	1.9	nc	(nc-nc)
Female	5	4.0	124.7	(40.2-291.0)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.8	nc	(nc-nc)
Male	0	1.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.6	nc	(nc-nc)	Male	0	2.4	nc	(nc-nc)
<u>Leukemia</u>					Female	5	6.8	73.9	(23.8-172.5)
Male	6	4.5	134.0	(48.9-291.7)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	4	3.7	nc	(nc-nc)	Female	8	11.2	71.3	(30.7-140.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	4.1	nc	(nc-nc)	Male	137	149.4	91.7	(77.0-108.4)
Female	1	1.6	nc	(nc-nc)	Female	143	167.9	85.2	(71.8-100.4)
<u>Lung and Bronchus</u>									
Male	20	21.7	92.0	(56.2-142.2)					
Female	14	26.0	53.8	(29.4-90.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Rowe

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	0.7	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	2.8	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	2	0.7	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male				
Male	0	0.0	nc	(nc-nc)	Female	1	2.4	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	1	0.4	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male				
Male	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	0	0.3	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Female				
Male	0	0.3	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	0	1.3	nc	(nc-nc)	Female	5	9.4	53.4	(17.2-124.6)
Female	0	1.3	nc	(nc-nc)	Female	2	8.9	nc	(nc-nc)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Rowley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	6	6.7	89.2	(32.6-194.1)	Male	6	4.6	131.1	(47.9-285.3)
Female	6	2.4	252.4	(92.2-549.4)	Female	7	3.6	196.3	(78.7-404.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.3	nc	(nc-nc)	Male	2	1.5	nc	(nc-nc)
Female	2	1.1	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	5	4.0	126.1	(40.6-294.2)
Female	31	28.5	108.8	(73.9-154.4)	Female	4	3.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.0	nc	(nc-nc)	Male	1	3.6	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	8	7.4	108.6	(46.7-213.9)	Female	4	2.5	nc	(nc-nc)
Female	7	7.1	97.9	(39.2-201.8)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	4	2.6	nc	(nc-nc)
Male	2	1.8	nc	(nc-nc)	Female	3	2.4	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	20	22.8	87.7	(53.6-135.5)
Male	0	0.5	nc	(nc-nc)	<u>Stomach</u>				
Female	1	0.4	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	1.0	nc	(nc-nc)
Male	1	4.3	nc	(nc-nc)	<u>Testis</u>				
Female	1	2.2	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	1.1	nc	(nc-nc)	Male	1	1.9	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	6	5.6	107.9	(39.4-234.9)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	4	2.8	nc	(nc-nc)	Female	4	6.3	nc	(nc-nc)
Female	0	2.0	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	81	91.6	88.4	(70.2-109.9)
Male	1	2.7	nc	(nc-nc)	Female	94	93.4	100.7	(81.3-123.2)
Female	1	0.8	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	10	12.4	80.8	(38.7-148.7)					
Female	7	12.4	56.5	(22.6-116.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Royalston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	1.5	nc	(nc-nc)	Male	2	1.0	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.3	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	7	6.2	112.0	(44.9-230.8)	Female	2	0.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	2	0.8	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	5	1.7	295.1	(95.1-688.6)	Female	1	0.5	nc	(nc-nc)
Female	0	1.4	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	1	0.6	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	10	5.3	189.2	(90.6-347.9)
Male	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	0.2	nc	(nc-nc)
Male	0	1.0	nc	(nc-nc)	<u>Testis</u>				
Female	0	0.5	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.3	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.6	nc	(nc-nc)	Female	1	1.5	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	27	20.8	129.9	(85.6-189.0)
Male	0	0.6	nc	(nc-nc)	Female	17	19.8	85.9	(50.0-137.5)
Female	0	0.2	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	2	2.7	nc	(nc-nc)					
Female	1	2.7	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Russell

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	1.6	nc	(nc-nc)	Male	3	1.1	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	2	0.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
Female	10	7.2	139.5	(66.8-256.5)	Female	0	0.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	6	1.8	332.1	(121.3-722.9)	Female	2	0.6	nc	(nc-nc)
Female	3	1.6	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	1	0.4	nc	(nc-nc)	Male	5	5.4	92.3	(29.8-215.5)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	2	1.1	nc	(nc-nc)	Female	0	1.6	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Leukemia</u>				
Male	0	0.3	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Lung and Bronchus</u>				
Male	1	0.6	nc	(nc-nc)	Male	3	3.0	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	3	3.0	nc	(nc-nc)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Rutland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	6.9	nc	(nc-nc)	Male	6	5.0	120.6	(44.1-262.6)
Female	2	2.3	nc	(nc-nc)	Female	1	3.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.7	nc	(nc-nc)	Male	3	1.6	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	6	4.5	134.1	(49.0-291.9)
Female	38	32.7	116.2	(82.2-159.5)	Female	2	3.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.1	nc	(nc-nc)	Male	3	4.2	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	11	8.2	134.7	(67.1-241.0)	Female	2	2.7	nc	(nc-nc)
Female	9	7.0	128.8	(58.8-244.4)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	3	2.8	nc	(nc-nc)
Male	2	2.0	nc	(nc-nc)	Female	5	2.4	207.0	(66.7-483.1)
Female	1	0.5	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	24	26.2	91.6	(58.7-136.3)
Male	1	0.7	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.5	nc	(nc-nc)	Male	1	1.8	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	1.0	nc	(nc-nc)
Male	2	5.0	nc	(nc-nc)	<u>Testis</u>				
Female	2	2.5	nc	(nc-nc)	Male	3	1.4	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	1.2	nc	(nc-nc)	Male	0	2.5	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	6	6.6	90.5	(33.1-197.1)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	7	3.2	220.5	(88.3-454.3)	Female	6	7.6	79.4	(29.0-172.7)
Female	2	2.0	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	103	101.9	101.1	(82.5-122.6)
Male	1	2.9	nc	(nc-nc)	Female	92	102.0	90.2	(72.7-110.6)
Female	1	0.9	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	18	12.5	143.6	(85.1-227.0)					
Female	7	13.0	53.7	(21.5-110.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Salem

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	39	35.0	111.4	(79.2-152.3)	Male	33	23.4	141.1	(97.1-198.2)
Female	13	16.1	80.6	(42.9-137.9)	Female	26	23.0	113.2	(73.9-165.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	10	7.4	134.3	(64.3-247.0)	Male	4	7.3	nc	(nc-nc)
Female	3	7.6	nc	(nc-nc)	Female	14	7.5	185.8	(101.5-311.8)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	3	1.3	nc	(nc-nc)	Male	21	20.9	100.5	(62.2-153.6)
Female	164	179.7	91.3	(77.8-106.4)	Female	23	22.3	103.1	(65.4-154.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	6	6.0	100.4	(36.7-218.6)	Male	24	17.6	136.2	(87.2-202.6)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	35	38.2	91.7	(63.9-127.5)	Female	12	15.7	76.3	(39.4-133.3)
Female	35	46.1	75.9	(52.8-105.5)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	12	9.0	133.7	(69.0-233.6)	Male	11	13.2	83.4	(41.6-149.2)
Female	5	3.1	159.8	(51.5-373.0)	Female	15	16.7	89.6	(50.1-147.7)
<u>Hodgkin Lymphoma</u>					<u>Stomach</u>				
Male	2	3.3	nc	(nc-nc)	Male	13	8.4	154.9	(82.4-265.0)
Female	8	3.3	240.5	(103.6-473.9)	Female	3	6.5	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					<u>Testis</u>				
Male	24	21.3	112.6	(72.1-167.6)	Male	7	6.4	109.8	(44.0-226.2)
Female	13	14.5	89.9	(47.8-153.7)	<u>Thyroid</u>				
<u>Larynx</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	6	5.3	113.2	(41.3-246.4)	Female	44	41.0	107.4	(78.0-144.1)
Female	5	2.0	250.7	(80.8-585.0)	<u>All Sites / Types</u>				
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	13	15.0	86.8	(46.2-148.4)	Male	549	462.5	118.7	(109.0-129.1)
Female	13	13.4	97.4	(51.8-166.5)	Female	614	607.6	101.1	(93.2-109.4)
<u>Liver and Intrahepatic Bile Ducts</u>									
Male	17	12.8	132.3	(77.0-211.8)					
Female	2	5.5	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	77	61.7	124.7	(98.4-155.9)					
Female	89	84.0	106.0	(85.1-130.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Salisbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	12	10.6	113.6	(58.6-198.4)	Male	11	6.8	162.8	(81.2-291.3)
Female	4	3.6	nc	(nc-nc)	Female	4	5.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	2.0	nc	(nc-nc)	Male	2	2.2	nc	(nc-nc)
Female	1	1.7	nc	(nc-nc)	Female	1	1.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	6	6.0	99.9	(36.5-217.4)
Female	41	43.5	94.2	(67.6-127.8)	Female	6	5.0	119.8	(43.7-260.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.4	nc	(nc-nc)	Male	13	5.2	249.4	(132.7-426.5)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	13	11.0	118.5	(63.0-202.6)	Female	7	3.6	192.9	(77.3-397.6)
Female	14	10.1	138.0	(75.4-231.6)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	5	4.0	125.7	(40.5-293.3)
Male	1	2.8	nc	(nc-nc)	Female	6	3.7	161.1	(58.8-350.6)
Female	1	0.7	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	30	35.2	85.3	(57.5-121.8)
Male	0	0.7	nc	(nc-nc)	<u>Stomach</u>				
Female	2	0.6	nc	(nc-nc)	Male	4	2.5	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	1.4	nc	(nc-nc)
Male	5	6.3	78.8	(25.4-184.0)	<u>Testis</u>				
Female	4	3.4	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	1.6	nc	(nc-nc)	Male	1	2.7	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	9	7.8	116.1	(53.0-220.3)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	3	4.2	nc	(nc-nc)	Female	12	10.2	117.3	(60.6-205.0)
Female	2	2.9	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	141	138.5	101.8	(85.7-120.1)
Male	3	3.9	nc	(nc-nc)	Female	163	140.6	115.9	(98.8-135.2)
Female	2	1.2	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	25	19.1	131.2	(84.9-193.7)					
Female	28	19.4	144.0	(95.6-208.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Sandisfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	2.2	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
Female	1	4.5	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	0	2.0	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	0	0.5	nc	(nc-nc)	Male	2	5.0	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.9	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Leukemia</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	2	0.3	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Lung and Bronchus</u>				
Male	0	0.6	nc	(nc-nc)	Male	1	3.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	3	2.0	nc	(nc-nc)
					Male	7	23.0	30.4	(12.2-62.6)
					Female	8	14.3	55.8	(24.0-110.0)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Sandwich

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	34	25.8	131.5	(91.1-183.8)	Male	19	16.3	116.2	(69.9-181.5)
Female	9	9.4	95.4	(43.5-181.1)	Female	16	12.8	125.3	(71.6-203.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	9	4.6	195.3	(89.1-370.7)	Male	8	5.3	149.6	(64.4-294.7)
Female	7	4.2	168.2	(67.4-346.5)	Female	2	4.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.9	nc	(nc-nc)	Male	21	14.5	145.2	(89.9-222.0)
Female	122	106.0	115.0	(95.5-137.4)	Female	15	12.9	116.3	(65.0-191.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	3.2	nc	(nc-nc)	Male	11	12.3	89.4	(44.6-160.0)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	22	26.6	82.7	(51.8-125.3)	Female	10	9.1	110.5	(52.9-203.2)
Female	22	26.2	83.8	(52.5-126.9)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	5	6.6	75.5	(24.3-176.2)	Male	83	80.5	103.1	(82.1-127.8)
Female	5	1.9	267.0	(86.0-623.0)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	0	1.6	nc	(nc-nc)	Male	4	2.6	nc	(nc-nc)
Female	2	1.4	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	10	14.8	67.4	(32.3-124.0)	Female	28	24.7	113.2	(75.2-163.6)
Female	7	8.5	82.6	(33.1-170.2)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Leukemia</u>				
Male	4	3.9	nc	(nc-nc)	Male	9	10.1	89.3	(40.8-169.6)
Female	0	1.2	nc	(nc-nc)	Female	6	7.4	80.6	(29.4-175.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Lung and Bronchus</u>				
Male	7	9.3	75.0	(30.1-154.6)	Male	33	45.7	72.2	(49.7-101.4)
Female	1	3.2	nc	(nc-nc)	Female	47	50.3	93.4	(68.7-124.3)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Saugus

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	53	33.5	158.1	(118.4-206.8)	Male	15	21.2	70.6	(39.5-116.5)
Female	18	13.9	129.4	(76.6-204.5)	Female	20	18.1	110.4	(67.4-170.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	7	5.9	117.9	(47.2-242.9)	Male	5	6.9	73.0	(23.5-170.3)
Female	7	5.8	121.0	(48.5-249.4)	Female	5	6.4	78.0	(25.1-182.0)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	3	1.2	nc	(nc-nc)	Male	36	18.8	191.6	(134.1-265.2)
Female	145	147.6	98.2	(82.9-115.6)	Female	24	18.7	128.6	(82.4-191.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	4.5	nc	(nc-nc)	Male	20	15.4	130.0	(79.3-200.7)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	48	34.6	138.7	(102.3-183.9)	Female	5	12.8	39.1	(12.6-91.3)
Female	27	38.9	69.5	(45.8-101.1)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	18	12.3	145.8	(86.3-230.4)
Male	16	8.3	192.8	(110.1-313.1)	Female	13	14.5	89.5	(47.6-153.1)
Female	6	2.7	222.1	(81.1-483.3)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	79	97.2	81.3	(64.3-101.3)
Male	1	2.2	nc	(nc-nc)	<u>Stomach</u>				
Female	4	2.1	nc	(nc-nc)	Male	3	7.8	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	2	5.4	nc	(nc-nc)
Male	24	18.8	127.9	(81.9-190.3)	<u>Testis</u>				
Female	8	12.0	66.8	(28.8-131.7)	Male	10	4.0	253.0	(121.1-465.4)
<u>Larynx</u>					<u>Thyroid</u>				
Male	6	4.9	122.8	(44.8-267.3)	Male	8	8.1	98.7	(42.5-194.5)
Female	0	1.7	nc	(nc-nc)	Female	22	24.7	88.9	(55.7-134.6)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	17	13.0	130.5	(76.0-209.0)	Female	37	34.1	108.6	(76.4-149.6)
Female	3	10.7	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	506	417.9	121.1	(110.8-132.1)
Male	21	11.6	181.5	(112.3-277.4)	Female	489	500.6	97.7	(89.2-106.7)
Female	5	4.6	109.9	(35.4-256.4)					
<u>Lung and Bronchus</u>									
Male	67	58.7	114.2	(88.5-145.0)					
Female	89	72.9	122.1	(98.1-150.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Savoy

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	1.2	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	2	0.2	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	3	3.2	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	0	1.2	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	0	0.4	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	Female	1	0.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	1	3.6	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.0	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.1	nc	(nc-nc)
Male	2	0.7	nc	(nc-nc)	<u>Testis</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	0.2	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	1	0.0	nc	(nc-nc)	Female	2	0.6	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.5	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	7	15.0	46.8	(18.7-96.4)
Male	0	0.4	nc	(nc-nc)	Female	11	10.0	110.3	(55.0-197.4)
Female	0	0.1	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	2	2.1	nc	(nc-nc)					
Female	1	1.3	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Scituate

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	23	23.2	99.0	(62.8-148.6)	Male	46	14.6	315.9	(231.3-421.4)
Female	12	8.9	134.9	(69.6-235.7)	Female	27	12.0	225.1	(148.3-327.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	8	4.1	196.1	(84.4-386.5)	Male	7	4.7	149.0	(59.7-307.1)
Female	2	3.8	nc	(nc-nc)	Female	2	4.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.8	nc	(nc-nc)	Male	7	12.8	54.7	(21.9-112.7)
Female	95	98.7	96.3	(77.9-117.7)	Female	9	12.0	74.8	(34.1-141.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	3.1	nc	(nc-nc)	Male	9	10.6	84.8	(38.7-161.0)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	20	23.7	84.2	(51.4-130.1)	Female	9	8.4	106.8	(48.7-202.7)
Female	20	25.8	77.5	(47.3-119.7)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	7	8.5	82.5	(33.1-170.0)
Male	11	5.7	191.4	(95.4-342.4)	Female	1	9.4	nc	(nc-nc)
Female	4	1.7	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	59	67.3	87.7	(66.7-113.1)
Male	4	1.4	nc	(nc-nc)	<u>Stomach</u>				
Female	0	1.2	nc	(nc-nc)	Male	5	5.4	93.2	(30.0-217.6)
<u>Kidney & Renal Pelvis</u>					Female	6	3.6	165.6	(60.5-360.5)
Male	11	12.9	85.1	(42.4-152.2)	<u>Testis</u>				
Female	7	7.8	89.3	(35.8-183.9)	Male	2	2.4	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	3	3.3	nc	(nc-nc)	Male	2	5.5	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)	Female	16	17.2	93.3	(53.3-151.5)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	9	9.1	99.3	(45.3-188.4)	Female	23	21.9	104.9	(66.5-157.3)
Female	5	7.1	70.0	(22.5-163.3)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	301	287.4	104.7	(93.2-117.3)
Male	9	8.0	112.7	(51.4-214.0)	Female	316	329.1	96.0	(85.7-107.2)
Female	4	3.0	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	33	40.3	81.8	(56.3-114.9)					
Female	48	45.8	104.8	(77.3-138.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Seekonk

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	11	18.0	61.0	(30.4-109.2)	Male	7	11.6	60.2	(24.1-124.1)
Female	1	6.1	nc	(nc-nc)	Female	9	8.8	101.8	(46.5-193.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	3.3	nc	(nc-nc)	Male	2	3.8	nc	(nc-nc)
Female	1	2.9	nc	(nc-nc)	Female	1	2.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.6	nc	(nc-nc)	Male	14	10.1	138.3	(75.6-232.1)
Female	40	74.0	54.0	(38.6-73.6)	Female	4	8.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	2.4	nc	(nc-nc)	Male	4	8.8	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	14	18.5	75.6	(41.3-126.9)	Female	6	6.3	95.9	(35.0-208.8)
Female	9	17.2	52.3	(23.9-99.4)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	5	6.7	74.2	(23.9-173.1)
Male	0	4.7	nc	(nc-nc)	Female	8	6.2	128.0	(55.1-252.3)
Female	0	1.2	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	35	58.4	59.9	(41.7-83.3)
Male	0	1.2	nc	(nc-nc)	<u>Stomach</u>				
Female	0	1.0	nc	(nc-nc)	Male	3	4.3	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	2.4	nc	(nc-nc)
Male	4	10.7	nc	(nc-nc)	<u>Testis</u>				
Female	0	5.8	nc	(nc-nc)	Male	0	2.1	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	2.8	nc	(nc-nc)	Male	0	4.5	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	10	13.5	74.2	(35.5-136.5)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	7	7.0	99.8	(40.0-205.7)	Female	9	17.4	51.7	(23.6-98.2)
Female	2	4.9	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	153	234.3	65.3	(55.4-76.5)
Male	3	6.5	nc	(nc-nc)	Female	144	239.6	60.1	(50.7-70.8)
Female	0	2.1	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	23	33.1	69.5	(44.0-104.3)					
Female	26	33.1	78.5	(51.2-115.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Sharon

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	11	20.5	53.7	(26.8-96.2)	Male	13	13.5	96.1	(51.1-164.4)
Female	7	6.0	116.4	(46.6-239.8)	Female	17	9.6	176.2	(102.6-282.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	4.0	125.9	(40.6-293.9)	Male	3	4.4	nc	(nc-nc)
Female	0	3.1	nc	(nc-nc)	Female	1	3.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.8	nc	(nc-nc)	Male	12	11.9	100.7	(52.0-176.0)
Female	88	81.0	108.6	(87.1-133.8)	Female	7	9.0	78.2	(31.3-161.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	2.8	nc	(nc-nc)	Male	8	10.7	74.6	(32.1-147.0)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	11	22.4	49.2	(24.5-88.1)	Female	5	6.7	74.3	(23.9-173.3)
Female	12	18.3	65.5	(33.8-114.5)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	10	7.9	127.4	(61.0-234.2)
Male	3	5.5	nc	(nc-nc)	Female	9	6.3	143.1	(65.3-271.7)
Female	2	1.2	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	57	68.1	83.7	(63.4-108.4)
Male	1	1.3	nc	(nc-nc)	<u>Stomach</u>				
Female	1	1.2	nc	(nc-nc)	Male	6	5.0	121.0	(44.2-263.4)
<u>Kidney & Renal Pelvis</u>					Female	4	2.5	nc	(nc-nc)
Male	7	12.9	54.4	(21.8-112.1)	<u>Testis</u>				
Female	7	6.1	115.3	(46.2-237.5)	Male	4	2.4	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	3.2	nc	(nc-nc)	Male	8	5.6	142.5	(61.3-280.7)
Female	0	0.9	nc	(nc-nc)	Female	24	15.9	150.9	(96.7-224.6)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	8	8.3	96.4	(41.5-189.9)	Female	22	18.3	119.9	(75.1-181.6)
Female	4	5.2	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	213	273.3	77.9	(67.8-89.1)
Male	5	7.7	64.6	(20.8-150.7)	Female	275	254.6	108.0	(95.6-121.6)
Female	3	2.1	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	20	36.7	54.5	(33.3-84.1)					
Female	44	32.5	135.5	(98.4-181.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Sheffield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	5.8	86.0	(27.7-200.8)	Male	2	3.4	nc	(nc-nc)
Female	0	1.6	nc	(nc-nc)	Female	0	2.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.9	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	4	3.0	nc	(nc-nc)
Female	15	17.7	84.8	(47.4-139.9)	Female	1	2.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.5	nc	(nc-nc)	Male	6	2.4	246.0	(89.8-535.5)
<u>Colon / Rectum</u>					Female	3	1.0	nc	(nc-nc)
Male	5	5.7	87.7	(28.3-204.7)	<u>Ovary</u>				
Female	5	4.4	113.3	(36.5-264.3)	Female	0	1.5	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	1.4	nc	(nc-nc)	Male	0	2.1	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	1.7	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.3	nc	(nc-nc)	Male	16	16.7	95.9	(54.8-155.8)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	1.3	nc	(nc-nc)
Male	3	3.0	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.4	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.2	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
<u>Leukemia</u>					Female	1	2.8	nc	(nc-nc)
Male	0	2.1	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	1.2	nc	(nc-nc)	Female	5	4.3	117.4	(37.8-274.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	1.8	nc	(nc-nc)	Male	54	69.4	77.9	(58.5-101.6)
Female	0	0.6	nc	(nc-nc)	Female	56	59.1	94.7	(71.5-123.0)
<u>Lung and Bronchus</u>									
Male	6	10.2	59.1	(21.6-128.6)					
Female	13	8.6	150.7	(80.2-257.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Shelburne

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	3.0	nc	(nc-nc)	Male	2	1.9	nc	(nc-nc)
Female	2	1.1	nc	(nc-nc)	Female	2	1.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	0.5	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
Female	2	0.4	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.7	nc	(nc-nc)
Female	11	11.6	95.0	(47.3-169.9)	Female	2	1.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.3	nc	(nc-nc)	Male	3	1.5	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	3	3.1	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
Female	2	2.9	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	2	1.1	nc	(nc-nc)
Male	1	0.8	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	10	9.9	100.8	(48.2-185.3)
Male	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
Female	1	0.1	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.4	nc	(nc-nc)
Male	1	1.8	nc	(nc-nc)	<u>Testis</u>				
Female	1	0.9	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.5	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	1.9	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	1.1	nc	(nc-nc)	Female	5	2.8	176.3	(56.8-411.3)
Female	1	0.8	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	35	38.9	90.0	(62.7-125.2)
Male	1	1.1	nc	(nc-nc)	Female	38	38.9	97.6	(69.1-134.0)
Female	0	0.4	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	2	5.5	nc	(nc-nc)					
Female	4	5.8	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Sherborn

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	12	6.0	201.0	(103.7-351.1)	Male	6	3.7	163.4	(59.7-355.7)
Female	3	1.7	nc	(nc-nc)	Female	1	2.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.0	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	2	3.2	nc	(nc-nc)
Female	19	20.6	92.2	(55.5-144.1)	Female	5	2.4	210.9	(68.0-492.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.7	nc	(nc-nc)	Male	1	2.7	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	9	6.1	147.0	(67.1-279.1)	Female	5	1.8	283.5	(91.4-661.6)
Female	3	5.0	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	5	2.2	230.3	(74.2-537.5)
Male	0	1.5	nc	(nc-nc)	Female	4	1.8	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	9	17.3	51.9	(23.7-98.5)
Male	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.3	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.7	nc	(nc-nc)
Male	2	3.3	nc	(nc-nc)	<u>Testis</u>				
Female	0	1.6	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.8	nc	(nc-nc)	Male	2	1.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	2	3.7	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	2	2.3	nc	(nc-nc)	Female	3	4.6	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	62	73.1	84.8	(65.0-108.7)
Male	0	2.0	nc	(nc-nc)	Female	55	66.6	82.6	(62.2-107.5)
Female	0	0.6	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	6	10.3	58.3	(21.3-126.9)					
Female	4	9.0	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Shirley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	14	7.1	196.9	(107.5-330.3)	Male	4	5.3	nc	(nc-nc)
Female	7	2.3	303.2	(121.5-624.7)	Female	1	3.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.7	nc	(nc-nc)	Male	3	1.6	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	9	4.7	192.0	(87.6-364.5)
Female	27	28.2	95.7	(63.0-139.2)	Female	3	3.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.9	nc	(nc-nc)	Male	3	4.3	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	11	8.6	127.7	(63.7-228.5)	Female	3	2.4	nc	(nc-nc)
Female	8	6.6	121.8	(52.5-240.1)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	1	2.9	nc	(nc-nc)
Male	5	2.0	249.7	(80.5-582.8)	Female	2	2.4	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	26	24.7	105.2	(68.7-154.1)
Male	0	0.8	nc	(nc-nc)	<u>Stomach</u>				
Female	1	0.4	nc	(nc-nc)	Male	0	1.8	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.9	nc	(nc-nc)
Male	6	5.1	117.5	(42.9-255.7)	<u>Testis</u>				
Female	3	2.2	nc	(nc-nc)	Male	1	1.9	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	1.2	nc	(nc-nc)	Male	2	2.7	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	5	5.2	95.5	(30.8-222.9)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	4	3.2	nc	(nc-nc)	Female	12	6.5	183.8	(94.9-321.0)
Female	1	1.8	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	115	104.0	110.6	(91.3-132.7)
Male	6	3.0	197.2	(72.0-429.2)	Female	98	91.2	107.5	(87.2-131.0)
Female	0	0.8	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	13	13.1	99.2	(52.8-169.7)					
Female	10	12.7	78.9	(37.8-145.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Shrewsbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	44	36.9	119.2	(86.6-160.0)	Male	19	23.9	79.5	(47.8-124.2)
Female	12	13.0	92.4	(47.7-161.4)	Female	21	19.0	110.8	(68.6-169.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	7.2	nc	(nc-nc)	Male	9	7.6	118.0	(53.9-224.1)
Female	2	6.3	nc	(nc-nc)	Female	7	6.0	116.1	(46.5-239.3)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	1.3	nc	(nc-nc)	Male	19	21.3	89.3	(53.7-139.4)
Female	175	152.8	114.5	(98.2-132.8)	Female	13	18.2	71.4	(38.0-122.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	7	5.4	130.2	(52.2-268.4)	Male	16	17.6	90.7	(51.8-147.4)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	42	39.5	106.4	(76.7-143.9)	Female	13	12.9	101.1	(53.8-172.9)
Female	30	38.0	78.9	(53.2-112.6)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	6	9.3	64.8	(23.7-141.0)	Male	113	108.2	104.5	(86.1-125.6)
Female	5	2.5	197.5	(63.6-460.9)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	2	2.8	nc	(nc-nc)	Male	4	5.4	nc	(nc-nc)
Female	2	2.4	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Thyroid</u>				
Male	29	21.5	134.7	(90.2-193.5)	Male	15	10.0	149.7	(83.7-247.0)
Female	8	12.0	66.7	(28.7-131.5)	Female	27	30.0	90.0	(59.3-130.9)
<u>Larynx</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	5	5.4	93.3	(30.1-217.8)	Female	29	33.1	87.7	(58.7-126.0)
Female	0	1.6	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Leukemia</u>					<u>All Sites / Types</u>				
Male	19	15.1	125.9	(75.8-196.6)	Male	479	469.9	101.9	(93.0-111.5)
Female	13	10.8	120.2	(64.0-205.6)	Female	501	503.0	99.6	(91.1-108.7)
<u>Liver and Intrahepatic Bile Ducts</u>									
Male	17	12.9	132.3	(77.0-211.8)					
Female	4	4.3	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	55	63.7	86.4	(65.0-112.4)					
Female	65	68.6	94.8	(73.2-120.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Shutesbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	1.8	nc	(nc-nc)	Male	2	1.3	nc	(nc-nc)
Female	2	0.6	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	7	9.0	77.8	(31.2-160.4)	Female	1	1.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.3	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	0	2.1	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
Female	2	1.9	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	3	0.7	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	1	7.3	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.3	nc	(nc-nc)
Male	0	1.3	nc	(nc-nc)	<u>Testis</u>				
Female	0	0.7	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.3	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	2	1.7	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	0.8	nc	(nc-nc)	Female	3	2.2	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	11	26.7	41.2	(20.6-73.8)
Male	1	0.8	nc	(nc-nc)	Female	22	27.8	79.2	(49.6-119.9)
Female	0	0.3	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	0	3.4	nc	(nc-nc)					
Female	2	3.6	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Somerset

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	36	28.3	127.2	(89.1-176.1)	Male	12	16.9	71.1	(36.7-124.2)
Female	11	9.5	116.0	(57.8-207.5)	Female	8	11.7	68.3	(29.4-134.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	4.6	130.7	(47.7-284.5)	Male	1	5.5	nc	(nc-nc)
Female	4	3.7	nc	(nc-nc)	Female	6	4.3	141.2	(51.5-307.3)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.9	nc	(nc-nc)	Male	15	14.9	100.7	(56.3-166.0)
Female	79	94.3	83.7	(66.3-104.4)	Female	18	12.3	146.0	(86.5-230.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	2.9	nc	(nc-nc)	Male	10	11.6	85.9	(41.1-157.9)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	27	27.5	98.1	(64.7-142.8)	Female	9	8.2	109.7	(50.1-208.3)
Female	30	26.2	114.7	(77.4-163.8)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	12	10.0	120.0	(61.9-209.6)
Male	8	6.7	120.1	(51.7-236.7)	Female	12	9.9	121.3	(62.6-211.9)
Female	1	1.8	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	72	77.5	93.0	(72.7-117.1)
Male	3	1.6	nc	(nc-nc)	<u>Stomach</u>				
Female	0	1.3	nc	(nc-nc)	Male	11	6.3	173.9	(86.7-311.1)
<u>Kidney & Renal Pelvis</u>					Female	6	3.7	163.1	(59.6-355.1)
Male	12	14.4	83.1	(42.9-145.2)	<u>Testis</u>				
Female	5	7.8	64.0	(20.6-149.5)	Male	5	2.7	186.1	(60.0-434.4)
<u>Larynx</u>					<u>Thyroid</u>				
Male	5	3.8	131.9	(42.5-307.8)	Male	6	5.8	104.1	(38.0-226.6)
Female	1	1.1	nc	(nc-nc)	Female	22	15.5	141.8	(88.9-214.8)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	11	10.6	103.9	(51.8-185.9)	Female	22	21.2	103.7	(65.0-157.0)
Female	9	7.1	126.3	(57.6-239.8)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	334	334.3	99.9	(89.5-111.2)
Male	6	8.9	67.3	(24.6-146.5)	Female	321	327.2	98.1	(87.7-109.4)
Female	1	3.0	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	48	48.4	99.2	(73.1-131.5)					
Female	46	49.1	93.6	(68.5-124.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Somerville

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	33	50.5	65.4	(45.0-91.8)	Male	29	34.5	84.1	(56.3-120.7)
Female	17	19.8	85.8	(49.9-137.4)	Female	26	31.2	83.4	(54.5-122.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	9	12.5	72.1	(32.9-137.0)	Male	8	10.5	76.5	(32.9-150.8)
Female	14	10.8	129.3	(70.6-216.9)	Female	10	9.2	108.8	(52.1-200.1)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.8	nc	(nc-nc)	Male	36	31.7	113.6	(79.5-157.2)
Female	195	222.1	87.8	(75.9-101.0)	Female	26	28.3	91.8	(59.9-134.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	12	8.3	144.7	(74.7-252.7)	Male	21	24.7	85.0	(52.6-130.0)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	52	54.7	95.1	(71.0-124.7)	Female	23	20.0	115.0	(72.9-172.6)
Female	45	57.1	78.9	(57.5-105.5)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	16	18.7	85.6	(48.9-139.0)
Male	11	12.7	86.7	(43.2-155.1)	Female	24	20.5	116.9	(74.9-173.9)
Female	2	3.8	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	137	148.6	92.2	(77.4-109.0)
Male	8	7.7	104.4	(45.0-205.8)	<u>Stomach</u>				
Female	5	6.7	74.3	(23.9-173.4)	Male	15	12.0	124.8	(69.8-205.9)
<u>Kidney & Renal Pelvis</u>					Female	13	8.1	160.6	(85.4-274.6)
Male	30	30.3	99.2	(66.9-141.6)	<u>Testis</u>				
Female	21	18.1	116.3	(71.9-177.7)	Male	14	16.4	85.2	(46.5-142.9)
<u>Larynx</u>					<u>Thyroid</u>				
Male	6	7.4	80.8	(29.5-175.9)	Male	20	17.2	116.2	(70.9-179.4)
Female	4	2.4	nc	(nc-nc)	Female	43	53.1	81.0	(58.6-109.1)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	20	23.4	85.6	(52.3-132.2)	Female	56	50.1	111.8	(84.5-145.2)
Female	17	17.8	95.4	(55.6-152.8)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	648	676.0	95.9	(88.6-103.5)
Male	22	17.9	122.7	(76.8-185.7)	Female	751	771.6	97.3	(90.5-104.5)
Female	12	6.7	179.2	(92.5-313.1)					
<u>Lung and Bronchus</u>									
Male	117	87.2	134.1	(110.9-160.7)					
Female	105	103.6	101.4	(82.9-122.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

South Hadley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	13	20.5	63.5	(33.8-108.7)	Male	10	12.7	78.8	(37.7-144.9)
Female	11	8.3	132.1	(65.8-236.3)	Female	11	10.6	104.0	(51.8-186.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	3.5	nc	(nc-nc)	Male	2	4.1	nc	(nc-nc)
Female	3	3.7	nc	(nc-nc)	Female	3	3.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.7	nc	(nc-nc)	Male	7	11.2	62.4	(25.0-128.6)
Female	91	85.0	107.1	(86.2-131.5)	Female	13	11.0	118.6	(63.1-202.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	2.6	nc	(nc-nc)	Male	5	9.1	54.9	(17.7-128.2)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	17	20.6	82.6	(48.1-132.3)	Female	8	7.5	106.6	(45.9-210.1)
Female	32	23.1	138.5	(94.8-195.6)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	2	7.5	nc	(nc-nc)
Male	4	5.0	nc	(nc-nc)	Female	11	8.7	126.9	(63.2-227.0)
Female	2	1.6	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	50	59.2	84.5	(62.7-111.4)
Male	2	1.3	nc	(nc-nc)	<u>Stomach</u>				
Female	0	1.4	nc	(nc-nc)	Male	4	4.7	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	3.2	nc	(nc-nc)
Male	8	11.1	72.3	(31.1-142.4)	<u>Testis</u>				
Female	6	7.0	85.3	(31.2-185.7)	Male	3	2.3	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	4	2.9	nc	(nc-nc)	Male	3	4.7	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	Female	16	14.5	110.3	(63.0-179.1)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	7	7.8	89.6	(35.9-184.6)	Female	27	19.4	139.0	(91.6-202.2)
Female	8	6.6	122.1	(52.6-240.6)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	194	251.3	77.2	(66.7-88.9)
Male	2	7.0	nc	(nc-nc)	Female	304	294.1	103.4	(92.1-115.7)
Female	0	2.7	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	25	35.3	70.8	(45.8-104.5)					
Female	36	43.1	83.5	(58.5-115.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Southampton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	7	8.7	80.8	(32.4-166.6)	Male	1	5.2	nc	(nc-nc)
Female	2	2.4	nc	(nc-nc)	Female	1	3.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.4	nc	(nc-nc)	Male	0	1.7	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)	Female	2	1.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	2	4.7	nc	(nc-nc)
Female	30	30.3	99.0	(66.8-141.3)	Female	3	3.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.0	nc	(nc-nc)	Male	4	3.8	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	9	8.7	103.4	(47.2-196.3)	Female	1	2.5	nc	(nc-nc)
Female	7	6.6	105.4	(42.2-217.2)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	1	3.1	nc	(nc-nc)
Male	4	2.2	nc	(nc-nc)	Female	3	2.5	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	21	25.8	81.5	(50.4-124.6)
Male	2	0.5	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.4	nc	(nc-nc)	Male	4	2.0	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	1.0	nc	(nc-nc)
Male	2	4.6	nc	(nc-nc)	<u>Testis</u>				
Female	4	2.3	nc	(nc-nc)	Male	2	0.8	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	3	1.2	nc	(nc-nc)	Male	2	1.9	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	5.5	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	3.3	nc	(nc-nc)	Female	9	7.2	124.4	(56.8-236.2)
Female	2	1.9	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	83	106.0	78.3	(62.3-97.0)
Male	5	2.9	171.7	(55.3-400.7)	Female	86	96.7	88.9	(71.1-109.8)
Female	1	0.8	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	10	14.7	68.1	(32.6-125.3)					
Female	13	13.4	97.2	(51.7-166.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Southborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	7	9.9	70.4	(28.2-145.0)	Male	8	6.9	116.6	(50.2-229.7)
Female	6	3.5	172.7	(63.1-376.0)	Female	4	5.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	2.1	nc	(nc-nc)	Male	4	2.2	nc	(nc-nc)
Female	2	1.7	nc	(nc-nc)	Female	1	1.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	2	6.0	nc	(nc-nc)
Female	50	43.4	115.3	(85.5-152.0)	Female	4	4.9	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.5	nc	(nc-nc)	Male	3	5.5	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	7	11.3	62.1	(24.9-128.0)	Female	1	3.7	nc	(nc-nc)
Female	7	10.4	67.6	(27.1-139.2)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	1	3.9	nc	(nc-nc)
Male	3	2.7	nc	(nc-nc)	Female	3	3.6	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	27	33.1	81.7	(53.8-118.8)
Male	3	0.8	nc	(nc-nc)	<u>Stomach</u>				
Female	1	0.6	nc	(nc-nc)	Male	0	2.5	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	1.4	nc	(nc-nc)
Male	7	6.5	107.6	(43.1-221.7)	<u>Testis</u>				
Female	2	3.4	nc	(nc-nc)	Male	3	1.4	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	3	1.6	nc	(nc-nc)	Male	4	3.1	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	9	8.4	106.9	(48.8-202.9)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	4	4.2	nc	(nc-nc)	Female	7	9.5	73.8	(29.6-152.2)
Female	4	2.9	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	118	136.1	86.7	(71.8-103.8)
Male	3	3.9	nc	(nc-nc)	Female	126	139.7	90.2	(75.1-107.4)
Female	1	1.2	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	12	17.9	67.2	(34.7-117.3)					
Female	13	18.8	69.2	(36.8-118.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Southbridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	13	17.5	74.2	(39.5-126.9)	Male	11	11.0	99.7	(49.7-178.5)
Female	7	7.2	96.9	(38.8-199.7)	Female	3	9.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	3.3	nc	(nc-nc)	Male	4	3.5	nc	(nc-nc)
Female	2	3.2	nc	(nc-nc)	Female	6	3.3	180.8	(66.0-393.4)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.6	nc	(nc-nc)	Male	13	9.9	131.9	(70.2-225.5)
Female	57	76.8	74.2	(56.2-96.1)	Female	12	9.7	123.7	(63.8-216.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	2.5	nc	(nc-nc)	Male	8	7.9	101.9	(43.9-200.8)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	18	18.1	99.5	(58.9-157.3)	Female	14	6.7	209.8	(114.6-352.0)
Female	21	20.5	102.2	(63.2-156.2)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	6	6.3	94.5	(34.5-205.7)
Male	2	4.2	nc	(nc-nc)	Female	1	7.6	nc	(nc-nc)
Female	0	1.4	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	50	48.5	103.0	(76.5-135.9)
Male	1	1.3	nc	(nc-nc)	<u>Stomach</u>				
Female	4	1.1	nc	(nc-nc)	Male	8	4.0	198.2	(85.3-390.5)
<u>Kidney & Renal Pelvis</u>					Female	3	2.9	nc	(nc-nc)
Male	10	9.6	104.0	(49.8-191.2)	<u>Testis</u>				
Female	8	6.2	128.8	(55.4-253.7)	Male	1	2.5	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	7	2.4	288.2	(115.4-593.8)	Male	2	4.4	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	Female	13	13.8	94.3	(50.1-161.2)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	9	7.1	126.5	(57.7-240.2)	Female	22	17.5	125.8	(78.8-190.4)
Female	10	5.8	171.9	(82.3-316.2)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	240	215.9	111.2	(97.6-126.2)
Male	8	5.9	136.2	(58.6-268.4)	Female	241	262.3	91.9	(80.6-104.2)
Female	2	2.4	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	45	29.7	151.7	(110.6-202.9)					
Female	31	36.9	84.0	(57.1-119.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Southwick

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	9	12.7	70.6	(32.2-134.0)	Male	5	7.8	64.1	(20.7-149.7)
Female	4	4.3	nc	(nc-nc)	Female	3	5.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	2.2	nc	(nc-nc)	Male	1	2.5	nc	(nc-nc)
Female	1	1.9	nc	(nc-nc)	Female	0	2.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	3	6.9	nc	(nc-nc)
Female	44	45.6	96.5	(70.1-129.6)	Female	4	5.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.5	nc	(nc-nc)	Male	6	5.5	109.4	(39.9-238.1)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	11	13.1	83.9	(41.8-150.1)	Female	4	3.9	nc	(nc-nc)
Female	14	12.5	112.1	(61.3-188.2)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	2	3.0	nc	(nc-nc)	Male	2	4.5	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	2	4.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.8	nc	(nc-nc)	Male	29	34.4	84.3	(56.4-121.0)
Female	1	0.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	8	6.7	119.1	(51.3-234.7)	Male	1	2.9	nc	(nc-nc)
Female	7	3.7	191.2	(76.6-393.9)	Female	2	1.8	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	2	1.7	nc	(nc-nc)	Male	2	1.5	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	2	4.9	nc	(nc-nc)	Male	3	3.0	nc	(nc-nc)
Female	6	3.5	173.6	(63.4-377.9)	Female	5	8.1	61.7	(19.9-144.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	3	4.1	nc	(nc-nc)	Female	9	9.8	91.6	(41.8-173.9)
Female	3	1.4	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	18	21.1	85.3	(50.5-134.8)	Male	120	152.6	78.7	(65.2-94.0)
Female	16	21.8	73.4	(41.9-119.2)	Female	133	155.1	85.8	(71.8-101.6)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Spencer

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	19	13.1	145.1	(87.3-226.6)	Male	14	8.6	162.3	(88.6-272.3)
Female	10	4.4	226.3	(108.4-416.3)	Female	8	6.4	124.5	(53.6-245.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	2.6	nc	(nc-nc)	Male	1	2.8	nc	(nc-nc)
Female	2	2.1	nc	(nc-nc)	Female	6	2.1	282.6	(103.2-615.2)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.5	nc	(nc-nc)	Male	7	7.6	91.9	(36.8-189.4)
Female	42	52.9	79.4	(57.2-107.4)	Female	7	6.3	111.9	(44.8-230.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	1.7	nc	(nc-nc)	Male	9	6.7	135.1	(61.7-256.6)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	9	13.7	65.8	(30.0-124.9)	Female	2	4.4	nc	(nc-nc)
Female	12	12.4	96.6	(49.9-168.7)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	4	3.5	nc	(nc-nc)	Male	36	43.8	82.1	(57.5-113.7)
Female	2	0.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	2	1.0	nc	(nc-nc)	Male	1	1.9	nc	(nc-nc)
Female	2	0.8	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Thyroid</u>				
Male	10	8.0	125.0	(59.8-229.9)	Male	5	3.6	139.9	(45.1-326.5)
Female	6	4.2	144.2	(52.7-314.0)	Female	10	9.9	101.4	(48.5-186.5)
<u>Larynx</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	3	2.1	nc	(nc-nc)	Female	15	12.3	122.0	(68.2-201.3)
Female	0	0.6	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Leukemia</u>					<u>All Sites / Types</u>				
Male	10	5.4	186.4	(89.2-342.8)	Male	191	174.9	109.2	(94.3-125.9)
Female	5	3.7	135.7	(43.7-316.8)	Female	189	173.0	109.3	(94.2-126.0)
<u>Liver and Intrahepatic Bile Ducts</u>									
Male	5	5.0	99.5	(32.1-232.1)					
Female	1	1.5	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	32	23.8	134.7	(92.1-190.2)					
Female	35	23.8	147.1	(102.4-204.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Springfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	94	124.8	75.3	(60.9-92.2)	Male	27	82.8	32.6	(21.5-47.5)
Female	36	48.7	73.9	(51.7-102.3)	Female	26	73.5	35.4	(23.1-51.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	26	27.1	95.8	(62.6-140.4)	Male	22	26.5	83.1	(52.1-125.9)
Female	22	25.3	87.1	(54.5-131.8)	Female	30	23.2	129.5	(87.3-184.8)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	4	4.5	nc	(nc-nc)	Male	73	74.0	98.6	(77.3-124.0)
Female	526	586.6	89.7	(82.2-97.7)	Female	74	69.6	106.3	(83.4-133.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	37	20.2	183.6	(129.2-253.0)	Male	73	62.7	116.4	(91.2-146.3)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	149	134.5	110.8	(93.7-130.0)	Female	41	50.2	81.6	(58.6-110.7)
Female	156	142.6	109.4	(92.9-128.0)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	48	46.9	102.4	(75.5-135.7)
Male	30	32.5	92.4	(62.3-131.9)	Female	49	50.7	96.6	(71.5-127.8)
Female	8	9.6	83.0	(35.7-163.5)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	310	385.0	80.5	(71.8-90.0)
Male	12	11.3	105.9	(54.7-185.0)	<u>Stomach</u>				
Female	14	10.6	131.7	(71.9-220.9)	Male	38	29.9	127.3	(90.1-174.7)
<u>Kidney & Renal Pelvis</u>					Female	20	20.1	99.6	(60.8-153.8)
Male	92	76.1	120.9	(97.5-148.3)	<u>Testis</u>				
Female	51	46.1	110.7	(82.4-145.6)	Male	12	21.6	55.6	(28.7-97.1)
<u>Larynx</u>					<u>Thyroid</u>				
Male	19	18.8	100.8	(60.7-157.4)	Male	15	36.1	41.6	(23.3-68.6)
Female	9	6.3	143.8	(65.6-273.0)	Female	79	117.6	67.2	(53.2-83.7)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	47	54.2	86.7	(63.7-115.2)	Female	125	131.2	95.3	(79.3-113.6)
Female	36	42.5	84.6	(59.3-117.1)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	1524	1645.7	92.6	(88.0-97.4)
Male	59	45.5	129.7	(98.7-167.3)	Female	1786	1931.8	92.5	(88.2-96.8)
Female	17	16.7	101.6	(59.2-162.7)					
<u>Lung and Bronchus</u>									
Male	244	219.8	111.0	(97.5-125.9)					
Female	247	258.2	95.7	(84.1-108.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Sterling

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	12	7.0	170.9	(88.2-298.6)	Male	6	4.8	124.4	(45.4-270.8)
Female	3	3.0	nc	(nc-nc)	Female	3	4.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.5	nc	(nc-nc)	Male	4	1.5	nc	(nc-nc)
Female	0	1.5	nc	(nc-nc)	Female	0	1.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	7	4.3	162.9	(65.3-335.7)
Female	45	37.1	121.2	(88.4-162.2)	Female	1	4.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.3	nc	(nc-nc)	Male	1	4.0	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	7	8.2	85.9	(34.4-177.0)	Female	2	3.1	nc	(nc-nc)
Female	3	9.2	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	4	2.7	nc	(nc-nc)
Male	2	1.9	nc	(nc-nc)	Female	5	3.2	153.9	(49.6-359.1)
Female	1	0.6	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	38	25.0	152.0	(107.5-208.6)
Male	0	0.6	nc	(nc-nc)	<u>Stomach</u>				
Female	2	0.5	nc	(nc-nc)	Male	2	1.7	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	1.3	nc	(nc-nc)
Male	10	4.8	209.5	(100.3-385.4)	<u>Testis</u>				
Female	5	2.9	175.2	(56.5-408.9)	Male	1	1.1	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	1.1	nc	(nc-nc)	Male	2	2.2	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	8	7.3	110.1	(47.4-216.9)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	6	3.0	197.1	(72.0-429.1)	Female	8	8.1	98.9	(42.6-194.8)
Female	2	2.6	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	126	98.6	127.8	(106.5-152.2)
Male	1	2.8	nc	(nc-nc)	Female	119	120.8	98.5	(81.6-117.9)
Female	0	1.0	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	10	12.6	79.1	(37.9-145.4)					
Female	17	15.8	107.8	(62.7-172.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Stockbridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	3.7	nc	(nc-nc)	Male	6	2.2	268.2	(97.9-583.8)
Female	0	1.4	nc	(nc-nc)	Female	5	1.6	305.3	(98.4-712.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.6	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	3	2.0	nc	(nc-nc)
Female	11	13.6	80.8	(40.3-144.5)	Female	4	1.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.4	nc	(nc-nc)	Male	2	1.5	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	5	3.6	137.7	(44.4-321.4)	Female	2	1.2	nc	(nc-nc)
Female	6	3.8	157.9	(57.7-343.8)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	1	1.3	nc	(nc-nc)
Male	2	0.9	nc	(nc-nc)	Female	3	1.5	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	10	9.9	100.6	(48.2-185.0)
Male	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.2	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.5	nc	(nc-nc)
Male	2	1.9	nc	(nc-nc)	<u>Testis</u>				
Female	2	1.2	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.5	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	1.9	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	3	1.3	nc	(nc-nc)	Female	6	3.2	187.1	(68.3-407.3)
Female	0	1.0	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	43	43.6	98.6	(71.3-132.8)
Male	0	1.2	nc	(nc-nc)	Female	51	48.0	106.3	(79.1-139.8)
Female	0	0.4	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	1	6.5	nc	(nc-nc)					
Female	4	7.7	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Stoneham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	32	30.0	106.5	(72.8-150.3)	Male	11	18.0	61.0	(30.4-109.2)
Female	10	9.9	100.6	(48.1-184.9)	Female	13	13.5	96.2	(51.2-164.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	7	4.9	141.6	(56.7-291.8)	Male	9	5.8	154.9	(70.7-294.1)
Female	5	4.3	115.0	(37.1-268.3)	Female	9	4.6	194.1	(88.6-368.4)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.0	nc	(nc-nc)	Male	12	15.9	75.6	(39.0-132.1)
Female	125	108.7	115.0	(95.7-137.0)	Female	13	13.5	96.2	(51.2-164.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	3.4	nc	(nc-nc)	Male	19	12.5	152.1	(91.5-237.5)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	32	29.7	107.8	(73.7-152.1)	Female	14	9.5	147.6	(80.6-247.6)
Female	28	28.2	99.2	(65.9-143.4)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	8	10.6	75.4	(32.5-148.6)
Male	3	7.1	nc	(nc-nc)	Female	15	10.4	144.5	(80.8-238.3)
Female	1	1.9	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	55	81.8	67.2	(50.6-87.5)
Male	3	1.8	nc	(nc-nc)	<u>Stomach</u>				
Female	0	1.6	nc	(nc-nc)	Male	10	6.8	148.1	(70.9-272.5)
<u>Kidney & Renal Pelvis</u>					Female	5	4.0	125.4	(40.4-292.7)
Male	10	15.4	64.9	(31.1-119.3)	<u>Testis</u>				
Female	12	8.8	136.8	(70.6-239.0)	Male	5	3.2	156.1	(50.3-364.3)
<u>Larynx</u>					<u>Thyroid</u>				
Male	5	4.0	124.5	(40.1-290.4)	Male	6	6.3	94.6	(34.5-205.9)
Female	4	1.3	nc	(nc-nc)	Female	30	19.4	154.8	(104.4-221.0)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	13	11.3	115.2	(61.3-197.1)	Female	35	25.2	138.9	(96.7-193.2)
Female	9	7.9	113.4	(51.7-215.2)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	327	356.0	91.9	(82.2-102.4)
Male	9	9.5	94.5	(43.1-179.3)	Female	425	367.0	115.8	(105.1-127.4)
Female	8	3.3	239.4	(103.1-471.7)					
<u>Lung and Bronchus</u>									
Male	42	50.9	82.5	(59.5-111.6)					
Female	55	51.8	106.3	(80.0-138.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Stoughton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	33	35.7	92.4	(63.6-129.8)	Male	15	21.7	69.0	(38.6-113.9)
Female	14	12.8	109.0	(59.5-182.9)	Female	21	17.5	120.3	(74.4-183.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	6.1	81.5	(26.3-190.1)	Male	10	7.0	141.9	(67.9-261.0)
Female	6	5.6	107.1	(39.1-233.1)	Female	7	6.0	116.8	(46.8-240.7)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.2	nc	(nc-nc)	Male	13	19.3	67.3	(35.8-115.1)
Female	142	141.4	100.4	(84.6-118.4)	Female	24	17.5	137.1	(87.8-204.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	4.5	nc	(nc-nc)	Male	11	15.5	70.7	(35.3-126.6)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	35	35.7	98.2	(68.4-136.5)	Female	12	12.2	98.6	(50.9-172.3)
Female	42	36.4	115.5	(83.2-156.1)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	11	8.7	126.6	(63.1-226.6)	Male	91	103.0	88.4	(71.2-108.5)
Female	3	2.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	2	2.3	nc	(nc-nc)	Male	6	4.0	151.4	(55.3-329.6)
Female	6	2.0	297.7	(108.7-647.9)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	26	18.9	137.4	(89.7-201.4)	Female	25	32.8	76.3	(49.4-112.6)
Female	16	11.3	141.2	(80.7-229.3)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Leukemia</u>				
Male	9	5.0	180.9	(82.5-343.4)	Male	13	13.7	94.7	(50.4-161.9)
Female	3	1.6	nc	(nc-nc)	Female	10	10.2	97.6	(46.7-179.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Lung and Bronchus</u>				
Male	14	11.9	117.9	(64.4-197.8)	Male	65	60.7	107.1	(82.7-136.5)
Female	2	4.3	nc	(nc-nc)	Female	55	66.9	82.2	(61.9-106.9)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Stow

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	12	8.1	147.3	(76.0-257.3)	Male	5	5.2	96.0	(30.9-224.1)
Female	2	2.5	nc	(nc-nc)	Female	3	3.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.5	nc	(nc-nc)	Male	1	1.7	nc	(nc-nc)
Female	0	1.3	nc	(nc-nc)	Female	3	1.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	4	4.6	nc	(nc-nc)
Female	30	34.2	87.8	(59.2-125.3)	Female	4	3.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.1	nc	(nc-nc)	Male	0	4.0	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	14	8.8	159.0	(86.8-266.7)	Female	5	2.8	178.0	(57.3-415.3)
Female	9	7.3	123.7	(56.5-234.9)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	3	3.0	nc	(nc-nc)
Male	3	2.1	nc	(nc-nc)	Female	2	2.6	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	22	25.3	86.8	(54.4-131.4)
Male	0	0.5	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.5	nc	(nc-nc)	Male	1	1.9	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	1.0	nc	(nc-nc)
Male	5	4.8	103.4	(33.3-241.3)	<u>Testis</u>				
Female	1	2.6	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	1.2	nc	(nc-nc)	Male	4	2.1	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	8	6.4	125.9	(54.2-248.1)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	2	3.3	nc	(nc-nc)	Female	8	7.9	101.0	(43.5-199.0)
Female	2	2.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	98	104.6	93.7	(76.0-114.2)
Male	0	2.9	nc	(nc-nc)	Female	101	106.4	94.9	(77.3-115.3)
Female	0	0.9	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	8	13.9	57.7	(24.8-113.6)					
Female	8	14.2	56.4	(24.3-111.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Sturbridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	13	9.9	131.2	(69.8-224.4)	Male	8	6.6	121.4	(52.3-239.1)
Female	5	3.7	135.9	(43.8-317.1)	Female	8	5.3	149.7	(64.5-295.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	2.0	nc	(nc-nc)	Male	5	2.1	238.0	(76.7-555.5)
Female	2	1.7	nc	(nc-nc)	Female	2	1.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	7	5.8	120.8	(48.4-249.0)
Female	35	43.6	80.3	(55.9-111.6)	Female	3	5.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.5	nc	(nc-nc)	Male	4	5.1	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	9	10.8	83.7	(38.2-158.9)	Female	1	3.7	nc	(nc-nc)
Female	11	10.8	101.7	(50.7-181.9)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	6	3.8	159.0	(58.0-346.0)
Male	6	2.6	229.3	(83.7-499.1)	Female	8	3.9	204.5	(88.1-403.0)
Female	0	0.7	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	28	32.1	87.4	(58.0-126.3)
Male	3	0.7	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.6	nc	(nc-nc)	Male	1	2.4	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	1.5	nc	(nc-nc)
Male	7	6.1	114.4	(45.8-235.7)	<u>Testis</u>				
Female	3	3.4	nc	(nc-nc)	Male	2	1.4	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	1.5	nc	(nc-nc)	Male	0	2.8	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	7	8.4	83.2	(33.3-171.3)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	5	4.1	122.8	(39.6-286.5)	Female	17	9.7	175.6	(102.2-281.2)
Female	2	3.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	142	131.6	107.9	(90.9-127.2)
Male	0	3.8	nc	(nc-nc)	Female	133	143.3	92.8	(77.7-110.0)
Female	1	1.2	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	24	17.6	136.0	(87.1-202.3)					
Female	11	19.4	56.7	(28.3-101.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Sudbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	13	19.8	65.6	(34.9-112.2)	Male	19	13.3	142.8	(85.9-223.0)
Female	1	6.4	nc	(nc-nc)	Female	11	10.0	110.2	(54.9-197.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	7	4.0	176.6	(70.8-363.9)	Male	4	4.3	nc	(nc-nc)
Female	5	3.2	154.9	(49.9-361.5)	Female	3	3.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.7	nc	(nc-nc)	Male	6	11.7	51.2	(18.7-111.5)
Female	114	83.9	135.9	(112.1-163.2)	Female	12	9.5	126.8	(65.4-221.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	2.9	nc	(nc-nc)	Male	3	10.6	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	24	21.9	109.5	(70.1-163.0)	Female	7	7.0	100.6	(40.3-207.3)
Female	14	19.3	72.6	(39.6-121.7)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	10	7.7	130.5	(62.5-239.9)
Male	2	5.3	nc	(nc-nc)	Female	5	6.6	75.3	(24.3-175.8)
Female	2	1.3	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	68	66.5	102.3	(79.4-129.7)
Male	1	1.3	nc	(nc-nc)	<u>Stomach</u>				
Female	2	1.1	nc	(nc-nc)	Male	3	4.8	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	3	2.7	nc	(nc-nc)
Male	12	12.7	94.4	(48.7-164.8)	<u>Testis</u>				
Female	8	6.4	125.9	(54.2-248.0)	Male	1	2.4	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	3.2	nc	(nc-nc)	Male	7	5.7	123.7	(49.6-254.8)
Female	0	0.9	nc	(nc-nc)	Female	18	16.1	111.7	(66.2-176.6)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	7	8.2	85.8	(34.4-176.7)	Female	16	18.7	85.4	(48.8-138.7)
Female	5	5.4	92.6	(29.8-216.0)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	226	267.6	84.5	(73.8-96.2)
Male	5	7.6	65.6	(21.1-153.1)	Female	285	265.3	107.4	(95.3-120.6)
Female	0	2.3	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	14	35.8	39.1	(21.4-65.7)					
Female	26	34.5	75.3	(49.2-110.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Sunderland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	2.6	nc	(nc-nc)	Male	1	1.7	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	Female	0	1.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.6	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
Female	17	9.9	171.3	(99.7-274.3)	Female	0	1.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.4	nc	(nc-nc)	Male	2	1.4	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	1	2.9	nc	(nc-nc)	Female	2	0.9	nc	(nc-nc)
Female	3	2.6	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	1	1.0	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	9	8.8	102.7	(46.8-194.9)
Male	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.3	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.4	nc	(nc-nc)
Male	1	1.6	nc	(nc-nc)	<u>Testis</u>				
Female	0	0.8	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	0.4	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	2.1	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	2	1.2	nc	(nc-nc)	Female	5	2.2	227.3	(73.2-530.4)
Female	0	0.8	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	29	36.0	80.6	(54.0-115.8)
Male	0	1.1	nc	(nc-nc)	Female	37	34.2	108.1	(76.1-149.1)
Female	0	0.3	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	4	4.4	nc	(nc-nc)					
Female	2	4.6	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Sutton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	11	10.9	101.3	(50.5-181.3)	Male	9	6.9	129.5	(59.1-245.8)
Female	3	2.8	nc	(nc-nc)	Female	7	4.6	150.6	(60.3-310.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	2.0	nc	(nc-nc)	Male	1	2.2	nc	(nc-nc)
Female	1	1.5	nc	(nc-nc)	Female	3	1.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	9	6.2	145.7	(66.5-276.6)
Female	38	38.3	99.2	(70.2-136.1)	Female	3	4.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.4	nc	(nc-nc)	Male	2	5.3	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	3	11.5	nc	(nc-nc)	Female	1	3.2	nc	(nc-nc)
Female	10	8.6	115.9	(55.5-213.1)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	2	2.8	nc	(nc-nc)	Male	1	4.0	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	0	3.0	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.7	nc	(nc-nc)	Male	33	33.3	99.1	(68.2-139.2)
Female	0	0.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	7	6.4	109.2	(43.7-225.0)	Male	2	2.6	nc	(nc-nc)
Female	6	2.9	209.7	(76.6-456.4)	Female	1	1.2	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	1	1.6	nc	(nc-nc)	Male	3	1.3	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	7	4.3	162.0	(64.9-333.8)	Male	6	2.8	212.9	(77.7-463.4)
Female	7	2.5	283.4	(113.5-583.9)	Female	6	7.7	77.7	(28.4-169.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	3.9	nc	(nc-nc)	Female	15	8.7	172.3	(96.4-284.3)
Female	1	1.0	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	18	18.9	95.4	(56.5-150.8)	Male	130	138.8	93.7	(78.3-111.2)
Female	15	15.1	99.1	(55.5-163.5)	Female	130	120.9	107.6	(89.9-127.7)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Swampscott

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	27	16.8	161.0	(106.1-234.3)	Male	20	10.5	190.0	(116.0-293.5)
Female	11	6.4	172.4	(85.9-308.5)	Female	16	8.7	184.2	(105.2-299.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	3.0	nc	(nc-nc)	Male	0	3.4	nc	(nc-nc)
Female	3	2.8	nc	(nc-nc)	Female	5	3.0	168.3	(54.2-392.8)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.6	nc	(nc-nc)	Male	17	9.3	183.0	(106.6-293.1)
Female	75	70.0	107.1	(84.2-134.3)	Female	11	8.7	126.7	(63.2-226.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	2.3	nc	(nc-nc)	Male	5	7.8	63.8	(20.5-148.8)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	19	17.4	109.5	(65.9-171.0)	Female	5	6.0	83.4	(26.9-194.7)
Female	16	18.4	87.2	(49.8-141.6)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	6	6.2	97.4	(35.6-211.9)
Male	4	4.2	nc	(nc-nc)	Female	6	6.8	88.6	(32.4-192.9)
Female	2	1.3	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	62	50.7	122.3	(93.7-156.7)
Male	2	1.0	nc	(nc-nc)	<u>Stomach</u>				
Female	4	1.0	nc	(nc-nc)	Male	3	3.9	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	3	2.6	nc	(nc-nc)
Male	7	9.5	73.4	(29.4-151.2)	<u>Testis</u>				
Female	4	5.6	nc	(nc-nc)	Male	1	1.8	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	2.4	nc	(nc-nc)	Male	7	4.0	173.5	(69.5-357.6)
Female	0	0.8	nc	(nc-nc)	Female	23	12.5	184.5	(116.9-276.9)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	6	6.6	90.3	(33.0-196.5)	Female	24	15.9	150.8	(96.6-224.3)
Female	9	5.2	174.1	(79.4-330.5)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	242	210.8	114.8	(100.8-130.2)
Male	3	5.9	nc	(nc-nc)	Female	273	235.7	115.8	(102.5-130.4)
Female	2	2.1	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	27	29.1	92.9	(61.2-135.2)					
Female	31	32.7	94.9	(64.5-134.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Swansea

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	23	22.4	102.5	(65.0-153.9)	Male	8	14.0	57.3	(24.7-112.9)
Female	11	7.5	146.5	(73.1-262.2)	Female	7	9.9	70.6	(28.3-145.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	3.9	154.7	(56.5-336.7)	Male	4	4.6	nc	(nc-nc)
Female	3	3.2	nc	(nc-nc)	Female	3	3.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.8	nc	(nc-nc)	Male	10	12.3	81.0	(38.8-149.0)
Female	71	82.2	86.4	(67.5-109.0)	Female	10	10.1	99.3	(47.5-182.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	2.5	nc	(nc-nc)	Male	4	10.2	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	22	22.6	97.2	(60.9-147.2)	Female	7	7.0	100.3	(40.2-206.6)
Female	18	20.6	87.5	(51.9-138.4)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	11	8.2	133.6	(66.6-239.0)
Male	3	5.6	nc	(nc-nc)	Female	7	7.7	90.4	(36.2-186.3)
Female	0	1.5	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	76	67.6	112.5	(88.6-140.8)
Male	3	1.3	nc	(nc-nc)	<u>Stomach</u>				
Female	1	1.2	nc	(nc-nc)	Male	4	5.2	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	5	2.9	171.4	(55.2-399.9)
Male	16	12.5	128.3	(73.3-208.4)	<u>Testis</u>				
Female	7	6.6	105.8	(42.4-218.1)	Male	5	2.3	213.9	(68.9-499.2)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	3.3	nc	(nc-nc)	Male	6	5.2	115.6	(42.2-251.7)
Female	2	0.9	nc	(nc-nc)	Female	12	14.1	84.9	(43.8-148.3)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	3	8.6	nc	(nc-nc)	Female	13	19.0	68.4	(36.4-117.0)
Female	6	5.7	106.0	(38.7-230.8)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	285	279.8	101.9	(90.4-114.4)
Male	7	7.8	90.1	(36.1-185.6)	Female	243	274.9	88.4	(77.6-100.2)
Female	2	2.4	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	42	39.3	106.7	(76.9-144.3)					
Female	37	40.5	91.4	(64.3-126.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Taunton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	54	56.6	95.3	(71.6-124.4)	Male	28	37.5	74.6	(49.6-107.8)
Female	26	22.4	116.1	(75.8-170.1)	Female	24	31.4	76.4	(48.9-113.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	13	11.5	112.8	(60.0-192.9)	Male	8	12.1	66.1	(28.5-130.2)
Female	8	10.2	78.5	(33.8-154.8)	Female	11	10.5	105.0	(52.3-187.9)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	4	2.0	nc	(nc-nc)	Male	34	33.3	102.1	(70.7-142.7)
Female	241	250.9	96.1	(84.3-109.0)	Female	30	30.8	97.4	(65.7-139.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	9	8.3	108.0	(49.3-205.0)	Male	46	29.0	158.8	(116.2-211.8)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	65	60.7	107.1	(82.6-136.5)	Female	15	21.7	69.0	(38.6-113.9)
Female	73	64.6	113.1	(88.6-142.1)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	13	21.5	60.5	(32.2-103.5)
Male	20	15.0	133.4	(81.4-206.0)	Female	24	23.4	102.4	(65.6-152.3)
Female	1	4.4	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	134	182.8	73.3	(61.4-86.8)
Male	8	4.6	174.4	(75.1-343.7)	<u>Stomach</u>				
Female	4	4.0	nc	(nc-nc)	Male	16	13.6	117.8	(67.3-191.2)
<u>Kidney & Renal Pelvis</u>					Female	10	9.1	110.5	(52.9-203.2)
Male	36	34.9	103.2	(72.3-142.9)	<u>Testis</u>				
Female	14	20.1	69.6	(38.0-116.8)	Male	8	8.6	92.6	(39.9-182.5)
<u>Larynx</u>					<u>Thyroid</u>				
Male	11	8.8	125.4	(62.5-224.4)	Male	19	15.9	119.5	(71.9-186.6)
Female	7	2.8	252.4	(101.1-520.0)	Female	61	47.0	129.9	(99.3-166.8)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	19	23.6	80.7	(48.5-126.0)	Female	58	57.1	101.6	(77.1-131.3)
Female	12	18.4	65.0	(33.6-113.6)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	766	752.7	101.8	(94.7-109.2)
Male	29	21.4	135.8	(90.9-195.0)	Female	834	842.6	99.0	(92.4-105.9)
Female	10	7.6	132.4	(63.4-243.4)					
<u>Lung and Bronchus</u>									
Male	135	101.4	133.1	(111.6-157.5)					
Female	123	116.5	105.6	(87.8-126.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Templeton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	8	11.0	72.8	(31.3-143.4)	Male	5	6.8	73.1	(23.6-170.7)
Female	4	3.2	nc	(nc-nc)	Female	2	4.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.9	nc	(nc-nc)	Male	3	2.2	nc	(nc-nc)
Female	0	1.5	nc	(nc-nc)	Female	2	1.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	2	6.1	nc	(nc-nc)
Female	30	38.5	77.9	(52.6-111.2)	Female	3	4.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	1.2	nc	(nc-nc)	Male	2	5.2	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	7	11.4	61.4	(24.6-126.4)	Female	4	3.3	nc	(nc-nc)
Female	7	9.2	76.0	(30.4-156.5)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	3	2.8	nc	(nc-nc)	Male	23	34.6	66.5	(42.1-99.7)
Female	2	0.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	0	0.7	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	7	6.3	111.5	(44.7-229.8)	Female	10	8.9	112.3	(53.8-206.5)
Female	3	3.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Leukemia</u>				
Male	0	1.6	nc	(nc-nc)	Male	5	4.3	117.6	(37.9-274.5)
Female	1	0.5	nc	(nc-nc)	Female	2	2.6	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Lung and Bronchus</u>				
Male	5	3.8	130.1	(41.9-303.6)	Male	20	18.9	105.8	(64.6-163.5)
Female	1	1.1	nc	(nc-nc)	Female	18	17.8	101.0	(59.8-159.7)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Tewksbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	36	33.3	108.1	(75.7-149.6)	Male	19	22.0	86.5	(52.0-135.0)
Female	12	12.8	93.9	(48.5-164.1)	Female	19	17.7	107.2	(64.5-167.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	8	6.4	124.1	(53.4-244.5)	Male	7	7.0	99.8	(40.0-205.6)
Female	7	5.8	121.6	(48.7-250.5)	Female	5	5.9	84.1	(27.1-196.2)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	1.2	nc	(nc-nc)	Male	17	19.3	88.0	(51.2-140.9)
Female	136	146.1	93.1	(78.1-110.1)	Female	21	17.6	119.4	(73.9-182.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	7	4.7	150.0	(60.1-309.0)	Male	20	16.9	118.5	(72.4-183.1)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	34	35.7	95.3	(66.0-133.2)	Female	11	12.4	88.6	(44.2-158.6)
Female	32	36.0	88.9	(60.8-125.5)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	14	12.6	110.9	(60.6-186.0)
Male	13	8.7	149.8	(79.7-256.2)	Female	11	13.2	83.6	(41.7-149.5)
Female	3	2.5	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	102	106.0	96.2	(78.5-116.8)
Male	1	2.4	nc	(nc-nc)	<u>Stomach</u>				
Female	3	2.1	nc	(nc-nc)	Male	8	8.0	100.4	(43.2-197.8)
<u>Kidney & Renal Pelvis</u>					Female	3	5.1	nc	(nc-nc)
Male	30	20.3	148.0	(99.8-211.2)	<u>Testis</u>				
Female	11	11.6	94.9	(47.3-169.7)	Male	5	4.5	110.9	(35.7-258.9)
<u>Larynx</u>					<u>Thyroid</u>				
Male	4	5.1	nc	(nc-nc)	Male	11	9.1	121.5	(60.6-217.5)
Female	1	1.6	nc	(nc-nc)	Female	28	26.4	106.2	(70.6-153.5)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	20	13.5	148.0	(90.4-228.7)	Female	30	33.3	90.2	(60.8-128.7)
Female	12	10.1	118.3	(61.0-206.6)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	473	437.8	108.0	(98.5-118.2)
Male	12	12.4	96.6	(49.9-168.8)	Female	483	483.1	100.0	(91.3-109.3)
Female	2	4.3	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	73	59.8	122.1	(95.7-153.6)					
Female	81	68.5	118.3	(93.9-147.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Tisbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	6	3.1	192.1	(70.2-418.2)	Male	6	2.2	267.2	(97.6-581.6)
Female	1	1.3	nc	(nc-nc)	Female	7	2.0	341.5	(136.8-703.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.7	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	2.0	nc	(nc-nc)
Female	25	16.7	149.8	(96.9-221.2)	Female	1	1.9	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.6	nc	(nc-nc)	Male	4	1.8	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	4	3.6	nc	(nc-nc)	Female	2	1.4	nc	(nc-nc)
Female	7	3.7	188.1	(75.4-387.6)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	0	0.9	nc	(nc-nc)	Male	13	11.3	114.9	(61.1-196.5)
Female	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	0	0.3	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	2.2	nc	(nc-nc)	Female	3	3.9	nc	(nc-nc)
Female	2	1.3	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Leukemia</u>				
Male	1	0.5	nc	(nc-nc)	Male	2	1.4	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Lung and Bronchus</u>				
Male	2	1.3	nc	(nc-nc)	Male	4	5.9	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	11	7.4	148.4	(74.0-265.5)
<u>Male</u>					<u>Female</u>				
					123.7 (93.5-160.7)				
					136.9 (107.5-171.8)				

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Tolland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	0.8	nc	(nc-nc)	Male	2	0.6	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	2.8	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	1	0.9	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	1	0.2	nc	(nc-nc)	Male	2	3.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	0.5	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Female</u>				
Male	0	0.1	nc	(nc-nc)	Male	9	11.5	78.3	(35.7-148.7)
Female	0	0.0	nc	(nc-nc)	Female	1	8.9	nc	(nc-nc)
<u>Leukemia</u>					<u>Male</u>				
Male	1	0.3	nc	(nc-nc)	<u>Female</u>				
Female	0	0.2	nc	(nc-nc)	<u>Male</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Female</u>				
Male	0	0.3	nc	(nc-nc)	<u>Male</u>				
Female	0	0.1	nc	(nc-nc)	<u>Female</u>				
<u>Lung and Bronchus</u>					<u>Male</u>				
Male	1	1.5	nc	(nc-nc)	<u>Female</u>				
Female	1	1.2	nc	(nc-nc)	<u>Male</u>				

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Topsfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	9.6	nc	(nc-nc)	Male	5	5.9	85.3	(27.5-199.2)
Female	4	3.5	nc	(nc-nc)	Female	8	4.3	184.7	(79.5-364.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	1.6	383.2	(139.9-834.1)	Male	0	1.9	nc	(nc-nc)
Female	2	1.4	nc	(nc-nc)	Female	3	1.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	6	5.1	117.3	(42.8-255.3)
Female	36	35.5	101.4	(71.0-140.4)	Female	1	4.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.1	nc	(nc-nc)	Male	2	4.2	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	3	9.6	nc	(nc-nc)	Female	4	3.1	nc	(nc-nc)
Female	6	9.8	61.2	(22.4-133.3)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	2	2.3	nc	(nc-nc)	Male	2	3.5	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	0	3.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Stomach</u>				
Male	1	0.5	nc	(nc-nc)	Male	3	2.2	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	2	1.4	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					<u>Testis</u>				
Male	8	5.2	154.1	(66.3-303.6)	Male	2	0.8	nc	(nc-nc)
Female	2	2.9	nc	(nc-nc)	<u>Thyroid</u>				
<u>Larynx</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	1.3	nc	(nc-nc)	Female	5	7.8	64.2	(20.7-149.8)
Female	1	0.4	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Leukemia</u>					<u>Female</u>				
Male	1	3.6	nc	(nc-nc)	Male	85	116.9	72.7	(58.1-89.9)
Female	2	2.7	nc	(nc-nc)	Female	105	121.3	86.5	(70.8-104.8)
<u>Liver and Intrahepatic Bile Ducts</u>									
Male	0	3.2	nc	(nc-nc)					
Female	1	1.1	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	13	16.9	76.8	(40.8-131.3)					
Female	11	17.9	61.4	(30.6-109.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Townsend

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	14	8.4	166.1	(90.7-278.7)	Male	3	5.9	nc	(nc-nc)
Female	3	2.7	nc	(nc-nc)	Female	8	4.5	177.1	(76.3-349.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.9	nc	(nc-nc)	Male	0	1.9	nc	(nc-nc)
Female	3	1.5	nc	(nc-nc)	Female	2	1.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	9	5.3	170.8	(77.9-324.3)
Female	35	37.0	94.5	(65.8-131.5)	Female	2	4.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.3	nc	(nc-nc)	Male	4	5.1	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	10	9.7	103.2	(49.4-189.8)	Female	1	3.1	nc	(nc-nc)
Female	17	8.2	206.8	(120.4-331.1)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	4	3.4	nc	(nc-nc)
Male	8	2.5	324.4	(139.7-639.2)	Female	1	2.8	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	23	32.3	71.1	(45.1-106.8)
Male	1	0.8	nc	(nc-nc)	<u>Stomach</u>				
Female	2	0.6	nc	(nc-nc)	Male	3	2.1	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	2	1.2	nc	(nc-nc)
Male	10	5.9	168.4	(80.6-309.7)	<u>Testis</u>				
Female	5	2.8	177.8	(57.3-414.9)	Male	2	1.4	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	1.5	nc	(nc-nc)	Male	3	2.8	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	9	7.6	118.3	(54.0-224.6)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	2	3.7	nc	(nc-nc)	Female	3	8.4	nc	(nc-nc)
Female	3	2.4	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	130	122.8	105.9	(88.5-125.7)
Male	2	3.6	nc	(nc-nc)	Female	128	116.9	109.5	(91.3-130.2)
Female	0	1.0	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	15	15.6	96.2	(53.8-158.7)					
Female	16	14.8	108.0	(61.7-175.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Truro

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	3.5	nc	(nc-nc)	Male	2	2.1	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)	Female	4	1.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.5	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	2	0.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	3	1.8	nc	(nc-nc)
Female	13	12.7	102.1	(54.3-174.6)	Female	1	1.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	2	1.6	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	6	3.4	175.4	(64.1-381.8)	Female	3	1.0	nc	(nc-nc)
Female	4	2.8	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	1	1.3	nc	(nc-nc)
Male	2	0.9	nc	(nc-nc)	Female	2	1.1	nc	(nc-nc)
Female	2	0.2	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	7	11.5	60.8	(24.4-125.2)
Male	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.4	nc	(nc-nc)
Male	1	1.9	nc	(nc-nc)	<u>Testis</u>				
Female	0	1.0	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.5	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	1.8	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	3	1.3	nc	(nc-nc)	Female	2	3.2	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	40	43.5	91.9	(65.7-125.2)
Male	4	1.2	nc	(nc-nc)	Female	46	41.2	111.7	(81.8-149.0)
Female	0	0.4	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	6	6.1	97.9	(35.7-213.0)					
Female	3	6.3	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Tyngsborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	6	8.9	67.3	(24.6-146.6)	Male	5	6.8	73.1	(23.6-170.6)
Female	7	3.3	215.3	(86.2-443.6)	Female	4	5.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	2.3	nc	(nc-nc)	Male	1	2.2	nc	(nc-nc)
Female	2	1.9	nc	(nc-nc)	Female	2	1.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	6	6.1	98.3	(35.9-213.9)
Female	50	46.1	108.4	(80.4-142.9)	Female	3	5.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.8	nc	(nc-nc)	Male	4	6.1	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	12	11.3	105.9	(54.7-185.1)	Female	4	3.8	nc	(nc-nc)
Female	6	10.5	57.2	(20.9-124.5)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	3	3.8	nc	(nc-nc)
Male	3	2.7	nc	(nc-nc)	Female	0	3.4	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	37	36.4	101.6	(71.5-140.0)
Male	0	1.0	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.8	nc	(nc-nc)	Male	5	2.4	209.8	(67.6-489.5)
<u>Kidney & Renal Pelvis</u>					Female	1	1.5	nc	(nc-nc)
Male	8	7.0	114.1	(49.1-224.8)	<u>Testis</u>				
Female	3	3.4	nc	(nc-nc)	Male	0	2.0	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	1.7	nc	(nc-nc)	Male	1	3.5	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	4	10.1	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	6	4.1	145.1	(53.0-315.8)	Female	11	10.1	109.2	(54.5-195.5)
Female	5	3.0	164.1	(52.9-383.0)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	139	139.6	99.6	(83.7-117.6)
Male	4	4.3	nc	(nc-nc)	Female	140	144.5	96.9	(81.5-114.3)
Female	2	1.2	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	22	16.8	130.7	(81.9-197.9)					
Female	22	17.1	128.3	(80.4-194.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Tyringham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	1.0	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	3	3.1	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	1	1.0	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	3.1	nc	(nc-nc)
Female	1	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.5	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Leukemia</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Lung and Bronchus</u>				
Male	0	0.3	nc	(nc-nc)	Male	1	1.9	nc	(nc-nc)
Female	1	0.1	nc	(nc-nc)	Female	0	1.8	nc	(nc-nc)
					Male	5	12.3	40.7	(13.1-94.9)
					Female	7	10.9	64.5	(25.8-132.9)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Upton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	6	7.2	83.4	(30.4-181.4)	Male	4	5.1	nc	(nc-nc)
Female	2	2.1	nc	(nc-nc)	Female	3	3.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.6	nc	(nc-nc)	Male	3	1.6	nc	(nc-nc)
Female	2	1.2	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.3	nc	(nc-nc)	Male	3	4.5	nc	(nc-nc)
Female	44	30.6	143.8	(104.5-193.0)	Female	5	3.3	153.1	(49.3-357.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.1	nc	(nc-nc)	Male	3	4.3	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	6	8.3	72.1	(26.3-156.9)	Female	5	2.6	195.4	(63.0-456.0)
Female	3	6.5	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	2	2.9	nc	(nc-nc)
Male	0	2.1	nc	(nc-nc)	Female	6	2.2	276.9	(101.1-602.8)
Female	2	0.4	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	26	26.4	98.4	(64.3-144.2)
Male	1	0.6	nc	(nc-nc)	<u>Stomach</u>				
Female	1	0.5	nc	(nc-nc)	Male	1	1.8	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	0.9	nc	(nc-nc)
Male	3	5.0	nc	(nc-nc)	<u>Testis</u>				
Female	1	2.3	nc	(nc-nc)	Male	2	1.1	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	1.2	nc	(nc-nc)	Male	2	2.3	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	7	6.4	108.9	(43.6-224.4)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	3	3.1	nc	(nc-nc)	Female	12	6.9	174.8	(90.2-305.3)
Female	2	1.9	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	93	103.4	90.0	(72.6-110.2)
Male	5	3.1	160.5	(51.7-374.6)	Female	125	94.8	131.8	(109.7-157.0)
Female	2	0.8	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	14	13.3	105.5	(57.7-177.1)					
Female	18	12.0	150.0	(88.9-237.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Uxbridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	18	10.1	178.6	(105.8-282.3)	Male	11	7.3	150.0	(74.8-268.4)
Female	5	5.1	97.4	(31.4-227.3)	Female	4	7.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	2.4	nc	(nc-nc)	Male	5	2.3	213.9	(68.9-499.1)
Female	2	2.5	nc	(nc-nc)	Female	4	2.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.4	nc	(nc-nc)	Male	8	6.6	122.0	(52.6-240.5)
Female	64	60.5	105.8	(81.5-135.2)	Female	6	7.2	83.4	(30.5-181.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	2.0	nc	(nc-nc)	Male	16	6.1	261.3	(149.3-424.4)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	17	11.9	143.0	(83.2-228.9)	Female	9	5.2	173.5	(79.2-329.4)
Female	11	15.1	73.0	(36.4-130.6)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	1	2.9	nc	(nc-nc)	Male	3	4.1	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	Female	3	5.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.0	nc	(nc-nc)	Male	51	37.8	134.8	(100.4-177.2)
Female	1	0.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	16	7.2	221.5	(126.5-359.7)	Male	3	2.6	nc	(nc-nc)
Female	5	4.8	105.0	(33.9-245.1)	Female	1	2.1	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	2	1.8	nc	(nc-nc)	Male	4	2.0	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	6	4.6	131.1	(47.9-285.3)	Male	1	3.6	nc	(nc-nc)
Female	5	4.3	116.5	(37.5-271.8)	Female	9	11.4	79.1	(36.1-150.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	5	4.4	112.6	(36.3-262.9)	Female	12	13.7	87.8	(45.3-153.3)
Female	2	1.8	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	26	18.8	138.3	(90.3-202.6)	Male	218	148.9	146.4	(127.6-167.2)
Female	28	26.9	104.1	(69.2-150.5)	Female	188	199.2	94.4	(81.4-108.9)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Wakefield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	27	31.9	84.7	(55.8-123.3)	Male	19	20.1	94.3	(56.8-147.3)
Female	12	10.1	118.9	(61.4-207.8)	Female	22	14.6	150.3	(94.1-227.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	8	5.8	138.4	(59.6-272.7)	Male	4	6.5	nc	(nc-nc)
Female	6	4.7	126.6	(46.2-275.6)	Female	4	4.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.1	nc	(nc-nc)	Male	11	17.7	62.2	(31.0-111.3)
Female	127	118.5	107.2	(89.4-127.5)	Female	15	14.1	106.2	(59.4-175.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	3.9	nc	(nc-nc)	Male	15	14.3	105.2	(58.8-173.5)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	30	32.1	93.4	(63.0-133.3)	Female	7	10.2	68.9	(27.6-142.0)
Female	29	29.3	99.0	(66.3-142.2)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	9	7.9	113.7	(51.9-215.8)	Male	53	90.8	58.4	(43.7-76.4)
Female	0	2.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	1	2.2	nc	(nc-nc)	Male	3	4.1	nc	(nc-nc)
Female	1	1.9	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	11	17.6	62.4	(31.1-111.6)	Female	24	27.1	88.5	(56.7-131.6)
Female	12	9.3	128.4	(66.3-224.3)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Leukemia</u>				
Male	2	4.6	nc	(nc-nc)	Male	18	12.5	144.1	(85.3-227.7)
Female	1	1.3	nc	(nc-nc)	Female	7	8.3	83.9	(33.6-172.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Lung and Bronchus</u>				
Male	8	10.8	73.9	(31.8-145.6)	Male	38	56.5	67.3	(47.6-92.3)
Female	3	3.4	nc	(nc-nc)	Female	57	53.3	107.0	(81.0-138.6)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Wales

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	2.3	nc	(nc-nc)	Male	0	1.5	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.4	nc	(nc-nc)	Male	2	0.5	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
Female	8	8.9	89.4	(38.5-176.2)	Female	0	1.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	2	1.1	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	1	2.4	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
Female	7	2.0	352.1	(141.1-725.4)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	1	0.6	nc	(nc-nc)	Male	5	7.5	66.8	(21.5-155.9)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	1	0.1	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	1.4	nc	(nc-nc)	Female	5	2.2	230.5	(74.3-538.0)
Female	0	0.7	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Leukemia</u>				
Male	1	0.4	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Lung and Bronchus</u>				
Male	2	0.8	nc	(nc-nc)	Male	3	4.1	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	Female	2	3.7	nc	(nc-nc)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Walpole

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	20	29.2	68.4	(41.8-105.7)	Male	18	18.8	95.5	(56.6-151.0)
Female	8	10.7	74.8	(32.2-147.4)	Female	12	14.7	81.6	(42.1-142.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	5.4	nc	(nc-nc)	Male	7	6.0	116.5	(46.7-240.0)
Female	6	4.7	126.3	(46.1-275.0)	Female	1	5.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.0	nc	(nc-nc)	Male	15	16.6	90.4	(50.5-149.1)
Female	129	119.4	108.1	(90.2-128.4)	Female	11	14.7	74.6	(37.2-133.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	3.8	nc	(nc-nc)	Male	9	14.4	62.4	(28.5-118.4)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	36	31.2	115.6	(80.9-160.0)	Female	15	10.2	146.5	(81.9-241.6)
Female	31	31.0	100.1	(68.0-142.0)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	13	10.9	118.8	(63.2-203.1)
Male	4	7.5	nc	(nc-nc)	Female	11	11.2	98.2	(48.9-175.6)
Female	3	2.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	114	91.1	125.1	(103.2-150.3)
Male	4	2.0	nc	(nc-nc)	<u>Stomach</u>				
Female	3	1.6	nc	(nc-nc)	Male	8	6.9	115.7	(49.8-228.0)
<u>Kidney & Renal Pelvis</u>					Female	4	4.3	nc	(nc-nc)
Male	17	17.2	98.8	(57.5-158.2)	<u>Testis</u>				
Female	8	9.5	84.5	(36.4-166.5)	Male	6	3.6	166.3	(60.7-362.0)
<u>Larynx</u>					<u>Thyroid</u>				
Male	4	4.3	nc	(nc-nc)	Male	4	7.6	nc	(nc-nc)
Female	2	1.3	nc	(nc-nc)	Female	24	21.2	113.2	(72.5-168.4)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	9	11.6	77.4	(35.3-147.0)	Female	21	26.8	78.4	(48.5-119.8)
Female	8	8.6	93.1	(40.1-183.4)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	389	376.4	103.4	(93.3-114.2)
Male	9	10.6	84.6	(38.6-160.6)	Female	386	398.4	96.9	(87.5-107.0)
Female	3	3.5	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	53	50.8	104.4	(78.2-136.5)					
Female	50	55.4	90.2	(67.0-119.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Waltham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	56	57.7	97.0	(73.3-126.0)	Male	19	37.0	51.4	(30.9-80.3)
Female	23	21.4	107.5	(68.2-161.4)	Female	16	29.5	54.3	(31.0-88.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	16	11.6	137.7	(78.7-223.7)	Male	9	11.6	77.6	(35.4-147.3)
Female	13	10.1	128.2	(68.2-219.2)	Female	6	9.8	61.3	(22.4-133.5)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	2.0	nc	(nc-nc)	Male	28	33.0	84.8	(56.3-122.5)
Female	251	223.0	112.6	(99.1-127.4)	Female	30	29.0	103.5	(69.8-147.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	10	7.4	134.8	(64.6-248.0)	Male	16	26.3	60.8	(34.7-98.8)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	67	59.2	113.1	(87.6-143.6)	Female	21	19.9	105.4	(65.2-161.1)
Female	65	60.7	107.1	(82.7-136.5)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	9	14.2	63.3	(28.9-120.2)	Male	141	166.9	84.5	(71.1-99.6)
Female	6	4.1	145.2	(53.0-316.1)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	6	5.5	108.6	(39.6-236.3)	Male	12	11.0	109.4	(56.5-191.1)
Female	5	4.8	104.3	(33.6-243.4)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Thyroid</u>				
Male	36	32.2	111.7	(78.2-154.6)	Male	23	15.5	148.6	(94.2-223.1)
Female	23	18.4	125.2	(79.3-187.8)	Female	44	43.8	100.4	(72.9-134.8)
<u>Larynx</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	6	8.2	73.0	(26.7-158.9)	Female	44	51.0	86.3	(62.7-115.8)
Female	3	2.5	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Leukemia</u>					<u>All Sites / Types</u>				
Male	20	23.9	83.6	(51.1-129.2)	Male	690	729.3	94.6	(87.7-101.9)
Female	16	17.9	89.4	(51.1-145.2)	Female	774	778.4	99.4	(92.6-106.7)
<u>Liver and Intrahepatic Bile Ducts</u>									
Male	22	19.7	111.9	(70.1-169.4)					
Female	4	7.1	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	106	99.9	106.1	(86.8-128.3)					
Female	102	109.1	93.5	(76.2-113.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Ware

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	11	11.2	98.2	(48.9-175.7)	Male	4	7.2	nc	(nc-nc)
Female	1	3.8	nc	(nc-nc)	Female	5	5.4	93.2	(30.0-217.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	2.1	nc	(nc-nc)	Male	3	2.3	nc	(nc-nc)
Female	0	1.8	nc	(nc-nc)	Female	2	1.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	7	6.4	109.0	(43.7-224.7)
Female	39	45.0	86.6	(61.6-118.3)	Female	7	5.3	133.3	(53.4-274.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.4	nc	(nc-nc)	Male	4	5.6	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	14	11.9	118.1	(64.5-198.2)	Female	4	3.8	nc	(nc-nc)
Female	11	10.7	103.1	(51.4-184.5)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	8	4.2	189.4	(81.5-373.2)
Male	1	2.9	nc	(nc-nc)	Female	7	3.9	177.7	(71.2-366.2)
Female	1	0.8	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	24	36.7	65.5	(41.9-97.4)
Male	1	0.8	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.7	nc	(nc-nc)	Male	2	2.7	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	3	1.5	nc	(nc-nc)
Male	3	6.7	nc	(nc-nc)	<u>Testis</u>				
Female	6	3.6	169.0	(61.7-367.8)	Male	2	1.4	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	1.7	nc	(nc-nc)	Male	2	2.9	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	4	8.1	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	2	4.5	nc	(nc-nc)	Female	12	10.5	114.4	(59.1-199.9)
Female	3	3.0	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	134	146.8	91.3	(76.5-108.1)
Male	5	4.1	120.6	(38.9-281.5)	Female	141	147.1	95.8	(80.7-113.0)
Female	2	1.3	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	23	19.8	116.1	(73.6-174.2)					
Female	20	20.8	96.2	(58.7-148.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Wareham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	39	29.4	132.6	(94.3-181.3)	Male	14	18.2	76.8	(41.9-128.8)
Female	21	9.6	218.4	(135.2-333.9)	Female	13	13.2	98.6	(52.4-168.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	10	5.1	196.8	(94.2-361.9)	Male	8	5.9	135.7	(58.4-267.4)
Female	1	4.3	nc	(nc-nc)	Female	4	4.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.0	nc	(nc-nc)	Male	18	16.1	112.1	(66.4-177.1)
Female	94	109.3	86.0	(69.5-105.3)	Female	8	13.2	60.5	(26.0-119.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	3.4	nc	(nc-nc)	Male	15	13.0	115.6	(64.7-190.7)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	33	29.6	111.4	(76.7-156.5)	Female	7	9.4	74.7	(29.9-153.8)
Female	36	26.8	134.1	(93.9-185.7)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	17	10.6	159.8	(93.0-255.9)
Male	9	7.1	126.0	(57.5-239.1)	Female	17	9.9	172.2	(100.3-275.8)
Female	1	1.9	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	88	83.3	105.7	(84.8-130.2)
Male	1	1.8	nc	(nc-nc)	<u>Stomach</u>				
Female	2	1.6	nc	(nc-nc)	Male	3	6.7	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	3	3.8	nc	(nc-nc)
Male	13	15.9	81.6	(43.4-139.5)	<u>Testis</u>				
Female	15	8.8	170.9	(95.6-281.9)	Male	5	3.1	160.7	(51.8-375.1)
<u>Larynx</u>					<u>Thyroid</u>				
Male	3	4.2	nc	(nc-nc)	Male	7	6.6	106.6	(42.7-219.6)
Female	2	1.2	nc	(nc-nc)	Female	20	19.3	103.6	(63.3-160.0)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	15	11.3	133.0	(74.4-219.4)	Female	24	25.4	94.5	(60.5-140.5)
Female	15	7.7	195.9	(109.6-323.1)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	418	359.4	116.3	(105.4-128.0)
Male	15	9.8	152.7	(85.4-251.9)	Female	408	362.4	112.6	(101.9-124.1)
Female	5	3.3	152.3	(49.1-355.5)					
<u>Lung and Bronchus</u>									
Male	71	51.7	137.4	(107.3-173.3)					
Female	74	51.8	143.0	(112.2-179.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Warren

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	5.1	98.2	(31.6-229.1)	Male	2	3.4	nc	(nc-nc)
Female	1	1.9	nc	(nc-nc)	Female	2	2.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.1	nc	(nc-nc)	Male	2	1.1	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	2	3.1	nc	(nc-nc)
Female	15	21.8	68.7	(38.4-113.4)	Female	2	2.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.8	nc	(nc-nc)	Male	1	2.8	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	8	5.7	140.9	(60.7-277.6)	Female	0	1.8	nc	(nc-nc)
Female	6	5.5	110.0	(40.2-239.5)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	4	2.0	nc	(nc-nc)
Male	4	1.4	nc	(nc-nc)	Female	0	1.9	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	13	17.9	72.5	(38.6-123.9)
Male	0	0.5	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.3	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	0.8	nc	(nc-nc)
Male	4	3.3	nc	(nc-nc)	<u>Testis</u>				
Female	1	1.7	nc	(nc-nc)	Male	3	0.9	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.8	nc	(nc-nc)	Male	0	1.5	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	3	4.3	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	2	2.1	nc	(nc-nc)	Female	7	4.7	150.0	(60.1-309.1)
Female	1	1.5	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	64	70.4	90.9	(70.0-116.1)
Male	1	1.9	nc	(nc-nc)	Female	53	71.6	74.1	(55.5-96.9)
Female	0	0.6	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	8	9.2	87.1	(37.5-171.7)					
Female	9	9.7	92.5	(42.2-175.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Warwick

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	1.4	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	3	4.4	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	2	1.4	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	0	0.4	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	5	4.1	120.6	(38.9-281.5)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	0	0.7	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	0	0.5	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.5	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	2	2.5	nc	(nc-nc)	Male	13	17.1	76.1	(40.5-130.1)
Female	3	2.1	nc	(nc-nc)	Female	14	14.4	97.0	(53.0-162.8)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Washington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	0.9	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.2	nc	(nc-nc)	Male	1	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	4	3.1	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	0	1.0	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	3.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.6	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Leukemia</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Lung and Bronchus</u>				
Male	0	0.4	nc	(nc-nc)	Male	1	1.7	nc	(nc-nc)
Female	1	0.1	nc	(nc-nc)	Female	2	1.4	nc	(nc-nc)
					Male	5	12.7	39.5	(12.7-92.2)
					Female	9	9.9	91.3	(41.7-173.4)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Watertown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	29	29.4	98.5	(66.0-141.5)	Male	12	19.7	61.0	(31.5-106.6)
Female	8	12.7	62.9	(27.1-123.9)	Female	21	18.2	115.6	(71.6-176.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	6.3	95.9	(35.0-208.8)	Male	8	6.2	129.4	(55.7-255.0)
Female	7	5.9	118.7	(47.6-244.7)	Female	5	6.0	83.9	(27.0-195.7)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	1.1	nc	(nc-nc)	Male	13	17.6	74.0	(39.3-126.5)
Female	160	140.5	113.8	(96.9-132.9)	Female	16	17.6	90.9	(51.9-147.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	9	4.7	192.8	(88.0-366.0)	Male	12	14.8	81.3	(41.9-142.0)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	42	32.2	130.4	(94.0-176.3)	Female	17	12.3	138.6	(80.7-221.9)
Female	33	35.5	92.8	(63.9-130.4)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	13	11.0	117.7	(62.6-201.4)
Male	7	7.6	92.7	(37.1-191.0)	Female	17	13.3	128.1	(74.6-205.0)
Female	1	2.5	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	72	90.7	79.4	(62.1-100.0)
Male	4	2.8	nc	(nc-nc)	<u>Stomach</u>				
Female	2	2.7	nc	(nc-nc)	Male	10	7.1	141.7	(67.8-260.5)
<u>Kidney & Renal Pelvis</u>					Female	8	5.0	158.9	(68.4-313.2)
Male	14	18.0	78.0	(42.6-130.8)	<u>Testis</u>				
Female	3	11.4	nc	(nc-nc)	Male	5	5.9	84.8	(27.3-198.0)
<u>Larynx</u>					<u>Thyroid</u>				
Male	7	4.4	157.7	(63.2-324.9)	Male	9	8.8	102.3	(46.7-194.2)
Female	0	1.6	nc	(nc-nc)	Female	35	27.5	127.2	(88.6-177.0)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	17	12.5	135.7	(79.0-217.2)	Female	27	32.9	82.1	(54.1-119.5)
Female	13	10.3	125.8	(66.9-215.1)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	373	389.1	95.9	(86.4-106.1)
Male	6	10.8	55.5	(20.3-120.9)	Female	499	478.1	104.4	(95.4-113.9)
Female	5	4.2	118.4	(38.2-276.3)					
<u>Lung and Bronchus</u>									
Male	52	51.5	100.9	(75.4-132.4)					
Female	60	67.7	88.7	(67.7-114.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Wayland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	17	17.9	95.1	(55.4-152.3)	Male	23	11.3	204.1	(129.4-306.3)
Female	6	6.4	93.4	(34.1-203.2)	Female	12	8.6	139.6	(72.1-243.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	3.1	nc	(nc-nc)	Male	4	3.7	nc	(nc-nc)
Female	4	2.7	nc	(nc-nc)	Female	4	3.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.6	nc	(nc-nc)	Male	8	9.9	80.9	(34.9-159.5)
Female	77	72.5	106.2	(83.8-132.7)	Female	12	8.7	137.3	(70.9-239.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	2.2	nc	(nc-nc)	Male	5	8.2	60.8	(19.6-141.8)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	13	18.5	70.3	(37.4-120.2)	Female	4	6.2	nc	(nc-nc)
Female	11	18.0	61.2	(30.5-109.4)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	2	4.5	nc	(nc-nc)	Male	65	51.9	125.3	(96.7-159.7)
Female	1	1.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	2	1.0	nc	(nc-nc)	Male	3	1.7	nc	(nc-nc)
Female	2	0.8	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	7	10.1	69.6	(27.9-143.3)	Female	13	16.6	78.4	(41.7-134.2)
Female	2	5.8	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Leukemia</u>				
Male	0	2.6	nc	(nc-nc)	Male	6	6.9	86.9	(31.7-189.2)
Female	0	0.8	nc	(nc-nc)	Female	3	4.9	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Lung and Bronchus</u>				
Male	2	6.1	nc	(nc-nc)	Male	16	31.4	51.0	(29.1-82.8)
Female	0	2.1	nc	(nc-nc)	Female	19	34.6	54.9	(33.0-85.8)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Webster

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	25	21.3	117.4	(76.0-173.3)	Male	12	13.0	92.6	(47.8-161.8)
Female	5	7.2	69.0	(22.2-161.0)	Female	8	9.8	81.6	(35.2-160.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	3.6	nc	(nc-nc)	Male	4	4.2	nc	(nc-nc)
Female	2	3.2	nc	(nc-nc)	Female	6	3.3	180.9	(66.1-393.7)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	3	0.7	nc	(nc-nc)	Male	13	11.4	113.8	(60.5-194.6)
Female	81	76.3	106.2	(84.3-132.0)	Female	11	9.7	113.0	(56.3-202.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	2.6	nc	(nc-nc)	Male	16	9.2	174.3	(99.5-283.0)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	20	21.5	93.0	(56.8-143.6)	Female	14	6.7	208.6	(113.9-350.0)
Female	19	20.9	90.8	(54.6-141.8)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	8	7.6	105.2	(45.3-207.3)
Male	7	5.1	136.7	(54.8-281.7)	Female	10	7.6	131.2	(62.8-241.2)
Female	3	1.4	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	58	59.1	98.2	(74.6-127.0)
Male	2	1.3	nc	(nc-nc)	<u>Stomach</u>				
Female	1	1.2	nc	(nc-nc)	Male	2	4.8	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	2	2.9	nc	(nc-nc)
Male	11	11.2	97.9	(48.8-175.1)	<u>Testis</u>				
Female	10	6.2	160.5	(76.8-295.1)	Male	3	2.3	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	6	2.9	205.3	(75.0-447.0)	Male	5	4.7	107.0	(34.5-249.8)
Female	2	0.9	nc	(nc-nc)	Female	16	14.3	111.7	(63.8-181.5)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	7	8.1	86.3	(34.6-177.8)	Female	22	16.8	130.6	(81.8-197.8)
Female	6	5.9	101.5	(37.1-221.0)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	292	256.2	114.0	(101.3-127.8)
Male	10	6.9	145.0	(69.4-266.6)	Female	321	262.6	122.3	(109.2-136.4)
Female	5	2.4	212.0	(68.3-494.9)					
<u>Lung and Bronchus</u>									
Male	49	36.3	134.9	(99.8-178.3)					
Female	59	36.9	159.8	(121.7-206.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Wellesley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	19	30.2	62.9	(37.8-98.2)	Male	35	19.0	183.8	(128.0-255.6)
Female	8	9.9	80.6	(34.7-158.8)	Female	26	14.3	181.8	(118.7-266.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	5.5	nc	(nc-nc)	Male	6	6.2	96.8	(35.3-210.7)
Female	7	5.1	136.1	(54.5-280.5)	Female	7	4.7	150.5	(60.3-310.1)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.1	nc	(nc-nc)	Male	15	16.9	88.6	(49.6-146.2)
Female	147	117.4	125.2	(105.8-147.2)	Female	7	14.0	50.0	(20.0-103.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	4.0	nc	(nc-nc)	Male	10	14.0	71.7	(34.3-131.8)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	23	31.3	73.4	(46.5-110.2)	Female	11	9.9	110.6	(55.1-198.0)
Female	24	29.2	82.3	(52.7-122.4)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	1	7.5	nc	(nc-nc)	Male	8	11.1	72.1	(31.0-142.1)
Female	1	1.9	nc	(nc-nc)	Female	9	10.3	87.3	(39.8-165.7)
<u>Hodgkin Lymphoma</u>					<u>Stomach</u>				
Male	2	1.8	nc	(nc-nc)	Male	7	7.0	99.5	(39.8-204.9)
Female	3	1.9	nc	(nc-nc)	Female	2	4.1	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					<u>Testis</u>				
Male	15	17.2	87.4	(48.9-144.2)	Male	3	3.2	nc	(nc-nc)
Female	5	9.2	54.5	(17.6-127.1)	<u>Thyroid</u>				
<u>Larynx</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	3	4.4	nc	(nc-nc)	Female	26	25.4	102.5	(66.9-150.1)
Female	0	1.2	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Leukemia</u>					<u>Female</u>				
Male	12	12.0	99.9	(51.5-174.4)	Male	322	377.5	85.3	(76.2-95.2)
Female	9	8.4	106.5	(48.6-202.3)	Female	387	385.6	100.4	(90.6-110.9)
<u>Liver and Intrahepatic Bile Ducts</u>									
Male	6	10.3	58.2	(21.3-126.7)					
Female	1	3.3	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	18	52.5	34.3	(20.3-54.2)					
Female	35	52.0	67.3	(46.9-93.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Wellfleet

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	6.2	nc	(nc-nc)	Male	5	3.6	138.6	(44.7-323.5)
Female	2	2.8	nc	(nc-nc)	Female	4	3.0	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.9	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	2	1.0	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	7	3.1	223.8	(89.7-461.1)
Female	22	25.8	85.4	(53.5-129.3)	Female	1	3.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.6	nc	(nc-nc)	Male	3	2.6	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	7	5.8	121.1	(48.5-249.6)	Female	3	2.3	nc	(nc-nc)
Female	4	7.1	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	0	2.2	nc	(nc-nc)
Male	1	1.5	nc	(nc-nc)	Female	5	2.9	173.6	(55.9-405.2)
Female	0	0.5	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	15	19.0	78.8	(44.1-130.0)
Male	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.2	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	1.0	nc	(nc-nc)
Male	3	3.2	nc	(nc-nc)	<u>Testis</u>				
Female	2	2.2	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	3	0.9	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	1	3.2	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	3	2.2	nc	(nc-nc)	Female	4	6.2	nc	(nc-nc)
Female	1	1.9	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	63	74.5	84.5	(64.9-108.1)
Male	1	2.0	nc	(nc-nc)	Female	71	90.5	78.5	(61.3-99.0)
Female	1	0.9	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	3	11.3	nc	(nc-nc)					
Female	10	14.8	67.7	(32.4-124.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Wendell

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	1.2	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.2	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	2	4.9	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	1	1.2	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	0	0.5	nc	(nc-nc)
Male	1	0.3	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	2	4.7	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.1	nc	(nc-nc)
Male	1	0.8	nc	(nc-nc)	<u>Testis</u>				
Female	1	0.4	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	2	0.9	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.5	nc	(nc-nc)	Female	2	1.2	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	14	16.8	83.5	(45.6-140.1)
Male	0	0.5	nc	(nc-nc)	Female	11	15.1	73.0	(36.4-130.6)
Female	0	0.1	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	4	2.3	nc	(nc-nc)					
Female	3	2.1	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Wenham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	6	5.8	103.9	(38.0-226.3)	Male	6	3.4	176.0	(64.3-383.1)
Female	1	2.0	nc	(nc-nc)	Female	7	2.6	272.2	(109.0-560.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.9	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Female	2	1.0	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	5	3.1	162.4	(52.3-379.0)
Female	27	20.7	130.5	(86.0-189.9)	Female	2	2.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.6	nc	(nc-nc)	Male	3	2.2	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	3	5.6	nc	(nc-nc)	Female	1	1.8	nc	(nc-nc)
Female	8	5.7	139.2	(59.9-274.2)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	4	1.3	nc	(nc-nc)	Male	20	14.0	142.9	(87.3-220.7)
Female	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	2	2.8	nc	(nc-nc)	Female	6	4.6	131.3	(48.0-285.9)
Female	1	1.7	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Leukemia</u>				
Male	0	0.8	nc	(nc-nc)	Male	1	2.2	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	Female	1	1.6	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Lung and Bronchus</u>				
Male	0	1.8	nc	(nc-nc)	Male	3	9.8	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	11	10.1	109.2	(54.4-195.3)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

West Boylston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	17	9.0	187.9	(109.4-300.8)	Male	8	5.9	134.6	(58.0-265.3)
Female	5	3.1	159.6	(51.4-372.4)	Female	3	3.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	1.9	nc	(nc-nc)	Male	1	1.9	nc	(nc-nc)
Female	3	1.2	nc	(nc-nc)	Female	2	1.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.3	nc	(nc-nc)	Male	3	5.3	nc	(nc-nc)
Female	23	29.8	77.1	(48.9-115.7)	Female	4	4.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.9	nc	(nc-nc)	Male	5	4.4	113.4	(36.6-264.7)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	5	9.5	52.8	(17.0-123.3)	Female	5	2.7	187.2	(60.3-436.9)
Female	7	8.8	79.9	(32.0-164.7)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	3	3.4	nc	(nc-nc)
Male	2	2.3	nc	(nc-nc)	Female	3	3.3	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	28	28.2	99.3	(66.0-143.5)
Male	1	1.0	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.4	nc	(nc-nc)	Male	0	2.1	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	1.2	nc	(nc-nc)
Male	9	5.3	168.3	(76.8-319.5)	<u>Testis</u>				
Female	3	2.5	nc	(nc-nc)	Male	2	1.9	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	1.3	nc	(nc-nc)	Male	1	2.6	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	9	4.7	191.8	(87.5-364.2)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	4	3.8	nc	(nc-nc)	Female	5	6.8	73.4	(23.7-171.3)
Female	4	2.4	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	136	118.7	114.6	(96.1-135.5)
Male	1	3.2	nc	(nc-nc)	Female	108	105.6	102.2	(83.9-123.4)
Female	0	1.0	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	25	15.9	157.1	(101.6-231.9)					
Female	13	15.8	82.4	(43.9-141.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

West Bridgewater

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	10	9.6	104.0	(49.8-191.2)	Male	10	5.9	170.8	(81.8-314.2)
Female	3	2.7	nc	(nc-nc)	Female	3	3.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	1.6	nc	(nc-nc)	Male	0	1.9	nc	(nc-nc)
Female	2	1.3	nc	(nc-nc)	Female	0	1.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	9	5.2	172.5	(78.7-327.5)
Female	38	31.5	120.6	(85.4-165.6)	Female	8	3.8	211.2	(90.9-416.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.0	nc	(nc-nc)	Male	7	4.2	167.3	(67.0-344.8)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	8	9.7	82.3	(35.4-162.2)	Female	2	2.7	nc	(nc-nc)
Female	17	7.9	215.2	(125.3-344.5)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	4	2.3	nc	(nc-nc)	Male	21	27.3	76.9	(47.6-117.6)
Female	0	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	1	0.6	nc	(nc-nc)	Male	3	1.0	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	5	5.1	97.9	(31.5-228.4)	Female	5	7.2	69.2	(22.3-161.6)
Female	3	2.5	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Leukemia</u>				
Male	2	1.3	nc	(nc-nc)	Male	0	3.7	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	2.2	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Lung and Bronchus</u>				
Male	2	3.2	nc	(nc-nc)	Male	18	16.4	110.1	(65.2-174.0)
Female	0	0.9	nc	(nc-nc)	Female	16	14.1	113.1	(64.6-183.7)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

West Brookfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	5.3	nc	(nc-nc)	Male	5	3.3	152.7	(49.2-356.4)
Female	0	2.1	nc	(nc-nc)	Female	1	2.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.9	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	3	0.8	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	2	2.9	nc	(nc-nc)
Female	16	19.2	83.2	(47.5-135.2)	Female	3	2.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.5	nc	(nc-nc)	Male	2	2.4	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	3	5.3	nc	(nc-nc)	Female	4	1.7	nc	(nc-nc)
Female	2	5.8	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	0	1.9	nc	(nc-nc)
Male	0	1.3	nc	(nc-nc)	Female	2	2.2	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	11	16.2	68.1	(33.9-121.8)
Male	1	0.3	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.3	nc	(nc-nc)	Male	2	1.2	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	0.8	nc	(nc-nc)
Male	5	2.9	169.6	(54.6-395.7)	<u>Testis</u>				
Female	2	1.6	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.8	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	3.0	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	2.0	nc	(nc-nc)	Female	6	4.4	134.9	(49.3-293.6)
Female	0	1.6	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	50	66.1	75.7	(56.2-99.8)
Male	3	1.9	nc	(nc-nc)	Female	61	69.0	88.4	(67.6-113.6)
Female	0	0.7	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	9	9.2	97.4	(44.5-185.0)					
Female	13	10.3	126.1	(67.1-215.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

West Newbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	8	5.3	149.8	(64.5-295.1)	Male	3	3.4	nc	(nc-nc)
Female	0	1.6	nc	(nc-nc)	Female	3	2.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.0	nc	(nc-nc)	Male	2	1.1	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	2	3.0	nc	(nc-nc)
Female	22	20.2	108.7	(68.1-164.6)	Female	0	2.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.7	nc	(nc-nc)	Male	3	2.7	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	4	5.7	nc	(nc-nc)	Female	2	1.7	nc	(nc-nc)
Female	2	4.7	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	1	2.0	nc	(nc-nc)
Male	0	1.4	nc	(nc-nc)	Female	1	1.6	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	23	17.4	132.4	(83.9-198.7)
Male	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.3	nc	(nc-nc)	Male	2	1.3	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.7	nc	(nc-nc)
Male	7	3.2	219.2	(87.8-451.6)	<u>Testis</u>				
Female	1	1.5	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.8	nc	(nc-nc)	Male	0	1.4	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	3	3.8	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	2	2.2	nc	(nc-nc)	Female	4	4.7	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	66	69.7	94.7	(73.2-120.5)
Male	0	2.0	nc	(nc-nc)	Female	50	64.4	77.7	(57.6-102.4)
Female	0	0.6	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	2	9.3	nc	(nc-nc)					
Female	4	8.4	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

West Springfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	35	29.4	118.9	(82.8-165.4)	Male	14	19.0	73.9	(40.4-124.0)
Female	11	11.5	95.5	(47.6-170.8)	Female	9	15.9	56.5	(25.8-107.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	7	5.8	120.5	(48.3-248.3)	Male	2	6.1	nc	(nc-nc)
Female	9	5.2	172.9	(78.9-328.2)	Female	4	5.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.0	nc	(nc-nc)	Male	18	17.0	106.1	(62.9-167.8)
Female	117	127.4	91.8	(75.9-110.0)	Female	16	15.7	102.1	(58.3-165.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	8	4.1	193.1	(83.2-380.6)	Male	18	14.3	125.5	(74.3-198.3)
Female					Female	7	7.0	100.4	(40.2-207.0)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	52	30.7	169.1	(126.3-221.8)	Female	7	11.1	63.2	(25.3-130.3)
Female	37	32.9	112.3	(79.1-154.8)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	10	11.0	90.8	(43.5-167.1)
Male	13	7.6	171.7	(91.3-293.6)	Female	10	12.0	83.2	(39.9-153.1)
Female	1	2.2	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	79	91.9	85.9	(68.0-107.1)
Male	1	2.3	nc	(nc-nc)	<u>Stomach</u>				
Female	2	2.0	nc	(nc-nc)	Male	5	6.9	72.2	(23.3-168.4)
<u>Kidney & Renal Pelvis</u>					Female	5	4.6	108.4	(34.9-253.1)
Male	15	17.3	86.9	(48.6-143.4)	<u>Testis</u>				
Female	13	10.2	126.9	(67.5-217.0)	Male	4	4.1	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	4.4	nc	(nc-nc)	Male	10	7.7	130.5	(62.5-240.0)
Female	2	1.4	nc	(nc-nc)	Female	18	23.5	76.5	(45.3-120.9)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	12	12.2	98.6	(50.9-172.3)	Female	27	28.8	93.7	(61.7-136.3)
Female	13	9.4	139.0	(73.9-237.7)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	389	381.3	102.0	(92.1-112.7)
Male	12	10.8	111.0	(57.3-193.9)	Female	439	429.1	102.3	(93.0-112.3)
Female	4	3.9	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	54	51.6	104.6	(78.6-136.5)					
Female	82	60.1	136.4	(108.5-169.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

West Stockbridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	2.1	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.4	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	4	1.1	nc	(nc-nc)
Female	4	7.1	nc	(nc-nc)	Female	2	0.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	0	2.1	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Female	1	1.6	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	1	0.6	nc	(nc-nc)	Male	6	7.1	84.5	(30.9-184.0)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	1.2	nc	(nc-nc)	Female	3	1.8	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Leukemia</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Lung and Bronchus</u>				
Male	0	0.8	nc	(nc-nc)	Male	7	3.9	179.9	(72.1-370.7)
Female	0	0.2	nc	(nc-nc)	Female	0	3.4	nc	(nc-nc)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

West Tisbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	8	3.1	257.5	(110.9-507.3)	Male	6	1.9	311.3	(113.7-677.6)
Female	1	1.6	nc	(nc-nc)	Female	3	2.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	0.6	nc	(nc-nc)	Male	2	0.7	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	4	1.7	nc	(nc-nc)
Female	20	18.4	108.8	(66.4-168.1)	Female	4	2.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.5	nc	(nc-nc)	Male	3	1.5	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	4	3.1	nc	(nc-nc)	Female	2	1.6	nc	(nc-nc)
Female	4	4.6	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	0	1.2	nc	(nc-nc)
Male	0	0.9	nc	(nc-nc)	Female	1	1.8	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	17	11.5	147.6	(85.9-236.3)
Male	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
Female	1	0.2	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.7	nc	(nc-nc)
Male	4	1.9	nc	(nc-nc)	<u>Testis</u>				
Female	0	1.5	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	3	0.5	nc	(nc-nc)	Male	2	0.7	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	2.8	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	1.2	nc	(nc-nc)	Female	3	4.7	nc	(nc-nc)
Female	0	1.3	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	63	41.6	151.4	(116.3-193.7)
Male	0	1.2	nc	(nc-nc)	Female	49	60.9	80.5	(59.5-106.4)
Female	0	0.6	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	2	5.9	nc	(nc-nc)					
Female	4	8.3	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Westborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	14	18.2	76.8	(41.9-128.8)	Male	14	12.2	114.9	(62.8-192.8)
Female	7	6.5	107.0	(42.8-220.4)	Female	9	9.7	92.8	(42.3-176.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	3.7	nc	(nc-nc)	Male	4	3.9	nc	(nc-nc)
Female	6	3.2	188.6	(68.9-410.4)	Female	2	3.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.7	nc	(nc-nc)	Male	8	10.8	73.9	(31.8-145.7)
Female	87	77.7	112.0	(89.7-138.1)	Female	5	9.2	54.1	(17.4-126.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	2.7	nc	(nc-nc)	Male	9	9.2	98.0	(44.7-186.0)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	16	20.1	79.6	(45.5-129.3)	Female	5	6.5	76.6	(24.7-178.8)
Female	14	19.5	72.0	(39.3-120.7)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	4	4.7	nc	(nc-nc)	Male	59	55.0	107.3	(81.7-138.4)
Female	3	1.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	2	1.5	nc	(nc-nc)	Male	5	3.1	158.9	(51.2-370.7)
Female	3	1.3	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	5	11.2	44.8	(14.4-104.6)	Female	22	16.8	130.8	(82.0-198.1)
Female	3	6.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Leukemia</u>				
Male	1	2.7	nc	(nc-nc)	Male	10	7.6	131.6	(63.0-242.1)
Female	0	0.8	nc	(nc-nc)	Female	10	5.6	179.6	(86.0-330.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Lung and Bronchus</u>				
Male	6	6.6	91.1	(33.3-198.4)	Male	18	31.9	56.4	(33.4-89.1)
Female	2	2.2	nc	(nc-nc)	Female	32	34.0	94.1	(64.3-132.8)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Westfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	44	43.8	100.5	(73.0-134.9)	Male	20	27.7	72.2	(44.1-111.5)
Female	12	15.8	76.1	(39.3-132.9)	Female	19	21.5	88.2	(53.1-137.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	8.4	nc	(nc-nc)	Male	10	9.0	111.3	(53.3-204.8)
Female	4	7.3	nc	(nc-nc)	Female	4	7.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	1.5	nc	(nc-nc)	Male	22	24.7	89.0	(55.8-134.7)
Female	196	174.8	112.1	(97.0-129.0)	Female	28	21.6	129.7	(86.2-187.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	8	5.5	145.8	(62.8-287.4)	Male	24	20.5	116.9	(74.9-174.0)
Female	8	5.5	145.8	(62.8-287.4)	Female	8	9.6	83.4	(35.9-164.3)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	67	45.1	148.7	(115.2-188.8)	Female	19	15.2	125.2	(75.4-195.6)
Female	50	44.6	112.1	(83.2-147.8)	Female	19	15.2	125.2	(75.4-195.6)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	19	11.1	171.4	(103.1-267.7)	Male	13	16.1	80.6	(42.9-137.9)
Female	4	3.1	nc	(nc-nc)	Female	10	16.4	60.9	(29.2-112.1)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	5	3.2	155.4	(50.1-362.5)	Male	125	132.4	94.4	(78.6-112.4)
Female	0	2.8	nc	(nc-nc)	Male	125	132.4	94.4	(78.6-112.4)
<u>Kidney & Renal Pelvis</u>					<u>Stomach</u>				
Male	26	24.9	104.3	(68.1-152.9)	Male	12	10.2	117.6	(60.7-205.4)
Female	7	14.1	49.8	(19.9-102.6)	Female	11	6.3	174.7	(87.1-312.7)
<u>Larynx</u>					<u>Testis</u>				
Male	5	6.4	78.0	(25.1-182.0)	Male	11	5.6	195.4	(97.4-349.7)
Female	4	2.0	nc	(nc-nc)	Male	11	5.6	195.4	(97.4-349.7)
<u>Leukemia</u>					<u>Thyroid</u>				
Male	18	17.8	101.2	(60.0-160.0)	Male	5	10.8	46.1	(14.9-107.6)
Female	9	12.8	70.4	(32.1-133.6)	Female	23	31.3	73.4	(46.5-110.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	10	15.4	64.8	(31.0-119.1)	Female	34	40.2	84.5	(58.5-118.1)
Female	4	5.3	nc	(nc-nc)	Female	34	40.2	84.5	(58.5-118.1)
<u>Lung and Bronchus</u>					<u>All Sites / Types</u>				
Male	86	76.7	112.1	(89.7-138.5)	Male	571	555.8	102.7	(94.5-111.5)
Female	81	83.1	97.5	(77.5-121.2)	Female	565	587.7	96.1	(88.4-104.4)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Westford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	15	22.3	67.2	(37.6-110.9)	Male	14	15.5	90.6	(49.5-152.0)
Female	3	7.1	nc	(nc-nc)	Female	16	11.6	137.7	(78.7-223.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	8	4.8	168.2	(72.4-331.4)	Male	8	5.0	161.6	(69.6-318.4)
Female	4	3.8	nc	(nc-nc)	Female	2	3.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.8	nc	(nc-nc)	Male	13	13.6	95.4	(50.7-163.1)
Female	114	97.9	116.4	(96.0-139.8)	Female	8	10.6	75.4	(32.5-148.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	3.5	nc	(nc-nc)	Male	6	12.4	48.4	(17.7-105.4)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	21	25.5	82.5	(51.0-126.1)	Female	5	8.0	62.1	(20.0-145.0)
Female	37	21.5	171.9	(121.0-236.9)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	8	8.7	91.9	(39.5-181.0)
Male	4	6.1	nc	(nc-nc)	Female	5	7.2	69.0	(22.2-161.0)
Female	2	1.4	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	92	74.7	123.2	(99.3-151.1)
Male	1	1.8	nc	(nc-nc)	<u>Stomach</u>				
Female	3	1.4	nc	(nc-nc)	Male	7	5.5	126.4	(50.6-260.4)
<u>Kidney & Renal Pelvis</u>					Female	1	3.0	nc	(nc-nc)
Male	11	14.9	74.0	(36.9-132.4)	<u>Testis</u>				
Female	1	7.3	nc	(nc-nc)	Male	3	3.3	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	5	3.6	138.7	(44.7-323.8)	Male	10	7.0	142.9	(68.4-262.8)
Female	0	1.0	nc	(nc-nc)	Female	17	19.8	85.9	(50.0-137.5)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	10	9.5	105.3	(50.4-193.7)	Female	32	21.5	149.0	(101.9-210.4)
Female	7	6.2	113.8	(45.6-234.5)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	295	307.2	96.0	(85.4-107.6)
Male	5	8.7	57.4	(18.5-133.9)	Female	317	304.9	104.0	(92.8-116.1)
Female	1	2.5	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	26	40.5	64.2	(42.0-94.1)					
Female	31	39.0	79.5	(54.0-112.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Westhampton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	2.4	nc	(nc-nc)	Male	6	1.6	379.3	(138.5-825.7)
Female	0	0.7	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	9	8.5	106.0	(48.4-201.2)	Female	0	1.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	0	2.6	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
Female	3	1.9	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	1	0.6	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male				
Male	0	0.1	nc	(nc-nc)	Female	8	8.1	98.5	(42.4-194.1)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	0	1.5	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male				
Male	0	0.4	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	1	0.9	nc	(nc-nc)	Female	0	1.5	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Female				
Male	1	0.9	nc	(nc-nc)	Male	25	32.0	78.0	(50.5-115.2)
Female	0	0.2	nc	(nc-nc)	Female	18	26.9	66.8	(39.6-105.6)
<u>Lung and Bronchus</u>					<u>All Sites / Types</u>				
Male	4	4.4	nc	(nc-nc)					
Female	2	3.7	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Westminster

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	7	8.2	85.4	(34.2-175.9)	Male	6	5.5	109.5	(40.0-238.4)
Female	3	2.2	nc	(nc-nc)	Female	7	3.7	189.0	(75.7-389.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.6	nc	(nc-nc)	Male	0	1.8	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	6	4.9	123.3	(45.0-268.4)
Female	42	31.3	134.0	(96.6-181.1)	Female	1	3.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	1.1	nc	(nc-nc)	Male	3	4.4	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	4	9.1	nc	(nc-nc)	Female	3	2.6	nc	(nc-nc)
Female	7	6.5	108.0	(43.3-222.6)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	0	3.2	nc	(nc-nc)
Male	2	2.2	nc	(nc-nc)	Female	2	2.3	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	22	28.0	78.5	(49.2-118.9)
Male	0	0.6	nc	(nc-nc)	<u>Stomach</u>				
Female	1	0.5	nc	(nc-nc)	Male	3	2.0	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.9	nc	(nc-nc)
Male	8	5.2	154.0	(66.3-303.5)	<u>Testis</u>				
Female	4	2.3	nc	(nc-nc)	Male	2	1.2	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	1.3	nc	(nc-nc)	Male	1	2.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	9	6.3	143.5	(65.5-272.5)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	4	3.4	nc	(nc-nc)	Female	9	7.4	122.1	(55.7-231.8)
Female	2	1.9	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	88	111.2	79.1	(63.5-97.5)
Male	0	3.2	nc	(nc-nc)	Female	112	97.0	115.5	(95.1-138.9)
Female	0	0.8	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	8	14.3	56.0	(24.1-110.3)					
Female	14	12.3	113.8	(62.2-190.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Weston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	17	15.4	110.3	(64.2-176.6)	Male	14	9.6	145.4	(79.4-244.0)
Female	1	5.1	nc	(nc-nc)	Female	7	6.9	101.0	(40.4-208.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	2.7	nc	(nc-nc)	Male	3	3.1	nc	(nc-nc)
Female	0	2.3	nc	(nc-nc)	Female	4	2.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.5	nc	(nc-nc)	Male	12	8.4	142.2	(73.4-248.3)
Female	56	57.2	97.9	(73.9-127.1)	Female	3	6.9	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	1.8	nc	(nc-nc)	Male	7	7.1	98.8	(39.6-203.6)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	11	15.6	70.4	(35.1-125.9)	Female	2	4.9	nc	(nc-nc)
Female	11	14.6	75.3	(37.5-134.7)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	3	5.7	nc	(nc-nc)
Male	2	3.9	nc	(nc-nc)	Female	13	5.3	245.6	(130.7-420.1)
Female	0	1.0	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	45	46.1	97.6	(71.2-130.7)
Male	0	0.9	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.7	nc	(nc-nc)	Male	1	3.6	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	2.1	nc	(nc-nc)
Male	6	8.7	69.3	(25.3-150.8)	<u>Testis</u>				
Female	0	4.6	nc	(nc-nc)	Male	2	1.4	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	2.2	nc	(nc-nc)	Male	5	3.5	141.7	(45.7-330.7)
Female	0	0.6	nc	(nc-nc)	Female	8	10.0	80.3	(34.6-158.2)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	5	6.0	83.3	(26.8-194.3)	Female	9	12.8	70.1	(32.0-133.0)
Female	5	4.1	120.6	(38.9-281.4)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	176	192.1	91.6	(78.6-106.2)
Male	5	5.3	94.6	(30.5-220.8)	Female	145	190.1	76.3	(64.4-89.8)
Female	1	1.7	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	16	27.2	58.8	(33.6-95.5)					
Female	11	26.6	41.4	(20.6-74.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Westport

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	27	22.8	118.3	(77.9-172.1)	Male	13	13.8	94.0	(50.0-160.8)
Female	4	7.6	nc	(nc-nc)	Female	5	10.1	49.6	(16.0-115.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	3.8	nc	(nc-nc)	Male	6	4.6	131.7	(48.1-286.7)
Female	2	3.2	nc	(nc-nc)	Female	5	3.6	139.8	(45.1-326.3)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.8	nc	(nc-nc)	Male	15	12.3	122.3	(68.4-201.8)
Female	78	84.2	92.7	(73.3-115.7)	Female	16	10.3	155.0	(88.5-251.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	2.6	nc	(nc-nc)	Male	7	9.9	71.0	(28.4-146.2)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	23	22.5	102.0	(64.7-153.1)	Female	6	7.1	84.4	(30.8-183.6)
Female	21	21.2	98.9	(61.2-151.2)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	12	8.2	145.8	(75.3-254.8)
Male	8	5.6	142.2	(61.2-280.3)	Female	11	8.0	136.8	(68.2-244.7)
Female	0	1.5	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	95	67.6	140.6	(113.7-171.8)
Male	1	1.3	nc	(nc-nc)	<u>Stomach</u>				
Female	0	1.0	nc	(nc-nc)	Male	5	5.2	96.0	(30.9-224.0)
<u>Kidney & Renal Pelvis</u>					Female	2	3.0	nc	(nc-nc)
Male	12	12.3	97.6	(50.4-170.6)	<u>Testis</u>				
Female	6	6.7	89.7	(32.8-195.3)	Male	5	2.2	226.8	(73.1-529.3)
<u>Larynx</u>					<u>Thyroid</u>				
Male	3	3.2	nc	(nc-nc)	Male	6	5.0	120.2	(43.9-261.7)
Female	0	1.0	nc	(nc-nc)	Female	17	14.0	121.2	(70.6-194.1)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	7	8.6	81.2	(32.5-167.3)	Female	14	19.7	71.1	(38.8-119.2)
Female	5	5.8	85.9	(27.7-200.4)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	312	279.0	111.8	(99.8-125.0)
Male	3	7.5	nc	(nc-nc)	Female	259	280.4	92.4	(81.5-104.3)
Female	1	2.5	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	37	39.8	93.1	(65.5-128.3)					
Female	37	40.3	91.8	(64.6-126.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Westwood

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	18	22.5	79.9	(47.3-126.3)	Male	26	13.6	191.6	(125.1-280.7)
Female	6	7.8	77.2	(28.2-168.0)	Female	15	9.9	151.7	(84.8-250.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	3.6	nc	(nc-nc)	Male	11	4.4	250.9	(125.1-448.9)
Female	4	3.2	nc	(nc-nc)	Female	6	3.5	170.7	(62.3-371.6)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	3	0.7	nc	(nc-nc)	Male	8	12.0	66.5	(28.6-131.0)
Female	103	78.8	130.8	(106.7-158.6)	Female	5	10.2	49.0	(15.8-114.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	2.5	nc	(nc-nc)	Male	7	9.5	73.4	(29.4-151.3)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	18	22.8	79.0	(46.8-124.8)	Female	7	6.8	102.3	(41.0-210.7)
Female	15	22.7	65.9	(36.9-108.8)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	13	8.1	161.2	(85.7-275.6)
Male	0	5.3	nc	(nc-nc)	Female	2	8.3	nc	(nc-nc)
Female	1	1.5	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	62	60.0	103.3	(79.2-132.4)
Male	3	1.1	nc	(nc-nc)	<u>Stomach</u>				
Female	1	0.9	nc	(nc-nc)	Male	0	5.1	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	2	3.2	nc	(nc-nc)
Male	12	11.6	103.6	(53.5-181.0)	<u>Testis</u>				
Female	6	6.4	94.0	(34.3-204.5)	Male	6	1.8	329.8	(120.4-717.9)
<u>Larynx</u>					<u>Thyroid</u>				
Male	4	3.0	nc	(nc-nc)	Male	4	4.7	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	Female	20	13.4	149.6	(91.3-231.0)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	10	8.4	119.6	(57.2-219.9)	Female	18	16.8	106.8	(63.3-168.9)
Female	10	6.2	162.3	(77.7-298.4)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	259	265.3	97.6	(86.1-110.2)
Male	7	7.3	96.4	(38.6-198.6)	Female	283	271.7	104.2	(92.4-117.0)
Female	4	2.5	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	25	37.5	66.6	(43.1-98.3)					
Female	31	38.4	80.8	(54.9-114.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Weymouth

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	68	59.9	113.5	(88.1-143.9)	Male	43	38.7	111.0	(80.3-149.5)
Female	37	25.1	147.3	(103.7-203.0)	Female	53	34.3	154.7	(115.9-202.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	9	11.4	78.8	(36.0-149.6)	Male	12	12.4	97.0	(50.1-169.5)
Female	10	11.0	91.1	(43.6-167.5)	Female	6	11.8	51.0	(18.6-110.9)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	2.1	nc	(nc-nc)	Male	40	34.2	116.9	(83.5-159.2)
Female	290	279.3	103.8	(92.2-116.5)	Female	29	34.4	84.3	(56.4-121.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	8.8	nc	(nc-nc)	Male	27	28.4	94.9	(62.5-138.1)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	70	62.5	112.1	(87.3-141.6)	Female	22	23.9	91.9	(57.6-139.1)
Female	68	70.3	96.7	(75.1-122.6)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	18	22.2	81.2	(48.1-128.3)
Male	19	15.1	125.7	(75.7-196.4)	Female	22	26.1	84.1	(52.7-127.4)
Female	8	5.0	161.3	(69.4-317.8)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	162	178.7	90.6	(77.2-105.7)
Male	6	4.5	133.9	(48.9-291.5)	<u>Stomach</u>				
Female	2	4.1	nc	(nc-nc)	Male	14	14.1	99.5	(54.4-167.0)
<u>Kidney & Renal Pelvis</u>					Female	7	10.0	70.3	(28.2-144.9)
Male	36	34.7	103.7	(72.6-143.5)	<u>Testis</u>				
Female	28	22.4	125.2	(83.2-180.9)	Male	10	8.5	117.6	(56.3-216.4)
<u>Larynx</u>					<u>Thyroid</u>				
Male	17	8.8	192.4	(112.0-308.0)	Male	14	15.6	89.6	(48.9-150.4)
Female	3	3.1	nc	(nc-nc)	Female	44	49.4	89.0	(64.7-119.5)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	18	24.2	74.4	(44.1-117.7)	Female	71	64.9	109.5	(85.5-138.1)
Female	14	19.8	70.7	(38.6-118.6)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	813	764.0	106.4	(99.2-114.0)
Male	20	21.2	94.5	(57.7-145.9)	Female	959	934.4	102.6	(96.2-109.3)
Female	9	8.4	107.0	(48.8-203.1)					
<u>Lung and Bronchus</u>									
Male	134	106.1	126.3	(105.9-149.6)					
Female	154	133.1	115.7	(98.2-135.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Whately

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	1.6	nc	(nc-nc)	Male	2	1.1	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.3	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
Female	5	7.4	67.4	(21.7-157.3)	Female	0	0.9	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	3	1.7	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Female	0	1.8	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	2	0.6	nc	(nc-nc)
Male	2	0.5	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	7	6.2	113.5	(45.5-233.8)
Male	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.3	nc	(nc-nc)
Male	0	1.1	nc	(nc-nc)	<u>Testis</u>				
Female	0	0.6	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	0.7	nc	(nc-nc)	Female	2	1.8	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	25	22.7	110.4	(71.4-162.9)
Male	0	0.7	nc	(nc-nc)	Female	14	24.3	57.7	(31.5-96.8)
Female	0	0.2	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	1	2.9	nc	(nc-nc)					
Female	3	3.3	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Whitman

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	21	13.3	157.4	(97.4-240.7)	Male	11	9.2	119.6	(59.6-214.0)
Female	11	4.8	227.9	(113.6-407.8)	Female	14	7.5	186.1	(101.7-312.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	2.9	nc	(nc-nc)	Male	1	2.9	nc	(nc-nc)
Female	1	2.5	nc	(nc-nc)	Female	1	2.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.5	nc	(nc-nc)	Male	4	8.1	nc	(nc-nc)
Female	54	60.9	88.6	(66.6-115.6)	Female	4	7.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	2.1	nc	(nc-nc)	Male	9	7.2	124.4	(56.8-236.2)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	17	14.9	114.2	(66.5-182.8)	Female	2	5.2	nc	(nc-nc)
Female	15	14.2	105.9	(59.2-174.6)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	3	5.2	nc	(nc-nc)
Male	5	3.6	139.1	(44.8-324.5)	Female	6	5.0	120.7	(44.1-262.8)
Female	0	1.0	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	43	44.6	96.4	(69.7-129.8)
Male	1	1.2	nc	(nc-nc)	<u>Stomach</u>				
Female	0	1.0	nc	(nc-nc)	Male	3	3.3	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	2.0	nc	(nc-nc)
Male	20	8.7	228.7	(139.6-353.2)	<u>Testis</u>				
Female	3	4.7	nc	(nc-nc)	Male	2	2.3	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	4	2.1	nc	(nc-nc)	Male	5	4.2	120.3	(38.8-280.7)
Female	1	0.7	nc	(nc-nc)	Female	13	12.2	106.3	(56.6-181.8)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	7	5.7	122.4	(49.0-252.1)	Female	6	13.9	43.2	(15.8-93.9)
Female	4	4.2	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	195	183.3	106.4	(92.0-122.4)
Male	2	5.2	nc	(nc-nc)	Female	203	196.9	103.1	(89.4-118.3)
Female	0	1.7	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	26	24.3	106.8	(69.8-156.5)					
Female	43	26.0	165.2	(119.5-222.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Wilbraham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	17	22.3	76.2	(44.4-122.1)	Male	17	13.5	125.9	(73.3-201.7)
Female	11	7.0	157.1	(78.3-281.1)	Female	9	9.2	98.4	(44.9-186.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	3.6	nc	(nc-nc)	Male	3	4.4	nc	(nc-nc)
Female	6	2.9	205.2	(74.9-446.5)	Female	3	3.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.7	nc	(nc-nc)	Male	8	11.9	67.3	(29.0-132.6)
Female	81	74.3	109.0	(86.6-135.5)	Female	10	9.3	107.9	(51.6-198.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	2.3	nc	(nc-nc)	Male	11	9.9	111.6	(55.6-199.7)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	18	22.4	80.4	(47.6-127.0)	Female	10	6.4	157.0	(75.2-288.8)
Female	12	20.5	58.7	(30.3-102.5)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	2	8.1	nc	(nc-nc)
Male	1	5.4	nc	(nc-nc)	Female	9	7.5	120.2	(54.9-228.2)
Female	3	1.4	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	45	65.8	68.4	(49.9-91.6)
Male	2	1.2	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.9	nc	(nc-nc)	Male	3	5.1	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	3	2.9	nc	(nc-nc)
Male	9	11.9	75.3	(34.4-143.0)	<u>Testis</u>				
Female	4	5.9	nc	(nc-nc)	Male	1	1.8	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	4	3.1	nc	(nc-nc)	Male	5	4.7	106.2	(34.2-247.9)
Female	0	0.8	nc	(nc-nc)	Female	10	12.6	79.3	(38.0-145.9)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	4	8.3	nc	(nc-nc)	Female	10	16.4	61.1	(29.3-112.4)
Female	6	5.6	107.8	(39.4-234.7)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	204	271.5	75.1	(65.2-86.2)
Male	6	7.4	80.8	(29.5-175.9)	Female	238	251.6	94.6	(82.9-107.4)
Female	2	2.2	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	26	38.4	67.8	(44.3-99.3)					
Female	27	35.2	76.7	(50.5-111.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Williamsburg

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	3.4	nc	(nc-nc)	Male	1	2.2	nc	(nc-nc)
Female	0	1.3	nc	(nc-nc)	Female	1	1.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.6	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.9	nc	(nc-nc)
Female	19	14.4	132.2	(79.5-206.4)	Female	1	1.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.4	nc	(nc-nc)	Male	1	1.7	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	2	3.5	nc	(nc-nc)	Female	3	1.3	nc	(nc-nc)
Female	3	3.6	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	1	1.3	nc	(nc-nc)
Male	2	0.9	nc	(nc-nc)	Female	0	1.3	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	5	11.3	44.3	(14.3-103.4)
Male	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.5	nc	(nc-nc)
Male	4	2.0	nc	(nc-nc)	<u>Testis</u>				
Female	2	1.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	0.5	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	2	2.3	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	1.3	nc	(nc-nc)	Female	5	3.5	144.1	(46.4-336.2)
Female	1	1.0	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	28	44.3	63.2	(42.0-91.3)
Male	1	1.3	nc	(nc-nc)	Female	45	47.4	94.9	(69.2-127.0)
Female	0	0.4	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	4	6.3	nc	(nc-nc)					
Female	3	6.7	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Williamstown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	9	9.9	91.3	(41.7-173.3)	Male	7	5.6	125.1	(50.1-257.7)
Female	3	3.8	nc	(nc-nc)	Female	2	4.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.5	nc	(nc-nc)	Male	1	1.8	nc	(nc-nc)
Female	2	1.6	nc	(nc-nc)	Female	1	1.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	7	5.0	139.8	(56.0-288.1)
Female	21	33.7	62.4	(38.6-95.4)	Female	3	4.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.9	nc	(nc-nc)	Male	2	3.7	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	6	9.3	64.8	(23.7-141.1)	Female	2	3.1	nc	(nc-nc)
Female	6	10.5	56.9	(20.8-123.9)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	3	2.2	nc	(nc-nc)	Male	21	25.1	83.8	(51.8-128.1)
Female	1	0.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	0	0.5	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	6	4.5	131.9	(48.2-287.2)	Female	4	7.8	nc	(nc-nc)
Female	2	2.9	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Leukemia</u>				
Male	1	1.2	nc	(nc-nc)	Male	0	3.7	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	2	2.9	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Lung and Bronchus</u>				
Male	1	3.0	nc	(nc-nc)	Male	5	16.2	30.8	(9.9-72.0)
Female	3	1.2	nc	(nc-nc)	Female	16	18.8	85.1	(48.6-138.1)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Wilmington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	24	23.9	100.5	(64.4-149.5)	Male	12	15.4	77.8	(40.2-136.0)
Female	6	8.6	70.0	(25.6-152.3)	Female	12	12.6	95.4	(49.2-166.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	4.6	107.9	(34.8-251.8)	Male	4	4.9	nc	(nc-nc)
Female	5	4.1	122.9	(39.6-286.7)	Female	4	4.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.8	nc	(nc-nc)	Male	10	13.8	72.5	(34.7-133.4)
Female	121	101.9	118.7	(98.5-141.9)	Female	17	12.1	140.1	(81.6-224.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	3.4	nc	(nc-nc)	Male	12	11.6	103.5	(53.4-180.8)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	23	25.6	89.7	(56.8-134.6)	Female	6	8.7	69.1	(25.2-150.3)
Female	29	25.3	114.6	(76.8-164.7)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	3	6.0	nc	(nc-nc)	Male	48	72.8	66.0	(48.6-87.4)
Female	0	1.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	4	1.8	nc	(nc-nc)	Male	2	3.4	nc	(nc-nc)
Female	2	1.5	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	20	14.1	141.9	(86.7-219.2)	Female	20	23.0	86.9	(53.1-134.3)
Female	5	8.0	62.8	(20.2-146.6)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Leukemia</u>				
Male	3	3.5	nc	(nc-nc)	Male	14	9.8	143.3	(78.3-240.4)
Female	0	1.1	nc	(nc-nc)	Female	5	7.1	70.0	(22.5-163.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Lung and Bronchus</u>				
Male	7	8.5	82.5	(33.0-169.9)	Male	43	41.1	104.6	(75.7-140.9)
Female	2	2.9	nc	(nc-nc)	Female	45	44.8	100.5	(73.3-134.5)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Winchendon

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	9	11.9	75.6	(34.5-143.5)	Male	1	7.7	nc	(nc-nc)
Female	3	3.8	nc	(nc-nc)	Female	3	5.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	2.3	nc	(nc-nc)	Male	3	2.4	nc	(nc-nc)
Female	1	1.8	nc	(nc-nc)	Female	1	1.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	5	6.8	73.9	(23.8-172.3)
Female	35	47.3	74.0	(51.5-102.9)	Female	1	5.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	1.5	nc	(nc-nc)	Male	11	5.7	194.6	(97.0-348.2)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	10	12.6	79.4	(38.0-146.1)	Female	4	4.0	nc	(nc-nc)
Female	16	11.1	144.4	(82.5-234.6)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	9	4.4	204.5	(93.3-388.2)
Male	5	3.0	167.3	(53.9-390.5)	Female	4	3.9	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	19	35.1	54.1	(32.5-84.4)
Male	0	0.9	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.7	nc	(nc-nc)	Male	1	2.8	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	2	1.5	nc	(nc-nc)
Male	8	6.9	116.6	(50.2-229.7)	<u>Testis</u>				
Female	8	3.7	217.2	(93.5-428.0)	Male	2	1.7	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	4	1.8	nc	(nc-nc)	Male	1	3.1	nc	(nc-nc)
Female	2	0.5	nc	(nc-nc)	Female	6	8.7	69.0	(25.2-150.1)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	4	4.8	nc	(nc-nc)	Female	7	10.8	64.7	(25.9-133.2)
Female	1	3.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	123	151.2	81.4	(67.6-97.1)
Male	3	4.2	nc	(nc-nc)	Female	129	152.2	84.7	(70.7-100.7)
Female	1	1.3	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	16	20.8	76.8	(43.8-124.7)					
Female	21	20.9	100.5	(62.2-153.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Winchester

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	20	24.8	80.7	(49.3-124.6)	Male	16	16.0	100.0	(57.1-162.3)
Female	8	9.3	86.0	(37.0-169.4)	Female	13	13.0	100.1	(53.3-171.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	4.6	129.8	(47.4-282.5)	Male	6	5.1	117.6	(42.9-256.0)
Female	4	4.2	nc	(nc-nc)	Female	4	4.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.9	nc	(nc-nc)	Male	15	14.1	106.2	(59.4-175.2)
Female	116	106.2	109.3	(90.3-131.1)	Female	14	12.8	109.7	(60.0-184.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	3.6	nc	(nc-nc)	Male	7	11.6	60.3	(24.1-124.2)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	26	26.1	99.7	(65.1-146.1)	Female	9	8.9	101.1	(46.1-192.0)
Female	25	27.1	92.4	(59.8-136.4)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	2	6.1	nc	(nc-nc)	Male	73	71.3	102.4	(80.2-128.7)
Female	0	1.8	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	0	1.6	nc	(nc-nc)	Male	0	3.1	nc	(nc-nc)
Female	0	1.4	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	9	14.4	62.7	(28.6-119.0)	Female	26	23.2	111.8	(73.0-163.9)
Female	16	8.4	191.4	(109.3-310.8)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Leukemia</u>				
Male	0	3.6	nc	(nc-nc)	Male	16	10.0	160.5	(91.7-260.6)
Female	0	1.2	nc	(nc-nc)	Female	8	7.6	105.3	(45.3-207.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Lung and Bronchus</u>				
Male	6	8.5	70.9	(25.9-154.4)	Male	25	43.4	57.5	(37.2-84.9)
Female	2	3.0	nc	(nc-nc)	Female	38	48.5	78.3	(55.4-107.5)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Windsor

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	1.3	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	0.2	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	5	4.5	111.6	(36.0-260.3)	Female	0	0.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	6	1.4	414.9	(151.5-903.1)	Female	1	0.4	nc	(nc-nc)
Female	2	0.9	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	4.7	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.8	nc	(nc-nc)	Female	2	1.1	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Leukemia</u>				
Male	0	0.2	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Lung and Bronchus</u>				
Male	0	0.5	nc	(nc-nc)	Male	1	2.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	3	1.8	nc	(nc-nc)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Winthrop

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	19	22.4	84.9	(51.1-132.6)	Male	25	14.2	176.0	(113.9-259.9)
Female	10	7.6	130.9	(62.7-240.8)	Female	24	10.8	223.2	(143.0-332.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	4.1	nc	(nc-nc)	Male	7	4.6	151.0	(60.5-311.2)
Female	3	3.5	nc	(nc-nc)	Female	3	3.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.8	nc	(nc-nc)	Male	9	12.5	71.9	(32.8-136.4)
Female	84	88.1	95.4	(76.1-118.1)	Female	6	10.6	56.5	(20.6-123.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	2.8	nc	(nc-nc)	Male	6	10.5	57.1	(20.8-124.2)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	29	22.7	127.9	(85.6-183.7)	Female	5	7.6	66.2	(21.3-154.5)
Female	26	21.6	120.3	(78.5-176.2)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	16	8.3	193.1	(110.3-313.7)
Male	9	5.7	157.3	(71.8-298.7)	Female	5	7.8	63.8	(20.6-149.0)
Female	1	1.5	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	66	69.0	95.7	(74.0-121.7)
Male	0	1.5	nc	(nc-nc)	<u>Stomach</u>				
Female	2	1.4	nc	(nc-nc)	Male	7	5.2	134.4	(53.8-276.9)
<u>Kidney & Renal Pelvis</u>					Female	4	3.0	nc	(nc-nc)
Male	20	12.8	156.6	(95.6-241.9)	<u>Testis</u>				
Female	8	7.0	114.0	(49.1-224.7)	Male	2	2.7	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	3.3	nc	(nc-nc)	Male	9	5.4	167.3	(76.4-317.6)
Female	0	1.0	nc	(nc-nc)	Female	9	16.2	55.5	(25.3-105.4)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	3	8.8	nc	(nc-nc)	Female	23	20.1	114.3	(72.4-171.5)
Female	9	6.1	146.5	(66.9-278.2)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	316	284.6	111.0	(99.1-124.0)
Male	7	8.0	87.4	(35.0-180.2)	Female	307	291.3	105.4	(93.9-117.9)
Female	2	2.6	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	54	40.1	134.8	(101.3-175.9)					
Female	56	41.1	136.1	(102.8-176.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Woburn

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	53	43.7	121.4	(90.9-158.8)	Male	31	27.7	111.9	(76.0-158.8)
Female	23	15.6	147.1	(93.2-220.7)	Female	14	21.4	65.5	(35.8-110.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	8.2	nc	(nc-nc)	Male	10	8.7	114.4	(54.8-210.5)
Female	9	6.9	130.5	(59.5-247.7)	Female	6	7.2	83.4	(30.5-181.5)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	1.5	nc	(nc-nc)	Male	34	24.5	138.6	(96.0-193.7)
Female	208	166.2	125.2	(108.7-143.4)	Female	29	21.2	136.9	(91.7-196.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	11	5.4	202.8	(101.1-362.9)	Male	15	19.9	75.3	(42.1-124.3)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	56	45.0	124.3	(93.9-161.4)	Female	13	14.6	89.0	(47.3-152.2)
Female	53	44.8	118.3	(88.6-154.7)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	10	15.9	63.0	(30.2-115.8)
Male	11	10.7	103.1	(51.4-184.5)	Female	15	16.3	91.8	(51.3-151.3)
Female	0	3.0	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	108	124.6	86.6	(71.1-104.6)
Male	2	3.4	nc	(nc-nc)	<u>Stomach</u>				
Female	2	2.8	nc	(nc-nc)	Male	11	10.1	108.9	(54.3-194.9)
<u>Kidney & Renal Pelvis</u>					Female	7	6.3	110.9	(44.4-228.5)
Male	27	24.3	111.2	(73.3-161.8)	<u>Testis</u>				
Female	13	13.5	96.2	(51.2-164.5)	Male	7	6.7	104.1	(41.7-214.4)
<u>Larynx</u>					<u>Thyroid</u>				
Male	4	6.1	nc	(nc-nc)	Male	13	11.1	117.0	(62.3-200.2)
Female	4	1.9	nc	(nc-nc)	Female	38	31.0	122.7	(86.8-168.4)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	14	17.6	79.6	(43.5-133.6)	Female	29	37.4	77.4	(51.9-111.2)
Female	12	12.7	94.3	(48.6-164.7)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	588	544.3	108.0	(99.5-117.1)
Male	18	14.9	121.1	(71.7-191.4)	Female	634	569.7	111.3	(102.8-120.3)
Female	2	5.2	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	101	75.2	134.4	(109.4-163.3)					
Female	88	80.0	109.9	(88.2-135.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Worcester

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	167	163.7	102.0	(87.1-118.7)	Male	73	106.2	68.7	(53.9-86.4)
Female	60	62.8	95.5	(72.9-123.0)	Female	68	88.8	76.6	(59.5-97.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	31	33.6	92.2	(62.6-130.8)	Male	29	33.5	86.6	(58.0-124.3)
Female	22	30.2	72.9	(45.7-110.4)	Female	25	29.0	86.1	(55.7-127.1)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	3	5.7	nc	(nc-nc)	Male	96	95.2	100.9	(81.7-123.2)
Female	634	692.0	91.6	(84.6-99.0)	Female	65	86.2	75.4	(58.2-96.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	31	23.2	133.4	(90.6-189.4)	Male	69	78.3	88.2	(68.6-111.6)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	164	174.3	94.1	(80.2-109.6)	Female	52	60.7	85.7	(64.0-112.4)
Female	159	181.8	87.4	(74.4-102.1)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	66	60.4	109.3	(84.5-139.0)
Male	56	40.9	137.1	(103.5-178.0)	Female	70	65.8	106.3	(82.9-134.4)
Female	16	12.1	132.0	(75.4-214.4)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	424	477.3	88.8	(80.6-97.7)
Male	13	14.6	88.9	(47.3-152.1)	<u>Stomach</u>				
Female	18	13.1	137.2	(81.2-216.8)	Male	39	38.5	101.4	(72.1-138.6)
<u>Kidney & Renal Pelvis</u>					Female	20	25.5	78.4	(47.9-121.1)
Male	97	94.7	102.5	(83.1-125.0)	<u>Testis</u>				
Female	66	55.9	118.1	(91.4-150.3)	Male	22	28.3	77.7	(48.7-117.7)
<u>Larynx</u>					<u>Thyroid</u>				
Male	22	23.6	93.3	(58.5-141.3)	Male	43	45.0	95.5	(69.1-128.7)
Female	12	7.7	156.2	(80.6-272.8)	Female	136	135.2	100.6	(84.4-118.9)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	70	69.3	101.0	(78.7-127.6)	Female	176	154.3	114.0	(97.8-132.2)
Female	57	52.9	107.7	(81.5-139.5)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	2052	2092.8	98.0	(93.9-102.4)
Male	75	57.6	130.2	(102.4-163.2)	Female	2313	2353.6	98.3	(94.3-102.4)
Female	27	20.8	129.6	(85.4-188.5)					
<u>Lung and Bronchus</u>									
Male	329	280.3	117.4	(105.0-130.8)					
Female	347	325.0	106.8	(95.8-118.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Worthington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	2.0	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	2	0.5	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	0.3	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.1	nc	(nc-nc)	Male	3	1.1	nc	(nc-nc)
Female	8	6.6	121.3	(52.2-238.9)	Female	1	0.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	1	2.0	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Female	1	1.5	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	0	0.7	nc	(nc-nc)
Male	1	0.5	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	1	6.0	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.2	nc	(nc-nc)
Male	1	1.1	nc	(nc-nc)	<u>Testis</u>				
Female	1	0.5	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	2	0.7	nc	(nc-nc)	Female	6	1.6	371.8	(135.8-809.3)
Female	0	0.4	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	23	24.4	94.1	(59.6-141.2)
Male	2	0.7	nc	(nc-nc)	Female	23	21.1	109.1	(69.1-163.6)
Female	0	0.2	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	7	3.4	208.2	(83.4-429.1)					
Female	0	2.8	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Wrentham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	12	10.3	116.2	(60.0-202.9)	Male	9	7.2	124.4	(56.8-236.1)
Female	3	4.5	nc	(nc-nc)	Female	11	6.4	173.2	(86.3-309.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	2.3	nc	(nc-nc)	Male	0	2.3	nc	(nc-nc)
Female	2	2.0	nc	(nc-nc)	Female	2	2.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	13	6.4	203.8	(108.4-348.6)
Female	62	51.5	120.4	(92.3-154.4)	Female	6	6.3	95.8	(35.0-208.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	1.7	nc	(nc-nc)	Male	4	5.9	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	18	12.1	148.6	(88.1-234.9)	Female	9	4.4	204.4	(93.3-388.0)
Female	13	13.3	98.1	(52.2-167.8)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	7	4.1	172.2	(69.0-354.9)
Male	4	2.8	nc	(nc-nc)	Female	3	4.6	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	56	34.7	161.5	(122.0-209.8)
Male	1	0.8	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.7	nc	(nc-nc)	Male	2	2.6	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	2	1.9	nc	(nc-nc)
Male	8	6.9	115.6	(49.8-227.7)	<u>Testis</u>				
Female	5	4.0	123.6	(39.8-288.4)	Male	1	1.6	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	1.7	nc	(nc-nc)	Male	8	3.2	246.8	(106.3-486.3)
Female	0	0.5	nc	(nc-nc)	Female	9	9.5	94.7	(43.2-179.8)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	4	4.5	nc	(nc-nc)	Female	6	11.2	53.4	(19.5-116.2)
Female	3	3.7	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	184	143.5	128.2	(110.3-148.1)
Male	4	4.3	nc	(nc-nc)	Female	170	169.8	100.1	(85.6-116.3)
Female	2	1.5	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	17	18.6	91.6	(53.3-146.6)					
Female	15	22.9	65.5	(36.6-108.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Yarmouth

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	50	47.0	106.5	(79.0-140.4)	Male	52	26.1	199.0	(148.6-261.0)
Female	22	17.4	126.1	(79.0-190.9)	Female	43	19.2	224.5	(162.4-302.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	7	6.3	111.1	(44.5-228.8)	Male	9	8.5	105.7	(48.2-200.7)
Female	6	6.1	98.3	(35.9-213.9)	Female	6	7.6	78.7	(28.7-171.2)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.5	nc	(nc-nc)	Male	21	23.1	90.9	(56.3-139.0)
Female	181	154.6	117.1	(100.6-135.4)	Female	24	21.6	111.2	(71.2-165.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	4.1	nc	(nc-nc)	Male	15	16.1	93.0	(52.0-153.5)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	37	43.3	85.4	(60.1-117.7)	Female	9	13.7	65.5	(29.9-124.4)
Female	39	46.5	83.9	(59.7-114.7)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	19	15.8	120.0	(72.2-187.5)
Male	19	10.1	188.5	(113.4-294.4)	Female	22	18.3	120.2	(75.3-182.0)
Female	8	3.3	243.3	(104.8-479.4)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	137	107.0	128.0	(107.5-151.4)
Male	3	2.0	nc	(nc-nc)	<u>Stomach</u>				
Female	3	1.8	nc	(nc-nc)	Male	6	10.0	59.8	(21.8-130.2)
<u>Kidney & Renal Pelvis</u>					Female	6	6.6	91.3	(33.4-198.8)
Male	17	20.3	83.6	(48.7-133.9)	<u>Testis</u>				
Female	11	13.3	82.4	(41.1-147.5)	Male	2	3.1	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	3	5.6	nc	(nc-nc)	Male	8	7.4	108.0	(46.5-212.8)
Female	2	1.9	nc	(nc-nc)	Female	12	21.4	56.0	(28.9-97.7)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	32	16.3	196.4	(134.3-277.3)	Female	28	35.5	78.8	(52.4-114.0)
Female	22	12.6	175.0	(109.6-264.9)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	573	503.7	113.8	(104.6-123.5)
Male	21	13.0	161.8	(100.1-247.4)	Female	623	558.3	111.6	(103.0-120.7)
Female	9	5.3	169.7	(77.4-322.1)					
<u>Lung and Bronchus</u>									
Male	73	76.1	95.9	(75.2-120.6)					
Female	98	89.2	109.9	(89.2-133.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

APPENDICES

APPENDIX I: INTERNATIONAL CLASSIFICATION OF DISEASES FOR ONCOLOGY (THIRD EDITION)

CODES USED FOR THIS REPORT ¹

Cancer Site/Type²	ICD-O-3
Brain & Other Nervous System	C70.0-C72.9 except 9050-9055, 9140, 9590-9992
Breast (includes <i>in situ</i>)	C50.0 – C50.9 except 9050-9055, 9140, 9590-9992
Bronchus & Lung	C34.0 – C34.9 except 9050-9055, 9140, 9590-9992
Cervix Uteri	C53.0 – C53.9 except 9050-9055, 9140, 9590-9992
Colon/ Rectum	C18.0-C18.9, C19.9, C20.9, C26.0 except 9050-9055, 9140, 9590-9992
Corpus Uteri & Uterus, NOS	C54.0 – C54.9, C55.9 except 9050-9055, 9140, 9590-9992
Esophagus	C15.0-C15.9 except 9050-9055, 9140, 9590-9992
Hodgkin Lymphoma	C00.00 – C80.9 (includes 9650-9667)
Kidney & Renal Pelvis³	C64.9, C65.9 except 9050-9055, 9140, 9590-9992
Larynx	C32.0 – C32.9 except 9050-9055, 9140, 9590-9992
Leukemia	C00.0 – C80.9 (includes 9733, 9742, 9800-9801, 9805-9809, 9820, 9826, 9831-9836, 9840, 9860-9861, 9863, 9865-9867, 9869-9876, 9891, 9895-9898, 9910-9911, 9920, 9930-9931, 9940, 9945-9946, 9948, 9963-9964)
	C42.0, C42.1, C42.4 (includes 9811-9818, 9823, 9827, 9837)

Liver and Intrahepatic Bile Ducts	C22.0, C22.1 except 9050-9055, 9140, 9590-9992
Melanoma of Skin	C44.0 – C44.9 (includes 8720-8790)
Multiple Myeloma	C00.0-C80.9 (includes 9731, 9732, 9734)
Non – Hodgkin Lymphoma	C02.4, C098, C099, C111, C142, C379, C422, C770-C779 (includes 9590-9597, 9670-9671, 9673, 9675, 9678-9680, 9684, 9687-9691, 9695, 9698-9702, 9705, 9708-9709, 9712, 9714-9719, 9724-9729, 9735, 9737-9738, 9811-9818, 9823, 9827, 9837)
	All sites except C02.4, C90.8-C09.9, C11.1, C14.2, C37.9, C42.2, C77.0-C77.9 (includes 9590-9597, 9670-9671, 9673, 9675, 9678-9680, 9684, 9687, 9688, 9689-9691, 9695, 9698- 9702, 9705, 9708-9709, 9712, 9714-9719, 9724-9729, 9735, 9737, 9738)
	All sites except C02.4, c09.8-C09.9, C11.1, C14.2, C37.9, C42.0-C42.2, c42.4, C77.0-C77.9 (includes 9811-9818, 9823, 9827, 9837)
Oral Cavity & Pharynx	C00.0 – C14.8 except 9050-9055, 9140, 9590-9992
Ovary	C56.9 except 9050-9055, 9140, 9590-9992
Pancreas	C25.0 – C25.9 except 9050-9055, 9140, 9590-9992
Prostate	C61.9 except 9050-9055, 9140, 9590-9992

Stomach	C16.0 – C16.9 except 9050-9055, 9140, 9590-9992
Testis	C62.0 – C62.9 except 9050-9055, 9140, 9590-9992
Thyroid	C73.9 except 9050-9055, 9140, 9590-9992
Urinary Bladder (includes <i>in situ</i>)	C67.0 – C67.9 except 9050-9055, 9140, 9590-9992

¹*International Classification of Diseases for Oncology, 3d Ed.* (includes codes added since publication)

²Only invasive cancers (those with invasive behaviors) are included in this publication except Bladder, Urinary, which includes invasive and *in situ* behaviors. Non-invasive (*in situ*) cancers are not included.

³Massachusetts hospital coding conventions may have assigned some cases to a “not otherwise specified” site category that is not included in this cancer type.

APPENDIX II: SELECTED RESOURCES FOR INFORMATION ON CANCER

This Appendix contains a listing of selected resources for additional information on cancer. Cancers are complex diseases, many of which have multiple factors that may contribute to their development.

For information on cancer risk factors or prevention, you may wish to contact the following:

Cancer Information Service (National Cancer Institute): 1-800-4-CANCER (1-800-422-6237)

Cancer Response Line (American Cancer Society): 1-800-ACS-2345 (1-800-227-2345)

In addition, the following selected Internet websites provide information on cancer. Many of these also provide links to other sites (not listed) which may be of interest.

Massachusetts Department of Public Health: <http://www.mass.gov/dph>

American Cancer Society: <http://www.cancer.org>

Centers for Disease Control and Prevention

Home Page: <http://www.cdc.gov>

Cancer Prevention and Control Program: <http://www.cdc.gov/cancer>

Fruits and Veggies More Matters™ Campaign (nutrition – formerly 5-A-Day Program):
<http://www.fruitsandveggiesmorematters.org/>

National Cancer Institute

Information: <http://www.cancer.gov>

Cancer Literature in PubMed:

https://www.ncbi.nlm.nih.gov/pubmed?cmd_current=Limits&pmfilter_Subsets=Cancer

Surveillance, Epidemiology, and End Results (SEER) Program data: <http://seer.cancer.gov>

Your Cancer Risk (Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; formerly at Harvard Center for Cancer Prevention):
<http://www.yourdiseaserisk.wustl.edu>

Oncolink (Abramson Cancer Center of the University of Pennsylvania):
<http://www.oncolink.org>

Cancerquest (Emory University – Winship Cancer Institute): www.cancerquest.org

National Coalition for Cancer Survivorship: <http://www.canceradvocacy.org>

APPENDIX III: MDPH CANCER PREVENTION AND CONTROL INITIATIVES

The Massachusetts Department of Public Health is working to reduce the incidence and mortality of cancer in the Commonwealth. Partnerships between MDPH programs, researchers, healthcare providers and nonprofit organizations collect information about cancer, lead quality improvement projects, coordinate evidenced-based workshops for managing living with chronic disease (including cancer), provide education for health professionals and bring shared messages to the public. Our collaborated efforts focus on reducing cancer risk, incidence and mortality through healthy lifestyles, early diagnosis, and increased access to care. The Department's programs address the impact of tobacco, alcohol, nutrition, and physical activity on cancer prevention, along with environmental and occupational hazards for cancer. Throughout all of our efforts there is an emphasis on reducing disparate health outcomes and unequal access to cancer care.

MDPH Bureaus and Programs:

Bureau of Environmental Health, www.mass.gov/dph/environmental_health

Bureau of Substance Abuse Services, www.mass.gov/dph/bsas

Comprehensive Cancer Prevention and Control Program, www.mass.gov/compcancer

Men's Health/Women's Health/Care Coordination Program

Tobacco Cessation and Prevention Program, www.mass.gov/dph/mtcp

Occupational Health Surveillance Program, www.mass.gov/dph/ohsp

Office of Elder Affairs www.mass.gov/elders/

Oral Health Program, www.mass.gov/dph/oralhealth

Division of Prevention and Wellness www.mass.gov/dph/healthpromotion

MDPH publications on cancer prevention and screening are available at the Massachusetts Health Promotion Clearinghouse, www.maclearinghouse.com.

Massachusetts Cancer Registry Publications are available through the Massachusetts Cancer Registry, telephone: 617-624-5642 and on the web at www.mass.gov/dph/mcr.

REFERENCES

1. Fritz A, Percy C, Jack A, et al. (eds). *International Classification of Diseases for Oncology, 3rd Ed.* Geneva: World Health Organization, 2000.
2. United States Census Bureau, American Community Survey, accessed June 22, 2018: <https://www.census.gov/library/publications/2009/acs/state-and-local.html>